ABSTRACT

This material provides documentation for users of the public use micro-data file for Community Health Center (CHC) data from the 2012 National Ambulatory Medical Care Survey (NAMCS). NAMCS is a national probability sample survey of visits to office-based physicians and CHC-based physicians and non-physician clinicians. Conducted by the National Center for Health Statistics, NAMCS is a component of the National Health Care Surveys which measure health care utilization across a variety of health care providers.

The CHC public use file includes visits to CHC physicians, physician assistants, nurse practitioners, and nurse midwives. Although visits to CHC physicians were included in the 2006-2011 NAMCS public use files, access to NAMCS data on visits to non-physician clinicians was only available through NCHS's Research Data Center. This documentation describes the first public use micro-data file for all visits to CHC physicians and non-physician clinicians.

In 2012, the NAMCS sampling design was changed to provide both national estimates and estimates for the 34 most populous states. To support state-specific estimates, the 2012 CHC sampling unit changed from CHC grantees and 'look-alikes' (CHCs that applied for Section 330 funding but were not funded) to CHC service delivery sites. The sample of CHCs increased from 104 CHC grantees and 'look-alikes' to 2,008 service delivery sites.

Section I, "Description of the National Ambulatory Medical Care Survey," includes information on the scope of the survey, the sample, field activities, data collection procedures, medical coding procedures, population estimates, and sampling errors. Section II provides a detailed description of the contents of each data record by location, and a list of physician specialties represented in the survey. Section III contains marginal data for selected items on the CHC visit file. The appendixes contain information on relative standard errors, instructions and definitions for completing the Patient Record form, and lists of codes used in the survey.

SUMMARY OF CHANGES FOR 2012

Since 2006, national samples of community health center (CHC) physicians and non-physician clinicians (physician assistants, nurse practitioners, and nurse midwives) have provided data on CHC visits. Although visits to CHC physicians were included in the 2006-2011 NAMCS public use files, access to NAMCS data on visits to non-physician clinicians was only available through NCHS's Research Data Center.

The NAMCS CHC public use micro-data file marks the first release of CHC physician and non-physician clinician visit data from the 2012 NAMCS. There have been important changes to the 2012 survey which must be understood in order to correctly use and interpret the survey data. These include a new sampling design which, for the first time, makes it possible to produce estimates for 34 states, and the switch from a paper-and-pencil mode of data collection to a computer-assisted method. A number of survey questions were added or modified as well. Highlights are summarized below and explained in more detail in Section I.

A. New sample design for CHC component of NAMCS

Starting in 2012, the traditional office-based component of NAMCS has been split from the CHC component. As a result, 2012 NAMCS web tables, Research Data Center files, and public use files only include visits to office-based physicians who were sampled from the master files of the American Medical Association and the American Osteopathic Association. If any of them saw patients in CHC locations, the CHC visits were excluded.

Although the CHC component of the 2012 NAMCS is a stand-alone sample survey of CHC providers, it was designed to complement the 2012 "traditional" sample of NAMCS office-based physicians. Similar to the office-based component of NAMCS, the CHC component provides estimates of CHC visits for the nation, as well as for the 34 most populous states. In the 2012 design, the sample of CHC grantees and 'look-alikes' (CHCs that applied for Section 330 funding but were not funded) which had been clustered in NAMCS geographic primary sampling units (PSUs) in the 2006-2011 design was replaced with a stratified list sample of CHC service delivery sites. The sampling strata were defined by 39 geographic areas consisting of the 34 most populous states and five Census division "remainders", or aggregates of the remaining states within their Census division. The sample size expanded 20-fold; from 104 CHC grantees and 'look-alikes' in 2011, to 2,008 CHC service delivery sites whose addresses could be verified. At each participating CHC service site, a sample of up to three clinicians (including any of the following types: physicians, nurse practitioners, physician assistants, and nurse midwives) was selected, and a sample of their scheduled visits during a randomly assigned week was selected.

While the overall number of CHC providers responding to the 2012 survey has increased substantially for the nation in general, the number of providers responding in each state/census division stratum can be low. NCHS considers an estimate to be reliable only if it is based on at least 30 sample records and the standard error is no more than 30 percent of the estimate. This is described in more detail in Section I and Appendix I.

B. Comparability of 2012 NAMCS CHC Estimates with Previous Years

Prior to the 2006 survey year, NAMCS public use files include traditional NAMCS physicians only (that is, physicians sampled from the master files of the American Medical Association and the American Osteopathic Association), but if the physician saw patients in a CHC setting, those visits were also included in the file. For survey years 2006-2011, in addition to the 'traditional' physician sample, NAMCS included a panel of Community Health Centers (CHCs), with up to three providers (including physicians, physician assistants, nurse practitioners and nurse midwives) being sampled per CHC grantee or 'lookalike'. Data for visits to CHC-sampled physicians were included in NAMCS web tables, Research Data

Center files, and public use data files. Data for visits to CHC-sampled non-physician clinicians in 2006-2011 are available only in the NCHS Research Data Center.

Starting in 2012, the office-based component of NAMCS was split from the Community Health Center component. As a result, 2012 NAMCS web tables, Research Data Center files, and public use files only include visits to office-based physicians who were sampled from the master files of the American Medical Association and the American Osteopathic Association. If any of them saw patients in CHC locations, the CHC visits were excluded.

The new CHC public use micro-data file includes visits to CHC physicians and non-physician clinicians. Separating NAMCS data into files of office-based (i.e., no CHC panel physicians and no CHC visits) and CHC (CHC panel physicians and non-physician providers) data without any overlap allows NCHS to make more of the data available to researchers and allows for combination of files without duplication. But, for this reason, it is important to recognize two important points.

First, data from the 2012 office-based component of NAMCS are not strictly comparable with data from 2006-2011, when physicians who were sampled in the CHC stratum were included in the public files. Also, prior to 2006, (i.e. before CHCs were sampled as a separate stratum), physicians who were sampled from the master files of the American Medical Association or American Osteopathic Association but who saw patients in CHCs were not excluded nor were their CHC visits excluded from survey eligibility. For that reason, in all previous years, it is possible to have at least some (albeit generally a very small percentage of) CHC visits in the data. This is not the case beginning in 2012 when there are no CHC visits on the NAMCS public use file. To compare 2012 data with previous years of NAMCS data, it is necessary to restrict one's analysis to non-CHC visits prior to 2012. This is explained more fully in the 2012 NAMCS Public Use Data File Documentation.

But more importantly for users of the NAMCS CHC data file, the 2012 CHC data are not directly comparable with CHC data included in the 2006-2011 NAMCS public use files. The most obvious reason for that is the 2006-2011 NAMCS data only include physician visits at CHCs; if non-physician clinicians were also sampled, those visits were not included on the public use file. To include them, one must submit a proposal to the NCHS Research Data Center and fees are charged. Also to be kept in mind is the change in sampling design for 2012, both geographically and administratively, as described elsewhere in this documentation,

For example, the estimated number of CHC visits from the 2012 NAMCS CHC Public Use File is 65.3 million. Of this number, 40.7 million visits were to physicians, the rest were to non-physician clinicians. But non-physician clinicians were not included in the 2011 NAMCS Public Use File. The total number of CHC visits to physicians in 2011 was estimated at 25.5 million. Adding the estimate for non-physician clinician visits in 2011, the total rises to 39.7 million. Since researchers using public data only have access to CHC physician visits prior to 2012, the better comparison for them when trending is to select the physician visits from the 2012 file.

One difference noted between 2011 and 2012 was the increase in CHC visits in non-metropolitan statistical areas (MSA). Looking at the full file across both years (physicians and non-physician clinicians), the number of non-MSA visits increased from 16.8% in 2011 to 26.7% in 2012. Using physician visits only, the corresponding figures were 18.8% and 22.9%. The difference is even more striking when comparing non-physician clinician visits across the two years (from 13.2% to 32.8%). These changes may be related to the shift in sampling design from a sample clustered in geographic PSUs to a list sample of CHC facilities. The potential differences between CHC visits to physicians and to non-physician clinicians should be taken into account when analyzing CHC data in general. Combining the data may mask important differences between the two provider groups.

For 2012, estimates of visits to all physicians (traditional NAMCS physicians and physicians sampled within the stratum of CHCs) can be derived by combining physician data from the 2012 NAMCS CHC

public use micro-data file with the traditional 2012 NAMCS public use micro-data file available at: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Datasets/NAMCS. Physician visits can be selected from the NAMCS CHC file by using a conditional statement which limits records to those where SPECR< 96. Values of SPECR of 96, 97, or 98 indicate that a physician assistant, nurse practitioner, or nurse midwife was sampled, respectively.

Combining the 2012 NAMCS file with the 2012 NAMCS CHC file is made easier because both files are similar in file layout and variable list. Because the same automated Patient Record forms were used in both settings, most of the data items are also the same. Several variables pertaining to type of provider retain variable names from the 2012 traditional NAMCS file, but include additional information on type of sampled non-physician clinician (i.e., PHYSWT, SPECR_14, SPECCAT, and MDDO). New items available only on the CHC public use file are included at the end of the file and include type of CHC sampled provider (SMPROV), imputed time spent with non-physician clinician (TIMECHC), and the impute flag for time spent with non-physician clinician (TIMECHCFL).

C. Mode of Data Collection

As mentioned above, NAMCS implemented computer-assisted data collection starting in 2012. This replaced the traditional pen-and-paper mode of data collection used since 1973. With the new method, Field Representatives (FRs) from the U.S. Census Bureau used laptops containing an automated version of each survey instrument to 1) select a sample of CHC providers (up to 3 of any of the following: physician, physician assistant, nurse practitioner, or nurse midwife), 2) conduct the induction interview with the sampled provider or his/her representative; 3) determine which visits to sample; and 4) abstract and record data from medical charts. The automated survey instruments were operationalized for field use by the Census Bureau, based on specifications provided by NCHS.

The U.S. Census Bureau has acted as the NAMCS data collection field agent since 1989 and the geographic areas (primary sampling units) in which they collected NAMCS data had remained the same through 2011. With the adoption of the state-based list sample, many geographic areas were sampled for the first time.

While the proportion of records obtained through abstraction by Census FRs had been increasing over the years, the data collection mode in 2012 relied heavily (97.3 percent of records collected) on Census FR abstraction rather than office staff. While a similar web-based tool or a laptop containing the automated survey instrument was available for physicians who requested it, this was seldom used (2.7 percent of records). Sampling and abstraction conducted by Census FRs had become, for the first time, the preferred mode of data collection.

Because of the important changes in sampling design and data collection for the 2012 NAMCS, extensive work had been done to compare 2012 NAMCS estimates with data from previous years. These efforts are described in detail in the 2012 NAMCS Public Use Data File Documentation. Researchers using the CHC data may wish to take note of these findings as they analyze the CHC data, as both components (traditional and CHC) shared similar survey instruments and may have been impacted in similar ways.

Table of Contents

| | Page |
|------------------------------------------------------------------------------|---------|
| Abstract | 1 |
| Summary | |
| I. Description of the NAMCS Community Health Center Component | 7-23 |
| A. Introduction | 7 |
| B. Scope of the survey | 7 |
| C. Sampling frame and size of sample | 8 |
| D. Sample design | 8 |
| E. Population figures | 10 |
| F. Field activities | 11 |
| G. Data collection | 11 |
| H. Confidentiality | 12 |
| I. Data processing | 13 |
| J. Medical coding | 15 |
| K. Estimation procedures | 20 |
| L. Sampling errors | 21 |
| M. Patient visit weight | |
| N. Provider code and patient code | |
| O. Use of the provider-level weight | 22 |
| References | 23 |
| II. Codob cale and Dhynician Chanielty Liet | 04.404 |
| II. Codebook and Physician Specialty List | |
| A. Codebook | |
| B. Physician Specialty List | |
| C. AMA Specialties Regrouped into primary, medical, and surgical specialties | 102 |
| III. Marginal Data | 105-111 |
| A. Patient visits | |
| B. Drug mentions | |
| C. Provider estimates | |
| D. State estimates | |
| | |
| Appendixes | |
| Appendix I | |
| A. Relative standard errors | |
| B. 2012 NAMCS Patient Record Form - Instructions and definitions | 115 |
| C. Definitions of certain terms used in the NAMCS | |
| Appendix II | |
| A. Reason for Visit Classification | 118 |
| , a reacon to thoir oldomodion | |
| Appendix III | 118-202 |
| A. Generic codes and names in numeric order | 118 |
| B. Drug entry codes and names in numeric order | 146 |
| C. Multum Lexicon end-user license agreement | |
| D. Multum classification of therapeutic classes (drug categories) | 202 |

Table of Contents (cont.)

List of Tables

| | Pa | age |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| | Number of in-scope sample of community health center (CHC) service delivery sites in total sample, CHC response rates, number of sampled CHC providers and provider response rate, number of participating providers and participation rate by division and selected states: National Ambulatory Medical Care Survey, 2012 | |
| Table II. | U.S. population estimates used in computing annual visit rates for the National Ambulatory Medical Care Survey, by selected characteristics: July 1, 2012 | . 10 |
| Table III. | U.S. population estimates used in computing average annual visit rates for the National Ambulatory Medical Care Survey by ethnicity, age, race, and sex: July 1, 2012 | . 10 |

I. DESCRIPTION OF THE NATIONAL AMBULATORY MEDICAL CARE SURVEY COMMUNITY HEALTH CENTER COMPONENT

A. INTRODUCTION

This micro-data file contains the first publically available data on visits to community health centers (CHCs) as part of the 2012 National Ambulatory Medical Care Survey (NAMCS). NAMCS is a national probability sample survey of visits to office-based physicians and community health center providers conducted by the Division of Health Care Statistics, National Center for Health Statistics (NCHS). Data in this file must be weighted to produce national and state estimates that describe the utilization of CHC medical care services in the United States.

In 2012, a total of 34,698 Patient Record forms (PRFs) were received from CHC physicians and non-physician clinicians who participated in the CHC component of NAMCS. For a brief description of the survey design and data collection procedures pertaining to this component in particular, see below. A more detailed description of the overall 2012 NAMCS design, data collection procedures, and estimation process is <u>available</u>. Information on the origin of NAMCS and the previous design has been published (1,2).

Please note the following important points concerning analysis of NAMCS CHC data on this micro-data file:

► PATIENT VISIT WEIGHTS

Micro-data file users should be fully aware of the importance and proper use of the two "patient visit weights" – one for producing national, regional, and divisional estimates, and one for producing state-based estimates. These should not be used interchangeably, and state-based estimates will not sum to national estimates because only the 34 most populous states were sampled in 2012. Information about the patient visit weights is presented on page 21. If more information is needed, the staff of the Ambulatory and Hospital Care Statistics Branch can be consulted by calling (301) 458-4600 during regular working hours.

► RELIABILITY OF ESTIMATES

Users should also be aware of the reliability or unreliability of survey estimates, particularly smaller estimates. The National Center for Health Statistics considers an estimate to be reliable if it meets TWO conditions: it is based on at least 30 sample records and it has a relative standard error of 30 percent or less (i.e., the standard error is no more than 30 percent of the estimate). For more information, see Appendix I or contact the staff of the Ambulatory and Hospital Care Statistics Branch.

B. SCOPE OF THE SURVEY

The basic sampling unit for NAMCS CHCs is the provider-patient encounter or visit. In 2012, NAMCS included, in addition to the traditional sample of office-based physicians, a separate sample of CHC service delivery sites, based on information from the Health Resources and Services Administration and the Indian Health Service. From each sampled service delivery site, an additional sample of health care providers scheduled to see patients during the sample week was selected. Health care providers could include physicians as well as non-physician clinicians -- physician assistants, nurse practitioners, and nurse midwives. Visits to CHC physicians and non-physician clinicians are included in this 2012 public use micro-data file.

Types of contacts not included in the 2012 NAMCS CHC component were those made by telephone, those made outside the CHC site (for example, house calls), visits made in hospital settings, visits made in institutional settings by patients for whom the institution has primary responsibility over time (for example, nursing homes), and visits to CHCs made for administrative purposes only (for example, to leave a specimen, pay a bill, or pick up insurance forms).

C. SAMPLING FRAME AND SIZE OF SAMPLE

The 2012 NAMCS CHC sampling frame was a list of Federally Qualified Health Center (FQHC) service delivery sites from the Health Resources and Services Administration's Bureau of Primary Health Care and the Indian Health Service. Three types of CHCs were eligible for NAMCS: CHCs that received Public Health Service Act, Section 330 funding, CHCs that applied for Section 330 funding but were not funded (also called "Look-alikes"), and urban Indian Health service outpatient clinics. Each participating CHC site provided a list of physicians and non-physician clinicians scheduled to see patients during the reporting period. This list became the frame for the selection of physicians and non-physician clinicians at the CHC site (see below for more details). All CHC physicians and non-physician clinicians were eligible to be sampled.

The 2012 NAMCS sample included 2,008 CHC service delivery sites. Of the 1,300 in-scope CHC service delivery sites, 1,057 participated, yielding an unweighted response rate of 81.3 percent (80.5 percent, weighted). A total of 2,279 providers who were scheduled to see patients during the sample week were selected from the CHC service delivery sites. Of these, 1,570 participated. Data were collected for 34,698 visits, either by Census Field Representative abstraction (33,772 visits) or by providers/CHC staff (926 visits). In either case, an automated tool was used which replaced the traditional paper Patient Record Form (PRF). For the sake of simplicity, the abstracted records will continue to be described as PRFs in the survey documentation.

A total of 171 providers saw no patients during their assigned reporting period because of vacations, illness, or other reasons for being temporarily not in practice and hence did not provide any PRFs. Of the 1,752 providers for whom PRFs were abstracted, 1,399 participated fully or adequately (i.e. at least half of the PRFs expected, based on the total number of visits during the reporting week, were submitted), and 353 participated minimally (i.e., fewer than half of the expected PRFs were submitted). The unweighted provider visit response rate was 68.9 percent (69.9 percent, weighted), based on the number of full responders and those who saw no patients during their sample week. The overall unweighted two-stage sampling response rate was 56.0 percent (56.2 percent, weighted). Response rates are shown in Table 1.

D. SAMPLE DESIGN

For the first stage, sampling (hard) strata were defined by Census division, and the 34 most populous states. The 34 most populous states were targeted for individual visit estimation. These include California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Michigan, New Jersey, Georgia, North Carolina, Virginia, Washington, Massachusetts, Indiana, Arizona, Tennessee, Missouri, Maryland, Wisconsin, Minnesota, Colorado, Alabama, South Carolina, Louisiana, Kentucky, Oregon, Oklahoma, Connecticut, Iowa, Mississippi, Arkansas, Kansas, and Utah. The remaining 16 states and the District of Columbia were grouped according to their U.S. Census Bureau divisions into five larger areas called 'division remainders'. These are composed of Maine, New Hampshire, Rhode Island, and Vermont from the New England Division; Nebraska, North Dakota, and South Dakota from the West North Central Division; Delaware, the District of Columbia, and West Virginia from the South Atlantic Division; Idaho, New Mexico, Montana, Nevada, and Wyoming from the Mountain Division; and Alaska and Hawaii from the Pacific Division. There are nine Census Bureau Divisions in all. All states were included separately

Table 1. Number of in-scope sample of community health center (CHC) service delivery sites in total sample, CHC response rates, number of sampled CHC providers and provider response rate, number of participating providers and participation rate by division and selected states: National Ambulatory Medical Care Survey, 2012

| Tenel (2,000 | Division/State | CHC service delivery sites sampled(1) | In-scope CHC service delivery sites | Partici- pating CHC service delivery sites | CHC service delivery site response rate: unweighted (weighted) | In-scope CHC providers | Responding CHC providers(2) | CHC provider response rate: unweighted (weighted) | Two-stage sample response rate: unweighted (weighted) (3) | Partici- pating CHC providers(4) | Two-stage sample participation rate: unweighted(5) |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------------------------------------------|-------------------------------------------------|-----------------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------|-----------------------------------|---------------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------|----------------------------------------------------------------|
| CT | | | | | | | | | | | 68.6 |
| CT 5 5 25 18 72.0172.0 36 2 3 63.0172.3 50.0151.4 31 MA | | | | | | | | | | | |
| Mar. | New England | | | | | | | | | | |
| MA | | | | | | | | | | | |
| Middle Atlantic | | | | | | | | | | | 62.0 |
| Middle Atlantic NS2 | | | | | | | | | | | 70.3 |
| NT | ME,NH,RI,VT | 27 | 21 | 15 | 71.4(71.4) | 32 | 24 | 75.0(74.8) | 53.6(53.4) | 27 | 60.3 |
| NT | Middle Atlantic | | | | | | | | | | |
| NY | | | | | | | | | | | |
| PA | NJ | 54 | 37 | 32 | 86.5(86.5) | 73 | 51 | 69.9(72.9) | 60.4(63.0) | 65 | 77.0 |
| East North Central II. 55 | NY | 54 | 33 | 21 | 63.6(63.6) | 47 | 28 | 59.6(58.2) | 37.9(37.0) | 38 | 51.5 |
| TL | PA | 54 | 45 | 35 | 77.8(77.8) | 79 | 49 | 62.0(57.3) | 48.2(44.5) | 63 | 62.0 |
| IL | | | | | | | | | | | |
| ME | East North Central | | | | - | | | | | | |
| ME | тт | | 25 | | 90 0/90 0 | 20 | 2.1 | 96 1/72 01 | 69 9/50 0 | 20 | 71 1 |
| ME | | | | | | | | | | | 71.1 |
| OK 54 41 33 80.5(80.5) 81 60 74.1(76.8) 94.4(92.3) 13 MEX 56 21 17 81.0(81.0) 42 23 54.8(27.5) 84.3(32.3) 31 Mext North Central 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>78.5</td></th<> | | | | | | | | | | | 78.5 |
| Met North Central | | | | | | | | | | | 72.5 |
| IA | | | | | | | | | | | 59.8 |
| IA | | | | | | | | | | | |
| KS 46 31 31 0) 65 47 72.3(78.5) 72.3(78.5) 55 MN 54 40 34 85.0(85.0) 62 50.80.6(85.7) 68.5(72.9) 56 MO 54 30 21 70.0(70.0) 46 33 71.7(77.2) 50.2(54.1) 39 NE, D, ND 19 12 11 91.7(91.7) 26 17 65.4(73.3) 59.9(67.2) 22 South Atlantic 11 12 11 91.7(91.7) 26 17 65.4(73.3) 59.9(67.2) 22 South Atlantic 15 28 24 85.7(85.7) 36 45 77.6(76.5) 66.5(65.5) 51 GA 34 38 31 81.7(85.7) 53 40 75.5(79.2) 61.6(61.6) 44 MD 54 35 28 80.7(85.7) 63 35.5(64.9.2) 77.4(76.2) 48 56.9(1.0) 51 49 49.10(1.0) 51 | West North Central | | | | | | | | | | |
| KS 46 31 31 0) 65 47 72.3(78.5) 72.3(78.5) 55 MN 54 40 34 85.0(85.0) 62 50.80.6(85.7) 68.5(72.9) 56 MO 54 30 21 70.0(70.0) 46 33 71.7(77.2) 50.2(54.1) 39 NE, D, ND 19 12 11 91.7(91.7) 26 17 65.4(73.3) 59.9(67.2) 22 South Atlantic 11 12 11 91.7(91.7) 26 17 65.4(73.3) 59.9(67.2) 22 South Atlantic 15 28 24 85.7(85.7) 36 45 77.6(76.5) 66.5(65.5) 51 GA 34 38 31 81.7(85.7) 53 40 75.5(79.2) 61.6(61.6) 44 MD 54 35 28 80.7(85.7) 63 35.5(64.9.2) 77.4(76.2) 48 56.9(1.0) 51 49 49.10(1.0) 51 | | | | | | | | | | | |
| MN | | | | | | | | | | | 98.1 |
| NO NE.SD.ND 19 12 11 91.7(91.7) 26 17 65.4(73.3) 59.2(54.1) 39 NE.SD.ND 19 12 11 91.7(91.7) 26 17 65.4(73.3) 59.9(67.2) 22 NE.SD.ND 19 12 11 91.7(91.7) 26 17 65.4(73.3) 59.9(67.2) 22 NE.SD.ND 19 12 11 91.7(91.7) 26 17 65.4(73.3) 59.9(67.2) 22 NE.SD.ND 19 12 NE. | | | | | | | | | | | 84.6 |
| Net South Central AL South Atlantic Rest South Central AR South Atlantic Rest South Central AR AR AR AR AR AR AR AR AR A | | | | | | | | | | | 76.8 59.3 |
| South Atlantic FL 54 28 24 85.7(85.7) 58 45 77.6(76.5) 66.5(65.5) 51 GA 54 38 31 81.6(81.6) 53 40 75.5(79.2) 61.6(64.6) 44 MD 54 42 36 85.7(85.7) 63 35 55.6(49.2) 47.6(42.2) 48 MD 54 42 36 85.7(85.7) 63 35 55.6(49.2) 47.6(42.2) 48 MD 54 42 36 85.7(85.7) 63 35 55.6(49.2) 47.6(42.2) 48 MD 54 35 27 77.1(77.1) 61 36 59.0(79.4) 45.5(54.3) 55 SC 54 35 28 80.0(80.0) 55 46 83.6(76.3) 66.9(61.0) 51 VA 54 33 30 90.9(90.9) 75 49 65.3(60.9) 89.4(55.4) 60 MV,DE,DC 54 28 20 71.4(71.4) 42 19 45.2(61.1) 32.3(43.7) 29 East South Central AL 54 39 32 82.1(82.1) 51 26 51.0(64.4) 41.8(52.9) 40 KY 54 38 26 68.4(68.4) 55 18 32.7(27.9) 22.4(19.1) 26 MS 54 37 31 83.8(83.8) 54 52 96.3(98.0) 80.7(82.1) 53 TN 54 34 27 79.4(79.4) 53 30 56.6(61.6) 45.0(48.9) 46 West South Central AR 54 47 28 59.6(59.6) 50 35 70.0(71.7) 41.7(42.7) 41 LA 54 44 37 84.1(84.1) 80 51 63.8(56.4) 53.6(47.4) 59 OK 54 36 35 97.2(97.2) 74 55 71.4(68.0) 54.9(52.3) 66 TX 54 39 30 76.9(76.9) 77 55 71.4(68.0) 54.9(52.3) 66 CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 72 MOUNTAIN 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | | | | | | | | | | | 77.6 |
| FL 54 28 24 85.7(85.7) 58 45 77.6(76.5) 66.5(65.5) 51 GA 54 38 33 81.6(81.6) 53 40 75.5(79.2) 61.6(64.6) 44 MD 54 42 36 85.7(85.7) 62 35 55.6(49.2) 47.6(42.2) 48 NC 54 35 27 77.1(77.1) 61 36 59.0(70.4) 45.5(84.3) 55 SC 54 54 35 28 80.0(80.0) 55 46 83.6(76.3) 66.9(61.0) 51 VA 54 33 30 90.9(90.9) 75 49 65.3(60.9) 59.4(55.4) 60 W.DE,DC 54 28 20 71.4(71.4) 42 19 45.2(61.1) 32.3(43.7) 29 East South Central | ,, | | | | , , , , , , , , , , , , , , , , , , , , | | | | | | |
| GA | South Atlantic | | | | | | | | | | |
| GA | | | | | | | | | | | |
| MD 54 42 36 85.7(85.7) 63 35 55.6(49.2) 47.6(42.2) 48 NC 54 35 27 77.1(77.1) 61 36 59.0(70.4) 45.5(54.3) 55 SC 54 35 28 80.0(80.0) 55 46 83.6(76.3) 66.9(61.0) 51 VA 54 35 28 80.0(80.0) 55 46 83.6(76.3) 66.9(61.0) 51 VA 54 35 28 80.0(80.0) 55 46 83.6(76.3) 66.9(61.0) 51 VA 54 38 30 90.9(90.9) 75 49 65.3(60.9) 59.4(55.4) 60 WV.DE.DC 54 28 20 71.4(71.4) 42 19 45.2(61.1) 32.3(43.7) 29 East South Central | FL | | | | | | 45 | | | | 75.4 |
| NC | | | | | | | - | | | | 67.7 |
| SC 54 35 28 80.0(80.0) 55 46 83.6(76.3) 66.9(61.0) 51 VA 54 33 30 90.9(90.9) 75 49 65.3(60.9) 59.4(55.4) 60 WV,DE,DC 54 28 20 71.4(71.4) 42 19 45.2(61.1) 32.3(43.7) 29 East South Central 38 28 21(82.1) 51 26 51.0(64.4) 41.8(52.9) 40 KY 54 38 26 68.4(68.4) 55 18 32.7(27.9) 22.4(19.1) 26 MS 54 38 26 68.4(68.4) 55 18 32.7(27.9) 22.4(19.1) 26 MS 54 37 31 83.8(83.8) 54 52 96.3(98.0) 80.7(82.1) 53 TN 54 34 27 79.4(79.4) 53 30 56.6(61.6) 45.0(48.9) 46 West South Central 42 28 59. | | | | | | | | | | | 65.3 |
| VA 54 33 30 90.9(90.9) 75 49 65.3(60.9) 59.4(55.4) 60 WV.DE,DC 54 28 20 71.4(71.4) 42 19 45.2(61.1) 32.3(43.7) 29 East South Central AL 54 39 32 82.1(82.1) 51 26 51.0(64.4) 41.8(52.9) 40 KY 54 38 26 68.4(68.4) 55 18 32.7(27.9) 22.4(19.1) 26 MS 54 37 31 83.8(83.8) 54 52 96.3(98.0) 80.7(82.1) 53 TN 54 34 27 79.4(79.4) 53 30 56.6(61.6) 45.0(48.9) 46 West South Central AR 54 47 28 59.6(59.6) 50 35 70.0(71.7) 41.7(42.7) 41 LA 54 44 37 84.1(84.1) 80 51 63.8(56.4) 53.6(47.4) 59 OK 54 36 35 97.2(97.2) 74 54 73.0(77.1) 70.9(75.0) 60 TX 54 43 38 88.4(88.4) 89 62 69.7(72.4) 61.6(64.0) 72 Mountain AZ 54 39 30 76.9(76.9) 77 55 71.4(68.0) 54.9(52.3) 66 CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV.NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | | | | | | | | | | | 69.6 74.2 |
| WV,DE,DC | | | | | | | | | | | 74.2 |
| East South Central AL 54 39 32 82.1(82.1) 51 26 51.0(64.4) 41.8(52.9) 40 KY 54 38 26 68.4(68.4) 55 18 32.7(27.9) 22.4(19.1) 26 MS 54 37 31 83.8(83.8) 54 52 96.3(98.0) 80.7(82.1) 53 TN 54 34 27 79.4(79.4) 53 30 56.6(61.6) 45.0(48.9) 46 West South Central AR 54 47 28 59.6(59.6) 50 35 70.0(71.7) 41.7(42.7) 41 LA 54 44 37 84.1(84.1) 80 51 63.8(56.4) 53.6(47.4) 59 OK 54 36 35 97.2(97.2) 74 54 73.0(77.1) 70.9(75.0) 60 TX 54 43 38 88.4(88.4) 89 62 69.7(72.4) 61.6(64.0) 72 Mountain AZ 54 39 30 76.9(76.9) 77 55 71.4(68.0) 54.9(52.3) 66 CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV,NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | | | | | | | | | | - | |
| AL 54 39 32 82.1(82.1) 51 26 51.0(64.4) 41.8(52.9) 40 KY 54 38 26 68.4(68.4) 55 18 32.7(27.9) 22.4(19.1) 26 MS 54 37 31 83.8(83.8) 54 52 96.3(98.0) 80.7(82.1) 53 TN 54 34 27 79.4(79.4) 53 30 56.6(61.6) 45.0(48.9) 46 West South Central | , | | | | | | | , | , | | |
| KY 54 38 26 68.4(68.4) 55 18 32.7(27.9) 22.4(19.1) 26 MS 54 37 31 83.8(83.8) 54 52 96.3(98.0) 80.7(82.1) 53 TN 54 34 27 79.4(79.4) 53 30 56.6(61.6) 45.0(48.9) 46 West South Central 4 47 28 59.6(59.6) 50 35 70.0(71.7) 41.7(42.7) 41 LA 54 47 28 59.6(59.6) 50 35 70.0(71.7) 41.7(42.7) 41 LA 54 47 28 59.6(59.6) 50 35 70.0(71.7) 41.7(42.7) 41 LA 54 44 37 84.1(84.1) 80 51 63.8(56.4) 53.6(47.4) 59 OK 54 43 38 88.4(88.4) 89 62 69.7(72.4) 61.6(64.0) 72 Mountain 7 7 | East South Central | | | | | | | | | | |
| KY 54 38 26 68.4(68.4) 55 18 32.7(27.9) 22.4(19.1) 26 MS 54 37 31 83.8(83.8) 54 52 96.3(98.0) 80.7(82.1) 53 TN 54 34 27 79.4(79.4) 53 30 56.6(61.6) 45.0(48.9) 46 West South Central 4 47 28 59.6(59.6) 50 35 70.0(71.7) 41.7(42.7) 41 LA 54 47 28 59.6(59.6) 50 35 70.0(71.7) 41.7(42.7) 41 LA 54 47 28 59.6(59.6) 50 35 70.0(71.7) 41.7(42.7) 41 LA 54 44 37 84.1(84.1) 80 51 63.8(56.4) 53.6(47.4) 59 OK 54 43 38 88.4(88.4) 89 62 69.7(72.4) 61.6(64.0) 72 Mountain 7 7 | | | | | | | | | | | |
| MS 54 37 31 83.8(83.8) 54 52 96.3(98.0) 80.7(82.1) 53 TN 54 34 27 79.4(79.4) 53 30 56.6(61.6) 45.0(48.9) 46 West South Central AR 54 47 28 59.6(59.6) 50 35 70.0(71.7) 41.7(42.7) 41 LA 54 44 37 84.1(84.1) 80 51 63.8(56.4) 53.6(47.4) 59 OK 54 36 35 97.2(97.2) 74 54 73.0(77.1) 70.9(75.0) 60 TX 54 43 38 88.4(88.4) 89 62 69.7(72.4) 61.6(64.0) 72 Mountain AZ 54 39 30 76.9(76.9) 77 55 71.4(68.0) 54.9(52.3) 66 CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV.NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | | | | | | | | | | | 64.4 |
| TN 54 34 27 79.4(79.4) 53 30 56.6(61.6) 45.0(48.9) 46 West South Central AR 54 47 28 59.6(59.6) 50 35 70.0(71.7) 41.7(42.7) 41 LA 54 44 37 84.1(84.1) 80 51 63.8(56.4) 53.6(47.4) 59 OK 54 36 35 97.2(97.2) 74 54 73.0(77.1) 70.9(75.0) 60 TX 54 43 38 88.4(88.4) 89 62 69.7(72.4) 61.6(64.0) 72 Mountain AZ 54 39 30 76.9(76.9) 77 55 71.4(68.0) 54.9(52.3) 66 CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV,NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | | | | | | | | | | | 32.3 |
| West South Central AR 54 47 28 59.6(59.6) 50 35 70.0(71.7) 41.7(42.7) 41 LA 54 44 37 84.1(84.1) 80 51 63.8(56.4) 53.6(47.4) 59 OK 54 36 35 97.2(97.2) 74 54 73.0(77.1) 70.9(75.0) 60 TX 54 43 38 88.4(88.4) 89 62 69.7(72.4) 61.6(64.0) 72 Mountain AZ 54 39 30 76.9(76.9) 77 55 71.4(68.0) 54.9(52.3) 66 CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV,NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | | | | | | | | | | | 82.2 |
| AR 54 47 28 59.6(59.6) 50 35 70.0(71.7) 41.7(42.7) 41 LA 54 44 37 84.1(84.1) 80 51 63.8(56.4) 53.6(47.4) 59 OK 54 36 35 97.2(97.2) 74 54 73.0(77.1) 70.9(75.0) 60 TX 54 43 38 88.4(88.4) 89 62 69.7(72.4) 61.6(64.0) 72 Mountain AZ 54 39 30 76.9(76.9) 77 55 71.4(68.0) 54.9(52.3) 66 CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV.NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | TN | 54 | 34 | 27 | 79.4(79.4) | 53 | 30 | 56.6(61.6) | 45.0(48.9) | 46 | 68.9 |
| AR 54 47 28 59.6(59.6) 50 35 70.0(71.7) 41.7(42.7) 41 LA 54 44 37 84.1(84.1) 80 51 63.8(56.4) 53.6(47.4) 59 OK 54 36 35 97.2(97.2) 74 54 73.0(77.1) 70.9(75.0) 60 TX 54 43 38 88.4(88.4) 89 62 69.7(72.4) 61.6(64.0) 72 Mountain AZ 54 39 30 76.9(76.9) 77 55 71.4(68.0) 54.9(52.3) 66 CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV.NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | West South Central | | | | | | | | | | |
| LA 54 44 37 84.1(84.1) 80 51 63.8(56.4) 53.6(47.4) 59 OK 54 36 35 97.2(97.2) 74 54 73.0(77.1) 70.9(75.0) 60 TX 54 43 38 88.4(88.4) 89 62 69.7(72.4) 61.6(64.0) 72 Mountain AZ 54 39 30 76.9(76.9) 77 55 71.4(68.0) 54.9(52.3) 66 CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV,NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | Nebe boden central | | | | | | | | | | |
| OK 54 36 35 97.2(97.2) 74 54 73.0(77.1) 70.9(75.0) 60 TX 54 43 38 88.4(88.4) 89 62 69.7(72.4) 61.6(64.0) 72 Mountain AZ 54 39 30 76.9(76.9) 77 55 71.4(68.0) 54.9(52.3) 66 CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV,NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | AR | 54 | 47 | 28 | 59.6(59.6) | 50 | 35 | 70.0(71.7) | 41.7(42.7) | 41 | 48.9 |
| TX 54 43 38 88.4(88.4) 89 62 69.7(72.4) 61.6(64.0) 72 Mountain AZ 54 39 30 76.9(76.9) 77 55 71.4(68.0) 54.9(52.3) 66 CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV.NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | | | | 37 | 84.1(84.1) | | | | | | 62 |
| Mountain AZ 54 39 30 76.9(76.9) 77 55 71.4(68.0) 54.9(52.3) 66 CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV,NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | OK | 54 | 36 | 35 | 97.2(97.2) | 74 | 54 | 73.0(77.1) | 70.9(75.0) | 60 | 78.8 |
| AZ 54 39 30 76.9(76.9) 77 55 71.4(68.0) 54.9(52.3) 66 CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV,NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | TX | 54 | 43 | 38 | 88.4(88.4) | 89 | 62 | 69.7(72.4) | 61.6(64.0) | 72 | 71.5 |
| AZ 54 39 30 76.9(76.9) 77 55 71.4(68.0) 54.9(52.3) 66 CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV,NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | | | | | - | | | | | | |
| CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV,NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | Mountain | | | | | | | | | | |
| CO 54 24 19 79.2(79.2) 41 34 82.9(83.4) 65.7(66.0) 37 UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV,NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | A 7 | F A | 20 | 20 | 76 9/76 0 | 77 | | 71 4/69 01 | 54 9/52 21 | | 65.9 |
| UT 37 21 19 90.5(90.5) 41 35 85.4(90.0) 77.2(81.4) 39 NV,NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | | | | | | | | | | | |
| NV,NM,ID,MT,WY 43 32 26 81.3(86.6) 58 38 65.5(58.8) 53.2(51.0) 48 Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | | | | | | | | | | | |
| Pacific CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | | | | | | | | | | | |
| CA 53 43 36 83.7(83.7) 87 57 65.5(70.7) 54.9(59.2) 75 | | | | | | | | | | | |
| | Pacific | | | | | | | | | | |
| | | | | | | | | | | | |
| OR 54 30 26 86.7(86.7) 64 27 42.2(50.8) 36.6(44.1) 44 | | | | | | | | | | | |
| WA 54 33 30 90.(90.9) 79 65 82.3(83.6) 74.8(76.0) 76 | | | | | | | | | | | |

NOTE: Division and State represent location of sampled CHC delivery site. A total of 34 states were targeted for separate estimation. States not targeted for separate estimation were grouped into 'division remainders' and sampled accordingly.

⁽¹⁾ The survey sampling frame consists of Federally Qualified Health Center (FQHC) service delivery sites included in lists obtained from the Health Resources and Services Administration's Bureau of Primary Health Care and the Indian Health Service.

(2) Responding CHC providers are providers for whom at least one-half of their expected number of Patient Record forms were completed (full responders) and also include providers who saw no patients at their sample CHC site during their that site's sampled week.

(3) The two-stage sample response rate is the product of the CHC service delivery site response rate multiplied by the CHC provider response rate.

(4) Participating CHC providers are providers for whom at least one Patient Record form was completed (full and minimal responders) and also include providers who saw no patients at their sample CHC site during their that site's sample week.

(5) Two-stage sample participation rate is the number of participating CHC providers divided by number of in-scope CHC providers, multiplied by the CHC delivery site response rate.

from the remaining four Divisions (Middle Atlantic, East North Central, East South Central, and West South Central). Therefore, there are a total of 39 geographical areas composed of states and division remainders which make up the United States.

For the first stage sample, CHC sites were given a random number and assigned to their respective sampling strata. Within each sampling stratum, a systematic random sample of sites was selected from lists in which the sites were sorted by CHC type (urban Indian Health Service outpatient clinics, 330 grantees, and "look-alikes") and within CHC type, by the random numbers assigned to them. Sampled sites that were known in advance to be "migrant" (sites that were open only in harvest season to serve migrants who work in the harvests) were randomly assigned to weeks in the seasons (primarily July through September) when they were scheduled to be open for business. The remaining sampled CHC sites were divided into 52 random subsamples of approximately equal size, and each subsample was randomly assigned to 1 of the 52 weeks in the survey year. Within each sampled site, a systematic random sample of up to three providers (physicians, physician assistants, nurse practitioners, or nurse midwives) was selected from among those who were expected to see visits at the site during the site's assigned week,

The final stage consisted of selecting a systematic random sample of patient visits seen by the sampled provider at the site during the assigned week. For the first time, this sampling was mainly conducted by Census Field Representatives, although providers or their service sites could select the samples, if desired. The sampling rate varied for this final step from a 100-percent sample for providers expected to see few visits to a 10-percent sample for providers expected to see very large numbers of visits during the CHC site's assigned survey week as determined in a presurvey interview. The method by which the sampling rate was determined is available (4).

E. POPULATION FIGURES

The base population used in computing annual visit rates is presented in <u>tables 2-5</u> of the 2012 NAMCS Public Use Data File Documentation. The denominators used in calculating 2012 visit rates for age, sex, race, ethnicity, and geographic region are Census 2010-based postcensal estimates of the civilian noninstitutional population of the United States. The population estimates are special tabulations developed by the Population Division, U.S. Census Bureau, from the July 1, 2012 set of state population estimates by age, sex, race, and ethnicity.

Population estimates by metropolitan statistical area (MSA) status are based on estimates of the civilian noninstitutionalized population from the 2012 National Health Interview Survey (NHIS), National Center for Health Statistics, compiled according to the December 2009 Office of Management and Budget definition of core-based statistical areas. See https://www.census.gov/programs-surveys/metro-micro.html for more information about MSA definitions.

Estimates of visit rates for metropolitan and non-metropolitan statistical areas from 2003-2012 may differ somewhat from those reported in 2002 and previous years because of methodological differences in how the denominators were calculated. In survey years 1995-2005, the NHIS used metropolitan areas as defined by the Office of Management and Budget, June 30, 1993. In survey years 1994-2002, the NHIS used 1990-based Census estimates as controls. Because NAMCS used Census 2000-based population estimates beginning in 2001, adjustments needed to be made to the MSA figures obtained from the NHIS in 2001 and 2002. For 2010, 2011, and 2012, special tabulations were obtained from the Office of Analysis and Epidemiology, NCHS, where each year of data was compiled according to the December 2009 OMB definition of core-based statistical areas. The 2010 NHIS estimates were further adjusted based on the 2010 population estimates obtained from the Census Bureau (which were based on Census 2000). For 2011 and 2012, the NHIS estimates were adjusted based on the 2011 and 2012 population estimates obtained from the Census Bureau (which were based on Census 2010).

Population estimates for race groups in the 2012 NAMCS are based on the 2010 U.S. Census in which respondents were able to indicate more than one race category. Since 2001, the denominators used for calculating race-specific visit rates in NAMCS reports reflect multiple-race reporting. Specific race denominators reflect persons with a single race identification, and a separate denominator is available for persons with more than one race designation.

Data indicate that multiple races are recorded for a patient less frequently in medical records compared to their numbers in the general population. The 2012 population estimates indicate that 2.4 percent of the total population identify themselves as being of multiple races. In contrast, multiple race patients account for just 0.5 percent of weighted NAMCS CHC visits (based on known race data only). (REMINDER: Since the 2009 NAMCS, NAMCS data only include imputed values for the race categories White, Black, and Other; see 2009 or 2010 NAMCS Public Use File Documentation Summary of Changes for more information.) This is roughly the same percentage reported in the 2010 NAMCS and earlier years. The difference may exist because abstractors are less likely to know and record the multiple race preference of the patient. It suggests that the race population rates calculated for 2012 may be slight overestimates for the single race categories and slight underestimates for the multiple race category, but it should be kept in mind that race data are missing for approximately one-fifth of 2012 NAMCS CHC records overall.

F. FIELD ACTIVITIES

The first contact with the sampled CHC service delivery site is through a letter from the Director, NCHS. After the CHC site administrator receives the introductory letter (along with letters from professional medical societies that endorse NAMCS), the Field Representative (FR) telephones the CHC site administrator to establish basic eligibility and to schedule an appointment. At the appointment, the FR explains the survey to the CHC site administrator and to any staff who may be involved in creating a frame of the CHC site's providers, and selecting a sample of providers. The decision is also made regarding who will perform the visit sampling and data abstraction. Also at the initial visit, the FR obtains the practice characteristics of the CHC service delivery site, including identifying physicians, physician assistants, nurse practitioners, and nurse midwives. If the CHC staff are performing data abstraction, the FR contacts the CHC site office just before, during and after the reporting week to remind them about the survey and to answer any questions that may arise. After abstraction has been completed, the provider is given a certificate of appreciation for her or his participation.

G. DATA COLLECTION

In 2012, NAMCS switched from its traditional paper and pencil mode of data collection to an automated survey tool. The adoption of computer-assisted data collection meant that most of the data collection and data processing systems developed over the years had to be redesigned. One of the first steps was the development of specifications, in conjunction with the U.S. Census Bureau, which detailed how each survey item would appear in the automated tool. This included wording, answer choices, variable length, skip patterns, and range checks. Numerous help screens were also created to provide field representatives with additional information to aid in data abstraction. Hard and soft edits were incorporated into the automated tool. Soft edits prompted field staff to double check a questionable entry but allowed them to proceed if the entry was thought to be correct, whereas hard edits resulted in strict range restrictions. Nevertheless, the first year of automated data collection was challenging as unforeseen problems arose related to various aspects of data collection and processing.

The automated survey tool was accessible either by Census laptop or by web portal. In past years, data collection for NAMCS was expected to be carried out by the physician (or in the case of CHCs, it could also be non-physician clinicians) or the health care provider's staff, but, over time, abstraction from medical charts by Census field representatives became the predominant mode. For 2012, Census FR abstraction using laptop computers and the automated instrument became the preferred mode for data collection. For providers who preferred to do their own data collection, a web portal containing a modified version of the automated tool was available, or a Census laptop could be left behind for provider use. In

2012, 97.3 percent of CHC sample records were obtained through Census FR abstraction, and 2.7 percent were obtained by physician/medical staff reporting.

CHC site staff were instructed to keep a daily listing of all patient visits for sample providers during the assigned reporting week using an arrival log, optional worksheet, or similar method. This list was the sampling frame to indicate the visits for which data were to be recorded. It was to include both scheduled and unscheduled patients, but not cancellations or no-shows. Visits were selected from the list either by Census FRs or medical staff using a random start and a predetermined sampling interval based on the provider's estimated visits for the week and the number of days the provider was expected to see patients that week. In this way, a systematic random sample of visits was obtained. The sampling procedures were designed so that about 30 electronic Patient Records would be completed during the assigned reporting week. This was intended to minimize the data collection workload and maintain equal reporting levels among sample providers regardless of the CHC site's visit volume.

Data for sampled visits were recorded on laptops using the automated survey tool which emulated the traditional survey instrument, the Patient Record form. The 2012 Patient Record "Sample Card" showing the data items included in the survey is available at the Ambulatory Health Care Data website: http://www.cdc.gov/nchs/ahcd/ahcd_survey_instruments.htm#namcs. Terms and definitions relating to the automated Patient Record are included in Appendix I.

H. CONFIDENTIALITY

In April 2003, the Privacy Rule of the Health Insurance Portability and Accountability Act (HIPAA) was implemented to establish minimum Federal standards for safeguarding the privacy of individually identifiable health information. No personally identifying information, such as patient's name or address or Social Security number, is collected in NAMCS. Data collection is authorized by Section 306 of the Public Health Service Act (Title 42, U.S. Code, 242k). All information collected is held in the strictest confidence according to law [Section 308(d) of the Public Health Service Act (42, U.S. Code, 242m(d))] and the Confidential Information Protection and Statistical Efficiency Act (Title 5 of PL 107-347). The NAMCS protocol has been approved by the NCHS Research Ethics Review Board annually starting in February 2003. Waivers of the requirements to obtain informed consent of patients and patient authorization for release of patient medical record data by health care providers were granted.

In the Spring of 2003, NAMCS implemented additional data collection procedures to help providers assure patient confidentiality. Census Bureau Field Representatives were trained on how the Privacy Rule allows providers to make disclosures of protected health information without patient authorization for public health purposes and for research that has been approved by a Research Ethics Review Board. Providers were encouraged to accept a data use agreement between themselves and CDC/NCHS, since the Privacy Rule allows providers to disclose limited data sets (i.e., data sets with no direct patient identifiers) for research and public health purposes if such an agreement exists.

Assurance of confidentiality was provided to all community health center providers according to Section 308 (d) of the Public Health Service Act (42 USC 242m). Strict procedures were utilized to prevent disclosure of NAMCS data. All information which could identify the physician was confidential and was seen only by persons engaged in NAMCS, and was not disclosed or released to others for any other purpose. Names or other identifying information for individual patients were not removed from the physician's office.

Prior to release of the public use data file, NCHS conducts extensive disclosure risk analysis to minimize the chance of any inadvertent disclosure. Based on research conducted by NCHS for 2012 NAMCS CHC sites, and because of the availability for the first time of state-level estimates, certain variables were either removed from the file altogether (urban-rural status of patient's ZIP code) or subject to masking in some cases (metropolitan statistical area status, and provider's diagnosis). Furthermore, outlier values for

certain variables (age, age of pregnant patient, height, weight, and number of past visits in last 12 months) were top coded in accordance with NCHS confidentiality requirements. Masking was performed in such a way to cause minimal impact on the data; data users who wish to use unmasked data can apply to the NCHS Research Data Center.

I. DATA PROCESSING

1. Edits

Once electronic data were collected by the Census Bureau, a number of steps were required for data processing. Specifications for checking, configuring, and transmitting the data files were developed by NCHS and applied by the Census Bureau. Data files were transmitted either to NCHS for further processing, or to SRA International, Durham, North Carolina. At NCHS, the data underwent multiple consistency checks and review of verbatim entries. SRA edited and coded verbatim entries which required medical coding (patient's reason for visit, provider's diagnosis, and procedures). For the first time, medication editing and coding were performed entirely at NCHS by the NAMCS Drug Database Coordinator.

2. Quality Control

All SRA medical coding and keying operations were subject to quality control procedures. The contractor randomly selected a 10 percent sample of records which were independently recoded and compared. Differences were adjudicated by a quality control supervisor with error rates reported to NCHS. Coding error rates for the 10 percent sample ranged between 0.3 and 1.0 percent. (It should be noted that the method of calculating error rates changed in 2012; in previous years, the error rate was calculated against the entire database rather than the 10 percent sample.)

3. Adjustments for Item Nonresponse

Unweighted item nonresponse rates exceeded 5.0 percent for the following data items:

Ethnicity - 17.9 percent

Race - 21.0 percent

Is female patient pregnant? – 15.3 percent of visits by females of childbearing age If pregnant, what is gestation week? – 23.9 percent of visits where pregnancy was reported Expected primary source of payment for this visit - recoded variable based on hierarchy - 8.6 percent Does patient use tobacco? – 17.7 percent

Is this injury/poisoning intentional or unintentional? – 34.9 percent of injury/poisoning related visits Are you the patient's primary care provider? – 15.6 percent

Was patient referred for this visit? – 24.6 percent of visits not made to patient's primary care provider How many past visits in last 12 months? – 12.8 percent of visits, 14.7 percent of visits by established patients

[Note: "Have your or anyone in your practice seen patient before?" (SENBEFOR) is imputed when missing, and, when this occurs, "Number of visits in past 12 months" (PASTVIS) is imputed together with it; this means that records can be imputed as SENBEFOR=No, in which case PASTVIS would be imputed to -7 or Not Applicable],

Asthma severity - 8.0 percent of visits where asthma was reported as a chronic condition Asthma control – 8.9 percent of visits where asthma was reported as a chronic condition Stage of patient's cancer – 82.1 percent of visits where cancer was reported Was biopsy provided? – 25.0 percent of visits with biopsy reported as either ordered or provided Was colonoscopy provided? – 25.3 percent of visits with colonoscopy reported as either ordered or provided

Was excision provided? – 67.1 percent of visits where excision was reported as either ordered or provided Was sigmoidoscopy provided? – 44.4 percent of visits where sigmoidoscopy was reported as either ordered or provided

Time spent with physician – 46.2 percent of visits where a physician was seen

Time spent with non-physician clinician (physician assistant nurse practitioner/nurse midwife) – 40.7 percent

When do you intend to first apply for 'Meaningful Use of Health IT' incentives – 15.7 percent of visits where plans to apply were reported

Does your practice have this computerized capability and how often is it used: providing standard order sets related to a particular condition or procedure? – 5.3 percent

If practice has computerized capability for viewing lab results, can the EHR/EMR automatically graph a specific patient's lab results over time – 11.7 percent

Does your practice have this computerized capability and how often is it used: viewing data on quality of care measures? – 8.8 percent

Does your practice have this computerized capability and how often is it used: reporting clinical quality measures to federal or state agencies (such as CMS or Medicaid)? – 11.8 percent

Does your practice have this computerized capability and how often is it used: generating lists of patients with particular health conditions? - 5.9 percent

Does your practice have this computerized capability and how often is it used: electronic reporting to immunization registries? - 6.1 percent

If practice shares any patient health information electronically (not fax) with other providers, including hospitals, ambulatory providers, or electronically (not fax) labs, do you share any of the previously mentioned types of information (lab results, imaging reports, patient problem lists, medication lists, medication allergy lists) using a Summary Care Record? – 13.7 percent

Roughly, what percent of your patient care revenue comes from:

Medicare – 20.1 percent Medicaid – 19.7 percent Private Insurance – 19.9 percent Patient Payments – 19.9 percent Other – 20.0 percent

Roughly, what percentage of the patient care revenue received by this practice comes from managed care payments? - 25.9 percent

Roughly, what percent of your patient care revenue comes from each of the following methods of payment:

Fee-for-service – 32.8 percent Capitation – 36.1 percent Case rates – 36.2 percent Other – 36.1 percent

If currently accepting new patients into practice, which of the following types of payment do you accept:

Capitated private insurance – 8.4 percent

Non-capitated private insurance – 6.9 percent

Private insurance – 6.5 percent

Workers compensation – 6.3 percent

No charge - 7.2 percent

Denominators for the above rates were adjusted to account for skip patterns on the data collection forms. For example, only visits to physicians who accepted new patients were included in the calculation of whether the physician accepted new patients with Medicaid, etc. If there is physician nonresponse to the

initial item and this is also taken into account, nonresponse rates for the secondary item will be somewhat higher.

Some missing data items were imputed by randomly assigning a value from a Patient Record form with similar characteristics. Imputations, in general, were based on physician specialty, geographic region, and 3-digit ICD-9-CM codes for primary diagnosis. Race and ethnicity were imputed using a model-based, single, sequential regression imputation method. The model for imputing race and ethnicity included the following: Census variables for ZIP code level race and ethnicity population estimates, duration of visit, patient age, patient sex, whether the visit occurred in an MSA, physician specialty recode, whether the visit included hypertension as a current diagnosis/chronic condition, diagnosis group, major reason for visit, and an indicator for patient ZIP code or provider ZIP (the latter was used for the Census variables if patient ZIP was not available). Also in 2012, time spent with physician and time spent with non-physician clinicians were each imputed using a similar model-based, single, sequential regression imputation method.

The following variables were imputed: birth year (0.1 percent), sex (0.7 percent), ethnicity (17.9 percent), race (21.0 percent), have you or anyone in your practice seen patient before? (1.5 percent), if yes, how many past visits in last 12 months? (14.7 percent of visits by established patients), time spent with physician (40.7 percent of visits where a physician was seen), and time spent with non-physician clinician (46.2 percent of visits seen by a physician assistant, nurse practitioner, or nurse midwife). Blank or otherwise missing responses are so noted in the data.

J. MEDICAL CODING

The Patient Record form contains several medical items which use three separate coding systems. As stated previously, the following items -- patient's reason for visit, physician's diagnosis, and procedures -- were transmitted to SRA International, Inc., Durham, North Carolina for processing. The medication item was coded by the NAMCS Drug Database Coordinator. These items and their coding systems are described briefly below.

1. Patient's Complaint(s), Symptoms(s) or Other Reason(s) for this Visit: Information on patient's reason for visit was collected in the automated Patient Record and coded according to A Reason for Visit Classification for Ambulatory Care (RVC) (5). The updated classification is available (6), and the list of codes is shown in Appendix II. The classification was updated to incorporate several new codes as well as changes to existing codes. The system continues to utilize a modular structure. The digits 1 through 8 precede the 3-digit RVC codes to identify the various modules as follows:

| <u>Prefix</u> | <u>Module</u> |
|--------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| "1" = "2" = "3" = "4" = "5" = "6" = "7" = "8" = "-9" = | Symptom module Disease module Diagnostic, screening, and preventive module Treatment module Injuries and adverse effects module Test results module Administrative module Uncodable entries Special code = blank |

Up to three reasons for visit were coded from the reason for visit item in sequence; coding instructions for this item are contained in the Reason for Visit Classification and Coding Manual (6).

2. <u>Provider's Diagnosis for this Visit</u>: Diagnostic information on the automated Patient Record was coded according to the <u>International Classification of Diseases</u>, <u>9th Revision</u>, <u>Clinical Modification</u> (ICD-9-CM) (7). The ICD-9-CM codes are provided in two formats, character and numeric. Please see page 34 in the Codebook section for information on the background, purpose, and appearance of the numeric recodes. The rest of this paragraph describes the format of the character version.

The character version ICD-9-CM codes are not prefixed or zerofilled on the data file. For example, 38100 = 381.00 = Acute nonsuppurative otitis media, unspecified.

There is an implied decimal between the third and fourth digits. For inapplicable fourth or fifth digits, a dash has been inserted.

For example, 4011- = 401.1 = Essential hypertension, benign.

Supplementary classification codes are not prefixed or zerofilled.

For example, V700- = V70.0 = Routine general medical examination at a health care facility

In addition to the diagnostic codes from the ICD-9-CM the following unique codes in the diagnostic fields were developed by AHCSB staff:

V990- = noncodable diagnosis, insufficient information for coding, illegible diagnosis V991- = left before being seen, patient walked out, not seen by doctor, left against

medical advice

V992- = transferred to another facility, sent to see specialist

V993- = HMO will not authorize treatment

V997- = entry of "none," "no diagnosis," "no disease," "healthy"

-9 = blank

A maximum of three diagnoses were coded in sequence. Coding instructions concerning diagnoses are contained in the NAMCS Coding Notebook, updated annually (8).

3. <u>Services</u>: The "Services" item allowed for the coding of up to 9 open-ended fields for procedures, which were classified and coded by SRA International, Durham, NC, according to the <u>International</u> Classification of Diseases (ICD-9-CM), using the procedure codes in Volume III.

NOTE: The "Services" item in the automated Patient Record combines the previously separate NAMCS items of "Diagnostic/Screening Services", "Non-Medication Treatment" and "Health Education". As stated earlier, it uses a checkbox format under the sub-headings of Examinations, Blood Tests, Imaging, Other Tests and Procedures, Non-Medication Treatment, and Health Education/Counseling. It also allows for the coding of up to 9 open-ended fields in the last section, Other Services Not Listed. The combined format for all of these items was already being used in the data files beginning with 2009 data, achieved through data processing methods as explained in the 2009 public use file documentation. The 2012 instrument reflects the combined format, which should eliminate much of the ambiguity found during data processing in past years where the same procedure was sometimes reported by survey participants under different items.

Character format codes have an implied decimal between the second and third position and do not use prefixes or zerofills. Codes without an applicable 4th digit have a dash inserted. Please note that, as with the diagnosis codes described above, the file also contains numeric recodes for procedures. These are described in the Record Format section.

For 2012, new checkboxes were added to the computerized tool, based on commonly reported writein procedures from previous years of data. This measure was intended to facilitate reporting and reduce costs associated with medical coding of text entries. The result of this change is a decrease in the number of visits with write-in procedures, with a resulting loss of detail.

4. <u>Medications & Immunizations</u>: The NAMCS drug data collected in item 10 have been classified and coded using the entry name (the entry made on the Patient Record form) according to a unique classification scheme developed at NCHS (9). The medical classification system of drugs by entry name uses a five-digit coding scheme which is updated regularly to include new products. It includes the following special codes:

-9 = blank99980 = unknown entry, other99999 = illegible entry

For 2012, up to 10 medications could be recorded for each visit. A list of drug codes by entry name is included in Appendix III.

In addition to drugs coded by entry name, this file contains the following drug information:

a. Generic drug code: Beginning with the 2006 data release, drugs are coded in terms of their generic components and therapeutic classifications using Lexicon Plus®, a proprietary database of Cerner Multum, Inc., also used by the National Health and Nutrition Examination Survey, NCHS. The Lexicon Plus is a comprehensive database of all prescription and some nonprescription drug products available in the U.S. drug market.

In accordance with the license agreement, NCHS publications, tabulations, and software applications should cite the Multum Lexicon as the source and basis for the coding and classification of NAMCS drug data. For additional information on the Multum Lexicon Drug Database, please refer to the following Web site: http://www.multum.com/Lexicon.htm.

Beginning with the 2006 data release, all drug codes based on entry name (using NCHS' classification system as cited above) were also assigned a unique generic drug code from Multum's Lexicon Drug Database, whenever possible. The structure of the Multum database is such that multiple ingredient drugs are assigned a single generic drug code encompassing all of a drug's ingredients rather than being assigned generic drug codes for each ingredient, as in past years of NAMCS drug data.

For example, prior to 2006, if Tylenol No. 3 was reported in NAMCS, it was assigned a drug entry code of 32920 to reflect the entry of Tylenol No. 3. Using the NCHS generic classification, it was also given a code of 51380 in the generic code field to represent a combination product, and then received separate ingredient codes for acetaminophen and codeine. Under Multum, there is a single generic code that reflects the combination of acetaminophen with codeine. The format of the generic drug code (now called DRUGID rather than GEN) also changed starting in 2006. Rather than the 5 digit numeric code used prior to 2006, the generic drug code is 6 digits, beginning with the letters "a", "c" or "d". Codes beginning with the letter "n" were also used, starting with 2009 data. All Multum codes begin with the letter "d", but there were some drug names reported by NAMCS participants that were not found in the Lexicon Drug Database. These were assigned unique drug codes beginning with an "a" where a drug's ingredients could be determined, or a "c" in the case where a drug's ingredients could not be determined for 2006-2007. Beginning with 2008 data, "n" codes have been used to code all drugs newly appearing in the NAMCS data for which a code could not be found in Multum. The variables DRUGID1 through DRUGID10 reflect the generic codes for each drug reported.

- b. Prescription status code: A code designed to identify the legal status (prescription or nonprescription) of the drug entry.
- c. Controlled substance status code: A code used to denote the degree of potential abuse and federal control of a drug entry.
- d. Composition status code: A code used to distinguish between single-ingredient and combination drugs.
- e. Therapeutic category code: In data years prior to 2006, a 4-digit code was used to identify up to three therapeutic classes to which the drug entry might belong. These were based on the standard drug classifications used in the National Drug Code Directory, 1995 edition (10).

However, as mentioned above, Multum's therapeutic classification system is now being used. The Multum Lexicon provides a 3-level nested category system that assigns a therapeutic classification to each drug and each ingredient of the drug (e.g., for naproxen: the broadest category is central nervous system agents [level 1]; the more detailed category is analgesics [level 2]; and the most detailed category is nonsteroidal anti-inflammatory agents [level 3]). Not all drugs have three classification levels; some may only have two [e.g. for digoxin: cardiovascular agents [level 1]; inotropic agents [level 2]), others only have one. See Appendix III for the complete Multum category scheme.

Each drug may have up to four therapeutic categories on the data file. The variables RX1CAT1 through RX10CAT4 reflect the unique Multum drug categories for a particular drug; these are character values with codes from '001' through '341'. This variable will always show the most detailed therapeutic level available of a particular drug. For example, psychotherapeutic agents in Multum are further classified into a second more detailed level as antidepressants or antipsychotics. Antidepressants are further classified into seven subcategories (miscellaneous antidepressants, SSRI antidepressants, tricyclic antidepressants, monoamine oxidase inhibitors, phenylpiperazine antidepressants, tetracyclic antidepressants, and SSNRI antidepressants); antipsychotics are further classified into five subcategories. For a drug categorized as a tricyclic antidepressant, it would have a drug category code of '209', reflecting the Level 3 code. Other drugs may have only two levels available, such as immunologic agents. There are seven level 2 categories of immunologic agents, and no further breakdowns into a third level in the Multum system. Therefore, RX1CAT1 would reflect only a second level code in that case. So, using RX1CAT1-RX10CAT4 will allow one to identify the most specific level of a drug, but will not, by itself, identify whether that code reflects the first, second, or third level.

In order to understand each level in terms of the Multum hierarchy, we have also placed on the file additional variables that show the full first, second, and third levels, if applicable, for each drug category for each drug. For example, in the case of the tricyclic antidepressant mentioned earlier, RX1CAT1='307'. But there are three additional variables corresponding to that drug's first therapeutic category. RX1V1C1 (meaning Drug 1, Level 1 of Therapeutic Category 1) would be '242' (psychotherapeutic agents), RX1V2C1 (Drug 1, Level 2 of Therapeutic Category 1) would be '249' (antidepressants), and RX1V3C1 (Drug 1, Level 3 of Therapeutic Category 1) would be '307' (tricyclic antidepressants). If there were no second or third level for a particular category, the entry would be blank (''). This is repeated for each of the drug's maximum of four therapeutic categories.

The three levels can easily be concatenated by data users if they wish to obtain a complete code showing the full level structure applicable to each drug's therapeutic categories. An advantage of having separate levels is that it allows data users to aggregate drugs at any level desired. SAS code is provided at the website for micro-data users who wish to group therapeutic categories in various ways.

All drugs were coded using Multum drug categories, even those drugs not found in Multum's drug database. "Unspecified" drugs were assigned to their respective therapeutic category (e.g., hormones – unspecified: category id=97, category name=hormones). Drugs that could not be assigned to any drug entry name (MED1-10 = 99980, 99999) were not assigned a therapeutic drug category.

In some cases, NCHS was able to categorize a drug's therapeutic class at the first or second Multum level, but not at the more detailed level. When this occurred, the undetermined levels are designated as '999' in the data.

Multum uses a "combination" category for some multiple ingredient drugs. These include antihypertensive combinations, antiasthmatic combinations, upper respiratory combinations, psychotherapeutic combinations, bronchodilator combinations, sex hormone combinations, skeletal muscle relaxant combinations, and narcotic analgesic combinations. This categorization may be sufficient for certain analyses but not for others because it lacks information about the therapeutic effect of the individual ingredients that make up the combination. For example, the drug HYDROCHLOROTHIAZIDE; LOSARTAN is identified as an antihypertensive combination. Therefore, we know that this drug has an antihypertensive drug effect. However, based on this combination category we do not know that the drug's single ingredients have the therapeutic effects of a diuretic and angiotensin II inhibitor, which is relevant for some analyses.

As a result, NCHS decided that, in addition to assigning therapeutic categories to each drug, a separate file would be provided listing the ingredients for each drug along with the therapeutic classes for each ingredient. In the case of single ingredient drugs, the ingredient therapeutic categories would be the same as the drug therapeutic categories. This separate downloadable file (the current version is DRUG_INGREDIENTS_2012 and can be found under the "DRUGS" folder in the Downloadable Documentation section of the website: http://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NAMCS/drugs/) can be matched to the main file using the DRUGID code. For each DRUGID on the main file, the supplemental file contains up to 5 ingredients and up to 3 therapeutic category codes for each ingredient. In past years, codes used to identify the active generic ingredients of combination drugs were included on the data file.

IMPORTANT: In 2012, we have continued to update and revise the drug characteristics in our ambulatory care drug database, which underwent substantial revision in 2002. From 2002-2005, each drug entry had up to three therapeutic classes associated with it, compared with a single therapeutic class in prior years. These factors made trend analysis more problematic, and the solution was to provide researchers with a Drug Characteristics file, which was updated annually, at our website. The characteristics from this file (prior to Multum adoption) could be applied by matching on drug codes to previous years of data in order to get the most accurate results when doing analysis of drug trends. A SAS program for applying drug characteristics from the then-current drug database to previous years of NAMCS data was also made available for downloading. These files are all still available on the NAMCS website, but are mainly of use only if the researcher is limiting analysis to years of data prior to 2006 and wishes to retain the old National Drug Code Directory therapeutic categories.

Starting with the 2006 survey, however, with the adoption of the Multum Lexicon for coding drugs according to generic ingredients and therapeutic categories, a new solution for trend analysis was necessary. Therefore, along with the 2006 data file release, we provided a separate downloadable mapping file (MEDCODE_DRUGID_MAP_2006), which allows data users to match all of the drug codes used in previous years (for example, MED1-MED8 in 2005) with the corresponding Multum DRUGID code for generic composition of the drug and its corresponding therapeutic categories. Once that has been accomplished, users can also, if they wish, match to the drug ingredient file as described above. **The mapping file is updated for each new year.** Researchers should keep in mind, however, that in cases where drug characteristics have legitimately changed over the years (e.g., moving from prescription to

non-prescription status), using the current updated version of the drug characteristics will overwrite all of the previous characteristics with current ones.

For users who are interested in analyzing drug data, one method involves the isolation of those records with drugs, or drug mentions, and the creation of a separate data file of drug mentions. Each automated Patient Record for 2012 can have up to ten drug mentions recorded, so whatever file is created would need to include all of them. This method can be used for obtaining estimates of drug mentions, but is not recommended for variance estimation. Rather, the structure of the visit file should be kept intact when estimating variance. In order to do this, estimates of drug mentions can be obtained by creating a new weight variable (called DRUGWT in this example). This variable is created by multiplying PATWT (the patient visit weight) by NUMMED (the number of medications recorded at the sampled visit) or DRUGWT=PATWT*NUMMED. DRUGWT can then be used in place of PATWT to weight one's data; it produces the estimated number of drug mentions rather than visits. (See Record Format for more on PATWT and NUMMED.)

This documentation contains some marginal data for drug mentions. Also provided are drug coding lists in Appendix III. To facilitate searching for drugs in Appendix III, it is recommended that researchers utilize the online search function in Adobe Acrobat with the pdf document, or visit the survey website and use the online drug database under Research Tools (http://www.cdc.gov/nchs/ahcd/ahcd_database.htm). Should the data user need additional assistance in analyzing data on drug mentions, the staff of the Ambulatory and Hospital Care Statistics Branch is available by calling (301) 458-4600. Our website can be accessed at: https://www.cdc.gov/nchs/ahcd/index.htm

K. ESTIMATION PROCEDURES

CHC statistics produced from the 2012 NAMCS were derived by a multistage estimation procedure. The procedure produces essentially unbiased estimates and has three components: 1) inflation by reciprocals of the probabilities of selection, 2) adjustment for nonresponse, and 3) weight smoothing. Each of these components is described below.

1. Inflation of Reciprocals by Sampling Probabilities

Because the survey utilized a three-stage sample design, there were three probabilities:

- a) the probability of selecting the CHC site within sample stratum (state/census division);
- b) the probability of selecting a provider within the CHC site; and
- c) the probability of selecting a patient visit within the provider's scheduled visits.

The last probability was defined to be the exact number of visits seen by the provider at the CHC site during the site's specified reporting week divided by the number of Patient Record forms completed. All weekly estimates were inflated by a factor of 52 to derive annual estimates.

2. Adjustment for Nonresponse

Estimates from NAMCS CHC data were adjusted to account for in-scope providers who failed to provide PRFs for visits by patients they did see at the sampled CHC site during their sample week. For 2012, these adjustments account for nonresponse by provider type, Census division, and metropolitan statistical area status. In addition, adjustments for state-level estimates also account for nonresponse within state.

3. Weight Smoothing

Occasionally there are a few sample providers whose final visit weights are large relative to those for the rest of the sample. When this happens, the weights for visits are smoothed within groups defined by provider type (physician, non-physician clinician), state/Census division, and CHC type. The "excess" in

the extreme weights for a smoothing group was shifted to the providers and visits with smaller weights within the same group so that the estimated total providers and visits within that group after weight smoothing are the same as they were before the weight smoothing.

L. SAMPLING ERRORS

Procedures for calculating sampling errors as well as estimates of standard errors of statistics derived from NAMCS are described elsewhere (2, 11) as well as in Appendix I of this document.

M. PATIENT VISIT WEIGHT

The 2012 NAMCS CHC data file contains two "patient visit weights" – one (PATWT) for producing national, regional and divisional estimates from sample data, and the other (PATWTST) for producing state estimates from sample data. These are vital components of the survey data and micro-data file users should understand how to use them correctly.

The statistics contained on the micro-data file reflect data concerning only a sample of CHC patient visits, not a complete count of all of the CHC visits that occurred in the United States. Each record on the data file represents one CHC visit in the sample of 34,698 visits. In order to obtain visit estimates from sample data, each record is assigned an inflation factor called the "patient visit weight." By aggregating the patient visit weights contained in the PATWT variable on the 34,698 sample records for 2012, the user can obtain the estimated sum of 65,332,722 CHC visits made in the United States during 2012. By aggregating the patient visit weights contained in the PATWTST variable within each of the 34 individual states targeted for separate estimates, data users can obtain the estimated totals of office visits made in those states.

The traditional weighting variable (PATWT) and the state weighting variable (PATWTST) are not interchangeable. That is, the state weighting variable is only to be used for individual state estimates and will not sum to national estimates because only 34 states were targeted for state-level estimation. Furthermore, PATWTST should not be used to make divisional estimates, even within the additional 5 'division remainders', which contain the smallest 16 states and the District of Columbia, grouped within their Census divisions. PATWT should be used to produce those estimates.

Users may notice that the PATWTST variable contains miniscule weights (0.00001) for visits that were sampled within division remainders rather than by state. These include the New England, West North Central, South Atlantic, Mountain and Pacific Division Remainders. This was done to ensure that such visits were not dropped from analysis due to having non-positive weights. If these visits were dropped, as occurs with SUDAAN software, variance estimation would be affected.

The marginal tables on pages 105-111 contain data on numbers of records for selected variables as well as the corresponding national estimated average number of CHC visits and drug mentions during 2012 obtained by aggregating the "patient visit weights" on those records. Similar tables are also provided for provider-level estimates.

N. PROVIDER CODE and PATIENT CODE

The purpose of these codes is to allow for greater analytical depth by permitting the user to link individual Patient Record forms on the NAMCS-CHC public use file with individual CHC providers. This linkage will enable users to conduct more comprehensive analysis without violating the confidentiality of patients or providers.

To uniquely identify a record, both the provider code and the patient code must be used. Patient codes are merely a sequential numbering of the visits recorded by the provider and alone will not uniquely identify visit records. In order to do so, both the unique 4-digit provider code and the 3-digit patient code must be used.

O. USE OF THE PROVIDER-LEVEL WEIGHT

A provider-level weight (PHYSWT) is included on the public use file. This weight allows users to calculate provider-level estimates for CHC physicians, nurse practitioners, physician assistants, and nurse midwives by using the SMPROV variable to identify type of provider. There is one weight for each provider type which appears on the first visit record only for that provider. When running an analysis of provider-level characteristics using PHYSWT, it is recommended to select only those records where PHYSWT is greater than 0. This will result in correct sample counts of providers with visit records, which is useful for assessing reliability. Weighted estimates will be correct either way, because of the one weight per provider format.

It should be kept in mind, however, that estimates at the provider level generated using PHYSWT only reflect those CHC providers who saw patients in their sample week. A total of 171 CHC providers participated in the 2012 NAMCS but did not see any patients at the CHC site where they were selected during that site's assigned week due to being on vacation or other reasons. While estimates made with PHYSWT are unbiased for total numbers of providers, the estimated distributions by provider characteristics may be biased due to the omission of such providers, if such providers differ from those who provided visit records. Provider-level estimates from the NAMCS CHC visit-level file are better for analyzing visit characteristics at the provider level, because such characteristics would not be biased by the omission of physicians who didn't see patients. For example, one could examine average time spent with providers across provider type rather than simply across visits. This type of analysis is slightly complicated; a description along with sample SAS code is available at the Ambulatory Health Care Data website.

For more information, contact the Ambulatory and Hospital Care Statistics Branch at 301-458-4600.

REFERENCES

- 1. Tenney JB, White KL, Williamson JW. National Ambulatory Medical Care Survey: Background and Methodology. National Center for Health Statistics. Vital Health Stat 2(61). 1974.
- 2. Schappert SM, Nelson CR. National Ambulatory medical Care Survey, 1995-96 Summary. National Center for Health Statistics. Vital Health Stat 13(142). 2000.
- 3. Massey JT, Moore TF, Parsons VL, Tadros W. Design and estimation for the National Health Interview Survey, 1985-94. National Center for Health Statistics. Vital Health Stat 2(110). 1989.
- 4. Community Health Center Induction Interview Form. National Ambulatory Medical Care Survey. OMB No. 0920-0234.
- 5. Schneider D, Appleton L, McLemore T. A Reason for Visit Classification for Ambulatory Care. National Center for Health Statistics. Vital Health Stat 2(78). 1979.
- 6. National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey Reason for Visit Classification and Coding Manual: (updated annually). Ambulatory and Hospital Care Statistics Branch, Division of Health Care Statistics, National Center for Health Statistics.
- 7. U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, Health Care Financing Administration. International Classification of Diseases, 9th Revision, Clinical Modification. Sixth Edition. October 2008.
- 8. National Ambulatory Medical Care Survey Coding Notebook (updated annually). Ambulatory and Hospital Care Statistics Branch, Division of Health Care Statistics, National Center for Health Statistics.
- 9. Koch H, Campbell W. The Collection and Processing of Drug Information. National Ambulatory Medical Care Survey, 1980. National Center for Health Statistics. Vital Health Stat 2(90). 1982.
- 10. Food and Drug Administration. National Drug Code Directory, 1995 edition. Washington: Public Health Service. 1995.
- 11. Hsiao CJ, Cherry DK, Beatty PC, Rechtsteiner EA. National Ambulatory Medical Care Survey: 2007 Summary. National health statistics reports; no 27. Hyattsville, MD: National Center for Health Statistics. 2010

II. CODEBOOK AND PHYSICIAN SPECIALTY LIST

A. CODEBOOK

Number of records = 34,698

This section consists of a detailed breakdown of each data record. For each item on the record, the user is provided with a sequential item number, field length, file location, and brief description of the item, along with valid codes. Most data are from the automated Patient Record form (PRF). Some information is obtained by recoding selected data from this source.

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|-------------------------------------------------------------------------------------------------------------------------|
| | | | DATE OF VISIT |
| 1 | 2 | 1-2 | [VMONTH] MONTH OF VISIT |
| | | | 01-12: January-December |
| 2 | 1 | 3 | [VDAYR] DAY OF WEEK OF VISIT |
| | | | 1 = Sunday 2 = Monday 3 = Tuesday 4 = Wednesday 5 = Thursday 6 = Friday 7 = Saturday |
| 3 | 3 | 4-6 | [AGE] PATIENT AGE (reported in years or derived from date of visit and date of birth) |
| | | | This variable has been top coded in accordance with NCHS confidentiality requirements. |
| | | | 000 = Under 1 year 001-086 = 1-86 years 087 = 87 years or older |
| 4 | 1 | 7 | [AGER] AGE RECODE |
| | | | 1 = Under 15 years 2 = 15-24 years 3 = 25-44 years 4 = 45-64 years 5 = 65-74 years 6 = 75 years and over |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5 | 3 | 8-10 | [AGEDAYS] AGE IN DAYS FOR PATIENTS LESS THAN ONE YEAR |
| | | | OF AGE (derived from date of visit and date of birth) -7 = Not applicable 0-364 (0 = Less than one day old) |
| 6 | 1 | 11 | [SEX] SEX |
| | | | 1 = Female 2 = Male |
| 7 | 2 | 12-13 | [PREGNANT] IF FEMALE. IS PATIENT PREGNANT? |
| | | | -9 = Blank -8 = Unknown -7 = Not Applicable 1 = Yes 2 = No |
| 8 | 2 | 14-15 | [GESTWK] IF PATIENT IS PREGNANT, SPECIFY GESTATION WEEK |
| | | | -9 = Blank -8 = Unknown -7 = Not Applicable 2-42 |
| 9 | 2 | 16-17 | [ETHUN] UNIMPUTED ETHNICITY |
| | | | This variable is NOT imputed. Ethnicity data were missing for 17.9 percent of NAMCS CHC visit records. -9 = Blank 1 = Hispanic or Latino 2 = Not Hispanic or Latino |
| 10 | 1 | 18 | [ETHIM] IMPUTED ETHNICITY |
| | | | Missing data for ethnicity were imputed for this variable. Ethnicity data were missing for 17.9 percent of NAMCS CHC visit records. 1 = Hispanic 2 = Not Hispanic |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 44 | • | 40.00 | IDAOELINI LINUMDUTED DAOE |
| 11 | 2 | 19-20 | [RACEUN] UNIMPUTED RACE This variable is NOT imputed. Race data were missing for 21.0 percent of NAMCS CHC visit records. -9 = Blank 1 = White 2 = Black or African American 3 = Asian 4 = Native Hawaiian or Other Pacific Islander 5 = American Indian or Alaska Native 6 = More than one race reported |
| 12 | 1 | 21 | [RACER] IMPUTED RACE |
| | | | Missing data for race were imputed for this variable. Race data were missing for 21.0 percent of NAMCS CHC visit records. 1 = White 2 = Black 3 = Other |
| 13 | 1 | 22 | [RACERETH] IMPUTED RACE/ETHNICITY |
| | | | Missing race and ethnicity data were imputed for this variable. Both race and ethnicity were missing for 10.9 percent of records. Race alone was missing for an additional 10.1 percent, and ethnicity alone was missing for an additional 7.1 percent of records. |
| | | | NOTE: In survey years prior to 2009, the categories were Non-Hispanic White, Non-Hispanic Black, Hispanic, Asian, Native Hawaiian/Other Pacific Islander, American Indian or Alaska Native, and Multiple Races. Starting in 2009, the decision was made to reformulate this item. Hispanic can now be of any race. |
| | | | 1 = White Only, Non-Hispanic 2 = Black Only, Non-Hispanic 3 = Hispanic 4 = Other Race/Multiple Race, Non-Hispanic |
| 14 | 1 | 23 | [NOPAY] NO RESPONSE TO EXPECTED SOURCE(S) OF PAYMENT FOR THIS VISIT |
| | | | 0 = At least one source of payment was reported 1 = All expected source of payment boxes are blank |
| 15 | 1 | 24 | [PAYPRIV] EXPECTED SOURCE OF PAYMENT: PRIVATE INSURANCE |
| | | | 0 = No 1 = Yes |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|--------------------------------------------------------------|
| 16 | 1 | 25 | [PAYMCARE] EXPECTED SOURCE OF PAYMENT: MEDICARE |
| | | | 0 = No 1 = Yes |
| 17 | 1 | 26 | [PAYMCAID] EXPECTED SOURCE OF PAYMENT: MEDICAID or CHIP |
| | | | 0 = No 1 = Yes |
| 18 | 1 | 27 | [PAYWKCMP] EXPECTED SOURCE OF PAYMENT: WORKER'S COMPENSATION |
| | | | 0 = No 1 = Yes |
| 19 | 1 | 28 | [PAYSELF] EXPECTED SOURCE OF PAYMENT: SELF-PAY |
| | | | 0 = No 1 = Yes |
| 20 | 1 | 29 | [PAYNOCHG] EXPECTED SOURCE OF PAYMENT: NO CHARGE/CHARITY |
| | | | 0 = No 1 = Yes |
| 21 | 1 | 30 | [PAYOTH] EXPECTED SOURCE OF PAYMENT: OTHER |
| | | | 0 = No 1 = Yes |
| 22 | 1 | 31 | [PAYDK] EXPECTED SOURCE OF PAYMENT: UNKNOWN |
| | | | 0 = No 1 = Yes |

| ITEM | FIELD | FILE | I [ITEM NAME], DESCRIPTION, AND CODES |
|------|--------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NO. | LENGTH | LOCATION | |
| 23 | 2 | 32-33 | [PAYTYPER] RECODED PRIMARY EXPECTED SOURCE OF PAYMENT FOR THIS VISIT (Recoded from 'Expected Sources of Payment for this Visit' using this hierarchy of payment categories: Medicare, Medicaid or CHIP, Private Insurance, Worker's Compensation, Self-Pay, No Charge/Charity, Other, Unknown) |

IMPORTANT: For more information about earlier versions of the variable PAYTYPE, and variable PAYTYPER which used a different hierarchy of payment categories, please see the 2009 NAMCS Public Use Data File Documentation.

-9 = Blank

-8 = Unknown

1 = Private insurance

2 = Medicare

3 = Medicaid or CHIP

4 = Worker's Compensation

5 = Self-pay

6 = No charge/charity

7 = Other

24 2 34-35 [USETOBAC] TOBACCO USE

-9 = Blank

-8 = Unknown

1 = Not current

2 = Current

INJURY VARIABLES

The collection of injury data changed in 2012, as described in more detail in the 2012 NAMCS Public Use File Documentation. There are now two separate injury-related variables, one which asks if the visit was related to injury/trauma, poisoning, or adverse effects of medical care. The second item asks about intentionality. This format is different than previous years when one item was used, which combined whether the visit was related to injury/poisoning/adverse effect and what the intent was. Also, in past years, 'poisoning' was not listed as a separate category.

For trending purposes, the variables INJURY, INJR1, and INJR2 are still available in 2012. The differences between these variables are explained in more detail in the 2010 NAMCS Public Use Data File Documentation. Briefly, INJURY reflects the broad definition of injury used traditionally in NAMCS. INJR1 has been recoded from INJURY and uses a narrower definition of injury which was recommended by subject matter experts in the NCHS Office of Analysis and Epidemiology (OAE). It is based mainly on first-listed reason for visit and first-listed diagnosis and does not include adverse effects of medical treatment. INJR2 is based on the narrower NCHS OAE definition, but includes second- and third-listed reasons and diagnoses, not just first-listed.

The INJDET variable from previous years, as already mentioned, is no longer collected. However, a similar item (INJDET_TRD) was created during data processing using data from the new injury items (INJPOISAD and INTENTO), as well as Reason for Visit and Diagnosis. In addition, each record contained verbatim entries which are not included in the public use file but which were used to evaluate

ITEM FIELD FILE

NO. LENGTH LOCATION [ITEM NAME], DESCRIPTION, AND CODES

whether a visit was injury related. INJDET_TRD can be compared with INJDET from previous years. Similarly, two recoded variables INJDETR1_TRD and INJDETR2_TRD were created, which can be trended with INJDETR1 and INJDETR2 from previous years. INJDETR1_TRD uses the narrower OAE definition, comparable to INJR1, and INJDETR2_TRD uses the OAE definition used with INJR2.

As mentioned previously, INJPOISAD and INTENTO replaced the previous INJDET variable on the survey instrument. INJPOISAD is provided here in three versions for consistency with the other injury items. The first version (INJPOISAD) is edited according to the broad injury definition used with NAMCS data and is comparable with INJURY and INJDET_TRD. INJPOISADR1 uses the narrower OAE definition comparable to INJR1 and INJDETR1_TRD. INJPOISADR2 uses the same definition as INJR2 and INJDETR2_TRD.

| 25 | 2 | 36-37 | [INJURY] Is this visit related to an injury, poisoning, or adverse effect of medical treatment? – Based on Injury, Reason for Visit, and Diagnosis items, using the broad definition of injury traditionally used with NAMCS data. |
|----|---|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | -9 = Blank -8 = Unknown 0 = No 1 = Yes |
| 26 | 1 | 38 | [INJR1] Is this visit related to an injury or poisoning? Recoded version #1 (recoded from Injury, Reason for Visit, and Diagnosis items). |
| | | | 0 = No (includes blank and unknown; can be crossed with INJURY to see where those occur) 1 = Yes |

This variable uses a definition of injury developed in conjunction with NCHS' Office of Analysis and Epidemiology and is based on **first-listed reason for visit and first-listed diagnosis** only. Note that adverse effects of medicinal drugs and adverse effects or complications of medical and surgical care are not included in this definition. However, that information, based on **first-listed reason for visit and first-listed diagnosis**, can be found in category 4 of the INJDETR1 TRD item.

27 1 39 [INJR2] Is this visit related to an injury or poisoning? Recoded version #2 (recoded from Injury, Reason for Visit, and Diagnosis items).

0 = No (includes blank and unknown; can be crossed with INJURY

to see where these occur)

1 = Yes

This variable uses a definition of injury developed in conjunction with NCHS' Office of Analysis and Epidemiology and is based on **any-listed reason for visit and any-listed diagnosis**. Note that adverse effects of medicinal drugs and adverse effects or complications of medical and surgical care are not included in this definition. However, that information, based on **any-listed reason for visit and any-listed diagnosis**, can be found in category 4 of the INJDETR2 TRD item.

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | |
| 28 | 2 | 40-41 | [INJPOISAD] Is this visit related to an injury/trauma, poisoning, or adverse effect of medical treatment? (2012 is the first year for this format on the automated Patient Record form.) |
| | | | -9 = Blank -8 = Unknown 1 = Yes, injury/trauma 2 = Yes, poisoning 3 = Yes, adverse effect of medical treatment 4 = No |
| 29 | 1 | 42 | [INJPOISADR1] Is this visit related to an injury/trauma, poisoning, or adverse effect of medical treatment? (Recoded version #1, based on first-listed Reason for Visit and Diagnosis.) |
| | | | 1 = Yes, injury/trauma 2 = Yes, poisoning 3 = Yes, adverse effect of medical treatment 4 = No (includes blank and unknown; can be crossed with INJURY to see where those occur) |

INJPOISADR1 uses a definition of injury developed in conjunction with NCHS' Office of Analysis and Epidemiology and is based on **first-listed reason for visit and first-listed diagnosis** only. In addition, **first-listed reason for visit and first-listed diagnosis** codes were used to edit checkbox 3.

30 1 43

[INJPOISADR2] Is this visit related to an injury/trauma, poisoning, or adverse effect of medical treatment? (Recoded version #2, based on any-listed (first, second, or third) Reason for Visit and Diagnosis.)

- 1 = Yes, injury/trauma
- 2 = Yes, poisoning
- 3 = Yes, adverse effect of medical treatment
- 4 = No (includes blank and unknown; can be crossed with INJURY to see where those occur)

INJPOISADR2 uses a definition of injury developed in conjunction with NCHS' Office of Analysis and Epidemiology and is based on **any-listed reason for visit and any-listed diagnosis**. In addition, **any-listed reason for visit and any-listed diagnosis** codes were used to edit checkbox 3.

31 2 44-45 [INTENT] Is this injury/poisoning unintentional or intentional?

- -9 = Blank
- -8 = Unknown
- 1 = Unintentional
- 2 = Intentional

| ITEM | FIELD | FILE | [ITEM NAME], DESCRIPTION, AND CODES |
|------|--------|----------|-------------------------------------------------------------|
| NO. | LENGTH | LOCATION | |
| 32 | 2 | 46-47 | [INJDET_TRD] Is this visit related to any of the following: |

This variable was created during data processing using INJURY, INTENT, Reason for Visit, and Diagnosis, as well as any relevant verbatim entries on the record.

- -9 = Blank
- -8 = Unknown
- -5 = Intentionality does not apply
- 1 = Unintentional injury/poisoning
- 2 = Intentional injury/poisoning
- 3 = Injury/poisoning unknown intent
- 4 = Adverse effect of medical/surgical care or adverse effect of medicinal drug
- 5 = None of the above
- 8 = More than one box is marked

33 1 48 [INJDETR1_TRD] (INJURY/POISONING/ADVERSE EFFECT – Recoded version #1).

Is this visit related to any of the following:

This variable uses a definition of injury developed in conjunction with NCHS' Office of Analysis and Epidemiology and is based on **first-listed reason for visit and first-listed diagnosis** only. In addition, **first-listed reason for visit and first-listed diagnosis** codes were used to edit checkbox 4.

- 1 = Unintentional injury/poisoning
- 2 = Intentional injury/poisoning
- 3 = Injury/poisoning unknown intent
- 4 = Adverse effect of medical/surgical care or adverse effect of medicinal drug
- 5 =None of the above

34 1 49 [INJDETR2_TRD] (INJURY/POISONING/ADVERSE EFFECT – Recoded version #2).

Is this visit related to any of the following:

This variable uses a definition of injury developed in conjunction with NCHS' Office of Analysis and Epidemiology and is based on **any-listed reason for visit and any-listed diagnosis**. In addition, **any-listed reason for visit and any-listed diagnosis** codes were used to edit checkbox 4.

- 1 = Unintentional injury/poisoning
- 2 = Intentional injury/poisoning
- 3 = Injury/poisoning unknown intent
- 4 = Adverse effect of medical/surgical care or adverse effect of medicinal drug
- 5 = None of the above

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|------------------------------------------------------------------------------------------|
| | | | PATIENT'S REASON(S) FOR VISIT (See page 15 in Section I and Coding List in Appendix II.) |
| 35 | 5 | 50-54 | [RFV1] REASON # 1 |
| | | | -9 = Blank 10050-89990 = 1005.0-8999.0 |
| 36 | 5 | 55-59 | [RFV2] REASON # 2 |
| | | | -9 = Blank 10050-89990 = 10050.0-8999.0 |
| 37 | 5 | 60-64 | [RFV3] REASON # 3 |
| | | | -9 = Blank 10050-89980 = 1005.0-8998.0 |
| 38 | 2 | 65-66 | [PRIMCARE] ARE YOU THE PATIENT'S PRIMARY CARE PHYSICIAN/PROVIDER? |
| | | | -9 = Blank -8 = Unknown 1 = Yes 2 = No |
| 39 | 2 | 67-68 | [REFER] WAS PATIENT REFERRED FOR THIS VISIT? |
| | | | -9 = Blank -8 = Unknown -7 = Not applicable 1 = Yes 2 = No |
| 40 | 1 | 69 | [SENBEFOR] HAS THE PATIENT BEEN SEEN IN YOUR PRACTICE BEFORE? |
| | | | 1 = Yes, established patient 2 = No, new patient |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | |
| 41 | 3 | 70-72 | [PASTVIS] HOW MANY PAST VISITS IN THE LAST 12 MONTHS? |
| | | | Top code values for each specialty group are the following: |
| | | | SPECR_14 = 1 (General and family practice) primary care - 30 SPECR_14 = 3 (Internal Medicine) - 30 SPECR_14 = 4 (Pediatrics) - 25 SPECR_14 = 5 (General surgery) - 8 SPECR_14 = 6 (Obstetrics-Gynecology) - 31 SPECR_14 = 11 (Psychiatry) - 58 SPECR_14 = 13 (Ophthalmology) - 31 SPECR_14 = 15 ("All other" specialty group) - 83 SPECR_14 = 96 (Nurse practitioner) - 42 SPECR_14 = 97 (Physician assistant) - 32 SPECR_14 = 98 (Nurse midwife) - 27 |
| | | | -7 = Not applicable (new patient) |
| 42 | 3 | 73-74 | [MAJOR] MAJOR REASON FOR THIS VISIT |
| | | | -9 = Blank 1 = New problem (<3 mos. onset) 2 = Chronic problem, routine 3 = Chronic problem, flare-up 4 = Pre-/Post-surgery 5 = Preventive care (e.g. routine prenatal, well-baby, screening, insurance, general exams) |
| 43 | | | PROVIDER'S DIAGNOSES (See page 16, Section 1 for explanation of coding.) |
| | | | Note: Provider's diagnosis was modified slightly on 0.6 percent of records due to confidentiality requirements. |
| 43 | 5 | 75-79 | [DIAG1] DIAGNOSIS # 1 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted. |
| | | | -9 = Blank 0010[-] - V829[-] = 001.0[0]-V82.9[0] V990- = Noncodable, insufficient information for coding, illegible V991- = Left before being seen; patient walked out; not seen by doctor; left against medical advice V992- = Transferred to another facility; sent to see specialist V993- = HMO will not authorize treatment V997- = Entry of "none," "no diagnosis," "no disease," or "healthy" |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 44 | 2 | 80-81 | [PRDIAG1] IS DIAGNOSIS #1 PROBABLE, QUESTIONABLE, OR RULE OUT? |
| | | | -7 = Not applicable 1 = Yes 2 = No |
| 45 | 5 | 82-86 | [DIAG2] DIAGNOSIS # 2 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted. See DIAGNOSIS #1 for details. |
| 46 | 2 | 87-88 | [PRDIAG2] IS DIAGNOSIS #2 PROBABLE, QUESTIONABLE, OR RULE OUT? |
| | | | -7 = Not applicable 1 = Yes 2 = No |
| 47 | 5 | 89-93 | [DIAG3] DIAGNOSIS # 3 (ICD-9-CM) There is an implied decimal between the third and fourth digits; for inapplicable fourth or fifth digits, a dash is inserted. See DIAGNOSIS #1 for details. |
| 48 | 2 | 94-95 | [PRDIAG3] IS DIAGNOSIS #3 PROBABLE, QUESTIONABLE, OR RULE OUT? |
| | | | -7 = Not applicable 1 = Yes 2 = No |
| | | | NUMERIC RECODES FOR DIAGNOSES |

The following items were included on the public use file to facilitate analysis of visits using ICD-9-CM codes. Prior to the 1995 public use file, all ICD-9-CM diagnosis codes on the NAMCS micro-data file were converted from alphanumeric to numeric fields according to the following coding conventions: A prefix of '1' was added to ICD-9-CM codes in the range of 001.0[-] through 999.9[-]. A prefix of '20' was substituted for the letter 'V' for codes in the range of V01.0[-] through V82.9[-]. Inapplicable fourth or fifth digits were zerofilled. This conversion was done to facilitate analysis of ICD-9-CM data using Ambulatory Care Statistics software systems. Specific coding conventions are discussed in the public use documentation for each data year.

In 1995, however, the decision was made to use actual ICD-9-CM codes on the public use data file. Codes were not prefixed, and a dash was inserted for inapplicable fourth or fifth digits. This had the advantage of preserving actual codes and avoiding possible confusion over the creation of some artificial codes due to zerofilling.

It had come to our attention in the past that some users of NAMCS data find it preferable to use the numeric field recodes rather than the alphanumeric fields in certain data applications. Therefore, since data year 1997, we have included numeric recodes for ICD-9-CM diagnosis codes on our datasets. These are in addition to the actual codes for these diagnoses which appear earlier on the public use file. Users can make their own choice about which format best suits their needs.

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 49 | 6 | 96-101 | [DIAG1R] DIAGNOSIS # 1 (Recode to Numeric Field) -9 = Blank 100200-208290 = 001.0[0]-V82.9[0] 209980 = Noncodable, insufficient information for coding, Illegible 209910 = Left before being seen; patient walked out; not seen by doctor; left against medical advice 209920 = Transferred to another facility; sent to see specialist 209930 = HMO will not authorize treatment |
| 50 | 6 | 102-107 | 209970 = Entry of "none," "no diagnosis," "no disease," or "healthy" [DIAG2R] DIAGNOSIS # 2 (Recode to Numeric Field) Same as DIAG1R. |
| 51 | 6 | 108-113 | [DIAG3R] DIAGNOSIS # 3 (Recode to Numeric Field) Same as DIAG1R. |
| | | | REGARDLESS OF THE DIAGNOSES WRITTEN ABOVE, DOES THE PATIENT NOW HAVE: |
| | | | 0 = No 1 = Yes |
| 52 53 | 1 1 | 114 115 | [ARTHRTIS] Arthritis [ASTHMA] Asthma |
| 54 | 2 | 116-117 | [ASTH_SEV] Asthma severity -9 = Blank -7 = Not applicable 1 = Intermittent 2 = Mild persistent 3 = Moderate persistent 4 = Severe persistent 5 = Other, specify 6 = None recorded |
| 55 | 2 | 118-119 | [ASTH_CON] Asthma control -9=Blank -7=Not applicable 1=Well-controlled 2=Not well controlled 3=Very poorly controlled 4=Other, specify 5=None recorded |
| 56 | 1 | 120 | [CANCER] Cancer |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|----------------------------------------------------------------|-------------------------------------------|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 57 | 2 | 121-122 | [CASTAGE] Stage of patient's cancer |
| | | | -9 = Blank -8 = Unknown stage -7 = Not applicable 0 = In situ 1 = Stage I 2 = Stage II 3 = Stage III 4 = Stage IV |
| 58 59 60 61 62 63 64 65 66 67 68 | 1 1 1 1 1 1 1 1 1 | 123 124 125 126 127 128 129 130 131 132 | [CEBVD] Cerebrovascular disease [COPD] Chronic obstructive pulmonary disease [CRF] Chronic renal failure [CHF] Congestive heart failure [DEPRN] Depression [DIABETES] Diabetes [HYPLIPID] Hyperlipidemia [HTN] Hypertension [IHD] Ischemic heart disease [OBESITY] Obesity [OSTPRSIS] Osteoporosis |
| 69 | 1 | 134 | [NOCHRON] None of the above 0 = "None" not checked 1 = "None" checked 2 = Entire item blank |
| 70 | 2 | 135-136 | [TOTCHRON] TOTAL NUMBER OF CHRONIC CONDITIONS -9 = Entire item blank 0-14 VITAL SIGNS |
| 71 | 1 | 137 | [HTTAKE] Was height measurement reported? (Created during data processing based on reported data.) 0 = No 1= Yes |
| 72 | 2 | 138-139 | [HTIN] PATIENT'S HEIGHT (inches) Height has been top coded in accordance with NCHS confidentiality requirements. -9 = Blank 72 = 72 inches or more (top code for females) 77 = 77 inches or more (top code for males) |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 73 | 1 | 140 | [WTTAKE] Was weight measurement reported? (Created during data processing based on reported data.) |
| | | | 0 = No 1= Yes |
| 74 | 3 | 141-143 | [WTLB] PATIENT'S WEIGHT (pounds) Weight has been top coded in accordance with NCHS confidentiality requirements. |
| | | | -9 = Blank 4-369 370 = 370 lbs. or more |
| 75 | 8 | 144-151 | [BMI] Body-Mass Index This was calculated from Patient's Height and Weight during data processing. It contains a decimal point and up to 2 decimal places. BMI was not calculated for pregnant females or patients under age 2. Also, BMI was recalculated to reflect topcoded values for height and weight. |
| | | | -9 = Missing data -7 = Not calculated 8.36-87.59 |
| 76 | 1 | 152 | [TEMPTAKE] Was temperature reported? (Created during data processing based on reported data.) |
| | | | 0 = No 1= Yes |
| 77 | 4 | 153-156 | [TEMPF] Temperature (Fahrenheit) There is an implied decimal between the third and fourth digits. |
| | | | -9 = Blank 900 - 1070 = 90.0-107.0 Fahrenheit |
| 78 | 1 | 157 | [BLODPRES] Was blood pressure reported? (Created during data processing based on reported data.) |
| | | | 0 = No 1= Yes |
| 79 | 3 | 158-160 | [BPSYS] Blood pressure – systolic |
| | | | -9 = Blank 62 - 241 |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|----------------------------------------------|---------------------------------|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | |
| 80 | 3 | 161-163 | [BPDIAS] Blood pressure – diastolic -9 = Blank 22-109 998 = P, Palp, DOP, or DOPPLER |
| | | | SERVICES |
| 81 | 1 | 164 | [SERVICES] Were any examinations, blood tests, imaging, other tests, non-medication treatment or health education ordered or provided at this visit? |
| | | | NOTE: In previous years, diagnostic and screening services were collected in one question on the Patient Record Form, non-medication services in another, and health education in a third. As described in the annual public use file documentation since 2009, the diagnostic and screening services item was combined with the non-medication services item to create a combined services item during data processing. For 2012, all services were combined into one item on the automated Patient Record Form. |
| | | | 0 = No services were reported 1 = At least one service was reported |
| | | | 0 = No, 1 = Yes for each category below |
| | | | Examinations: |
| 82 83 84 85 86 87 88 89 | 1 1 1 1 1 1 1 | 165 166 167 168 169 170 171 172 | [BREAST] Breast exam [DEPRESS] Depression screening exam [FOOT] Foot exam [PHYSICAL] General physical exam [NEURO] Neurologic exam [PELVIC] Pelvic exam [RECTAL] Rectal exam [RETINAL] Retinal exam [SKIN] Skin exam |
| | | | Blood Tests: |
| 91 92 93 94 95 | 1 1 1 1 | 174 175 176 177 178 | [CBC] CBC (Complete blood count) [GLUCOSE] Glucose [HGBA] HgbA1C (Glycohemoglobin) [CHOLEST] Lipid profile [PSA] PSA (Prostate specific antigen) |
| | | | Imaging: |
| 96 | 1 | 179 | [ANYIMAGE] This item was created during data processing and indicates whether any of the imaging boxes were checked. |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-----------------------------------------------|----------------------------|-----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 97 98 99 100 101 102 103 | 1 1 1 1 1 1 | 180 181 182 183 184 185 186 | [BONEDENS] Bone mineral density [CATSCAN] CT Scan [ECHOCARD] Echocardiogram [OTHULTRA] Other ultrasound [MAMMO] Mammography [MRI] MRI [XRAY] X-ray and procedures |
| 104 | 1 | 187 | [OTHIMAGE] Other imaging NOTE: This was not a checkbox category on the survey. It was created during data processing based on responses to the "other services not listed" items, in which data respondents could enter names of procedures which were later coded using ICD-9-CM procedure codes. |
| • | | | Other tests: |
| 105 106 | 1 1 | 188 189 | [AUDIO] Audiometry [BIOPSY] Biopsy |
| 107 | 2 | 190-191 | [BIOPROV] Biopsy provided -9 = Blank -8 = Unknown -7 = Not applicable 1 = Yes 2 = No |
| 108 109 110 111 112 113 114 | 1 1 1 1 1 1 | 192 193 194 195 196 197 198 | [CARDIAC] Cardiac stress test [CHLAMYD] Chlamydia test [COLON] Colonoscopy [EKG] EKG/ECG [EEG] Electroencephalogram (EEG) [EMG] Electromyogram (EMG) [EXCISION] Excision of tissue |
| 115 | 2 | 199-200 | [EXCIPROV] Excision of tissue provided -9 = Blank -8 = Unknown -7 = Not applicable 1 = Yes 2 = No |
| 116 117 118 119 120 121 122 | 1 1 1 1 1 1 | 201 202 203 204 205 206 207 | [FETAL] Fetal monitoring [HIVTEST] HIV test [HPVDNA] HPV DNA test [PAP] PAP test [PEAK] Peak flow [PREGTEST] Pregnancy test/HCG test [SIGMOID] Sigmoidoscopy |

| ITEM NO. | FIELD LENGTH | FILE LOCATION [ITEM NAME], DESCRIPTION, AND CODES | | |
|----------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| 123 | 2 | 208-209 | [SIGPROV] Sigmoidoscopy provided -9 = Blank -8 = Unknown -7 = Not applicable 1 = Yes 2 = No | |
| 124 125 126 | 1 1 1 | 210 211 212 | [SPIRO] Spirometry [TONO] Tonometry [URINE] Urinalysis (UA) | |
| 127 | 1 | 213 | [SIGCOLON] Sigmoidoscopy/Colonoscopy This item was created during data processing and indicates whether any type of sigmoidoscopy or colonoscopy was ordered or provided, as reported in the checkbox data or write-in procedures. This estimate will be slightly greater than just combining data from SIGMOID and COLON because of the addition of overlapping ICD-9-CM procedure codes that couldn't be assigned to either SIGMOID or COLON. This is a summary variable only and should not be added to results from the checkbox or write-in procedure fields. | |
| 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 | [CSW] Cast/Splint/Wrap [CAM] Complementary alternative medicine [DME] Durable medical equipment [HOMEHLTH] Home health care [MENTAL] Mental health counseling, excluding psychotherapy [PT] Physical therapy [PSYCHOTH] Psychotherapy [RADTHER] Radiation therapy [WOUND] Wound care [ASTHMAED] Asthma education [DIETNUTR] Diet/Nutrition [EXERCISE] Exercise [FAMPLAN] Family planning/Contraception [GRWTHDEV] Growth/Development [INJPREV] Injury prevention [STRESMGT] Stress management [TOBACED] Tobacco use/Exposure [WTREDUC] Weight reduction [OTHSERV] Other services not listed | |

| ITEM | FIELD | FILE | |
|------|--------|------------|-------------------------------------|
| NO. | LENGTH | LOCATION [| [ITEM NAME], DESCRIPTION, AND CODES |

PROCEDURES

Procedures 1-9 are derived from the write-in fields under "Other Services Not Listed" on the automated Patient Record Form. To get a complete picture of the number and type of procedures reported at a visit, data users should include results from all of the procedure fields.

| 147 | 4 | 233-236 | [PROC1] Write-in procedure #1 |
|-----|---|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | ICD-9-CM Vol.3, Procedure Classification) A left-justified alphanumeric code with an implied decimal after the first two digits; inapplicable fourth digits have a dash inserted9 = Blank 0392-999 = 03.92-99.99 |
| 148 | 4 | 237-240 | [PROC2] Write-in procedure #2: see PROC1 for details |
| 149 | 4 | 241-244 | [PROC3] Write-in procedure #3: see PROC1 for details |
| 150 | 4 | 245-248 | [PROC4] Write-in procedure #4: see PROC1 for details |
| 151 | 4 | 249-252 | [PROC5] Write-in procedure #5: see PROC1 for details |
| 152 | 4 | 253-256 | [PROC6] Write-in procedure #6: see PROC1 for details |
| 153 | 4 | 257-260 | [PROC7] Write-in procedure #7: see PROC1 for details |
| 154 | 4 | 261-264 | [PROC8] Write-in procedure #8: see PROC1 for details |
| 155 | 4 | 265-268 | [PROC9] Write-in procedure #9: see PROC1 for details |

NUMERIC RECODES FOR PROCEDURES 1-9

The following recodes are included on the public use file to facilitate analysis of visits using ICD-9-CM codes. It had come to our attention in the past that some users of NAMCS data find it preferable to use the numeric field recodes rather than the alphanumeric fields in certain data applications. Users can make their own choice about which format best suits their needs.

| 156 | 4 | 269-272 | [PROC1R] Write-in procedure #1 A left-justified numeric code with an implied decimal after the first two digits; inapplicable fourth digits are zero-filled9 = Blank 0392-999 = 03.92-99.99 |
|-----|---|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 157 | 4 | 273-276 | [PROC2R] Write-in procedure #2: see PROC1R for details |
| 158 | 4 | 277-280 | [PROC3R] Write-in procedure #3: see PROC1R for details |
| 159 | 4 | 281-284 | [PROC4R] Write-in procedure #4: see PROC1R for details |
| 160 | 4 | 285-288 | [PROC5R] Write-in procedure #5: see PROC1R for details |
| 161 | 4 | 289-292 | [PROC6R] Write-in procedure #6: see PROC1R for details |
| 162 | 4 | 293-296 | [PROC7R] Write-in procedure #7: see PROC1R for details |
| 163 | 4 | 297-300 | [PROC8R] Write-in procedure #8: see PROC1R for details |
| 164 | 4 | 301-304 | [PROC9R] Write-in procedure #9: see PROC1R for details |
| 165 | 1 | 305 | [EXAM] Examination |

This item was created during data processing and indicates whether any of the write-in procedures reflect an ICD-9-CM code indexed specifically to Examinations. It is a summary variable only and should not be added to results from the write-in procedure fields.

| ITEM NO. | FIELD LENGTH | FILE LOCATION | I [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 166 | 2 | 306-307 | [SERVCNT] Total number of services reported as ordered or provided at the visit. Includes all services and vital sign determinations, including write-in entries for procedures (adjusted to avoid double counting between procedures that could be reported as both a checkbox and with more detail in the write-in field). 0-58 (23 was the highest number reported in 2012) |
| 167 | 1 | 308 | [ALLSERV] Were any services ordered or provided at the visit, including vital sign determinations? 0 = No services were ordered or provided at the visit 1 = At least one service was ordered or provided at the visit |
| | | | MEDICATIONS & IMMUNIZATIONS (See page 17 for more information. See Appendix III for Code List.) |
| 168 | 1 | 309 | [MED] WERE ANY PRESCRIPTION OR NON-PRESCRIPTION DRUGS ORDERED OR PROVIDED (BY ANY ROUTE OF ADMINISTRATION) AT THIS VISIT? 0 = No 1 = Yes 2 = Entire item blank, including "None" box |
| 169 | 5 | 310-314 | [MED1] MEDICATION #1 -9 = Blank 00001-99227 = 00001-99227 99980 = Unknown Entry; Other 99999 = Illegible Entry |
| 170 | 5 | 315-319 | [MED2] MEDICATION #2 -9 = Blank 00001-99227 = 00001-99227 99980 = Unknown Entry; Other 99999 = Illegible Entry |
| 171 | 5 | 320-324 | [MED3] MEDICATION #3 -9 = Blank 00001-99227 = 00001-99227 99980 = Unknown Entry; Other 99999 = Illegible Entry |
| 172 | 5 | 325-329 | [MED4] MEDICATION #4 -9 = Blank 00001-99227 = 00001-99227 99980 = Unknown Entry; Other 99999 = Illegible Entry |
| 173 | 5 | 330-334 | [MED5] MEDICATION #5 -9 = Blank 00001-99227 = 00001-99227 99980 = Unknown Entry; Other 99999 = Illegible Entry |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|------------------------------------------------------|------------------------------------------------|-------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 174 | 5 | 335-339 | [MED6] MEDICATION #6 -9 = Blank 00001-99227 = 00001-99227 99980 = Unknown Entry; Other 99999 = Illegible Entry |
| 175 | 5 | 340-344 | [MED7] MEDICATION #7 -9 = Blank 00001-99227 = 00001-99227 99980 = Unknown Entry; Other 99999 = Illegible Entry |
| 176 | 5 | 345-349 | [MED8] MEDICATION #8 -9 = Blank 00001-99227 = 00001-99227 99980 = Unknown Entry; Other 99999 = Illegible Entry |
| 177 | 5 | 350-354 | [MED9] MEDICATION #9 -9 = Blank 00001-99227 = 00001-99227 99980 = Unknown Entry; Other 99999 = Illegible Entry |
| 178 | 5 | 355-359 | [MED10] MEDICATION #10 -9 = Blank 00001-99227 = 00001-99227 99980 = Unknown Entry; Other 99999 = Illegible Entry |
| 179 | 2 | 360-361 | [NCMED1] Was medication #1 new or continued? -9 = Blank -7 = Not applicable (no drug listed) 1 = New 2 = Continued 3 = Both "New" and "Continued" were checked |
| 180 181 182 183 184 185 186 187 | 2 2 2 2 2 2 2 2 2 2 | 362-363 364-365 366-367 368-369 370-371 372-373 374-375 376-377 378-379 | [NCMED2] Was medication #2 new or continued? See NCMED1. [NCMED3] Was medication #3 new or continued? See NCMED1. [NCMED4] Was medication #4 new or continued? See NCMED1. [NCMED5] Was medication #5 new or continued? See NCMED1. [NCMED6] Was medication #6 new or continued? See NCMED1. [NCMED7] Was medication #7 new or continued? See NCMED1. [NCMED8] Was medication #8 new or continued? See NCMED1. [NCMED9] Was medication #9 new or continued? See NCMED1. [NCMED10] Was medication #10 new or continued? See NCMED1. |

| ITEM NO. | FIELD LENGTH | FILE LOCATION [ITEM NAME], DESCRIPTION, AND CODES | | |
|------------------------------------------------------|----------------------------|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| | | | | |
| 189 | 2 | 380-381 | [NUMMED] NUMBER OF MEDICATIONS CODED 0 – 10 | |
| 190 | 2 | 382-383 | [NUMNEW] NUMBER OF NEW MEDICATIONS CODED 0 – 10 | |
| 191 | 2 | 384-385 | [NUMCONT] NUMBER OF CONTINUED MEDICATIONS CODED 0 – 10 | |
| | | | NOTE: For NUMNEW and NUMCONT, the value '0' can reflect the following situations: for NUMNEW, a) no drug listed; b) drug listed as continued medication only; or c) drug listed but unknown whether new or continued; for NUMCONT, a) no drug listed; b) drug listed as new medication only, or c) drug listed but unknown whether new or continued | |
| | | | PROVIDERS SEEN | |
| | | | 0 = No, 1 = Yes | |
| 192 193 194 195 196 197 198 199 | 1 1 1 1 1 1 | 386 387 388 389 390 391 392 393 | [NOPROVID] No answer to item [PHYS] Physician [PHYSASST] Physician assistant [NPNMW] Nurse practitioner/Midwife [RNLPN] RN/LPN [MHP] Mental health provider [OTHPROV] Other provider [PROVNONE] None; no providers seen | |
| 200 | 3 | 394-396 | [TIMEMD] TIME SPENT WITH MD (in minutes) (See also TIMECHC) -7 = Not applicable (Sampled provider was non-physician clinician) 0-240 | |
| | | | VISIT DISPOSITION | |
| | | | 0 = No, 1 = Yes | |
| 201 202 203 204 205 | 1 1 1 1 | 397 398 399 400 401 | [NODISP] No answer to item [REFOTHMD] Refer to other physician [RETAPPT] Return at specified time [ERADMHOS] Refer to emergency department/Admit to hospital [OTHDISP] Other visit disposition | |
| | | | TESTS | |

NOTE: These data were only collected for visits to selected specialties. Specialties not included were the following: general surgery, orthopedic surgery, dermatology, urology, neurology, psychiatry, ophthalmology, and otolaryngology.

| ITEM | FIELD | FILE | |
|------|--------|----------|-------------------------------------|
| NO. | LENGTH | LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |

Valid ranges for lab values were hardcoded into the automated Patient Record form; in some cases, these ranges were later found to be questionable. For example, the top value allowed to be entered for TGS was 400; 1.4% of 2012 NAMCS records reporting a TGS value were at this level, suggesting that the top range should have been higher.

| 206 | 2 | 402-403 | [CHOL] WAS BLOOD FOR TOTAL CHOLESTEROL TEST DRAWN ON THE DAY OF THE SAMPLED VIIST OR DURING THE 12 MONTHS PRIOR TO THE VISIT? -9 = Blank -7 = Not applicable, provider not sampled 1 = Yes 2 = None found within 12 months |
|-----|---|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 207 | 3 | 404-406 | [CHOLRES] MOST RECENT RESULT FOR TOTAL CHOLESTEROL -9 = Blank -7 = Not applicable, provider not sampled 50-349 mg/dL 350 = 350 mg/dL or higher |
| 208 | 4 | 407-410 | [DAYDCHOL] DIFFERENCE IN DAYS BETWEEN VISIT DATE AND DATE OF CHOLESTEROL LAB RESULT -900 = Blank -800 = Unknown -700 = Not applicable, provider not sampled -365 to 365 = Up to 365 days before to 365 days after the sampled visit |
| 209 | 2 | 411-412 | [HDL] WAS BLOOD FOR HIGH DENSITY LIPOPROTEIN (HDL) TEST DRAWN ON THE DAY OF THE SAMPLED VIIST OR DURING THE 12 MONTHS PRIOR TO THE VISIT? -9 = Blank -7 = Not applicable, provider not sampled 1 = Yes 2 = None found within 12 months |
| 210 | 3 | 413-415 | [HDLRES] MOST RECENT RESULT FOR HIGH DENSITY LIPOPROTEIN -9 = Blank -7 = Not applicable, provider not sampled 20-99 mg/dL 100 = 100 mg/dL or higher |
| 211 | 4 | 416-419 | [DAYDHDL] DIFFERENCE IN DAYS BETWEEN VISIT DATE AND DATE OF HDL LAB RESULT -900 = Blank -800 = Unknown -700 = Not applicable, provider not sampled -365 to 365 = Up to 365 days before to 365 days after the sampled visit |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 212 | 2 | 420-421 | [LDL] WAS BLOOD FOR LOW DENSITY LIPOPROTEIN (LDL) TEST DRAWN ON THE DAY OF THE SAMPLED VISIT OR DURING THE 12 MONTHS PRIOR TO THE VISIT? -9 = Blank -7 = Not applicable, provider not sampled 1 = Yes 2 = None found within 12 months |
| 213 | 3 | 422-424 | [LDLRES] MOST RECENT RESULT FOR LOW DENSITY LIPOPROTEIN (LDL) -9 = Blank -7 = Not applicable, provider not sampled 40-299 mg/dL 300 = 300 mg/dL or higher |
| 214 | 4 | 425-428 | [DAYDLDL] DIFFERENCE IN DAYS BETWEEN VISIT DATE AND DATE OF LOW DENSITY LIPOPROTEIN (LDL) LAB RESULT -900 = Blank -800 = Unknown -700 = Not applicable, provider not sampled -365 to 365 = Up to 365 days before to 365 days after the sampled visit |
| 215 | 4 | 429-432 | [LIPIDERR] CALCULATED LDL RESULT. NOT TO BE USED FOR ANALYSIS. This variable is to be used for comparison to the LDLRES value to point out possible errors in the lipid test reporting9999 = Blank -15 - 285 |

Note: LIPIDERR was calculated for records with non-negative values for ALL lipid numbers (cholesterol, HDL, LDL, and TGS) and only when all of these tests dated from the same day. The following formula was used: LIPIDERR=(CHOLRES-HDLRES-(TGSRES/5)). The value was then rounded. Some lab values were capped during data collection, which should be considered when interpreting LIPIDERR.

| 216 | 4 | 433-436 | [LDLDIFF] DIFFERENCE BETWEEN REPORTED LDL RESULT (LDLRES) AND CALCULATED LDL (LIPIDERR). NOT TO BE USED FOR ANALYSIS. This variable is to be used for comparison to the LDLRES value in order to point out possible errors that may exist in the lipid test reporting. -9999 = Blank -113 - 213 |
|-----|---|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 217 | 2 | 437-438 | [TGS] WAS BLOOD FOR TRIGLYCERIDES TEST DRAWN ON THE DAY OF THE SAMPLED VISIT OR DURING THE 12 MONTHS PRIOR TO THE VISIT? -9 = Blank -7 = Not applicable, provider not sampled |

2 = None found within 12 months

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 218 | 3 | 439-441 | [TGSRES] MOST RECENT RESULT FOR TRIGLYCERIDES -9 = Blank -7 = Not applicable, provider not sampled 30-399 mg/dL 400 = 400 mg/dL or higher |
| 219 | 4 | 442-445 | [DAYDTGS] DIFFERENCE IN DAYS BETWEEN VISIT DATE AND DATE OF TRIGLYCERIDES LAB RESULT -900 = Blank -800 = Unknown -700 = Not applicable, provider not sampled -365 to 365 = Up to 365 days before to 365 days after the sampled visit |
| 220 | 2 | 446-447 | [A1C] WAS BLOOD FOR GLYCOHEMOGLOBIN (HbA1c) TEST DRAWN ON THE DAY OF THE SAMPLED VISIT OR DURING THE 12 MONTHS PRIOR TO THE VISIT? -9 = Blank -7 = Not applicable, provider not sampled 1 = Yes 2 = None found within 12 months |
| 221 | 4 | 448-451 | [A1CRES] MOST RECENT RESULT FOR GLYCOHEMOGLOBIN (HbA1c)TRIGLYCERIDES TEST -9 = Blank -7 = Not applicable, provider not sampled 3.0 - 12.8% 12.9 % = 12.9 % or higher |
| 222 | 4 | 452-455 | [DAYDA1C] DIFFERENCE IN DAYS BETWEEN VISIT DATE AND DATE OF GLYCOHEMOGLOBIN (HbA1c) LAB RESULT -900 = Blank -800 = Unknown -700 = Not applicable, provider not sampled -365 to 365 = Up to 365 days before to 365 days after the sampled visit |
| 223 | 2 | 456-457 | [FBG] WAS BLOOD FOR FASTING BLOOD GUCOSE (FBG) TEST DRAWN ON THE DAY OF THE SAMPLED VISIT OR DURING THE 12 MONTHS PRIOR TO THE VISIT? -9 = Blank -7 = Not applicable, provider not sampled 1 = Yes 2 = None found within 12 months |
| 224 | 3 | 458-460 | [FBGRES] MOST RECENT RESULT FOR FASTING BLOOD GLUCOSE (FBG) TEST -9 = Blank -7 = Not applicable, provider not sampled 50-499 mg/dL 500 = 500 mg/dL or higher |

| ITEM | FIELD | FILE | [ITEM NAME], DESCRIPTION, AND CODES |
|------|--------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NO. | LENGTH | LOCATION | |
| 25 | 4 | 461-464 | [DAYDFBG] DIFFERENCE IN DAYS BETWEEN VISIT DATE AND DATE OF FASTING BLOOD GLUCOSE (FBG) LAB RESULT -900 = Blank -800 = Unknown -700 = Not applicable, provider not sampled -365 to 365 = Up to 365 days before to 365 days after the sampled visit |

**** THE FOLLOWING FIELDS SHOW WHETHER DATA WERE REPORTED ON THE AUTOMATED PATIENT RECORD FORM OR CALCULATED DURING DATA PROCESSING, OR WHETHER DATA WERE IMPUTED TO REPLACE BLANKS ****

| 226 | 2 | 465-466 | [AGEFLAG] Was patient age reported on the automated Patient Record Form or calculated during data processing based on date of visit and date of birth? |
|------------|--------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | -9 = Birth date imputed 0 = Calculated by NCHS 1 = Entered by respondent |
| 227 | 1 | 467 | [GESTFL] Was gestation week calculated by NCHS during data processing based on date of visit and date of last menstrual period? 0 = Calculated by NCHS 1 = Not calculated by NCHS |
| | | | IMPUTED ITEMS |
| | | | 0 = Not imputed 1 = Imputed |
| 228 | 1 | 468 469 | [BDATEFL] Patient birth year |
| 229 230 | 1 1 | 469 470 | [SEXFL] Patient sex [ETHNICFL] Patient ethnicity |
| 231 | 1 | 471 | [RACERFL] Patient race |
| 232 | 1 | 472 | [SENBEFL] Has patient been seen in your practice before? |
| 233 | 1 | 473 | [PASTFL] If yes, how many past visits in last 12 months? |
| 234 | 2 | 474-475 | [TIMEMDFL] Time spent with physician (minutes) -7 = Not applicable (Sampled provider was non-physician clinician) 0 = Not imputed 1 = Imputed |
| 235 | 6 | 476-481 | [PHYCODE] PHYSICIAN/ NON-PHYSICIAN CLINICIAN CODE - A unique code assigned to all records from a particular physician, nurse practitioner, physician assistant, or nurse midwife. 600059-621721 |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AI | ND CODES |
|-------------|-----------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| 236 | 2 | 482-483 | [PATCODE] PATIENT CODE - A ridentify each individual record from practitioner, physician assistant, o 1-52 | n a particular physician, nurse |
| 237 | 2 | 484-485 | [SPECR_14] PHYSICIAN SPECIAL RECODE This is a 14-group specialty variable variable in previous NAMCS surve sampled. Because of the nature of appear in the data. Type of non-p | eys when similar groups were f CHCs, not all of the 14 groups |
| | | | 01 = General and family practice 03 = Internal medicine 04 = Pediatrics 05 = General surgery 06 = Obstetrics and gynecology 11 =Psychiatry | 13 = Ophthalmology 15 = All other 96 = Nurse practitioner 97 = Physician assistant 98 = Nurse midwife |

(Note: Some CHC physicians identified themselves as doctors of osteopathy. For SPECR_14, doctors of osteopathy (formerly stratum 02 in NAMCS) have been aggregated with doctors of medicine according to their self-designated practice specialty, and therefore are not differentiated in the variable range. To isolate doctors of osteopathy from medical doctors using the Physician Specialty Recode variable, it is necessary to crosstabulate it with Type of Doctor located in position 492.

238 2 486-487 [SPECR_17] PHYSICIAN SPECIALTY/ NON-PHYSICIAN CLINICIAN RECODE

This variable appears on the 2012 NAMCS Public Use File and is continued here for consistency, even though there is no difference between it and SPECR_14 for CHCs. Results will be the same on the file using either variable.

On the NAMCS (non-CHC) file, this is a 17-group specialty variable that reflects the previous NAMCS samples of 14 specialty groups (with doctors of osteopathy aggregated with doctors of medicine according to their self-designated practice specialty), but also separates out 3 special panels selected for the traditional 2012 NAMCS sample The CHC sample did not include these additional panels.

01 = General and family practice 13 = Ophthalmology 03 = Internal medicine 15 = All other

04 = Pediatrics 96 = Nurse practitioner

05 = General surgery 97 = Physician assistant

98 = Nurse midwife 06 = Obstetrics and gynecology

11 = Psychiatry

| PA | \sim | - |
|----|--------|-----|
| | (| 211 |
| | | |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | I [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | |
| 239 | 4 | 488-491 | [SPECR17_SPECCAT] PHYSICIAN SPECIALTY RECODE, 17 GROUPS, WITH DETAIL ON TYPE OF SPECIALTY |
| | | | This is the 17-group specialty variable from SPECR_17, with the addition of information on primary, medical or surgical specialty The SPECR_17 code appears in the first two columns followed by a decimal. To the right of the decimal is the code for primary, medical or surgical specialty. Please see page 8 for more information about the sample design in 2012. As mentioned earlier, not all 17 groups appear in the CHC file, just those described below. |
| | | | 1.1 = General/Family practice/Primary care specialty 3.1 = Internal medicine/Primary care specialty 4.1 = Pediatrics/Primary care specialty 4.3 = Pediatrics/Medical care specialty 5.2 = General surgery/Surgical care specialty 6.1 = OB-GYN/Primary care specialty 13.2 = Ophthalmology/Surgical care specialty 15.2 = Other specialty/Surgical care specialty 15.3 = Other specialty/Medical care specialty 96 = Nurse practitioner 97 = Physician assistant 98 = Nurse midwife |
| 240 | 1 | 492 | [SPECCAT] PHYSICIAN SPECIALTY GROUP (Recoded from internal data using categories on page 102.) 1 = Primary care specialty 2 = Surgical care specialty 3 = Medical care specialty 4 = Non-physician clinician |
| 241 | 1 | 493 | [MDDO] TYPE OF DOCTOR 1 = M.D Doctor of Medicine 2 = D.O Doctor of Osteopathy 3 = Non-physician clinician |
| 242 | 1 | 494 | [RETYPOFFR] TYPE OF OFFICE SETTING FOR THIS VISIT This is a variable used in the 2012 NAMCS Public Use Data File, but that file has no values of 3 because no CHC visits are included. In contrast, the 2012 NAMCS CHC file only contains CHC visits. Therefore, only one category is applicable to this file and can serve as a marker for CHC data when combining data for both files. |
| | | | 3 = Community Health Center |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 243 | 2 | 495-496 | [SOLO] DO YOU HAVE A SOLO PRACTICE, OR ARE YOU ASSOCIATED WITH OTHER PHYSICIANS IN A PARTNERSHIP, A GROUP PRACTICE, OR SOME OTHER WAY AT THIS VISIT LOCATION? -9 = Blank -8 = Unknown -6 = Refused to answer question 1 = Solo 2 = Non-solo |
| 244 | 2 | 497-498 | [EMPSTAT] ARE YOU A FULL OR PART OWNER, EMPLOYEE, OR INDEPENDENT CONTRACTOR AT THIS VISIT LOCATION? |
| | | | NOTE: In the 2011 NAMCS, only 3 categories were used (Owner, Employee, Contractor). For 2012 NAMCS, 'Owner' was split into Full Owner and Part Owner (categories 1 and 2). These categories were not applicable to the CHC data and are not included below. |
| | | | -9 = Blank -8 = Unknown -6 = Refused to answer question 3 = Employee 4 = Contractor |
| 245 | 2 | 499-500 | [OWNS_CHC] WHO OWNS THE PRACTICE AT THIS VISIT LOCATION? (Recoded) |
| | | | This variable is similar to the OWNS variable in the 2012 NAMCS Public Use File. Data users should note the difference in categories. |
| | | | -9 = Blank -8 = Unknown -6 = Refused to answer question 4 = Community Health Center 5 = Other |
| 246 | 2 | 501-502 | [PATEVEN] DO YOU SEE PATIENTS IN THE OFFICE DURING THE EVENING OR ON WEEKENDS? -9 = Blank -8 = Unknown -6 = Refused to answer question 1 = Yes 2 = No |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | DURING LAST NORMAL WEEK OF PRACTICE, DID YOU MAKE ENCOUNTERS OF THE FOLLOWING TYPES WITH PATIENTS: |
| 247 | 2 | 503-504 | [NHVISR] NURSING HOME VISITS -9 = Blank -8 = Unknown -6 = Refused to answer question 0 = No 1 = Yes |
| 248 | 2 | 505-506 | [HOMVISR] OTHER HOME VISITS -9 = Blank -8 = Unknown -6 = Refused to answer question 0 = No 1 = Yes |
| 249 | 2 | 507-508 | [HOSVISR] HOSPITAL VISITS -9 = Blank -8 = Unknown -6 = Refused to answer question 0 = No 1 = Yes |
| 250 | 2 | 509-510 | [TELCONR] TELEPHONE CONSULTS -9 = Blank -8 = Unknown -6 = Refused to answer question 0 = No 1 = Yes |
| 251 | 2 | 511-512 | [ECONR] INTERNET/EMAIL CONSULTS -9 = Blank -8 = Unknown -6 = Refused to answer question 0 = No 1 = Yes |
| 252 | 2 | 513-514 | [EBILLREC] DOES YOUR PRACTICE SUBMIT ANY CLAIMS ELECTRONICALLY (ELECTRONIC BILLING)? -9 = Blank -8 = Unknown -6 = Refused to answer question 1 = Yes 2 = No |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 253 | 2 | 515-516 | [EINS] DO YOU OR YOUR STAFF VERIFY AN INDIVIDUAL PATIENT'S INSURANCE ELIGIBLITY REQUIREMENTS? -9 = Blank -8 = Unknown -6 = Refused to answer question 1 = Yes 2 = No |
| 254 | 2 | 517-518 | [EINSHOW] HOW DO YOU OR YOUR STAFF ELECTRONICALLY VERIFY AN INDIVIDUAL PATIENT'S INSURANCE ELIGIBILITY? IS IT THROUGH AN EHR/EMR SYSTEM, A STAND-ALONE PRACTICE MANAGEMENT SYSTEM, OR SOME OTHER ELECTRONIC SYSTEM? -9 = Blank -8 = Unknown -7 = Not applicable -6 = Refused to answer question 1 = Yes, with a stand-alone practice management system 2 = Yes, with a EMR/EHR system 3 = Yes, using another electronic system |
| 255 | 2 | 519-520 | [EINSFAST] WHEN YOU ELECTRONICALLY VERIFY A PATIENT'S INSURANCE ELIGIBILITY, DO YOU USUALLY GET RESULTS BACK BEFORE THE PATIENT LEAVES THE OFFICE? -9 = Blank -8 = Unknown -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No |
| 256 | 2 | 521-522 | [EMEDREC] DOES YOUR PRACTICE USE AN ELECTRONIC HEALTH RECORD (EHR) OR ELECTRONIC MEDICAL RECORD (EMR) SYSTEM? Do not include billing records systems. -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, all electronic 2 = Yes, part paper and part electronic 3 = No |
| 257 | 2 | 523-524 | [EMRINS] AT YOUR PRACTICE, ARE THERE PLANS FOR INSTALLING A NEW EMR SYSTEM OR REPLACING THE CURRENT SYSTEM WITHIN THE NEXT 18 MONTHS? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No 3 = Maybe |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 258 | 2 | 525-526 | [MUINC] MEDICARE AND MEDICAID OFFER INCENTIVES TO PRACTICES THAT DEMONSTRATE, MEANINGFUL USE OF HEALTH IT. AT YOUR PRACTICE, ARE THERE PLANS TO APPLY FOR THESE INCENTIVE PAYMENTS? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, we already applied 2 = Yes, we intend to apply 3 = Uncertain if we will apply 4 = No, we will not apply |
| 259 | 2 | 527-528 | [INTENDYR] WHEN DO YOU INTEND TO FIRST APPLY? [for meaningful use payments] -9 = Blank -8 = Unknown -7 = Not applicable 1 = 2012 2 = 2013 or later |

IMPORTANT NOTE: Questions on features of a practice's computerized capabilities have changed over the years. In the following section, items with an "R" suffix have been recoded in each year since 2010 to be consistent with the format used in the 2009 Physician Induction Interview, to make trending easier. Items without the "R" suffix reflect the current format.

| | | | PLEASE INDICATE WHETHER YOUR PRACTICE HAS EACH OF THE FOLLOWING COMPUTERIZED CAPABILITIES AND HOW OFTEN THESE CAPABILITIES ARE USED (APPLIES TO ITEMS 260-315) |
|-----|---|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 260 | 2 | 529-530 | [EDEMOG] RECORDING PATIENT HISTORY AND DEMOGRAPHIC INFORMATION -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 261 | 2 | 531-532 | [EDEMOGR] RECORDING PATIENT HISTORY AND DEMOGRAPHIC INFORMATION (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 262 | 2 | 533-534 | [EPROLST] IF YES TO RECORDING PATIENT HISTORY AND DEMOGRAPHIC INFORMATION, DOES THIS INCLUDE A PATIENT PROBLEM LIST -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 263 | 2 | 535-536 | [EPROLSTR] IF YES TO RECORDING PATIENT HISTORY AND DEMOGRAPHIC INFORMATION, DOES THIS INCLUDE A PATIENT PROBLEM LIST (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 264 | 2 | 537-538 | [EVITALS] RECORDING AND CHARTING VITAL SIGNS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 265 | 2 | 539-540 | [EVITALSR] RECORDING AND CHARTING VITAL SIGNS (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 266 | 2 | 541-542 | [ESMOKE] RECORDING PATIENT SMOKING STATUS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | |
| 267 | 2 | 543-544 | [ESMOKER] RECORDING PATIENT SMOKING STATUS (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 268 | 2 | 545-546 | [EPNOTES] RECORDING CLINICAL NOTES -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 269 | 2 | 547-548 | [EPNOTESR] RECORDING CLINICAL NOTES (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 270 | 2 | 549-550 | [EMEDALG] IF YES TO RECORDING CLINICAL NOTES, DO THE NOTES INCLUDE A LIST OF PATIENT'S MEDICATIONS AND ALLERGIES? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 271 | 2 | 551-552 | [EMEDALGR] IF YES TO RECORDING CLINICAL NOTES, DO THE NOTES INCLUDE A LIST OF PATIENT'S MEDICATIONS AND ALLERGIES? (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|--------------------------|------------------|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 272 | 2 | 553-554 | [ECPOE] ORDERING PRESCRIPTIONS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 273 | 2 | 555-556 | [ECPOER] ORDERING PRESCRIPTIONS (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 274 | 2 | 557-558 | [ESCRIP] IF YES TO ORDERING PRESCRIPTIONS, ARE PRESCRIPTIONS SENT ELECTRONICALLY TO THE PHARMACY? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 275 | 2 | 559-560 | [ESCRIPR] IF YES TO ORDERING PRESCRIPTIONS, ARE PRESCRIPTIONS SENT ELECTRONICALLY TO THE PHARMACY? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| | | | WHEN ORDERS FOR PRESCRIPTIONS ARE SUBMITTED ELECTRONICALLY ARE THEY SUBMITTED BY (check all that apply): |
| 276 277 278 279 | 2 2 2 2 | 561-562 563-564 565-566 567-568 | [EWHOPRACP] Prescribing practitioner [EWHOOTHP] Someone else [EWHOUNKP] Unknown [EWHOREFP] Refused to answer |
| | | | -9 = Entire item (22.e(2) on Physician Induction Interview) blank -7 = Not applicable 0 = Box is not marked 1= Box is marked |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 280 | 2 | 569-570 | [EWARN] IF YES TO ORDERING PRESCRIPTIONS, ARE WARNINGS OF DRUG INTERACTIONS OR CONTRAINDICATIONS PROVIDED? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 281 | 2 | 571-572 | [EWARNR] IF YES TO ORDERING PRESCRIPTIONS, ARE WARNINGS OF DRUG INTERACTIONS OR CONTRAINDICATIONS PROVIDED? (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 282 | 2 | 573-574 | [EREMIND] REMINDERS FOR GUIDELINE-BASED INTERVENTIONS AND/OR SCREENING TESTS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 283 | 2 | 575-576 | [EREMINDR] REMINDERS FOR GUIDELINE-BASED INTERVENTIONS AND/OR SCREENING TESTS (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 284 | 2 | 577-578 | [ESETS] PROVIDING STANDARD ORDER SETS RELATED TO A PARTICULAR CONDITION OR PROCEDURE -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4=No |
| 285 | 2 | 579-580 | [ESETSR] PROVIDING STANDARD ORDER SETS RELATED TO A PARTICULAR CONDITION OR PROCEDURE (recoded) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 286 | 2 | 581-582 | [ECTOE] ORDERING LAB TESTS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 287 | 2 | 583-584 | [ECTOER] ORDERING LAB TESTS (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 288 | 2 | 585-586 | [EORDER] IF YES TO ORDERING LAB TESTS, ARE ORDERS SENT ELECTRONICALLY? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|--------------------------|------------------|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 289 | 2 | 587-588 | [EORDERR] IF YES TO ORDERING LAB TESTS, ARE ORDERS SENG ELECTRONICALLY? (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 290 291 292 293 | 2 2 2 2 | 589-590 591-592 593-594 595-596 | WHEN ORDERS FOR TESTS ARE SUBMITTED ELECTRONICALLY ARE THEY SUBMITTED BY (check all that apply): [EWHOPRACL] Prescribing practitioner [EWHOOTHL] Someone else [EWHOUNKL] Unknown [EWHOREFL] Refused to answer |
| | | | -9 = Entire item (22.h(2) on Physician Induction Interview) blank -7 = Not applicable 0 = Box is not marked 1= Box is marked |
| 294 | 2 | 597-598 | [ERESULT] VIEWING LAB RESULTS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 295 | 2 | 599-600 | [ERESULT] VIEWING LAB RESULTS (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 296 | 2 | 601-602 | [EGRAPH] IF YES TO VIEWING LAB RESULTS, CAN THE EHR/EMR AUTOMATICALLY GRAPH A SPECIFIC PATIENT'S LAB RESULTS OVER TIME? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 297 | 2 | 603-604 | [EGRAPHR] IF YES TO VIEWING LAB RESULTS, CAN THE EHR/EMR AUTOMATICALLY GRAPH A SPECIFIC PATIENT'S LAB RESULTS OVER TIME? (recoded) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 298 | 2 | 605-606 | [EIMGRES] VIEWING IMAGING RESULTS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 299 | 2 | 607-608 | [EIMGRESR] VIEWING IMAGING RESULTS (recoded for trending) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 300 | 2 | 609-610 | [EQOC] VIEWING DATA ON QUALITY OF CARE MEASURES -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 301 | 2 | 611-612 | [EQOCR] VIEWING DATA ON QUALITY OF CARE MEASURES (recoded) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 302 | 2 | 613-614 | [ECQM] REPORTING CLINICAL QUALITY MEASURES TO FEDERAL OR STATE AGENCIES (SUCH AS CMS OR MEDICAID) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 303 | 2 | 615-616 | [ECQMR] REPORTING CLINICAL QUALITY MEASURES TO FEDERAL OR STATE AGENCIES (SUCH AS CMS OR MEDICAID) (recoded) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes 2 = No 4 = Turned off |
| 304 | 2 | 617-618 | [EGENLIST] GENERATING LISTS OF PATIENTS WITH PARTICULAR HEALTH CONDITIONS -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 305 | 2 | 619-620 | [EGENLISTR] GENERATING LISTS OF PATIENTS WITH PARTICULAR HEALTH CONDITIONS (recoded) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 306 | 2 | 621-622 | [EIMMREG] ELECTRONIC REPORTING TO IMMUNIZATION REGISTRIES -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 307 | 2 | 623-624 | [EIMMREGR] ELECTRONIC REPORTING TO IMMUNIZATION REGISTRIES (recoded) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 308 | 2 | 625-626 | [EMUREP] IF YES TO ELECTRONIC REPORTING TO IMMUNIZATION REGISTRIES, ARE THEY REPORTED IN STANDARDS SPECIFIED BY MEANINGFUL USE CRITERIA? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 309 | 2 | 627-628 | [EMUREPR] IF YES TO ELECTRONIC REPORTING TO IMMUNIZATION REGISTRIES, ARE THEY REPORTED IN STANDARDS SPECIFIED BY MEANINGFUL USE CRITERIA? (recoded) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 310 | 2 | 629-630 | [ESUM] PROVIDING PATIENTS WITH CLINICAL SUMMARIES FOR EACH VISIT -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | |
| 311 | 2 | 631-632 | [ESUMR] PROVIDING PATIENTS WITH CLINICAL SUMMARIES FOR EACH VISIT (recoded) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 312 | 2 | 633-634 | [EMSG] EXCHANGING SECURE MESSAGES WITH PATIENTS |
| | | | -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 313 | 2 | 635-636 | [EMSGR] EXCHANGING SECURE MESSAGES WITH PATIENTS (recoded) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |
| 314 | 2 | 637-638 | [EHLTHINFO] PROVIDING PATIENTS WITH AN ELECTRONIC COPY OF THEIR HEALTH INFORMATION -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes, used routinely 2 = Yes, but NOT used routinely 3 = Yes, but turned off or not used 4 = No |
| 315 | 2 | 639-640 | [EHLTHINFOR] PROVIDING PATIENTS WITH AN ELECTRONIC COPY OF THEIR HEALTH INFORMATION (recoded) -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No 4= Turned off |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|---------------------------------|-----------------------|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 316 | 2 | 641-642 | [ESHARE] DO YOU SHARE ANY PATIENT HEALTH INFORMATION ELECTRONICALLY (NOT FAX) WITH OTHER PROVIDERS, INCLUDING HOSPITALS, AMBULATORY PROVIDERS, OR ELECTRONICALLY (NOT FAX) LABS? -9 = Blank -8 = Don't know -6 = Refused to answer question 1= Yes 2= No |
| | | | HOW DO YOU ELECTRONICALLY SHARE PATIENT HEALTH INFORMATION? |
| 317 318 319 320 321 | 2 2 2 2 2 | 643-644 645-646 647-648 649-650 651-652 | [ESHAREEHR] EHR/EMR [ESHAREWEB]Web portal (separate from EHR/EMR) [ESHAREOTH] Other electronic method [ESHAREUNK] Unknown [ESHAREREF] Refused to answer question |
| | | | -9 = Entire item (23.b on Physician Induction Interview) blank -7 = Not applicable 0 = Box is not marked 1= Box is marked |
| | | | DO YOU SHARE LAB RESULTS ELECTRONICALLY (NOT FAX) WITH: |
| 322 323 | 2 2 | 653-654 655-656 | [LABRES1] HOSPITALS WITH WHICH YOU ARE AFFILIATED? [LABRES2] AMBULATORY PROVIDERS INSIDE YOUR OFFICE/GROUP? |
| 324 | 2 | 657-658 | [LABRES3] HOSPITALS WITH WHICH YOU ARE NOT |
| 325 | 2 | 659-660 | AFFILIATED? [LABRES4] AMBULATORY PROVIDERS OUTSIDE YOUR OFFICE/GROUP? |
| 326 327 | 2 2 | 661-662 663-664 | [LABRESUNK] UNKNOWN [LABRESREF] REFUSED TO ANSWER QUESTION |
| | | | -9 = Entire item (24.a on Physician Induction Interview) blank -7 = Not applicable |

0 = Box is not marked 1= Box is marked

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | DO YOU SHARE IMAGING REPORTS ELECTRONICALLY (NOT FAX) WITH: |
| 328 329 | 2 2 | 665-666 667-668 | [IMAGREP1] HOSPITALS WITH WHICH YOU ARE AFFILIATED? [IMAGREP2] AMBULATORY PROVIDERS INSIDE YOUR OFFICE/GROUP? |
| 330 | 2 | 669-670 | [IMAGREP3] HOSPITALS WITH WHICH YOU ARE NOT AFFILIATED? |
| 331 | 2 | 671-672 | [IMAGREP4] AMBULATORY PROVIDERS OUTSIDE YOUR OFFICE/GROUP? |
| 332 333 | 2 2 | 673-674 675-676 | [IMAGREPUNK] UNKNOWN [IMAGREPREF] REFUSED TO ANSWER QUESTION |
| | | | -9 = Entire item (24.b on Physician Induction Interview) blank -7 = Not applicable 0 = Box is not marked 1= Box is marked |
| | | | DO YOU SHARE PATIENT PROBLEM LISTS ELECTRONICALLY (NOT FAX) WITH: |
| 334 | 2 | 677-678 | [PTPROB1] HOSPITALS WITH WHICH YOU ARE AFFILIATED? |
| 335 | 2 | 679-680 | [PTPROB2] AMBULATORY PROVIDERS INSIDE YOUR OFFICE/GROUP? |
| 336 | 2 | 681-682 | [PTPROB3] HOSPITALS WITH WHICH YOU ARE NOT AFFILIATED? |
| 337 | 2 | 683-684 | [PTPROB4] AMBULATORY PROVIDERS OUTSIDE YOUR OFFICE/GROUP? |
| 338 339 | 2 2 | 685-686 687-688 | [PTPROBUNK] UNKNOWN [PTPROBREF] REFUSED TO ANSWER QUESTION |
| 339 | 2 | 687-688 | -9 = Entire item (24.c on Physician Induction Interview) blank -7 = Not applicable 0 = Box is not marked 1= Box is marked |
| | | | DO YOU SHARE MEDICATIONS LISTS ELECTRONICALLY (NOT FAX) WITH: |
| 340 341 | 2 2 | 689-690 691-692 | [MEDLIST1] HOSPITALS WITH WHICH YOU ARE AFFILIATED? [MEDLIST2] AMBULATORY PROVIDERS INSIDE YOUR OFFICE/GROUP? |
| 342 | 2 | 693-694 | [MEDLIST3] HOSPITALS WITH WHICH YOU ARE NOT |
| 343 | 2 | 695-696 | AFFILIATED? [MEDLIST4] AMBULATORY PROVIDERS OUTSIDE YOUR OFFICE/GROUP? |
| 344 345 | 2 2 | 697-698 699-700 | [MEDLISTUNK] UNKNOWN [MEDLISTREF] REFUSED TO ANSWER QUESTION -9 = Entire item (24.d on Physician Induction Interview) blank -7 = Not applicable 0 = Box is not marked 1= Box is marked |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | DO YOU SHARE MEDICATION ALLERGY LISTS ELECTRONICALLY (NOT FAX) WITH: |
| 346 347 | 2 2 | 701-702 703-704 | [ALGLIST1] HOSPITALS WITH WHICH YOU ARE AFFILIATED? [ALGLIST2] AMBULATORY PROVIDERS INSIDE YOUR OFFICE/GROUP? |
| 348 | 2 | 705-706 | [ALGLIST3] HOSPITALS WITH WHICH YOU ARE NOT AFFILIATED? |
| 349 | 2 | 707-708 | [ALGLIST4] AMBULATORY PROVIDERS OUTSIDE YOUR OFFICE/GROUP? |
| 350 351 | 2 2 | 709-710 711-712 | [ALGLISTUNK] UNKNOWN [ALGLISTREF] REFUSED TO ANSWER QUESTION |
| | | | -9 = Entire item (24.e on Physician Induction Interview) blank -7 = Not applicable 0 = Box is not marked 1= Box is marked |
| 352 | 2 | 713-714 | [SUMREC] DO YOU SHARE ANY OF THE PREVIOUSLY MENTIONED TYPES OF INFORMATION USING A SUMMARY CARE RECORD? (A Summary Record is an electronic file that contains the previously mentioned health data in a standardized format.) |
| | | | -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1= Yes 2= No |
| 353 | 2 | 715-716 | [CONSULTOUT] WHEN YOU REFER A PATIENT TO A PROVIDER OUTSIDE OF YOUR OFFICE OR GROUP, DO YOU RECEIVE A REPORT BACK FROM THE OTHER PROVIDER WITH RESULTS OF THE CONSULTATION? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, routinely 2 = Yes, but NOT routinely 3 = No |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 354 | 2 | 717-718 | [CONSULTOUTE] IF YES TO "WHEN YOU REFER A PATIENT TO PROVIDER OUTSIDE OF YOUR OFFICE OR GROUP, DO YOU RECEIVE A REPORT BACK FROM THE OTHER PROVIDER WITH RESULTS OF THE CONSULTATION?", DO YOU RECEIVE IT ELECTRONICALLY (NOT FAX)? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, routinely 2 = Yes, but NOT routinely 3 = No |
| 355 | 2 | 719-720 | [CONSULTIN] WHEN YOU SEE A PATIENT REFERRED TO YOU BY A PROVIDER OUTSIDE OF YOUR OFFICE OR GROUP, DO YOU RECEIVE NOTIFICATION OF BOTH THE PATIENT'S HISTORY AND REASON FOR CONSULTATION? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, routinely 2 = Yes, but NOT routinely 3 = No |
| 356 | 2 | 721-722 | [CONSULTINE] IF YES TO "WHEN YOU SEE A PATIENT REFERRED TO YOU BY A PROVIDER OUTSIDE OF YOUR OFFICE OR GROUP, DO YOU RECEIVE NOTIFICATION OF BOTH THE PATIENT'S HISTORY AND REASON FOR CONSULTATION?", DO YOU RECEIVE THAT NOTIFICATION ELECTRONICALLY (NOT FAX)? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, routinely 2 = Yes, but NOT routinely 3 = No |
| 357 | 2 | 723-724 | [INPTINFO] WHEN YOUR PATIENT IS DISCHARGED FROM AN INPATIENT SETTING, DO YOU RECEIVE ALL OF THE INFORMATION YOU NEED TO CONTINUE MANAGING THE PATIENT? -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, routinely 2 = Yes, but NOT routinely 3 = No |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 358 | 2 | 725-726 | [INPTINFOT] IF YES TO "WHEN YOUR PATIENT IS DISCHARGED FROM AN INPATIENT SETTING, DO YOU RECEIVE ALL OF THE INFORMATION YOU NEED TO CONTINUE MANAGING THE PATIENT?", IS THE INFORMATION TIMELY, AVAILABLE WHEN NEEDED? |
| | | | -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, routinely 2 = Yes, but NOT routinely 3 = No |
| 359 | 2 | 727-728 | [INPTINFOE] IF YES TO "WHEN YOUR PATIENT IS DISCHARGED FROM AN INPATIENT SETTING, DO YOU RECEIVE ALL OF THE INFORMATION YOU NEED TO CONTINUE MANAGING THE PATIENT?", IS THE INFORMATION RECEIVED ELECTRONICALLY (NOT FAX)? |
| | | | -9 = Blank -8 = Don't know -7 = Not applicable -6 = Refused to answer question 1 = Yes, routinely 2 = Yes, but NOT routinely 3 = No |
| 360 | 2 | 729-730 | [PRMCARER] Roughly, what percent of your patient care revenue comes from Medicare? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent |
| 361 | 2 | 731-732 | [PRMAIDR] Roughly, what percent of your patient care revenue comes from Medicaid? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 362 | 2 | 733-734 | [PRPRVTR] Roughly, what percent of your patient care revenue comes from private insurance? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent |
| 363 | 2 | 735-736 | [PRPATR] Roughly, what percent of your patient care revenue comes from patient payments? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent |
| 364 | 2 | 737-738 | [PROTHR] Roughly, what percent of your patient care revenue comes from other sources? (including charity, research, Champus, VA, etc.) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent |
| 365 | 2 | 739-740 | [PRMANR] Roughly, what percentage of the patient care revenue received by this practice comes from (these) managed care contracts? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 366 | 2 | 741-742 | [REVFFSR] Roughly, what percent of your patient care revenue comes from usual, customary, and reasonable fee-for-service? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent |
| 367 | 2 | 743-744 | [REVCAPR] Roughly, what percent of your patient care revenue comes from capitation? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent |
| 368 | 2 | 745-746 | [REVCASER] Roughly, what percent of your patient care revenue comes from case rates (e.g. package pricing/episode of care)? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent |
| 369 | 2 | 747-748 | [REVOTHR] Roughly, what percent of your patient care revenue comes from other sources? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Less than or equal to 25 percent 2 = 26-50 percent 3 = 51-75 percent 4 = More than 75 percent |
| 370 | 2 | 749-750 | [ACEPTNEW] Are you currently accepting "new" patients into your practice? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | I [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 371 | 2 | 751-752 | [CAPITATE] From those "new" patients, which of the following types of payment do you accept? - Capitated private insurance -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No |
| 72 | 2 | 753-754 | [NOCAP] From those "new" patients, which of the following types of payment do you accept? – Non-capitated private insurance -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No |
| 373 | 2 | 755-756 | [PRIVATE] (Derived from responses to CAPITATE and NOCAP) From those "new" patients, which of the following types of payment do you accept? – Private insurance (capitated or non-capitated) -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No |
| 374 | 2 | 757-758 | [NMEDCARE] From those "new" patients, which of the following types of payment do you accept? – Medicare -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No |
| 375 | 2 | 759-760 | [NMEDCAID] From those "new" patients, which of the following types of payment do you accept? – Medicaid -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No |
| 376 | 2 | 761-762 | [NWORKCMP] From those "new" patients, which of the following types of payment do you accept? – Workers compensation -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 377 | 2 | 763-764 | [NSELFPAY] From those "new" patients, which of the following types of payment do you accept? – Self-pay -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No |
| 378 | 2 | 765-766 | [NNOCHRGE] From those "new" patients, which of the following types of payment do you accept? – No charge -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Yes 2 = No |
| 379 | 2 | 767-768 | [PHYSCOMP] WHICH OF THE FOLLOWING METHODS BEST DESCRIBES YOUR BASIC COMPENSATION? -9 = Blank -8 = Don't know -6 = Refused to answer question 1 = Fixed salary 2 = Share of practice billings or workload 3 = Mix of salary and share of billings or other measures of performance(e.g., your own billings, practice financial performance, quality measures, practice profiling) 4 = Shift, hourly or other time-based payment 5 = Other |
| | | | CLINICAL PRACTICES MAY TAKE VARIOUS FACTORS INTO ACCOUNT WHEN DETERMINING THE COMPENSATION (SALARY, BONUS, PAY RATE, ETC.) PAID TO THE PHYSICIANS IN THE PRACTICE. PLEASE INDICATE WHETHER THE PRACTICE EXPLICITLY CONSIDERS EACH OF THE FOLLOWING FACTORS IN DETERMINING YOUR COMPENSATION: |
| 380 | 2 | 769-770 | [COMPPROD] FACTORS THAT REFLECT YOUR OWN PRODUCTIVITY -9 = Entire item 32 on Physician Induction Interview blank 0 = Box is not marked 1 = Box is marked |
| 381 | 2 | 771-772 | [COMPSAT] RESULTS OF SATISFACTION SURVEYS FROM YOUR OWN PATIENTS -9 = Entire item 32 on Physician Induction Interview blank 0 = Box is not marked 1 = Box is marked |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 382 | 2 | 773-774 | [COMPQUAL] SPECIFIC MEASURES OF QUALITY, SUCH AS RATES OF PREVENTIVE SERVICES FOR YOUR PATIENTS -9 = Entire item 32 on Physician Induction Interview blank 0 = Box is not marked 1 = Box is marked |
| 383 | 2 | 775-776 | [COMPDROF] RESULTS OF PRACTICE PROFILING, THAT IS, COMPARING YOUR PATTERN OF USING MEDICAL RESOURCES WITH THAT OF OTHER PHYSICIANS -9 = Entire item 32 on Physician Induction Interview blank 0 = Box is not marked 1 = Box is marked |
| 384 | 2 | 777-778 | [COMPFIN] THE OVERALL FINANCIAL PERFORMANCE OF THE PRACTICE -9 = Entire item 32 on Physician Induction Interview blank 0 = Box is not marked 1 = Box is marked |
| 385 | 2 | 779-780 | [COMPUNK] UNKNOWN -9 = Entire item 32 on Physician Induction Interview blank 0 = Box is not marked 1 = Box is marked |
| 386 | 2 | 781-782 | [COMPREF] REFUSED TO ANSWER -9 = Entire item 32 on Physician Induction Interview blank 0 = Box is not marked 1 = Box is marked |
| 387 | 3 | 783-785 | [SDAPPT] Roughly, what percent of your daily visits are same day appointments? -9 = Blank -6 = Refused to answer question 0-100 |
| 388 | 2 | 786-787 | [SASDAPPT] Does your practice set time aside for same day appointments? -9 = Blank -8 = Unknown -6 = Refused to answer question 1 = Yes 2 = No |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 389 | 2 | 788-789 | [APPTTIME] On average, about how long does it take to get an appointment for a routine medical exam? -9 = Blank -8 = Unknown -6 = Refused to answer question 1 = Within 1 week 2 = 1-2 weeks 3 = 3-4 weeks 4 = 1-2 months 5 = 3 or more months 6 = Do not provide routine exams |
| 390 | 1 | 790 | [REGIONOFF] GEOGRAPHIC REGION (Based on location where majority of visit records were sampled) 1= Northeast 2= Midwest 3= South 4= West |
| 391 | 1 | 791 | [DIVISIONOFF] CENSUS CIVIL DIVISION (Based on location where majority of visit records were sampled) 1 = New England (Northeast Region) 2 = Middle Atlantic (Northeast Region) 3 = East North Central (Midwest Region) 4 = West North Central (Midwest Region) 5 = South Atlantic (South Region) 6 = East South Central (South Region) 7 = West South Central (South Region) 8 = Mountain (West Region) 9 = Pacific (West Region) |

| PAGE 7 | 6 | | 2012 NAMCS CHC MICRO-DATA FILE DOCUMENTATION |
|--------|--------|---------|-------------------------------------------------------------------|
| ITEM | FIELD | FILE | |
| NO. | LENGTH | | I [ITEM NAME], DESCRIPTION, AND CODES |
| | | | |
| 392 | 2 | 792-793 | [FIPSSTOFF] STATE/DIVISION REMAINDER |
| | | | (Based on location where majority of visit records were sampled) |
| | | | NOTE: The 34 most populous states were targeted for sampling. The |
| | | | remaining states were grouped within their Census division and |
| | | | sampled as 'division remainders'. Records in division remainders |
| | | | should only be weighted using the PATWT variable; records in |
| | | | targeted states should only be weighted using the PATWTST |
| | | | variable. |
| | | | 01=Alabama 02=Alaska |
| | | | 04=Arizona |
| | | | 05=Arkansas |
| | | | 06=California |
| | | | 08=Colorado |
| | | | 09=Connecticut 10=Delaware |
| | | | 11=District of Columbia |
| | | | 12=Florida |
| | | | 13=Georgia |
| | | | 15=Hawaii |
| | | | 16=Idaho |
| | | | 17=Illinois 18=Indiana |
| | | | 19=lowa |
| | | | 20=Kansas |
| | | | 21=Kentucky |
| | | | 22=Louisiana |
| | | | 23=Maine |
| | | | 24=Maryland 25=Massachusetts |
| | | | 26=Michigan |
| | | | 27=Minnesota |
| | | | 28=Mississippi |
| | | | 29=Missouri |
| | | | 30=Montana 31=Nebraska |
| | | | 31=Nebraska 32=Nevada |
| | | | 33=New Hampshire |
| | | | 34=New Jersey |
| | | | 35=New Mexico |
| | | | 36=New York |
| | | | 37=North Carolina |
| | | | 38=North Dakota 39=Ohio |
| | | | 40=Oklahoma |
| | | | 41=Oregon |
| | | | 42=Pennsylvania |
| | | | 44=Rhode Island |
| | | | 4E Cauth Carolina |

45=South Carolina 46=South Dakota

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | 47=Tennessee 48=Texas 49=Utah 50=Vermont 51=Virginia 53=Washington 54=West Virginia 55=Wisconsin 56=Wyoming 91=New England Division Remainder 92=West North Central Division Remainder 93=South Atlantic Division Remainder 94=Mountain Division Remainder 95=Pacific Division Remainder |
| 393 | 1 | 794 | [MSA] METROPOLITAN/NON-METROPOLITAN STATUS (Based on physician location in conjunction with the definition of the Bureau of the Census and the U.S. Office of Management and Budget.) |
| | | | 1 = MSA (Metropolitan Statistical Area) 2 = Not MSA (includes micropolitan statistical areas) |

ITEM FIELD FILE

NO. LENGTH LOCATION [ITEM NAME], DESCRIPTION, AND CODES

DRUG-RELATED INFO FOR MEDICATION #1

NOTE: Starting with the 2006 data release, all drug codes based on entry name (using NCHS' standard classification system) were also assigned a unique generic drug code from Multum's Lexicon Drug Database, where possible. The structure of the Multum database is such that multiple ingredient drugs are assigned a single generic drug code encompassing all of a drug's ingredients rather than being assigned generic drug codes for each ingredient, as in past years of NAMCS drug data. All Multum codes start with the letter "d" but there were some drugs reported in NAMCS that could not be assigned a code in Multum. For 2006 and 2007, these received a prefix of either "a" (when ingredients could be determined) or "c" (when ingredients could not be determined). Beginning with 2008, the use of "a" and "c" codes was replaced with "n" codes. For more on the structure of the drug data (including information on therapeutic class and drug ingredients, please see page 17.)

| 394 | 6 | 795-800 | [DRUGID1] DRUG ID (See p. 118 for more information.) |
|-----|---|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | a07001-a96067 = NCHS code (for drugs not found in Multum but for which ingredients could be determined, for drugs added to the database for survey years 2006 and 2007) c00001-c00898, c00900-c92511 = NCHS code (for drugs not found in Multum and with undetermined ingredients) c00899 – Undetermined pharmaceutical aid d00001-d07899 = Multum code n0000-n12008 = NCHS code (for drugs not found in Multum that were added to the database beginning with survey year 2008) |
| 395 | 1 | 801 | [PRESCR1] PRESCRIPTION STATUS CODE 1 = Prescription Drug |
| 396 | 1 | 802 | [CONTSUB1] CONTROLLED SUBSTANCE STATUS CODE 1 = Schedule I (Research Only) 2 = Schedule II |
| 397 | 1 | 803 | [COMSTAT1] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined |
| 398 | 3 | 804-806 | [RX1CAT1] MULTUM DRUG CATEGORY # 1 |

[&]quot; " = Blank/Not applicable

^{001 - 899 =} Drug category 999 = Undetermined category

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| 399 | 3 | 807-809 | [RX1CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1. |
| 400 | 3 | 810-812 | [RX1CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1. |
| 401 | 3 | 813-815 | [RX1CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1. |
| | | | DRUG CATEGORY LEVELS |
| | | | See RX1CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III. |
| 402 | 3 | 816-818 | [RX1V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 |
| 403 404 | 3 3 | 819-821 822-824 | [RX1V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX1V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 |
| 405 | 3 | 825-827 | [RX1V1C4] Level 1 of MULTUM DRUG CATEGORY # 4 |
| 406 | 3 | 828-830 | [RX1V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 |
| 407 | 3 | 831-833 | [RX1V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 |
| 408 | 3 | 834-836 | [RX1V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 |
| 409 | 3 | 837-839 | [RX1V2C4] Level 2 of MULTUM DRUG CATEGORY # 4 |
| 410 | 3 | 840-842 | [RX1V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 |
| 411 | 3 | 843-845 | [RX1V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 |
| 412 | 3 | 846-848 | [RX1V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 |
| 413 | 3 | 849-851 | [RX1V3C4] Level 3 of MULTUM DRUG CATEGORY # 4 |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | I [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | DRUG-RELATED INFO FOR MEDICATION #2 |
| 414 | 6 | 852-857 | [DRUGID2] DRUG ID (See p. 118 for more information.) |
| | | | a07001-a96067 = NCHS code (for drugs not found in Multum but for which ingredients could be determined, for drugs added to the database for survey years 2006 and 2007) c00001-c00898, c00900-c92511 = NCHS code (for drugs not found in Multum and with undetermined ingredients) c00899 – Undetermined pharmaceutical aid d00001-d07899 = Multum code n0000-n12008 = NCHS code (for drugs not found in Multum that were added to the database beginning with survey year 2008) |
| 415 | 1 | 858 | [PRESCR2] PRESCRIPTION STATUS CODE 1 = Prescription Drug |
| 416 | 1 | 859 | [CONTSUB2] CONTROLLED SUBSTANCE STATUS CODE417 1 = Schedule I (Research Only) 2 = Schedule II |
| 417 | 1 | 860 | [COMSTAT2] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined |
| 418 | 3 | 861-863 | [RX2CAT1] MULTUM DRUG CATEGORY # 1 |

| | | | " = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category |
|-----|---|---------|--------------------------------------------------------------------------------------|
| 419 | 3 | 864-866 | [RX2CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1. |
| 420 | 3 | 867-869 | [RX2CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1. |
| 421 | 3 | 870-872 | [RX2CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1. |

| ITEM | FIELD | FILE | |
|------|--------|----------|-------------------------------------|
| NO. | LENGTH | LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |

| 422 423 424 425 | 3 3 3 | 873-875 876-878 879-881 882-884 | [RX2V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX2V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX2V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 [RX2V1C4] Level 1 of MULTUM DRUG CATEGORY # 4 |
|--------------------------|-------------|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 423 | 3 | 002-004 | [IXX2V104] Level 1 of MOLTOM DIXOG CATEGORT # 4 |
| 426 | 3 | 885-887 | [RX2V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 |
| 427 | 3 | 888-890 | [RX2V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 |
| 428 | 3 | 891-893 | [RX2V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 |
| 429 | 3 | 894-896 | [RX2V2C4] Level 2 of MULTUM DRUG CATEGORY # 4 |
| 430 | 3 | 897-899 | [RX2V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 |
| 431 | 3 | 900-902 | [RX2V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 |
| 432 | 3 | 903-905 | [RX2V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 |
| 433 | 3 | 906-908 | [RX2V3C4] Level 3 of MULTUM DRUG CATEGORY # 4 |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | I [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | DRUG-RELATED INFO FOR MEDICATION #3 |
| 434 | 6 | 909-914 | [DRUGID3] DRUG ID (See p. 118 for more information.) |
| | | | a07001-a96067 = NCHS code (for drugs not found in Multum but for which ingredients could be determined, for drugs added to the database for survey years 2006 and 2007) c00001-c00898, c00900-c92511 = NCHS code (for drugs not found in Multum and with undetermined ingredients) c00899 – Undetermined pharmaceutical aid d00001-d07899 = Multum code n0000-n12008 = NCHS code (for drugs not found in Multum that were added to the database beginning with survey year 2008) |
| 435 | 1 | 915 | [PRESCR3] PRESCRIPTION STATUS CODE 1 = Prescription Drug |
| 436 | 1 | 916 | [CONTSUB3] CONTROLLED SUBSTANCE STATUS CODE 1 = Schedule I (Research Only) 2 = Schedule II |
| 437 | 1 | 917 | [COMSTAT3] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined |
| 438 | 3 | 918-920 | [RX3CAT1] MULTUM DRUG CATEGORY # 1 |

| | | | " = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category |
|-----|---|---------|--------------------------------------------------------------------------------------|
| 439 | 3 | 921-923 | [RX3CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1. |
| 440 | 3 | 924-926 | [RX3CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1. |
| 441 | 3 | 927-929 | [RX3CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1. |

| ITEM | FIELD | FILE | |
|------|--------|----------|-------------------------------------|
| NO. | LENGTH | LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
| | | | |
| | | | |
| | | | DRUG CATEGORY LEVELS |

| 442 | 3 | 930-932 | [RX3V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 |
|-----|---|---------|-----------------------------------------------|
| 443 | 3 | 933-935 | [RX3V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 |
| 444 | 3 | 936-938 | [RX3V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 |
| 445 | 3 | 939-941 | [RX3V1C4] Level 1 of MULTUM DRUG CATEGORY # 4 |
| 446 | 3 | 942-944 | [RX3V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 |
| 447 | 3 | 945-947 | [RX3V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 |
| 448 | 3 | 948-950 | [RX3V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 |
| 449 | 3 | 951-953 | [RX3V2C4] Level 2 of MULTUM DRUG CATEGORY # 4 |
| 450 | 3 | 954-956 | [RX3V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 |
| 451 | 3 | 957-959 | [RX3V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 |
| 452 | 3 | 960-962 | [RX3V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 |
| 453 | 3 | 963-965 | [RX3V3C4] Level 3 of MULTUM DRUG CATEGORY # 4 |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | I [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | DRUG-RELATED INFO FOR MEDICATION #4 |
| 454 | 6 | 966-971 | [DRUGID4] DRUG ID (See p. 118 for more information.) |
| | | | a07001-a96067 = NCHS code (for drugs not found in Multum but for which ingredients could be determined, for drugs added to the database for survey years 2006 and 2007) c00001-c00898, c00900-c92511 = NCHS code (for drugs not found in Multum and with undetermined ingredients) c00899 – Undetermined pharmaceutical aid d00001-d07899 = Multum code n0000-n12008 = NCHS code (for drugs not found in Multum that were added to the database beginning with survey year 2008) |
| 455 | 1 | 972 | [PRESCR4] PRESCRIPTION STATUS CODE 1 = Prescription Drug |
| 456 | 1 | 973 | [CONTSUB4] CONTROLLED SUBSTANCE STATUS CODE 1 = Schedule I (Research Only) 2 = Schedule II |
| 457 | 1 | 974 | [COMSTAT4] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined |
| 458 | 3 | 975-977 | [RX4CAT1] MULTUM DRUG CATEGORY # 1 |

| | | | " = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category |
|-----|---|---------|--------------------------------------------------------------------------------------|
| 459 | 3 | 978-980 | [RX4CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1. |
| 460 | 3 | 981-983 | [RX4CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1. |
| 461 | 3 | 984-986 | [RX4CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1. |

| NO LENGTH LOCATION STEMMANNES DECODIDATION AND CODES | ITEM | FIELD | FILE | | |
|---------------------------------------------------------|------|--------|----------|-------------------------------------|--|
| NO. LENGTH LOCATION [ITEM NAME], DESCRIPTION, AND CODES | NO. | LENGTH | LOCATION | [ITEM NAME], DESCRIPTION, AND CODES | |

| 462 | 3 | 987-989 | [RX4V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 |
|-----|---|-----------|-----------------------------------------------|
| 463 | 3 | 990-992 | [RX4V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 |
| 464 | 3 | 993-995 | [RX4V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 |
| 465 | 3 | 996-998 | [RX4V1C4] Level 1 of MULTUM DRUG CATEGORY # 4 |
| | | | |
| 466 | 3 | 999-1001 | [RX4V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 |
| 467 | 3 | 1002-1004 | [RX4V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 |
| 468 | 3 | 1005-1007 | [RX4V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 |
| 469 | 3 | 1008-1010 | [RX4V2C4] Level 2 of MULTUM DRUG CATEGORY # 4 |
| | | | |
| 470 | 3 | 1011-1013 | [RX4V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 |
| 471 | 3 | 1014-1016 | [RX4V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 |
| 472 | 3 | 1017-1019 | [RX4V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 |
| 473 | 3 | 1020-1022 | [RX4V3C4] Level 3 of MULTUM DRUG CATEGORY # 4 |

| \neg | ιGΕ | 86 |
|-----------|-----|----|
| P^{μ} | | രന |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | DRUG-RELATED INFO FOR MEDICATION #5 |
| 474 | 6 | 1023-1028 | [DRUGID5] DRUG ID (See p. 118 for more information.) |
| | | | a07001-a96067 = NCHS code (for drugs not found in Multum but for which ingredients could be determined, for drugs added to the database for survey years 2006 and 2007) c00001-c00898, c00900-c92511 = NCHS code (for drugs not found in Multum and with undetermined ingredients) c00899 – Undetermined pharmaceutical aid d00001-d07899 = Multum code n0000-n12008 = NCHS code (for drugs not found in Multum that were added to the database beginning with survey year 2008) |
| 475 | 1 | 1029 | [PRESCR5] PRESCRIPTION STATUS CODE 1 = Prescription Drug |
| 476 | 1 | 1030 | [CONTSUB5] CONTROLLED SUBSTANCE STATUS CODE 1 = Schedule I (Research Only) 2 = Schedule II |
| 477 | 1 | 1031 | [COMSTAT5] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined |
| 478 | 3 | 1032-1034 | [RX5CAT1] MULTUM DRUG CATEGORY # 1 |

| | | | " = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category |
|-----|---|-----------|--------------------------------------------------------------------------------------|
| 479 | 3 | 1035-1037 | [RX5CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1. |
| 480 | 3 | 1038-1040 | [RX5CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1. |
| 481 | 3 | 1041-1043 | [RX5CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1. |

| ITEM | FIELD | FILE | |
|------|--------|----------|-------------------------------------|
| NO. | LENGTH | LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |

| 482 483 | 3 | 1044-1046 1047-1049 | [RX5V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX5V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 |
|------------|--------|------------------------|------------------------------------------------------------------------------------------------|
| 463 484 | ა 3 | 1050-1052 | [RX5V1C3] Level 1 of MULTUM DRUG CATEGORY # 2 |
| 485 | 3 | 1053-1055 | [RX5V1C4] Level 1 of MULTUM DRUG CATEGORY # 4 |
| 486 | 3 | 1056-1058 | [RX5V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 |
| 487 | 3 | 1059-1061 | [RX5V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 |
| 488 | 3 | 1062-1064 | [RX5V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 |
| 489 | 3 | 1065-1067 | [RX5V2C4] Level 2 of MULTUM DRUG CATEGORY # 4 |
| 490 | 3 | 1068-1070 | [RX5V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 |
| 491 | 3 | 1071-1073 | [RX5V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 |
| 492 | 3 | 1074-1076 | [RX5V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 |
| 493 | 3 | 1077-1079 | [RX5V3C4] Level 3 of MULTUM DRUG CATEGORY # 4 |

| P | Λ, | \sim | _ | 0 | 0 |
|---|----|--------|---|---|----|
| - | 41 | 1 | _ | 8 | χ. |
| | | | | | |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | DRUG-RELATED INFO FOR MEDICATION #6 |
| 494 | 6 | 1080-1085 | [DRUGID6] DRUG ID (See p. 118 for more information.) |
| | | | a07001-a96067 = NCHS code (for drugs not found in Multum but for which ingredients could be determined, for drugs added to the database for survey years 2006 and 2007) c00001-c00898, c00900-c92511 = NCHS code (for drugs not found in Multum and with undetermined ingredients) c00899 – Undetermined pharmaceutical aid d00001-d07899 = Multum code n0000-n12008 = NCHS code (for drugs not found in Multum that were added to the database beginning with survey year 2008) |
| 495 | 1 | 1086 | [PRESCR6] PRESCRIPTION STATUS CODE 1 = Prescription Drug |
| 496 | 1 | 1087 | [CONTSUB6] CONTROLLED SUBSTANCE STATUS CODE 1 = Schedule I (Research Only) 2 = Schedule II |
| 497 | 1 | 1088 | [COMSTAT6] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined |
| 498 | 3 | 1089-1091 | [RX6CAT1] MULTUM DRUG CATEGORY # 1 |

" = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category
 499 3 1092-1094 [RX6CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1.
 500 3 1095-1097 [RX6CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1.
 501 3 1098-1100 [RX6CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1.

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|-------------------------------------|
| | | | |
| | | | DRUG CATEGORY LEVELS |

| 502 | 3 | 1101-1103 | [RX6V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 |
|-----|---|-----------|-----------------------------------------------|
| 503 | 3 | 1104-1106 | [RX6V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 |
| 504 | 3 | 1107-1109 | [RX6V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 |
| 505 | 3 | 1110-1112 | [RX6V1C4] Level 1 of MULTUM DRUG CATEGORY # 4 |
| | | | |
| 506 | 3 | 1113-1115 | [RX6V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 |
| 507 | 3 | 1116-1118 | [RX6V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 |
| 508 | 3 | 1119-1121 | [RX6V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 |
| 509 | 3 | 1122-1124 | [RX6V2C4] Level 2 of MULTUM DRUG CATEGORY # 4 |
| | | | |
| 510 | 3 | 1125-1127 | [RX6V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 |
| 511 | 3 | 1128-1130 | [RX6V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 |
| 512 | 3 | 1131-1133 | [RX6V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 |
| 513 | 3 | 1134-1136 | [RX6V3C4] Level 3 of MULTUM DRUG CATEGORY # 4 |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | DRUG-RELATED INFO FOR MEDICATION #7 |
| 514 | 6 | 1137-1142 | [DRUGID7] DRUG ID (See p. 118 for more information.) |
| | | | a07001-a96067 = NCHS code (for drugs not found in Multum but for which ingredients could be determined, for drugs added to the database for survey years 2006 and 2007) c00001-c00898, c00900-c92511 = NCHS code (for drugs not found in Multum and with undetermined ingredients) c00899 – Undetermined pharmaceutical aid d00001-d07899 = Multum code n0000-n12008 = NCHS code (for drugs not found in Multum that were added to the database beginning with survey year 2008) |
| 515 | 1 | 1143 | [PRESCR7] PRESCRIPTION STATUS CODE 1 = Prescription Drug |
| 516 | 1 | 1144 | [CONTSUB7] CONTROLLED SUBSTANCE STATUS CODE 1 = Schedule I (Research Only) 2 = Schedule II 5 = Schedule V 8 = Multiple Schedules 3 = Schedule III 6 = No Control 4 = Schedule IV 7 = Undetermined |
| 517 | 1 | 1145 | [COMSTAT7] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined |
| 518 | 3 | 1146-1148 | [RX7CAT1] MULTUM DRUG CATEGORY # 1 |

" " = Blank/Not applicable

3

3

3

3

530 531

532 533

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | |
| | | | DRUG CATEGORY LEVELS |
| | | | See RX1CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III. |
| 522 | 3 | 1158-1160 | [RX7V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 |
| 523 | 3 | 1161-1163 | [RX7V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 |
| 524 | 3 | 1164-1166 | [RX7V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 |
| 525 | 3 | 1167-1169 | [RX7V1C4] Level 1 of MULTUM DRUG CATEGORY # 4 |
| 526 | 3 | 1170-1172 | [RX7V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 |
| 527 | 3 | 1173-1175 | [RX7V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 |
| 528 | 3 | 1176-1178 | [RX7V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 |
| 529 | 3 | 1179-1181 | [RX7V2C4] Level 2 of MULTUM DRUG CATEGORY # 4 |

1182-1184 [RX7V3C1] Level 3 of MULTUM DRUG CATEGORY # 1

1185-1187 [RX7V3C2] Level 3 of MULTUM DRUG CATEGORY # 2

1188-1190 [RX7V3C3] Level 3 of MULTUM DRUG CATEGORY # 3

1191-1193 [RX7V3C4] Level 3 of MULTUM DRUG CATEGORY # 4

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | DRUG-RELATED INFO FOR MEDICATION #8 |
| 534 | 6 | 1194-1199 | [DRUGID8] DRUG ID (See p. 118 for more information.) |
| | | | a07001-a96067 = NCHS code (for drugs not found in Multum but for which ingredients could be determined, for drugs added to the database for survey years 2006 and 2007) c00001-c00898, c00900-c92511 = NCHS code (for drugs not found in Multum and with undetermined ingredients) c00899 – Undetermined pharmaceutical aid d00001-d07899 = Multum code n0000-n12008 = NCHS code (for drugs not found in Multum that were added to the database beginning with survey year 2008) |
| 535 | 1 | 1200 | [PRESCR8] PRESCRIPTION STATUS CODE 1 = Prescription Drug |
| 536 | 1 | 1201 | [CONTSUB8] CONTROLLED SUBSTANCE STATUS CODE 1 = Schedule I (Research Only) 2 = Schedule II |
| 537 | 1 | 1202 | [COMSTAT8] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined |
| 538 | 3 | 1203-1205 | [RX8CAT1] MULTUM DRUG CATEGORY # 1 |

" " = Blank/Not applicable

| ITEM | FIELD | FILE | |
|------|--------|----------|-------------------------------------|
| NO. | LENGTH | LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
| | | | |

| 542 | 3 | 1215-1217 | [RX8V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 |
|-----|---|-----------|-----------------------------------------------|
| 543 | 3 | 1218-1220 | [RX8V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 |
| 544 | 3 | 1221-1223 | [RX8V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 |
| 545 | 3 | 1224-1226 | [RX8V1C4] Level 1 of MULTUM DRUG CATEGORY # 4 |
| 546 | 3 | 1227-1229 | [RX8V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 |
| 547 | 3 | 1230-1232 | [RX8V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 |
| 548 | 3 | 1233-1235 | [RX8V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 |
| 549 | 3 | 1236-1238 | [RX8V2C4] Level 2 of MULTUM DRUG CATEGORY # 4 |
| | | | IDVOVOCALL LO CARRETURA DELLO CATTOCONY " C |
| 550 | 3 | 1239-1241 | [RX8V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 |
| 551 | 3 | 1242-1244 | [RX8V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 |
| 552 | 3 | 1245-1247 | [RX8V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 |
| 553 | 3 | 1248-1250 | [RX8V3C4] Level 3 of MULTUM DRUG CATEGORY # 4 |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | DRUG-RELATED INFO FOR MEDICATION #9 |
| 554 | 6 | 1251-1256 | [DRUGID9] DRUG ID (See p. 118 for more information.) |
| | | | a07001-a96067 = NCHS code (for drugs not found in Multum but for which ingredients could be determined, for drugs added to the database for survey years 2006 and 2007) c00001-c00898, c00900-c92511 = NCHS code (for drugs not found in Multum and with undetermined ingredients) c00899 – Undetermined pharmaceutical aid d00001-d07899 = Multum code n0000-n12008 = NCHS code (for drugs not found in Multum that were added to the database beginning with survey year 2008) |
| 555 | 1 | 1257 | [PRESCR9] PRESCRIPTION STATUS CODE 1 = Prescription Drug |
| 556 | 1 | 1258 | [CONTSUB9] CONTROLLED SUBSTANCE STATUS CODE 1 = Schedule I (Research Only) 2 = Schedule II 5 = Schedule V 8 = Multiple Schedules 3 = Schedule III 6 = No Control 4 = Schedule IV 7 = Undetermined |
| 557 | 1 | 1259 | [COMSTAT9] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined |
| 558 | 3 | 1260-1262 | [RX9CAT1] MULTUM DRUG CATEGORY # 1 |

| | | | " " = Blank/Not applicable 001 - 899 = Drug category 999 = Undetermined category |
|-----|---|-----------|----------------------------------------------------------------------------------------|
| 559 | 3 | 1263-1265 | [RX9CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1. |
| 560 | 3 | 1266-1268 | [RX9CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1. |
| 561 | 3 | 1269-1271 | [RX9CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1. |

| ITEM | FIELD | FILE | |
|------|--------|----------|-------------------------------------|
| NO. | LENGTH | LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
| | | | |

| 562 | 3 | 1272-1274 | [RX9V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 |
|-----|---|-----------|-----------------------------------------------|
| 563 | 3 | 1275-1277 | [RX9V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 |
| 564 | 3 | 1278-1280 | [RX9V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 |
| 565 | 3 | 1281-1283 | [RX9V1C4] Level 1 of MULTUM DRUG CATEGORY # 4 |
| | | | |
| 566 | 3 | 1284-1286 | [RX9V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 |
| 567 | 3 | 1287-1289 | [RX9V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 |
| 568 | 3 | 1290-1292 | [RX9V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 |
| 569 | 3 | 1293-1295 | [RX9V2C4] Level 2 of MULTUM DRUG CATEGORY # 4 |
| | | | |
| 570 | 3 | 1296-1298 | [RX9V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 |
| 571 | 3 | 1299-1301 | [RX9V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 |
| 572 | 3 | 1302-1304 | [RX9V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 |
| 573 | 3 | 1305-1307 | [RX9V3C4] Level 3 of MULTUM DRUG CATEGORY # 4 |

| GF | ٩A |
|----|----|
| | |

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | |
| | | | DRUG-RELATED INFO FOR MEDICATION #10 |
| 574 | 6 | 1308-1313 | [DRUGID10] DRUG ID (See p. 118 for more information.) |
| | | | a07001-a96067 = NCHS code (for drugs not found in Multum but for which ingredients could be determined, for drugs added to the database for survey years 2006 and 2007) c00001-c00898, c00900-c92511 = NCHS code (for drugs not found in Multum and with undetermined ingredients) c00899 – Undetermined pharmaceutical aid d00001-d07899 = Multum code n0000-n12008 = NCHS code (for drugs not found in Multum that were added to the database beginning with survey year 2008) |
| 575 | 1 | 1314 | [PRESCR10] PRESCRIPTION STATUS CODE 1 = Prescription Drug |
| 576 | 1 | 1315 | [CONTSUB10] CONTROLLED SUBSTANCE STATUS CODE 1 = Schedule I (Research Only) 2 = Schedule II |
| 577 | 1 | 1316 | [COMSTAT10] COMPOSITION STATUS CODE 1 = Single Entity Drug 2 = Combination Drug 3 = Undetermined |
| 578 | 3 | 1317-1319 | [RX10CAT1] MULTUM DRUG CATEGORY # 1 |
| 5 4 . | | | |

" " = Blank/Not applicable

| | | | 001 - 899 = Drug category 999 = Undetermined category |
|-----|---|-----------|----------------------------------------------------------|
| 579 | 3 | 1320-1322 | [RX10CAT2] MULTUM DRUG CATEGORY # 2 See RX1CAT1. |
| 580 | 3 | 1323-1325 | [RX10CAT3] MULTUM DRUG CATEGORY # 3 See RX1CAT1. |
| 581 | 3 | 1326-1328 | [RX10CAT4] MULTUM DRUG CATEGORY # 4 See RX1CAT1. |

| ITEM | FIELD | FILE | |
|------|--------|----------|-------------------------------------|
| NO. | LENGTH | LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
| | | | |

See RX1CAT1 for general coding conventions that apply to all Multum drug categories. Complete Multum classification scheme is shown in Appendix III.

| 582 583 584 | 3 3 3 | 1329-1331 1332-1334 1335-1337 | [RX10V1C1] Level 1 of MULTUM DRUG CATEGORY # 1 [RX10V1C2] Level 1 of MULTUM DRUG CATEGORY # 2 [RX10V1C3] Level 1 of MULTUM DRUG CATEGORY # 3 |
|-------------------|-------------|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| 585 | 3 | 1338-1340 | [RX10V1C4] Level 1 of MULTUM DRUG CATEGORY # 4 |
| | | | |
| 586 | 3 | 1341-1343 | [RX10V2C1] Level 2 of MULTUM DRUG CATEGORY # 1 |
| 587 | 3 | 1344-1346 | [RX10V2C2] Level 2 of MULTUM DRUG CATEGORY # 2 |
| 588 | 3 | 1347-1349 | [RX10V2C3] Level 2 of MULTUM DRUG CATEGORY # 3 |
| 589 | 3 | 1350-1352 | [RX10V2C4] Level 2 of MULTUM DRUG CATEGORY # 4 |
| | | | |
| 590 | 3 | 1353-1355 | [RX10V3C1] Level 3 of MULTUM DRUG CATEGORY # 1 |
| 591 | 3 | 1356-1358 | [RX10V3C2] Level 3 of MULTUM DRUG CATEGORY # 2 |
| 592 | 3 | 1359-1361 | [RX10V3C3] Level 3 of MULTUM DRUG CATEGORY # 3 |
| 593 | 3 | 1362-1364 | [RX10V3C4] Level 3 of MULTUM DRUG CATEGORY # 4 |

NAMCS SAMPLE DESIGN VARIABLES

NAMCS sampling design variables (in masked format) were first added to the 2000 public use file, and data years from 1993-1999 were re-released to include them. These variables were for use with statistical software such as SUDAAN that takes into account the complex sampling design of the survey. However, for those running versions of SAS, Stata, SPSS and other software that assumes a single stage of sampling, the multi-stage design variables provided on the public use files could not be used without modification. Therefore, in 2002, two new variables, CSTRATM and CPSUM, were developed, that could be used in such programs instead of the multi-stage variables. In 2003, the decision was made to include on the public use file just these two variables and not the multi-stage design variables that appeared in the past.

Until such time as the older public use files may be re-released to include these variables, data users wishing to combine data from 2003 and later years with data from earlier years will find it necessary to create CSTRATM and CPSUM for the earlier files. A technical paper, *Using Ultimate Cluster Models with NAMCS and NHAMCS Public Use Files*, is available for downloading at the Ambulatory Health Care Data website: http://www.cdc.gov/nchs/ahcd/ahcd_questionnaires.htm. This paper gives instructions on how to configure data files prior to 2002 for variance estimation based on 1-stage sampling models, such as those used in SAS proc surveymeans, Stata, SPSS, and the SUDAAN with-replacement option, and how to handle instances of single-case strata in the data on the older files. Please also see the section on Relative Standard Errors in the current document for more information on these variables and how to use them. PSU is primary sampling unit.

In 2012, NAMCS utilized a list sample, as described in more detail on page 8. For consistency with previous years, the same names used in earlier years have been used for the two new sample design variables. For additional information on combining data across years with the old and new sample designs, please see p. 112.

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| 594 | 8 | 1365-1372 | [CSTRATM] Masked clustered stratum marker 12301-12341 |
| 595 | 6 | 1373-1378 | [CPSUM] Masked CHC clinic marker 160011-162177 |
| 596 | 4 | 1379-1382 | [YEAR] SURVEY YEAR 2012 |
| 597 | 1 | 1383 | [SETTYPE] SETTING TYPE This item is intended for use when combining data from NAMCS and NHAMCS. |
| | | | 1 = NAMCS (only CHC visits included in CHC file) 2 = Hospital outpatient department (NHAMCS) 3 = Hospital emergency department (NHAMCS) |

Note: If combining data from the 2012 NAMCS Public Use File with the 2012 NAMCS CHC Public Use File, category 1 alone will not distinguish the records from each component because it is used to designate NAMCS data in general in both files. The RETYPOFFR variable in column 494 can be used to identify CHC records in a combined fine, as all of the CHC records have a REYTPOFFR value of 3.

| 598 | 11 | 1384-1394 | [PATWT] PATIENT VISIT WEIGHT (NOT FOR STATE ESTIMATES) (See page 21 for more information.) |
|-----|----|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | | This variable has been produced as an unrounded integer in 2012, which will make estimates slightly more precise. It is ONLY for use in producing national, regional, division, and MSA-level estimates, NOT state estimates. |
| | | | 168.792 – 82313.10758 |
| 599 | 12 | 1395-1406 | [PATWTST] PATIENT VISIT WEIGHT FOR STATE ESTIMATES (See page 21 for more information.) |

This variable has been produced as an unrounded integer in 2012, which will make estimates slightly more precise. It is ONLY for use in producing state estimates, NOT national, regional, division, or MSA-level estimates.

NOTE: Records sampled in 'division remainders' (that is, not part of the 34 most populous states, but in states aggregated within their division) were given miniscule values for PATWTST (.00016826). State estimates cannot be produced from these records (a total of 6,826 records), but assigning some value for PATWTST was necessary to avoid the records being dropped from statistical software when calculating variances.

0.00016826 - 114499.13409

| ITEM NO. | FIELD LENGTH | FILE LOCATION | [ITEM NAME], DESCRIPTION, AND CODES |
|-------------|-----------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 600 | 9 | 1407-1415 | [PHYSWT] PROVIDER WEIGHT |
| | | | Provider weight enables data users to make provider-level estimates, based on type of sampled provider (SMPROV). See also "Description of the NAMCS," Marginal Data, and Appendix I. |
| | | | 3.52556 - 849.86677 |
| 601 | 1 | 1416 | [SMPROV] SAMPLED PROVIDER TYPE |
| | | | 1 = Physician 2 = Nurse practitioner 3 = Physician assistant 4 = Nurse midwife |
| 602 | 3 | 1417-1419 | [TIMECHC] TIME SPENT WITH NON-PHYSICIAN CLINICIAN (in minutes) (See also TIMEMD) |
| | | | -7 = Not applicable (Sampled provider was a physician) 0-240 |
| 603 | 2 | 1420-1421 | [TIMECHCFL] Imputation indicator for TIMECHC |
| | | | -7 = Not applicable (Sampled provider was a physician) 0 = Not imputed 1 = Imputed |

B. PHYSICIAN SPECIALTY LIST

Physicians within each CHC self-identified their specialty during the NAMCS induction interview. Below is a list of the broad specialty groupings used in the CHC file, along with the American Medical Association physician specialties used to define them, for survey tabulation purposes. The specialties within each broader group are the same as those in the 2012 NAMCS public use file.

GENERAL AND FAMILY PRACTICE

AMF – Adolescent Medicine (Family Practice)

EFM - Emergency Medicine/Family Medicine

FP - Family Practice

FPG - Family Practice, Geriatric Medicine

GP - General Practice

HPF – Hospice & Palliative Medicine (Family Medicine)

AMI - Adolescent Medicine (Internal Medicine)

IFP - Internal Medicine Family Practice

IMG - Geriatric Medicine (Internal Medicine)

IPM - Internal Medicine/Preventive Medicine

INTERNAL MEDICINE

IM - Internal Medicine

PEDIATRICS

ADL - Adolescent Medicine (Pediatrics)

CAP - Child Abuse Pediatrics

CCP - Pediatric Critical Care Medicine

DBP - Developmental - Behavioral Pediatrics

EMP - Pediatrics - Emergency Medicine

MPD - Internal Medicine/Pediatrics

NDN – Neurodevelopmental Disabilities (Psychiatry & Neurology)

NDP - Neurodevelopmental Disabilities (Pediatrics)

NPM - Neonatal-Perinatal Medicine

PD - Pediatrics

PDA - Pediatric Allergy

PDC - Pediatric Cardiology

PDE - Pediatric Endocrinology

PDI - Pediatric Infectious Diseases

PDP - Pediatric Pulmonology

PDT - Medical Toxicology (Pediatrics)

PEM - Pediatric Emergency Medicine (Pediatrics)

PG - Pediatric Gastroenterology

PHO - Pediatric Hematology/Oncology

PMG - Pediatrics - Medical Genetics

PN - Pediatric Nephrology

PPR - Pediatric Rheumatology

PSM - Pediatric Sports Medicine

GENERAL SURGERY

GS - General Surgery

OBSTETRICS AND GYNECOLOGY

GO - Gynecological Oncology

GYN - Gynecology

HPO -- Hospice & Palliative Med (Obstetrics & Gynecology)

MFM - Maternal & Fetal Medicine

OBG - Obstetrics & Gynecology

OBS - Obstetrics

OCC - Critical Care Medicine (Obstetrics & Gynecology)

PSYCHIATRY

ADP - Addiction Psychiatry

CHP - Child and Adolescent Psychiatry

CPP - Pediatrics/Psychiatry/Child & Adolescent Psychiatry

NUP - Neuropsychiatry

P - Psychiatry

PFP - Forensic Psychiatry

PYA - Psychoanalysis

PYG - Geriatric Psychiatry

PYM - Psychosomatic Medicine

OPHTHALMOLOGY

OPH - Ophthalmology

PO - Pediatric Ophthalmology

ALL OTHER

A - Allergy

ADM - Addiction Medicine

AI - Allergy and Immunology

ALI – Clinical Laboratory Immunology (Allergy & immunology)

AM - Aerospace Medicine

AS - Abdominal Surgery

CBG - Clinical Biochemical Genetics

CCG - Clinical Cytogenetics

CCM - Critical Care Medicine (Internal medicine)

CCS - Surgical Critical Care (Surgery)

CFS - Craniofacial Surgery

CG - Clinical Genetics

ALL OTHER (cont.)

CHS -- Congenital Cardiac Surgery (Thoracic Surgery)

CMG - Clinical Molecular Genetics

CRS - Colon & Rectal Surgery

CS - Cosmetic Surgery

DDL - Clinical and Lab Derm Immunology

DIA - Diabetes

DS - Dermatologic Surgery

EM - Emergency Medicine

END - Endocrinology, diabetes and metabolism

EP - Epidemiology

ESM - Sports Medicine (Emergency Medicine)

ETX - Medical Toxicology (Emergency Medicine)

FPP - Psychiatry/Family Practice

FPS - Facial Plastic Surgery

FSM - Family Practice/Sports Medicine

GE - Gastroenterology

GPM - General Preventive Medicine

HEM – Hematology (Internal medicine)

HEP - Hepatology

HNS - Head & Neck Surgery

HO - Hematology/Oncology

HPE – Hospice & Palliative Medicine (Emergency Medicine)

HPI – Hospice & Palliative Medicine (Internal Medicine)

HPM - Hospice & Palliative Medicine

HPR-- Hospice & Palliative Med (Physical Med & Rehab)

HS - Hand Surgery

HSP - Hand Surgery (Plastic Surgery)

HSS - Hand Surgery (Surgery)

IC - Interventional Cardiology

ICE - Clinical Cardiac Electrophysiology

ID - Infectious Diseases

IEC – Internal Medicine Emergency Medicine/Critical Care Medicine

IG - Immunology

ILI – Clinical and Laboratory Immunology (Internal Medicine)

IMD – Internal Medicine/Dermatology

ISM - Internal Medicine - Sports Medicine

LM - Legal Medicine

MDM - Medical Management

MEM - Internal Medicine/Emergency Medicine

MG - Medical Genetics

MN – Internal Medicine/Neurology

MP – Internal Medicine/Psychiatry

MPM – Internal Medicine/Physical Medicine and Rehabilitation

NC - Nuclear Cardiology

NEP - Nephrology

NMN - Neuromuscular medicine

ALL OTHER (cont.)

NS - Neurological Surgery

NTR - Nutrition

OM - Occupational Medicine

OMF - Oral & Maxillofacial Surgery

OMM - Osteopathic Manipulative Medicine

ON - Medical Oncology

PA - Clinical Pharmacology PCC - Pulmonary Critical Care Medicine

PCS - Pediatric Cardiothoracic Surgery

PDD - Pediatric Dermatology

PDM - Pediatrics/Dermatology

PDS - Pediatric Surgery (Surgery)

PE - Pediatric Emergency Medicine (Emergency Medicine)

PHL - Phlebology

PHM - Pharmaceutical Medicine

PHP - Public Health and General Preventive Medicine

PLI – Clinical and Laboratory Immunology (Pediatrics) Immunology

PLM - Palliative Medicine

PM - Physical Medicine and

Rehabilitation

PMM - Pain Medicine

PMN – Pain Management (Neurology)

PMP – Pain Medicine (Physical Medicine and Rehabilitation)

PPM - Pediatrics/Physical Medicine & Rehabilitation

PPN - Pain Medicine (Psychiatry)

PRD - Procedural Dermatology

PRO - Proctology

PRS – Sports Medicine (Physical Medicine and Rehabilitation)

PS -- Plastic Surgery

PSH -- Plastic Surgery within the Head & Neck

PSP -- Plastic Surgery within the Head & Neck (Plastic Surgery)

PTX - Medical Toxicology (Preventive Medicine)

PUD - Pulmonary Diseases PYN - Psychiatry (Neurology)

REN - Reproductive Endocrinology

RHU - Rheumatology

RPM - Pediatric Rehabilitation Medicine

SCI - Spinal Cord Injury Medicine

SME - Sleep Medicine

SMI – Sleep Medicine (Internal Medicine)

SMN – Sleep Medicine (Psychiatry & Neurology)

SO - Surgical Oncology

THP - Transplant Hepatology (Internal

Medicine)

TRS - Traumatic Surgery

TS - Thoracic Surgery

TTS - Transplant Surgery

UCM - Urgent Care Medicine

ALL OTHER (cont.)

UM - Underseas Medicine (Preventive Medicine)

UME – Underseas Medicine (Emergency Medicine)

VM - Vascular Medicine

ALL OTHER (cont.)

VS - Vascular Surgery OS - Other Specialty

US - Unspecified

C. AMA SPECIALTIES REGROUPED INTO PRIMARY CARE, SURGICAL, AND MEDICAL SPECIALTIES

Below is a list of the AMA physician specialties regrouped into primary care, surgical, and medical specialties for analytic purposes (see SPECCAT variable on file layout).

PRIMARY CARE SPECIALTIES

ADL - Adolescent Medicine (Pediatrics)

AMF - Adolescent Medicine (Family Practice)

AMI - Adolescent Medicine (Internal Medicine)

EFM - Emergency Medicine/Family Medicine

FP - Family Practice

FPG - Geriatric medicine (Family Practice)

GP - General Practice

GYN - Gynecology

HPF - Hospice & Palliative Medicine (Family Medicine)

IFP - Internal Medicine/Family Practice

IM - Internal Medicine

IMG - Geriatric Medicine (Internal Medicine)

IPM - Internal Medicine/Preventive Medicine

MPD - Internal Medicine/Pediatrics

OBG - Obstetrics & Gynecology

OBS - Obstetrics

PD - Pediatrics

PSM - Pediatric Sports Medicine

SURGICAL SPECIALTIES

AS - Abdominal Surgery

CCS - Surgical Critical Care (Surgery)

CFS - Craniofacial Surgery

CHS - Congenital Cardiac Surgery (Thoracic Surgery)

CRS - Colon & Rectal Surgery

CS - Cosmetic Surgery

DS - Dermatologic Surgery

FPS - Facial Plastic Surgery

GO - Gynecological Oncology

GS - General Surgery

HO - Hematology/Oncology

HNS - Head & Neck Surgery

HS - Hand Surgery

HSO - Hand Surgery (Orthopedics)

HSP - Hand Surgery (Plastic Surgery)

HSS - Hand Surgery (Surgery)

MFM - Maternal & Fetal Medicine

NO - Neurotology (Otolaryngology)

NS - Neurological Surgery

SURGICAL SPECIALTIES (cont.)

NSP - Pediatric Surgery (Neurology)

OAR - Adult Reconstructive Orthopedics

OCC - Critical Care Medicine (Obstetrics &

Gynecology)

OFA - Foot And Ankle, Orthopedics

OMF - Oral and Maxillofacial Surgery

OMO- Musculoskeletal Oncology

ON - Medical Oncology

OP - Pediatric Orthopedics

OPH - Ophthalmology

ORS - Orthopedic Surgery

OSM - Sports Medicine (Orthopedic Surgery)

OSS - Orthopedic Surgery Of The Spine

OTO - Otolaryngology

OTR - Orthopedic Trauma

PCS - Pediatric Cardiothoracic Surgery

PDO - Pediatric Otolaryngology

PDS - Pediatric Surgery (Surgery)

PO - Pediatric Ophthalmology

PRD - Procedural Dermatology

PS - Plastic Surgery

PSH - Plastic Surgery Within the Head & Neck

SO - Surgical Oncology

TRS - Trauma Surgery

TS - Thoracic Surgery

TTS - Transplant Surgery

U - Urology

UP - Pediatric Urology

VS - Vascular Surgery

MEDICAL SPECIALTIES

A - Allergy

ADM -Addiction Medicine

ADP - Addiction Psychiatry

AI - Allergy & Immunology

ALI - Clinical Laboratory Immunology (Allergy & Immunology)

AM - Aerospace Medicine

CAP - Child Abuse Pediatrics

CBG - Clinical Biochemical Genetics

CCG -Clinical Cytogenetics

CCM -Critical Care Medicine (Internal Medicine)

MEDICAL SPECIALTIES (cont.)

CCP - Pediatric Critical Care Medicine

CD - Cardiovascular Disease

CG - Clinical Genetics

CHN - Child Neurology

CHP - Child and Adolescent Psychiatry

CMG -Clinical Molecular Genetics

CN - Clinical Neurophysiology

CPP - Pediatrics/Psychiatry/Child & Adolescent Psychiatry

D - Dermatology

DBP - Developmental-Behavioral Pediatrics

DDL - Clinical And Lab Derm Immunology

DIA - Diabetes

EM - Emergency Medicine

EMP - Pediatrics/Emergency Medicine

END - Endocrinology, Diabetes and Metabolism

EP - Epidemiology

ESM - Sports Medicine (Emergency Medicine)

ETX - Medical Toxicology (Emergency Medicine)

FPP - Psychiatry/Family Practice

FSM - Family Practice/Sports Medicine

GE - Gastroenterology

GPM -General Preventive Medicine

HEM -Hematology (Internal Medicine)

HEP - Hepatology

HO - Hematology/Oncology

HPE - Hospice & Palliative Medicine (Emergency Medicine)

HPI - Hospice & Palliative Medicine (Internal Medicine)

HPM -Hospice & Palliative Medicine

HPR - Hospice & Palliative Medicine (Physical Medicine)

IC - Interventional Cardiology

ICE - Clinical Cardiac Electrophysiology

ID - Infectious Disease

IEC - Internal Medicine/Emergency Medicine/ Critical Care Medicine

IG - Immunology

ILI - Clinical and Laboratory Immunology (Internal Medicine)

IMD - Internal Medicine/Dermatology

ISM - Internal Medicine - Sports Medicine

LM - Legal Medicine

MDM -Medical Management

MEM- Internal Medicine/Emergency Medicine

MG - Medical Genetics

MN - Internal Medicine/Neurology

MP - Internal Medicine/Psychiatry

MPM - Internal Medicine/Physical Medicine And Rehabilitation

MEDICAL SPECIALTIES (cont.)

N - Neurology

NC - Nuclear Cardiology

NDN - Neurodevelopmental Disabilities (Psychiatry & Neurology)

NDP - Neurodevelopmental Disabilities (Pediatrics)

NEP - Nephrology

NMN - Neuromuscular Medicine

NMP – Neuromuscular Medicine (Physician Medicine and Rehabilitation)

NPM - Neonatal-Perinatal Medicine

NRN - Neurology/Diagnostic Radiology/Neuroradiology

NTR - Nutrition

NUP - Neuropsychiatry

OM - Occupational Medicine

OMM - Osteopathic Manipulative Medicine

ON - Medical Oncology

P - Psychiatry

PA - Clinical Pharmacology

PCC - Pulmonary Critical Care Medicine

PDA - Pediatric Allergy

PDC - Pediatric Cardiology

PDD - Pediatric Dermatology

PDE - Pediatric Endocrinology

PDI - Pediatric Infectious Diseases

PDM -Pediatrics/Dermatology

PDP - Pediatric Pulmonology

PDT - Medical Toxicology (Pediatrics)

PE - Pediatric Emergency Medicine (Emergency Medicine)

PEM - Pediatric Emergency Medicine (Pediatrics)

PFP - Forensic Psychiatry

PG - Pediatric Gastroenterology

PHL - Phlebology

PHM - Pharmaceutical Medicine

PHO - Pediatric Hematology/Oncology

PHP - Public Health and General Preventive Medicine

PLI - Clinical and Laboratory Immunology (Pediatrics)

PLM - Palliative Medicine

PM - Physical Medicine & Rehabilitation

PMM - Pain Medicine

PMN - Pain Medicine (Neurology)

PMP - Pain Management (Physical Medicine & Rehabilitation)

PN - Pediatric Nephrology

PPM - Pediatrics/Physical Medicine & Rehabilitation

PPN - Pain Medicine (Psychiatry)

MEDICAL SPECIALTIES (cont.)

PPR - Pediatric Rheumatology

PRO - Proctology

PRS - Sports Medicine (Physical Medicine & Rehabilitation)

PTX - Medical Toxicology (Preventive Medicine)

PUD - Pulmonary Disease

PYA - Psychoanalysis

PYG - Geriatric Psychiatry

PYM - Psychosomatic Medicine

PYN - Psychiatry/Neurology

REN - Reproductive Endocrinology

RHU - Rheumatology

RPM - Pediatric Rehabilitation Medicine

SCI - Spinal Cord Injury Medicine

MEDICAL SPECIALTIES (cont.)

SME - Sleep Medicine

SMI - Sleep Medicine (Internal Medicine)

SMN -Sleep Medicine (Psychiatry & Neurology)

THP – Transplant Hepatology (Internal Medicine)

UCM -Urgent Care Medicine

UCM -Urgent Care Medicine

UM - Underseas Medicine (Preventive Medicine)

UME -Underseas Medicine (Emergency Medicine)

VM - Vascular Medicine

VN - Vascular Neurology

OS - Other Specialty

US - Unspecified Specialty

III. MARGINAL DATA

A. PATIENT VISITS

| PATIENT AGE | | | | |
|------------------------|------------|------------------|---------|--|
| CATEGORY | RECORDS | WEIGHTED VISITS | PERCENT | |
| Total | 34,698 | 65,332,722 | 100.000 | |
| 1 - Under 15 years | 7,844 | 14,690,679 | 22.486 | |
| 2 - 15-24 years | 4,149 | 7,929,870 | 12.138 | |
| 3 - 25-44 year | 9,096 | 17,369,404 | 26.586 | |
| 4 - 45-64 years | 10,168 | 19,179,479 | 29.357 | |
| 5 - 65-74 years | 2,129 | 3,925,599 | 6.009 | |
| 6 - 75 years and over | 1,312 | 2,237,691 | 3.425 | |
| PATIENT SEX | | | | |
| CATEGORY | RECORDS | WEIGHTED VISITS | PERCENT | |
| Total | 34,698 | 65,332,722 | 100.000 | |
| 1 - Female | 21,554 | 40,746,810 | 62.368 | |
| 2 - Male | 13,144 | 24,585,911 | 37.632 | |
| PATIENT RACE RECODE (W | TITH MISSI | NG DATA IMPUTED) | | |
| CATEGORY | RECORDS | WEIGHTED VISITS | PERCENT | |
| Total | 34,698 | 65,332,722 | 100.000 | |
| 1 - White | 25,089 | 51,857,257 | 79.374 | |
| 2 - Black | 7,409 | 9,982,561 | 15.280 | |
| 3 - Other | 2,200 | 3,492,904 | | |

EXPECTED PRIMARY SOURCE OF PAYMENT [based on PAYTYPER, a recoded variable, see more about this variable on page 28]

| CATEGORY | RECORDS | WEIGHTED VISITS | PERCENT |
|---------------------------------------|-----------|-----------------|---------|
| Total | 34,698 | 65,332,722 | 100.000 |
| -9 - All sources of payment are blank | 811 | 1,784,157 | 2.731 |
| -8 - Unknown | 2,164 | 2,808,101 | 4.298 |
| 1 - Private insurance | 6,012 | 10,876,895 | 16.648 |
| 2 - Medicare | 4,418 | 7,856,609 | 12.026 |
| 3 - Medicaid | 12,393 | 26,668,663 | 40.820 |
| 4 - Worker's compensation | 57 | 78,605 | 0.120 |
| 5 - Self-pay | 6,226 | 9,303,353 | 14.240 |
| 6 - No charge | 575 | 976,910 | 1.495 |
| 7 - Other | 2,042 | 4,979,429 | 7.622 |
| MAJOR REASON FOR VISIT | | | |
| CATEGORY | RECORDS | WEIGHTED VISITS | PERCENT |
| Total | 34,698 | 65,332,722 | 100.000 |
| -9 - Blank | 168 | 396,952 | 0.608 |
| 1 - New problem (less than 3 mos. | | | |
| onset) | 14,292 | 25,951,758 | 39.722 |
| 2 - Chronic problem, routine | 8,580 | 16,646,534 | 25.480 |
| 3 - Chronic problem, flare-up | 2,087 | 4,129,886 | 6.321 |
| 4 - Pre-/Post-surgery | 368 | 877,908 | 1.344 |
| 5 - Preventive care | 9,203 | 17,329,683 | 26.525 |
| HAS THE PATIENT BEEN SEEN IN YOUR PR | ACTICE BE | FORE? | |
| CATEGORY | RECORDS | WEIGHTED VISITS | PERCENT |
| Total | 34,698 | 65,332,722 | 100.000 |
| 1 - Yes, established patient | 29,590 | 56,050,935 | 85.793 |
| 2 - No, new patient | 5,108 | 9,281,786 | 14.207 |
| | | | |

NUMBER OF MEDICATION CODES THIS VISIT

| CATEGORY | RECORDS | WEIGHTED VISITS | PERCENT |
|----------|---------|-----------------|---------|
| Total | 34,698 | 65,332,722 | 100.000 |
| 0 | 7,791 | 16,476,015 | 25.219 |
| 1 | 7,037 | 13,347,130 | 20.429 |
| 2 | 5,555 | 9,214,992 | 14.105 |
| 3 | 3,810 | 7,083,365 | 10.842 |
| 4 | 2,661 | 4,795,283 | 7.340 |
| 5 | 1,904 | 3,714,178 | 5.685 |
| 6 | 1,358 | 2,530,401 | 3.873 |
| 7 | 1,037 | 1,940,274 | 2.970 |
| 8 | 820 | 1,511,621 | 2.314 |
| 9 | 817 | 1,456,716 | 2.230 |
| 10 | 1,908 | 3,262,747 | 4.994 |

PHYSICIAN SPECIALTY - 14 SPECIALTY GROUPS/NON-PHYSICIAN CLINICIANS

| CATEGORY | RECORDS | WEIGHTED VISITS | PERCENT |
|-------------------------------|---------|-----------------|---------|
| Total | 34,698 | 65,332,722 | 100.000 |
| 1 - General/family practice | 11,343 | 20,450,300 | 31.302 |
| 3 - Internal medicine | 2,346 | 6,495,130 | 9.942 |
| 4 - Pediatrics | 3,812 | 7,728,395 | 11.829 |
| 5 - General surgery | 10 | 151,839 | 0.232 |
| 6 - Obstetrics and gynecology | 1,254 | 3,645,261 | 5.580 |
| 11 - Psychiatry | 305 | 1,043,973 | 1.598 |
| 13 - Ophthalmology | 8 | 81,320 | 0.124 |
| 15 - Other specialties | 422 | 1,058,078 | 1.620 |
| 96 - Nurse practitioner | 9,876 | 12,932,590 | 19.795 |
| 97 - Physician assistant | 4,795 | 10,720,856 | 16.410 |
| 98 - Nurse midwife | 527 | 1,024,979 | 1.569 |

B. DRUG MENTIONS

PATIENT AGE

| CATEGORY | RECORDS | WEIGHTED MENTIONS | PERCENT |
|-----------------------|---------|-------------------|---------|
| Total | 98,141 | 177,374,433 | 100.000 |
| 1 - Under 15 years | 12,933 | 23,680,847 | 13.351 |
| 2 - 15-24 years | 6,757 | 12,782,031 | 7.206 |
| 3 - 25-44 years | 22,608 | 40,078,871 | 22.596 |
| 4 - 45-64 years | 39,597 | 72,308,408 | 40.766 |
| 5 - 65-74 years | 9,972 | 18,425,252 | 10.388 |
| 6 - 75 years and over | 6,274 | 10,099,024 | 5.694 |
| | | | |

PATIENT SEX

| CATEGORY | RECORDS | WEIGHTED MENTIONS | PERCENT | |
|------------|---------|-------------------|---------|--|
| Total | 98,141 | 177,374,433 | 100.000 | |
| 1 - Female | 61,085 | 110,415,663 | 62.250 | |
| 2 - Male | 37,056 | 66,958,770 | 37.750 | |
| | | | | |

PHYSICIAN SPECIALTY - 14 SPECIALTY GROUPS/NON-PHYSICIAN CLINICIAN

| CATEGORY | RECORDS | WEIGHTED MENTIONS | PERCENT |
|-------------------------------|---------|-------------------|---------|
| Total | 98,141 | 177,374,433 | 100.000 |
| 1 - General/family practice | 36,700 | 61,494,565 | 34.669 |
| 3 - Internal medicine | 7,907 | 23,468,719 | 13.231 |
| 4 - Pediatrics | 7,142 | 13,376,508 | 7.541 |
| 5 - General surgery | 62 | 941,404 | 0.531 |
| 6 - Obstetrics and gynecology | 1,889 | 5,575,725 | 3.143 |
| 11 - Psychiatry | 835 | 2,550,077 | 1.438 |
| 13 - Ophthalmology | 6 | 60,990 | 0.034 |
| 15 - Other specialties | 1,262 | 5,603,459 | 3.159 |
| 96 - Nurse practitioner | 28,520 | 35,217,661 | 19.855 |
| 97 - Physician assistant | 13,062 | 27,560,027 | 15.538 |
| 98 - Nurse midwife | 756 | 1,525,298 | 0.860 |

DRUG THERAPEUTIC CATEGORIES (USING LEVEL 1 CODES)

| CATEGORY | RECORDS | WEIGHTED MENTIONS | PERCENT |
|-------------------------------------|---------|-------------------|---------|
| | | | |
| Total | 104,826 | 190,213,720 | 100.000 |
| '001'=Anti-infectives | 7,753 | 12,734,730 | 6.695 |
| '020'=Antineoplastics | 581 | 1,151,810 | 0.606 |
| '028'=Biologicals | 70 | 259,681 | 0.137 |
| '040'=Cardiovascular agents | 14,554 | 24,695,054 | 12.983 |
| '057'=Central nervous system agents | 21,492 | 39,779,253 | 20.913 |
| '081'=Coagulation modifiers | 2,798 | 5,299,095 | 2.786 |
| '087'=Gastrointestinal agents | 5,389 | 9,897,520 | 5.203 |
| '097'=Hormones | 4,909 | 8,817,217 | 4.635 |
| '105'=Miscellaneous agents | 1,448 | 2,835,486 | 1.491 |
| '113'=Genitourinary tract agents | 635 | 1,035,271 | 0.544 |
| '115'=Nutritional products | 5,491 | 10,750,199 | 5.652 |
| '122'=Respiratory agents | 11,289 | 19,185,874 | 10.086 |
| '133'=Topical agents | 5,887 | 10,770,397 | 5.662 |
| '153'=Plasma expanders | 3 | 4,689 | 0.002 |
| '218'=Alternative medicines | 1,338 | 2,283,035 | 1.200 |
| '242'=Psychotherapeutic agents | 6,551 | 12,538,098 | 6.592 |
| '254'=Immunological agents | 4,935 | 9,887,009 | 5.198 |
| '331'=Radiologic agents | 10 | 31,867 | 0.017 |
| '358'=Metabolic agents | 9,630 | 18,155,576 | 9.545 |
| '365'=Medical gases | 34 | 48,928 | 0.026 |
| '899'=Pharmaceutical aids | 29 | 52,930 | 0.028 |

Therapeutic categories are based on Lexicon Plus®, a proprietary database of Cerner Multum, Inc. The Lexicon Plus is a comprehensive database of all prescription and some nonprescription drug products available in the U.S. drug market. For additional information on the Multum Lexicon Drug Database, please refer to the following Web site: http://www.multum.com/Lexicon.htm. For more information on coding therapeutic categories in NAMCS, see page 17.

C. PHYSICIAN/NON-PHYSICIAN CLINICIAN ESTIMATES

PHYSICIAN SPECIALTY/NON-PHYSICIAN CLINICIAN

| CATE | GORY | RECORDS | WEIGHTED PROVIDERS | PERCENT |
|------|---------------------------|---------|--------------------|---------|
| | Total | 1,752 | 26,308 | 100.000 |
| 1 - | General/family practice | 553 | 7,053 | 26.810 |
| 3 | Internal medicine | 119 | 2,037 | 7.741 |
| 4 | Pediatrics | 173 | 2,933 | 11.147 |
| 5 | General surgery | 1 | 435 | 1.652 |
| 6 | Obstetrics and gynecology | 70 | 2,264 | 8.604 |
| 11 | Psychiatry | 16 | 517 | 1.964 |
| 13 | Ophthalmology | 1 | 96 | 0.365 |
| 15 | Other specialties | 22 | 837 | 3.180 |
| 96 | Nurse practitioner | 528 | 5,719 | 21.740 |
| 97 | Physician assistant | 239 | 3,838 | 14.590 |
| 98 | Nurse midwife | 30 | 580 | 2.206 |

IS THIS A SOLO PRACTICE?

| CATEGORY | RECORDS | WEIGHTED PROVIDER | S PERCENT |
|------------|---------|-------------------|-----------|
| Total | 1,752 | 26,308 | 100.000 |
| -9 - Blank | 1 | 2 | 0.008 |
| 1 - Yes | 175 | 1,909 | 7.257 |
| 2 - No | 1,576 | 24,397 | 92.736 |
| | | | |

SPECIALTY TYPE/NON-PHYSICIAN CLINICIAN

| CATEGORY | RECORDS | WEIGHTED PHYSICIA | ANS PERCENT |
|-----------------------------|---------|-------------------|-------------|
| Total | 1,752 | 26,308 | 100.000 |
| 1 - Primary care specialty | 914 | 14,265 | 54.223 |
| 2 - Surgical care specialty | 3 | 541 | 2.056 |
| 3 - Medical care specialty | 38 | 1,364 | 5.185 |
| 4 - Non-physician clinician | 797 | 10.138 | 38.536 |

D. STATE ESTIMATES

| OT 4 TE | | MA LODITAL | \sim $-$ | DDOL/TDED LO | \/TOTTO | | 0 4 1 4 D 1 E D |
|---------|-------|------------|------------|--------------|---------|------|-----------------|
| STATE | WHERE | MAJORLIY | OF | PROVIDER'S | VISIIS | WERE | SAMPLED |

| Total (34 most populous states) | 31,737 | 54,272,922 | 100.000 |
|----------------------------------|--------|------------|---------|
| Alabama | 586 | 466,495 | 0.860 |
| Arizona | 1,528 | 1,606,944 | 2.961 |
| Arkansas | 899 | 406,893 | 0.750 |
| California | 1,463 | 17,177,225 | 31.650 |
| Colorado | 643 | 719,867 | 1.326 |
| Connecticut | 533 | 971,927 | 1.791 |
| Florida | 1,030 | 2,364,505 | 4.357 |
| Georgia | 777 | 540,857 | 0.997 |
| Illinois | 641 | 3,458,852 | 6.373 |
| Indiana | 1,622 | 879,899 | 1.621 |
| Iowa | 1,164 | 545,551 | 1.005 |
| Kansas | 1,059 | 218,663 | 0.403 |
| Kentucky | 396 | 408,121 | 0.752 |
| Louisiana | 954 | 666,816 | 1.229 |
| Maryland | 834 | 780,411 | 1.438 |
| Massachusetts | 589 | 1,483,821 | 2.734 |
| Michigan | 1,163 | 2,265,147 | 4.174 |
| Minnesota | 880 | 404,702 | 0.746 |
| Mississippi | 936 | 692,451 | 1.276 |
| Missouri | 630 | 1,793,789 | 3.305 |
| New Jersey | 1,039 | 915,880 | 1.688 |
| New York | 441 | 3,032,530 | 5.588 |
| North Carolina | 770 | 695,599 | 1.282 |
| Ohio | 1,387 | 1,701,532 | 3.135 |
| Oklahoma | 1,094 | 413,005 | 0.761 |
| Oregon | 550 | 773,153 | 1.425 |
| Pennsylvania | 903 | 1,304,292 | 2.403 |
| South Carolina | 1,157 | 943,240 | 1.738 |
| Tennessee | 694 | 729,715 | 1.345 |
| Texas | 1,283 | 2,368,547 | 4.364 |
| Utah | 753 | 177,114 | 0.326 |
| Virginia | 1,175 | 857,566 | 1.580 |
| Washington | 1,713 | 2,131,758 | 3.928 |
| Wisconsin | 451 | 376,055 | 0.693 |
| NOTE: Cincore in this table madi | 04 . | | ± A |

NOTE: Figures in this table reflect the 34 most populous states. An additional 2,961 records were sampled in state aggregates within their Census division. To produce estimates by division, one must use the patient visit weight PATWT, not the state-based patient visit weight PATWTST.

APPENDIX I

A. STANDARD ERRORS AND VARIANCE ESTIMATION

The standard error is primarily a measure of the sampling variability that occurs by chance because only a sample is surveyed, rather than the entire universe. The relative standard error (RSE) of an estimate is obtained by dividing the standard error of the estimate by the estimate itself and is expressed as a percentage of the estimate.

In the past, NAMCS micro-data file documentation contained formulas for approximating relative standard errors based on generalized variance curves as well as tables showing lowest reliable estimates based on curve coefficients. This was provided as an alternative for data users who lacked analytic software to produce standard errors and other measures of sampling variability. However, it has long been recognized that such approximations are less accurate than those produced using a statistical software package that takes into account the complex sample designs of surveys. As more data users have obtained access to sophisticated computer software over time, and as recent efforts by NCHS research staff to refine the generalized variance curves did not yield significant improvements, the decision was made starting with 2011 NAMCS data to discontinue the provision of these approximate methods of variance estimation.

Using computer software like SUDAAN to produce standard errors will, in general, yield results that are more accurate than those produced using generalized variance curves. This is especially true for clustered variables like race, provider seen, or expected source of payment. However, standard errors produced with such software using masked design variables, while improving substantially over generalized variance curve results, will not always be as accurate as those produced using unmasked data. Data files containing unmasked variables are confidential and are only available through the NCHS Research Data Center.

Starting with the 2012 NAMCS, a new sampling methodology was employed that used a list sample rather than a clustered sample. The design variables reflect the new sampling methodology. Examples of SUDAAN, SAS, Stata, and SPSS statements which incorporate these new design variables for variance estimation purposes are presented below.

The following example is for use with the 2012 NAMCS public use file and the 2012 NAMCS CHC public use file. It can also be used to approximate variances for visit estimates when 2012 NAMCS data are combined with data from the National Hospital Ambulatory Medical Care Survey, which still uses the pre-2012 NAMCS clustered PSU sample design, or with previous years of NAMCS data.

SUDAAN 1-stage WR (With-Replacement) Option

This code provides a with-replacement ultimate cluster (1-stage) estimate of standard errors for a cross-tabulation with a dataset called TEST.

PROC CROSSTAB DATA = TEST DESIGN=WR; NEST CSTRATM CPSUM /MISSUNIT;

It is important to keep the following in mind when trying to combine or analyze data across years:

NAMCS public use files from 2003-2011 only include first-stage design variables in their masked form, CSTRATM and CPSUM, for use in WR design options. From 1993-2002, a full set of masked design variables was provided. The decision to switch to ultimate cluster variables was initially made because many popular software products could not make use of the full set of design variables. Instructions are provided for public use file data users on the survey website regarding how to create CSTRATM and

CPSUM for data years prior to 2002, in order to have a consistent set of design variables for analysis. See the technical paper, *Using Ultimate Cluster Models with NAMCS and NHAMCS Public Use Files*, for more information: http://www.cdc.gov/nchs/namcs.htm.

If software other than SUDAAN is used to approximate estimate variances, other statements will be required by that software. The variance variables required by that software are the same as those defined above for SUDAAN software.

SAS - PROC SURVEYMEANS

PROC SURVEYMEANS DATA=TEST; CLUSTER CPSUM; STRATA CSTRATM;

Stata - For use with ultimate cluster design option:

The pweight (PATWT), strata (CSTRATM), and PSU (CPSUM) are set with the svyset command as follows:

Stata 8:

svyset [pweight=patwt], psu(cpsum) strata(cstratm)

Stata 9 and later:

svyset cpsum [pweight=patwt], strata(cstratm)

SPSS

To obtain variance estimates which take the sample design into account, IBM SPSS Inc.'s Complex Samples module can be used. This description applies to version 21.0. From the main menu, first click on 'Analyze', then 'Complex Samples', then 'Prepare for Analysis'. The 'Analysis Preparation Wizard' can be used to set CSTRATM as the stratum variable, CPSUM as the cluster variable, and PATWT as the weighting variable. The WR design option may be chosen. This will create the PLAN FILE syntax, which should resemble the code below, where PLAN FILE reflects the location you have selected to store the file on your computer:

CSPLAN ANALYSIS

/PLAN FILE='DIRECTORY\PLANNAME.CSAPLAN'
/PLAN VARS ANALYSISWEIGHT=PATWT
/PRINT PLAN
/DESIGN STAGELABEL= 'ANY LABEL' STRATA=CSTRATM CLUSTER=CPSUM
/ESTIMATOR TYPE=WR.

After creating the plan file, various analyses can be selected from the 'Complex Samples' menu. This is an example of a crosstabulation with options selected for counts, percents, and standard errors, with missing data (if any) included:

CSTABULATE

/PLAN FILE='DIRECTORY\PLANNAME.CSAPLAN'
/TABLES VARIABLES = AGER BY SEX
/CELLS POPSIZE ROWPCT COLPCT
/STATISTICS SE COUNT
/MISSING SCOPE = TABLE CLASSMISSING = INCLUDE.

Results using IBM SPSS with the WR option were found to be the same as those obtained using SUDAAN Release 11.0.1 with the WR option.

IMPORTANT NOTE REGARDING CHC PROVIDER-LEVEL ESTIMATES: The examples above can be used when producing visit or drug estimates. For provider-level estimates, the statements are the same, but replace PATWT with PHYSWT.

The PHYSWT variable itself should only be used to make estimates at the provider level. For this reason, it is only placed on the first record for each provider on the public use file. When running purely provider-level analysis, it is recommended that only records with PHYSWT > 0 be selected; this will give the correct sample counts and will not affect estimation of variance. Weighted estimates will be correct either way. For RDC researchers, please be sure to specify if PHYSWT is required and how it will be used, so that files can be constructed properly.

In addition to generating estimates for provider characteristics at the provider level, the addition of PHYSWT also means that one can link visit data with provider data. For example, one could examine average time spent with physicians across physicians rather than simply across visits. This type of analysis is slightly complicated; a description along with sample SAS code is available at the Ambulatory Health Care Data website. For more information, contact the Ambulatory and Hospital Care Statistics Branch at 301-458-4600.

B. 2012 NAMCS PATIENT RECORD FORM - INSTRUCTIONS AND DEFINITIONS

NOTE: The 2012 NAMCS Patient Record Form was used to collect visit data from both office-based physicians and CHC service delivery sites. The instructions are <u>available</u> in the 2012 NAMCS Public Use File Documentation.

C. DEFINITIONS OF CERTAIN TERMS USED IN NAMCS CHC COMPONENT

Many of the definitions used in the NAMCS office-based component also apply to the CHC component. The following includes common terms and those with changes that are specific to the CHC component.

Ambulatory patient -- An individual presenting for personal health services, neither bedridden nor currently admitted to any health care institution on the premises.

Community health center – Community health centers are medical facilities that serve low-income and medically underserved communities. The CHC structure is similar to group practices. CHCs are operated from a central office that may support multiple satellite offices and/or mobile health care units. Eligible types of CHCs include:

 Federally-funded Community Health Center (as authorized by Section 330 of the Public Health Service Act)

Community Health Center (CHC)

Migrant Health Center (MHC)

Health Care for the Homeless (HCH)

Public Housing Primary Care (PHPC) grant program

- Federally Qualified Health Center, but not federally funded (330 look-alike)
- Urban Indian Health Centers (funded under Title V of the Indian Health Care Improvement Act, PL 94-437, as amended)

Continuity of care -- Continuity of care is a goal of health care achieved through an interdisciplinary process involving patients, families, health care professionals, and providers in the management of a coordinated plan of care. Based on changing needs and available resources, the process optimizes quality outcomes in the health status of patients. It may involve professionals from many different disciplines within multiple systems.

Drug mention(s) --The provider's entry of a pharmaceutical agent ordered or provided--by any route of administration--for prevention, diagnosis, or treatment. Generic as well as brand-name drugs are included. Along with all new drugs, the provider also records continued medications if the patient was specifically instructed or expected to continue the medication.

Drug visit -- A drug visit is a visit at which medication was prescribed or provided by the provider.

Visit --A direct, personal exchange between ambulatory patient and the sampled CHC provider (or members of his/her staff) for the purpose of seeking care and rendering health services.

PATIENTS

In-scope -- All patients seen by the sampled CHC provider at the sampled CHC service delivery site during the site's sample (reporting) week.

Out-of-scope -- Patients seen by the provider outside of the sampled CHC service delivery site, for example in a different CHC service delivery site, a private practice, a hospital, nursing home, or other extended care institution, or the patient's home. The following types of patients are also considered out-of-scope:

- patients seen by the provider in any institution (including outpatient clinics of hospitals) for which the institution has the primary responsibility for the care of the patient over time;
- patients who telephone and receive advice from the provider;
- patients who come to the CHC service delivery site only to leave a specimen, pick up insurance forms, or pay their bills;
- patients who come to the CHC service delivery site only to pick up medications previously prescribed by the provider.

PHYSICIANS/PROVIDERS

In-Scope -- All duly licensed doctors of medicine and doctors of osteopathy currently in practice who see ambulatory patients at the sampled CHC service delivery site. Also in-scope are CHC providers who are physician assistants (PAs), nurse practitioners (NPs), and nurse-midwives (NMWs) who care for patients at the sampled CHC service delivery site. Physicians and eligible providers may be employed part-time by a federal or institutional facility or work in private practice, but must provide services at least part time in the sampled CHC.

Out-of-Scope – The survey medical specialty eligibility criteria for CHC physicians are the same as for office-based physicians. PAs, NPs, and NMWs do not list a specialty. For physicians, out-of-scope specialties include anesthesiology, pathology, forensic pathology, radiology, therapeutic radiology, and diagnostic radiology. Ineligible specialty providers in CHCs also include dentists, hygienists, optometrists, podiatrists, psychologists, therapists (physical, speech, occupational), and social workers.

Physician specialty -- Principal specialty (including general practice) as designated by the physician at the time of the survey. Those physicians for whom a specialty was not obtained were assigned the specialty recorded for the physician in the provider sampling frame from which the physician was selected at the CHC.

Metropolitan status — CHC service delivery sites are classified by their location in metropolitan statistical area as follows:

Metropolitan statistical area (MSA)—As defined by the U.S. Office of Management and Budget, the definition of an individual MSA involves two considerations: first, a city or cities of specified population, that constitute the central city and identify the county in which it is located as the central county; second, economic and social relationships with "contiguous" counties that are metropolitan in character so that the periphery of the specific metropolitan area may be determined. MSAs may cross state lines. In New England, MSAs consist of cities and towns rather than counties.

Non-MSA—Non-MSA areas are those not defined as MSAs, including rural and micropolitan areas.

Region of CHC service delivery site location -- The four geographic regions which correspond to those used by the U.S. Bureau of the Census, are as follows:

| <u>Region</u> | States Included |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Northeast | Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont |
| Midwest | Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin |
| South | Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, West Virginia |
| West | Arizona, California, Colorado, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, Wyoming, Alaska, Hawaii |

| <u>Division</u> | States Included |
|-----------------|-----------------|
| | |

| 1 - New England |
|------------------------------------------------------------------------------------------------|
| 5 – South Atlantic Delaware, District of Columbia, Florida, Georgia, Maryland, North Carolina, |
| South Carolina, Virginia, West Virginia |
| 6 – East South Central Alabama, Kentucky, Mississippi, Tennessee |
| 7 - West South Central Arkansas, Louisiana, Oklahoma, Texas |
| 8 - Mountain Arizona, Colorado, Idaho, New Mexico, Montana, Utah, Nevada, Wyoming |
| 9 – Pacific Alaska, California, Hawaii, Oregon, Washington |

APPENDIX II REASON FOR VISIT CLASSIFICATION

NOTE: The Reason for Visit Classification used for the 2012 NAMCS Community Health Center Public Use Micro-Data File is the same as that used for the 2012 National Ambulatory Medical Care Survey Public Use Micro-Data File and is available here.

APPENDIX III

A. GENERIC CODES AND NAMES IN NUMERIC ORDER

NOTE: This list of drugs only includes those found in the 2012 NAMCS CHC data.

- a07001 FOLIC ACID; NIACIN; VITAMIN E; PYRIDOXINE; CYANOCOBALAMIN a07002 CHOLECALCIFEROL-CALCIUM CITRATE a07027 CALCIUM; MAGNESIUM; CHOLECALCIFEROL a07035 ANALGESICS; DIETARY SUPPLEMENT; ANTIOXIDANTS a07050 ANGIOTENSIN II RECEPTOR BLOCKERS a07069 CYANOACRYLATE a07071 TYROSINE a10001 ACACIA GUM;HYDROCORTISONE;LEVONORGESTREL;NEOMYCIN;POLYMYXIN B **SULFATE** a10051 BENZYL ALCOHOL; SOYBEAN OIL; STARCH TOPICAL a10068 ASCORBIC ACID; BIOTIN; VITAMIN B COMPLEX
- a10096 ASPIRIN-BUFFERS
- a10127 CALCIUM REPLACEMENT-CHOLECALCIFEROL
- a10133 CALCIUM ION; CHLORIDE ION; MAGNESIUM ANTACIDS; POTASSIUM ION; SODIUM ION
- a10136 CALCIUM ION; CHOLECALCIFEROL; IRON PREPARATIONS; VITAMIN A; VITAMIN B **COMPLEX**
- a10155 CARMELLOSE; GELATIN; MINERAL OIL; PECTIN
- a10160 CASEIN; COCONUT OIL; MAGNESIUM AMINO ACIDS CHELATE; SUCROSE; TAPIOCA
- a10163 CASEIN; MULTIVITAMIN; SAFFLOWER OIL; SOYBEAN OIL; SUCROSE
- a10166 CERESIN WAX; MINERAL OIL; PETROLATUM TOPICAL; WOOLWAX ALCOHOL
- a10172 CETEARETH:PETROLATUM TOPICAL:PROPYLENE GLYCOL:SORBITOL
- a10176 AMMONIUM LACTATE TOPICAL;CETYL ALCOHOL;GLYCERYL;MINERAL OIL;PARABENS
- a10192 CHLORIDE ION; POTASSIUM CITRATE; SODIUM ION
- a10205 CHROMIUN:COPPER GLUCONATE:MANGANESE GLUCONATE:ZINC SULFATE
- a10224 COLLODION; ETHANOL; ETHER; SALICYLIC ACID TOPICAL; ZINC TOPICAL AGENTS, **EXTERNAL USE**
- a10242 DEXTROSE; FRUCTOSE; PHOSPHORIC ACID
- a10300 ASCORBIC ACID: ELECTROLYTES: MINERALS: VITAMIN B COMPLEX
- a10312 ETHANOL; EUCALYPTUS OIL; MENTHOL TOPICAL; METHYL SALICYLATE TOPICAL:THYMOL
- a10327 FIBRINOLYSIN-FIBRINOLYSIN AND DESOXYRIBONUCLEASE TOPICAL
- a10362 HYDROCORTISONE TOPICAL;IODOCHLORHYDROXYQUIN;PRAMOXINE TOPICAL
- a10379 IRON PREPARATIONS-VITAMIN B COMPLEX
- a10383 IRON PREPARATIONS-VITAMINS
- a10385 ETHINYL ESTRADIOL; IRON PREPARATIONS; NORETHINDRONE
- a10387 CALCIUM CARBONATE; FOLIC ACID; IRON PREPARATIONS; MULTIVITAMIN; NIACIN
- a10399 FOLIC ACID; IRON PREPARATIONS; MULTIVITAMIN
- a10414 ASCORBIC ACID; CHOLECALCIFEROL; IRON PREPARATIONS; VITAMIN A; VITAMIN E
- a10419 ASCORBIC ACID:ERGOCALCIFEROL:IRON PREPARATIONS:VITAMIN A
- a10421 CYANOCOBALAMIN; IRON PREPARATIONS; PYRIDOXINE; RIBOFLAVIN; THIAMINE

- a10435 ASCORBIC ACID-IRON PREPARATIONS
- a10438 FLUORIDE: IRON PREPARATIONS: MULTIVITAMIN
- a10442 IRON PREPARATIONS-MULTIVITAMIN
- a10452 LACTOSE-NORETHINDRONE
- a10453 LACTOSE-MOMETASONE NASAL
- a10454 EPLERENONE-LACTOSE
- a10455 LACTOSE-TROSPIUM
- a10456 LEMON OIL; MENTHOL; PEPPERMINT; THYME
- a10460 MAGNESIUM ANTACIDS; STARCH TOPICAL; TALC
- a10461 ALUMINUM HYDROXIDE; ASPIRIN; CODEINE; MAGNESIUM ANTACIDS
- a10463 ALUMINUM HYDROXIDE;DIPHENHYDRAMINE TOPICAL;LIDOCAINE;MAGNESIUM ANTACIDS
- a10464 ASPIRIN; CALCIUM CARBONATE; MAGNESIUM ANTACIDS
- a10465 ALUMINUM HYDROXIDE; ASPIRIN; MAGNESIUM ANTACIDS
- a10471 CALCIUM CARBONATE-MAGNESIUM ANTACIDS
- a10472 ALUMINUM HYDROXIDE; CALCIUM CARBONATE; MAGNESIUM ANTACIDS
- a10474 ALUMINUM HYDROXIDE-MAGNESIUM ANTACIDS
- a10475 ALUMINUM HYDROXIDE; MAGNESIUM ANTACIDS; SIMETHICONE
- a10482 GUAIFENESIN; MENTHOL; PARABENS; PHENYLALANINE
- a10497 ASPARTAME;DEXTROMETHORPHAN;GUAIFENESIN; METHYLPARABEN;PHENYLALANINE
- a10500 ALLANTOIN TOPICAL;ALLIUM CEPA;METHYLPARABEN;POLYETHYLENE GLYCOL 3350;SORBIC ACID
- a10502 GLYCERIN TOPICAL;METHYLPARABEN;MINERAL OIL;STERILE WATER
- a10530 MINERALS-MULTIVITAMIN
- a10579 NIACIN; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE
- a10588 MINERAL OIL-PEANUT OIL
- a10597 DIMENHYDRINATE;NIACIN;PENTYLENETETRAZOL
- a10623 ASPARTAME; MANNITOL; NICOTINE; PHENYLALANINE
- a10625 LIVE YEAST CELL; PHENYLMERCURIC NITRATE; SHARK LIVER OIL
- a10664 HP GUAR; POLYETHYLENE GLYCOL 3350; PROPYLENE GLYCOL; SODIUM BORATE TOPICAL
- a10675 GLYCERIN TOPICAL-PROPYLENE GLYCOL
- a10678 CARBOHYDRATES; MULTIVITAMIN; PROTEIN SUPPLEMENT
- a10697 GINSENG;MEADOWFOAM OIL;PETROLATUM TOPICAL;SAFFLOWER OIL;SESAME OIL
- a10707 SOAP-WATER
- a10715 MULTIVITAMIN-SODIUM FLUORIDE
- a10716 ERTAPENEM; SODIUM BICARBONATE; SODIUM HYDROXIDE
- a10726 POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE
- a10730 HORSETAIL; MANGANESE SULFATE; STEARIC ACID
- a10732 CORN STARCH TOPICAL;LANOLIN TOPICAL;PETROLEUM;STEARYL ALCOHOL;ZINC OXIDE TOPICAL
- a10749 TALC-ZINC TOPICAL AGENTS, EXTERNAL USE
- a10785 CALCIUM CARBONATE; CHOLECALCIFEROL; VITAMIN K
- a10834 CYANOCOBALAMIN; FOLIC ACID; VITAMIN B
- a10840 ASCORBIC ACID; FOLIC ACID; VITAMIN B COMPLEX; VITAMIN E; ZINC
- a10842 ASCORBIC ACID; D-BIOTIN; FOLIC ACID; VITAMIN B COMPLEX
- a10849 ASCORBIC ACID; FOLIC ACID; VITAMIN B COMPLEX
- a10851 ASCORBIC ACID; CHOLECALCIFEROL; VITAMIN A; VITAMIN B COMPLEX; VITAMIN E
- a10864 CARBOHYDRATES;FAT SUPPLEMENT, ORAL;MAGNESIUM AMINO ACIDS CHELATE:MULTIVITAMIN:PROTEIN
- a10879 PENICILLIN (OBSOLETE)-PENICILLIN G BENZATHINE

- a10884 ASPARTIC ACID:MANGANESE SULFATE;POTASSIUM ACETATE
- a10890 CLINDAMYCIN TOPICAL-METHYL PARABEN
- a10897 HOMATROPINE METHYL BROMIDE-HYDROCODONE
- a10899 ESTRADIOL; ESTRIOL; ESTRONE
- a10900 ESTRADIOL-ESTRIOL
- a10903 ASCORBIC ACID; COPPER GLUCONATE; LUTEIN; VITAMIN E; ZINC
- a10904 BETA-CAROTENE; BILBERRY; LUTEIN; LYCOPENE; VITAMIN E
- a10915 CALCIUM ACETATE; CHOLECAL CIFEROL; COPPER GLUCONATE; MAGNESIUM; ZINC
- a10916 CALCIUM ACETATE; COPPER GLUCONATE; IRON; MULTIVITAMIN; ZINC
- a10927 EDETATE DISODIUM; METRONIDAZOLE TOPICAL; PARABENS
- a10928 BENZONATATE-PARABENS
- a10947 BIFIDOBACTERIUM BIFIDUM;LACTOBACILLUS ACIDOPHILUS;LACTOBACILLUS BULGARICUS;LACTOBACILLUS CASEI;LACTOBACILLUS RHAMNOSUS
- a10956 CHLORPHENIRAMINE-HYDROCODONE POLISTIREX
- a10961 BUROW'S SOLUTION; CAMPHOR TOPICAL; MENTHOL TOPICAL; PHENOL TOPICAL
- a10963 ALOE VERA TOPICAL;MENTHOL TOPICAL;SALICYLIC ACID TOPICAL;TEA TREE OIL;VITAMIN E TOPICAL
- a10968 MINERAL OIL; MINERAL WAX; PETROLATUM TOPICAL; WOOLWAX ALCOHOL
- a10971 ACETIC ACID TOPICAL; PROPYLENE GLYCOL DIACETATE; SODIUM ACETATE
- a10972 ACETIC ACID TOPICAL;HYDROCORTISONE OTIC;PROPYLENE GLYCOL DIACETATE;SODIUM ACETATE
- a10978 DIPHTHERIA TOXOID;FILAMENTOUS HEMAGGLUTININ;PERTACTIN;PERTUSSIS, ACELLULAR;TETANUS TOXOID
- a10988 L-METHYLFOLATE; METHYLCOBALAMIN; PYRIDOXINE
- a10991 CHICORY ROOT EXTRACT-LACTOBACILLUS GG
- a10995 CALCIUM ACETATE-MAGNESIUM
- a11004 ALOE VERA TOPICAL;BLACK WALNUT;CASCARA SAGRADA;RHUBARB;SENNA
- a11013 IRON-MULTIVITAMIN
- a11020 ASCORBIC ACID;CALCIUM SULFATE;CHOLECALCIFEROL;VITAMIN A;VITAMIN E
- a11027 ACETAMINOPHEN-MISCELLANEOUS ANALGESICS
- a11030 CONTRACEPTIVES-NORETHINDRONE
- a11041 CIPROFLOXACIN-DEXAMETHASONE
- a11042 CIPROFLOXACIN-HYDROCORTISONE
- a11076 BUTALBITAL-CODEINE
- a11087 CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOMYCIN
- a11092 ERYTHROMYCIN-NEOMYCIN
- a11114 ACETAMINOPHEN-PHENYLPROPANOLAMINE
- a11126 BUPIVACAINE-LIDOCAINE
- a11134 LIDOCAINE-TRIAMCINOLONE
- a11135 LIDOCAINE-METHYLPREDNISOLONE TOPICAL
- a11156 HYOSCYAMINE;METHENAMINE;METHYLENE BLUE;PHENYL SALICYLATE;SODIUM PHOSPHATE
- a11159 HYOSCYAMINE;METHENAMINE;METHYLENE BLUE;PHENYL SALICYLATE;SODIUM BIPHOSPHATE
- a11163 POLYMYXIN B SULFATE-TRIMETHOPRIM
- a11166 DORZOLAMIDE OPHTHALMIC-TIMOLOL
- a11190 ASPIRIN; CAFFEINE; CINNAMEDRINE
- a11206 ALUMINUM HYDROXIDE;ATROPINE;HYOSCYAMINE;PHENOBARBITAL;SCOPOLAMINE
- a11216 BUPIVACAINE-TRIAMCINOLONE
- a11256 CHLORPHENIRAMINE; METHSCOPOLAMINE; PHENYLEPHRINE NASAL
- a11259 AMMONIUM CHLORIDE-DEXTROMETHORPHAN
- a11271 BROMPHENIRAMINE; DEXTROMETHORPHAN; GUAIFENESIN
- a11273 DEXTROMETHORPHAN-IODINATED GLYCEROL
- a11284 ETHINYL ESTRADIOL:FERROUS FUMARATE;NORETHINDRONE

- a11292 ARGININE;CYANOCOBALAMIN;FOLIC ACID;PYRIDOXINE
 a11294 CYANOCOBALAMIN-FOLIC ACID
 a11300 FOLIC ACID-MULTIVITAMIN
 a11315 INSULIN-INSULIN ISOPHANE
 a11325 NEOMYCIN-POLYMYXIN B SULFATE
 a11327 HYDROCORTISONE TOPICAL;NEOMYCIN;POLYMYXIN B SULFATE
 a11328 BACITRACIN TOPICAL;NEOMYCIN;POLYMYXIN B SULFATE
 a11330 BACITRACIN OPHTHALMIC;HYDROCORTISONE OPHTHALMIC;NEOMYCIN;POLYMYXIN B
 SULFATE
 a11331 DEXAMETHASONE OPHTHALMIC;NEOMYCIN;POLYMYXIN B SULFATE
 a11332 HYDROCORTISONE OTIC;NEOMYCIN;POLYMYXIN B SULFATE
- a11332 HYDROCORTISONE OTIC; NEOMYCIN; POLYMYXIN B SULFATE a11334 GRAMICIDIN OPHTHALMIC; NEOMYCIN; POLYMYXIN B SULFATE a11344 HYDROCORTISONE OTIC; NEOMYCIN; POLYMYXIN B OPHTHALMIC
- a11345 NEOMYCIN-POLYMYXIN B OPHTHALMIC
- a11351 ASCORBIC ACID; ERGOCALCIFEROL; NIACIN; PYRIDOXINE; VITAMIN A
- a11354 ASCORBIC ACID; NIACIN; RIBOFLAVIN; THIAMINE; VITAMIN E
- a11357 CYANOCOBALAMIN;NIACIN;PYRIDOXINE;RIBOFLAVIN;THIAMINE
- a11360 DEXPANTHENOL; NIACIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE
- a11370 MULTIVITAMIN-NIACIN
- a11394 BACITRACIN TOPICAL-POLYMYXIN B SULFATE
- a11396 DEXAMETHASONE OPHTHALMIC; NEOMYCIN OPHTHALMIC; POLYMYXIN B SULFATE
- a11403 DEXTRAN, HIGH MOLECULAR WEIGHT;HYDROXYPROPYL METHYLCELLULOSE OPHTHALMIC;POTASSIUM CHLORIDE;SODIUM BORATE TOPICAL;SODIUM CHLORIDE
- a11415 ERGOCALCIFEROL;RIBOFLAVIN;THIAMINE;VITAMIN A;VITAMIN E
- a11419 ASCORBIC ACID; COPPER GLUCONATE; VITAMIN A; VITAMIN E; ZINC OXIDE TOPICAL
- a11420 CYANOCOBALAMIN; PYRIDOXINE; RIBOFLAVIN; VITAMIN A
- a11421 CYANOCOBALAMIN; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
- a11424 ERGOCALCIFEROL; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A
- a11429 ASCORBIC ACID; ERGOCALCIFEROL; RIBOFLAVIN; THIAMINE; VITAMIN A
- a11431 ASCORBIC ACID; CHOLECALCIFEROL; FLUORIDE; VITAMIN A
- a11432 ASCORBIC ACID; ERGOCALCIFEROL; VITAMIN A
- a11436 CHOLECALCIFEROL-VITAMIN A
- a11440 ASCORBIC ACID-VITAMIN E
- a11445 ASCORBIC ACID; CYANOCOBALAMIN; PYRIDOXINE; RIBOFLAVIN
- a11447 CYANOCOBALAMIN;L-METHYLFOLATE;PYRIDOXINE;RIBOFLAVIN
- a11449 CYANOCOBALAMIN:LIVER DERIVATIVE COMPLEX:RIBOFLAVIN
- a11458 PANCREATIN-PYRIDOXINE
- a11465 CYANOCOBALAMIN-THIAMINE
- a11471 CALCIUM CARBONATE; CALCIUM CITRATE; MAGNESIUM CITRATE; MAGNESIUM OXIDE
- a11472 CALCIUM CARBONATE-CHOLECALCIFEROL
- a11473 CALCIUM CARBONATE; MAGNESIUM GLUCONATE; MAGNESIUM OXIDE
- a11477 FLUORIDE-MULTIVITAMIN
- a11490 POTASSIUM CITRATE-SODIUM CHLORIDE
- a11493 SODIUM CHLORIDE-STERILE WATER
- a11501 SODIUM BICARBONATE-SODIUM CHLORIDE NASAL
- a11518 CONJUGATED ESTROGENS-PROGESTERONE
- a11520 NYSTATIN-TRIAMCINOLONE
- a11523 NYSTATIN TOPICAL-TRIAMCINOLONE
- a11549 EDETATE DISODIUM-RIFAXIMIN
- a11558 NAPHAZOLINE OPHTHALMIC-PHENIRAMINE
- a11576 ANTIPYRINE OTIC-BENZOCAINE TOPICAL
- a11585 BENZOCAINE TOPICAL-RESORCINOL TOPICAL
- a11608 BALSAM PERU TOPICAL;BORIC ACID TOPICAL;CASTOR OIL;PETROLATUM

```
TOPICAL; ZINC OXIDE TOPICAL
a11614 MINERAL OIL-PETROLATUM TOPICAL
a11615 LANOLIN TOPICAL; MINERAL OIL; PETROLATUM TOPICAL
a11620 COLLOIDAL OATMEAL TOPICAL-MINERAL OIL
a11621 AMMONIUM LACTATE TOPICAL-MINERAL OIL
a11631 DIPHTHERIA TOXOID; HAEMOPHILUS B CONJUGATE VACCINE
      (OBSOLETE); PERTUSSIS, ACELLULAR; TETANUS TOXOID
a11632 HEPATITIS A VACCINE (OBSOLETE)-HEPATITIS B VACCINE
a11657 BENZALKONIUM CHLORIDE TOPICAL; CHLOROXYLENOL TOPICAL; HYDROCORTISONE
      TOPICAL:PRAMOXINE TOPICAL
a11664 ALUMINUM SULFATE TOPICAL; CAMPHOR TOPICAL; LACTOBACILLUS
      ACIDOPHILUS; MENTHOL TOPICAL; SALICYLIC ACID TOPICAL
a11671 LACTIC ACID TOPICAL-SALICYLIC ACID TOPICAL
a11684 BENZALKONIUM CHLORIDE TOPICAL-BROMFENAC
a11685 BENZALKONIUM CHLORIDE TOPICAL-CYANOCOBALAMIN NASAL
a11689 DEXTRAN 1-METHYLCELLULOSE
a11702 CHOLECALCIFEROL-MULTIVITAMIN
a11703 CALCIUM ACETATE-CHOLECALCIFEROL
a11705 CALCIUM ACETATE-MULTIVITAMIN
a11706 CETYLPYRIDINIUM TOPICAL-ETHANOL
a11715 MENTHOL TOPICAL-ZINC OXIDE TOPICAL
a11717 BETAMETHASONE TOPICAL-CLOTRIMAZOLE TOPICAL
a11724 BACITRACIN TOPICAL; NEOMYCIN TOPICAL; POLYMYXIN B OPHTHALMIC
a11730 BUDESONIDE NASAL-FORMOTEROL
a11732 LANOLIN TOPICAL-PETROLATUM TOPICAL
a11741 CAMPHOR TOPICAL;MENTHOL TOPICAL;METHYL SALICYLATE TOPICAL
a11748 BACITRACIN TOPICAL-POLYMYXIN B OPHTHALMIC
a11759 CETEARETH; DIMETHICONE; GLYCERIN TOPICAL; HYALURONIC ACID
a50770 CALCIUM REPLACEMENT
a50860 CANTHARIDIN
a51209 CHROMIUM
a51325 COCOA BUTTER
a51330 COCONUT OIL
a51675 DEXTROSE
a51740 DIETARY SUPPLEMENT
a51865 DIPHENIDOL
a52023 ELECTROLYTES
a52535 HAMAMELIS WATER
a52775 INFANT FORMULA
a52885 IRON PREPARATIONS
a52965 KARAYA GUM
a52968 KELP
a52990 LACTOSE
a53175 MAGNESIUM ANTACIDS
a53315 MENINGOCOCCAL VACCINE
a53940 NITROGEN
a54015 OINTMENT HYDROPHILIC
a54030 OLIVE OIL
a54175 PANTOTHENIC ACID
a54193 PARAFFIN
a54325 PERTUSSIS IMMUNE GLOBULIN
```

a54575 POLIO VACCINE

a54555 PNEUMOCOCCAL VACCINE

a54535 PLACEBO

```
a54650 POTASSIUM CARBONATE
```

a54655 POTASSIUM REPLACEMENT SOLUTIONS

a54760 PRAZEPAM

a54922 PROTEIN SUPPLEMENT

a55115 RINGERS LACTATED

a55330 SODIUM FLUORIDE

a55645 TALC

a56198 VITAMIN K

a56214 WHEAT GERM

a56265 ZINC TOPICAL AGENTS, EXTERNAL USE

a56345 VITAMIN B COMPLEX

a56740 INTERFERON BETA

a57001 BLOOD SUGAR DIAGNOSTIC

a57024 MAGNESIUM ION

a57034 PHOSPHORUS

a57092 RECOMBINANT HUMAN DEOXYRIBONUCLEASE

a57144 GLIBENCLAMIDE

a57158 TECHNETIUM

a57204 HEPATITIS C VACCINE

a57210 QUERCETIN

a59603 HEPATITIS VACCINE

a59611 THYROID STIMULATING HORMONE

a59632 DEHYDROEPIANDROSTERENE

a59717 ANDROGENS

a59812 DOMPERIDONE

a59841 GRAPESEED

a70009 HYALURONIC ACID

a70048 OIL OF EVENING PRIMROSE

a70071 DOCOSAHEXAENOIC ACID

a70105 HAWTHORN

a70116 SOY

a70123 BISMUTH

a70159 SILVER

a70271 SPIRULINA

a70294 RED CLOVER

a70327 ISOFLAVONES

a70385 SILYBUM

a70479 BORAGE OIL

a70480 ALPHA LIPOICACID

a70491 HYOSCYNAMINE SULFATE

a70521 GRIFFONIA SIMPLICIFOLIA

a70699 LYCOPENE

a70759 ALFALFA

a70886 IRON

a70892 SILICONE (LIQUID)

a70960 TEMOCAPRIL

c00007 ANTIVIRAL AGENTS

c00012 MISCELLANEOUS ANTIBIOTICS

c00014 QUINOLONES

c00025 MISCELLANEOUS ANTINEOPLASTICS

c00027 RADIOPHARMACEUTICALS

c00033 IMMUNE GLOBULINS

c00039 MISCELLANEOUS BIOLOGICALS

- c00042 ANGIOTENSIN CONVERTING ENZYME INHIBITORS
- c00048 CALCIUM CHANNEL BLOCKING AGENTS
- c00051 MISCELLANEOUS CARDIOVASCULAR AGENTS
- c00055 ANTIHYPERTENSIVE COMBINATIONS
- c00058 ANALGESICS
- c00059 MISCELLANEOUS ANALGESICS
- c00060 NARCOTIC ANALGESICS
- c00061 NONSTEROIDAL ANTI-INFLAMMATORY AGENTS
- c00070 MISCELLANEOUS ANXIOLYTICS, SEDATIVES AND HYPNOTICS
- c00072 GENERAL ANESTHETICS
- c00080 MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS
- c00087 GASTROINTESTINAL AGENTS
- c00088 ANTACIDS
- c00090 ANTIDIARRHEALS
- c00095 LAXATIVES
- c00096 MISCELLANEOUS GI AGENTS
- c00099 ANTIDIABETIC AGENTS
- c00100 MISCELLANEOUS HORMONES
- c00102 CONTRACEPTIVES
- c00105 MISCELLANEOUS AGENTS
- c00109 LOCAL INJECTABLE ANESTHETICS
- c00110 MISCELLANEOUS UNCATEGORIZED AGENTS
- c00115 NUTRITIONAL PRODUCTS
- c00117 MINERALS AND ELECTROLYTES
- c00118 ORAL NUTRITIONAL SUPPLEMENTS
- c00119 VITAMINS
- c00123 ANTIHISTAMINES
- c00124 ANTITUSSIVES
- c00127 DECONGESTANTS
- c00129 MISCELLANEOUS RESPIRATORY AGENTS
- c00131 ANTIASTHMATIC COMBINATIONS
- c00132 UPPER RESPIRATORY COMBINATIONS
- c00135 ANTISEPTIC AND GERMICIDES
- c00138 TOPICAL STEROIDS
- c00140 MISCELLANEOUS TOPICAL AGENTS
- c00169 MISCELLANEOUS OPHTHALMIC AGENTS
- c00172 MISCELLANEOUS OTIC AGENTS
- c00174 MISCELLANEOUS ANTIHYPERLIPIDEMIC AGENTS
- c00178 SKELETAL MUSCLE RELAXANTS
- c00187 MISCELLANEOUS SEX HORMONES
- c00194 ANTIGOUT AGENTS
- c00198 MISCELLANEOUS ANTIEMETICS
- c00208 SSRI ANTIDEPRESSANTS
- c00209 TRICYCLIC ANTIDEPRESSANTS
- c00219 NUTRACEUTICAL PRODUCTS
- c00220 HERBAL PRODUCTS
- c00248 TOPICAL EMOLLIENTS
- c00269 MISCELLANEOUS VAGINAL AGENTS
- c00292 TOPICAL ANTIFUNGALS
- c00301 GLUCOCORTICOIDS
- c00320 SMOKING CESSATION AGENTS
- c00361 MISCELLANEOUS METABOLIC AGENTS
- c00363 PROBIOTICS
- c00899 PHARMACEUTICAL AID

```
c07002 ANTIFUNGALS-ANTISEPTIC AND GERMICIDES
d00001 ACYCLOVIR
d00002 AMIODARONE
d00003 AMPICILLIN
d00004 ATENOLOL
d00006 CAPTOPRIL
d00007 CEFAZOLIN
d00009 CEFTAZIDIME
d00011 CIPROFLOXACIN
d00012 CODEINE
d00013 ENALAPRIL
d00014 GENTAMICIN
d00015 IBUPROFEN
d00016 LABETALOL
d00017 MEPERIDINE
d00018 NADOLOL
d00019 NAPROXEN
d00020 QUINIDINE
d00021 RANITIDINE
d00022 WARFARIN
d00023 ALLOPURINOL
d00024 AZATHIOPRINE
d00027 HALOPERIDOL
d00028 KETOPROFEN
d00031 PROBENECID
d00032 PROPRANOLOL
d00033 SULINDAC
d00034 ZIDOVUDINE
d00035 CHLOROQUINE
d00036 CYCLOPHOSPHAMIDE
d00037 DOXYCYCLINE
d00039 INDOMETHACIN
d00040 OXAZEPAM
d00041 TETRACYCLINE
d00042 CHLORPROPAMIDE
d00043 CLINDAMYCIN
d00044 CLONIDINE
d00045 DILTIAZEM
d00046 ERYTHROMYCIN
d00047 RIFAMPIN
d00048 VERAPAMIL
d00049 ACETAMINOPHEN
d00050 METHADONE
d00051 NIFEDIPINE
d00052 CEFTRIAXONE
d00054 TOLMETIN
d00056 CEFUROXIME
d00058 CARBAMAZEPINE
d00059 LIDOCAINE
d00060 METHOTREXATE
d00061 LITHIUM
```

d00064 CHLORPROMAZINE d00067 AZTREONAM

- d00069 TOBRAMYCIN
- d00070 FUROSEMIDE
- d00071 FLUCONAZOLE
- d00072 CEFIXIME
- d00073 CEFPROZIL
- d00077 AMPHOTERICIN B
- d00078 DIDANOSINE
- d00079 CYCLOSPORINE
- d00080 CEFADROXIL
- d00081 CEFACLOR
- d00083 VALPROIC ACID
- d00084 PREDNISOLONE
- d00085 RIBAVIRIN
- d00086 AMANTADINE
- d00088 AMOXICILLIN
- d00089 AMOXICILLIN-CLAVULANATE
- d00091 AZITHROMYCIN
- d00095 CEFPODOXIME
- d00096 CEPHALEXIN
- d00097 CLARITHROMYCIN
- d00098 DAPSONE
- d00100 GRISEOFULVIN
- d00101 ISONIAZID
- d00102 ITRACONAZOLE
- d00103 KETOCONAZOLE
- d00104 LOMEFLOXACIN
- d00106 METHENAMINE
- d00108 METRONIDAZOLE
- d00110 MINOCYCLINE
- d00112 NITROFURANTOIN
- d00114 OFLOXACIN
- d00116 PENICILLIN
- d00117 PYRAZINAMIDE
- d00118 SULFADIAZINE
- d00119 SULFAMETHOXAZOLE
- d00123 TRIMETHOPRIM
- d00124 SULFAMETHOXAZOLE-TRIMETHOPRIM
- d00125 VANCOMYCIN
- d00128 ACEBUTOLOL
- d00132 HYDRALAZINE
- d00133 METHYLDOPA
- d00134 METOPROLOL
- d00135 MINOXIDIL
- d00137 PINDOLOL
- d00138 PRAZOSIN
- d00139 TIMOLOL
- d00140 CIMETIDINE
- d00141 FAMOTIDINE
- d00142 THEOPHYLLINE
- d00143 PHENYTOIN
- d00144 NORTRIPTYLINE
- d00145 DESIPRAMINE
- d00146 AMITRIPTYLINE
- d00148 DIAZEPAM

- d00149 LORAZEPAM
- d00150 COLCHICINE
- d00153 DICLOXACILLIN
- d00154 MEBENDAZOLE
- d00155 MICONAZOLE
- d00157 NALIDIXIC ACID
- d00161 ACETAZOLAMIDE
- d00168 ALPRAZOLAM
- d00170 ASPIRIN
- d00174 ATROPINE
- d00175 BENZTROPINE
- d00178 BROMOCRIPTINE
- d00179 BUMETANIDE
- d00180 BUPIVACAINE
- d00181 BUPROPION
- d00182 BUSPIRONE
- d00189 CHLORDIAZEPOXIDE
- d00191 CHLORPHENIRAMINE
- d00192 CHLORTHALIDONE
- d00193 CHOLESTYRAMINE
- d00197 CLONAZEPAM
- d00198 CLORAZEPATE
- d00199 CLOZAPINE
- d00200 CROMOLYN
- d00206 DEXAMETHASONE
- d00207 DEXTROMETHORPHAN
- d00208 DIFLUNISAL
- d00210 DIGOXIN
- d00212 DIPHENHYDRAMINE
- d00213 DIPYRIDAMOLE
- d00214 DISOPYRAMIDE
- d00217 DOXEPIN
- d00218 DOXORUBICIN
- d00223 EPOETIN ALFA
- d00227 ETHOSUXIMIDE
- d00231 FELODIPINE
- d00233 FENTANYL
- d00234 FLECAINIDE
- d00235 FLUOROURACIL
- d00236 FLUOXETINE
- d00237 FLUPHENAZINE
- d00238 FLURAZEPAM
- d00241 FOLIC ACID
- d00242 FOSINOPRIL
- d00245 GEMFIBROZIL
- d00246 GLIPIZIDE
- d00248 GLYBURIDE
- d00252 HEPARIN
- d00253 HYDROCHLOROTHIAZIDE
- d00254 HYDROCORTISONE
- d00255 HYDROMORPHONE
- d00259 IMIPRAMINE
- d00260 INDAPAMIDE

- d00262 INSULIN
- d00265 IPRATROPIUM
- d00268 ISOSORBIDE DINITRATE
- d00269 ISOSORBIDE MONONITRATE
- d00270 ISRADIPINE
- d00273 KETOROLAC
- d00277 LEVODOPA
- d00278 LEVOTHYROXINE
- d00279 LINCOMYCIN
- d00280 LOVASTATIN
- d00284 MEDROXYPROGESTERONE
- d00285 MEFENAMIC ACID
- d00286 MEFLOQUINE
- d00290 METHIMAZOLE
- d00293 METHYLPREDNISOLONE
- d00295 METHYLTESTOSTERONE
- d00298 METOCLOPRAMIDE
- d00299 METOLAZONE
- d00301 MIDAZOLAM
- d00303 MISOPROSTOL
- d00308 MORPHINE
- d00310 NABUMETONE
- d00312 NEOMYCIN
- d00314 NIACIN
- d00316 NICOTINE
- d00321 NITROGLYCERIN
- d00322 NIZATIDINE
- d00325 OMEPRAZOLE
- d00328 OXYBUTYNIN
- d00329 OXYCODONE
- d00336 PENTOXIFYLLINE
- d00337 PHENAZOPYRIDINE
- d00340 PHENOBARBITAL
- d00343 PIROXICAM
- d00344 POLYMYXIN B SULFATE
- d00345 POTASSIUM CHLORIDE
- d00346 POVIDONE IODINE TOPICAL
- d00348 PRAVASTATIN
- d00349 PRAZIQUANTEL
- d00350 PREDNISONE
- d00352 PRIMIDONE
- d00355 PROCHLORPERAZINE
- d00358 PROPAFENONE
- d00360 PROPOXYPHENE
- d00361 PROPYLTHIOURACIL
- d00363 PYRIDOSTIGMINE
- d00364 PYRIMETHAMINE
- d00365 QUINAPRIL
- d00366 QUININE
- d00371 SOTALOL
- d00373 SPIRONOLACTONE
- d00377 SUCRALFATE
- d00379 SULFASALAZINE
- d00381 TAMOXIFEN

```
d00384 TEMAZEPAM
d00386 TERAZOSIN
d00389 THIORIDAZINE
d00391 THIOTHIXENE
d00393 TOLAZAMIDE
d00395 TRAZODONE
d00396 TRIAMTERENE
d00397 TRIAZOLAM
d00400 VINBLASTINE
d00402 VITAMIN A
d00405 VITAMIN E
d00409 RIBOFLAVIN
d00412 PYRIDOXINE
d00413 CYANOCOBALAMIN
d00425 CALCIUM CARBONATE
d00426 ASCORBIC ACID
d00427 POTASSIUM PHOSPHATE-SODIUM PHOSPHATE
d00428 FLUORIDE
d00438 SODIUM CHLORIDE
d00440 SODIUM BICARBONATE
d00468 MAGNESIUM SULFATE
d00485 IODINE TOPICAL
d00488 LYSINE
d00491 LEVOCARNITINE
d00497 OMEGA-3 POLYUNSATURATED FATTY ACIDS
d00512 FILGRASTIM
d00529 TRANEXAMIC ACID
d00537 ESTRADIOL
d00541 CONJUGATED ESTROGENS
d00543 ESTROPIPATE
d00550 PROGESTERONE
d00554 HYDROXYPROGESTERONE
d00555 NORETHINDRONE
d00557 LEVONORGESTREL
d00558 TESTOSTERONE
d00563 FINASTERIDE
d00568 NANDROLONE
d00569 CLOMIPHENE
d00572 CHORIONIC GONADOTROPIN (HCG)
d00578 ARGININE
d00583 DESMOPRESSIN
d00584 OXYTOCIN
d00587 METHYLERGONOVINE
d00593 GLUCAGON
d00595 GLUCOSE
d00598 CALCITONIN
d00601 PAMIDRONATE
d00604 CORTICOTROPIN
d00608 FLUDROCORTISONE
d00609 CORTISONE
d00620 TRIAMCINOLONE
d00626 DEXAMETHASONE TOPICAL
d00628 BETAMETHASONE
```

- d00651 UREA TOPICAL
- d00652 GLYCERIN
- d00653 ISOSORBIDE
- d00655 THYROID DESICCATED
- d00658 LIOTHYRONINE
- d00689 AMLODIPINE
- d00699 EPINEPHRINE
- d00704 PHENYLEPHRINE
- d00709 BISOPROLOL
- d00717 GUANFACINE
- d00726 DOXAZOSIN
- d00728 RAMIPRIL
- d00730 BENAZEPRIL
- d00732 LISINOPRIL
- d00743 SODIUM POLYSTYRENE SULFONATE
- d00744 COLESTIPOL
- d00746 SIMVASTATIN
- d00749 ALBUTEROL
- d00750 METAPROTERENOL
- d00755 PIRBUTEROL
- d00758 AMINOPHYLLINE
- d00760 BECLOMETHASONE
- d00769 PSEUDOEPHEDRINE
- d00771 NAPHAZOLINE OPHTHALMIC
- d00772 OXYMETAZOLINE NASAL
- d00773 TETRAHYDROZOLINE OPHTHALMIC
- d00780 CLEMASTINE
- d00785 BROMPHENIRAMINE
- d00787 PROMETHAZINE
- d00790 CYPROHEPTADINE
- d00796 BENZONATATE
- d00797 GUAIFENESIN
- d00799 IODINATED GLYCEROL
- d00801 CAFFEINE
- d00803 AMPHETAMINE
- d00804 DEXTROAMPHETAMINE
- d00806 PHENTERMINE
- d00807 BENZPHETAMINE
- d00809 PHENDIMETRAZINE
- d00813 BENZOCAINE TOPICAL
- d00817 HYDROXYCHLOROQUINE
- d00833 OXYMORPHONE
- d00838 BUTORPHANOL
- d00839 NALBUPHINE
- d00840 BUPRENORPHINE
- d00842 SALSALATE
- d00848 DICLOFENAC
- d00851 ETODOLAC
- d00853 OXAPROZIN
- d00855 PERPHENAZINE
- d00859 MECLIZINE
- d00861 DIMENHYDRINATE
- d00862 TRIMETHOBENZAMIDE
- d00866 DRONABINOL

```
d00867 ONDANSETRON
```

d00876 CLOMIPRAMINE

d00880 SERTRALINE

d00884 TRANYLCYPROMINE

d00890 TRIFLUOPERAZINE

d00897 LOXAPINE

d00898 PIMOZIDE

d00900 METHYLPHENIDATE

d00902 ERGOLOID MESYLATES

d00907 HYDROXYZINE

d00910 ZOLPIDEM

d00960 CARISOPRODOL

d00962 CHLORZOXAZONE

d00963 CYCLOBENZAPRINE

d00964 METAXALONE

d00965 METHOCARBAMOL

d00966 ORPHENADRINE

d00967 BACLOFEN

d00968 DANTROLENE

d00970 TRIHEXYPHENIDYL

d00982 MAGNESIUM HYDROXIDE

d00985 HYOSCYAMINE

d00986 SCOPOLAMINE

d00988 BELLADONNA

d00992 GLYCOPYRROLATE

d00999 DICYCLOMINE

d01002 PANCRELIPASE

d01003 PANCREATIN

d01005 URSODIOL

d01008 MAGNESIUM CITRATE

d01013 SENNA

d01015 BISACODYL

d01017 POLYCARBOPHIL

d01017 PSYLLIUM

d01019 MINERAL OIL

d01021 DOCUSATE

d01024 LACTULOSE

d01025 LOPERAMIDE

d01026 BISMUTH SUBSALICYLATE

d01027 SIMETHICONE

d01028 CHARCOAL

d01031 MESALAMINE

d01115 BACITRACIN

d01120 ATOVAQUONE

d01123 PYRANTEL

d01137 TETANUS IMMUNE GLOBULIN

d01138 VARICELLA ZOSTER IMMUNE GLOBULIN

d01139 RHO (D) IMMUNE GLOBULIN

d01156 TYPHOID VACCINE, INACTIVATED

d01158 HAEMOPHILUS B CONJUGATE VACCINE (OBSOLETE)

d01159 MEASLES VIRUS VACCINE

d01160 RUBELLA VIRUS VACCINE

d01163 POLIOVIRUS VACCINE, INACTIVATED

- d01164 INFLUENZA VIRUS VACCINE, INACTIVATED
- d01165 YELLOW FEVER VACCINE
- d01166 HEPATITIS B VACCINE (OBSOLETE)
- d01168 TETANUS TOXOID
- d01171 TUBERCULIN PURIFIED PROTEIN DERIVATIVE
- d01187 LEVOBUNOLOL OPHTHALMIC
- d01191 PILOCARPINE OPHTHALMIC
- d01201 CYCLOPENTOLATE OPHTHALMIC
- d01208 SULFACETAMIDE SODIUM OPHTHALMIC
- d01219 FLUORESCEIN OPHTHALMIC
- d01231 CHLORHEXIDINE TOPICAL
- d01232 CARBAMIDE PEROXIDE TOPICAL
- d01233 NYSTATIN
- d01236 CLOTRIMAZOLE
- d01238 TERCONAZOLE TOPICAL
- d01239 GENTIAN VIOLET TOPICAL
- d01240 SULFANILAMIDE TOPICAL
- d01241 CLINDAMYCIN TOPICAL
- d01242 NONOXYNOL 9 TOPICAL
- d01244 TRETINOIN TOPICAL
- d01246 BENZOYL PEROXIDE TOPICAL
- d01259 SILVER SULFADIAZINE TOPICAL
- d01263 PYRITHIONE ZINC TOPICAL
- d01265 SULFACETAMIDE SODIUM TOPICAL
- d01267 MUPIROCIN TOPICAL
- d01271 ECONAZOLE TOPICAL
- d01272 CICLOPIROX TOPICAL
- d01274 TOLNAFTATE TOPICAL
- d01277 NAFTIFINE TOPICAL
- d01278 LINDANE TOPICAL
- d01279 PERMETHRIN TOPICAL
- d01280 CROTAMITON TOPICAL
- d01282 ALCLOMETASONE TOPICAL
- d01283 AMCINONIDE TOPICAL
- d01288 CLOBETASOL TOPICAL
- d01290 DESONIDE TOPICAL
- d01291 DESOXIMETASONE TOPICAL
- d01293 FLUOCINOLONE TOPICAL
- d01294 FLUOCINONIDE TOPICAL
- d01296 FLUTICASONE
- d01298 HALOBETASOL TOPICAL
- d01303 PRAMOXINE TOPICAL
- d01307 SALICYLIC ACID TOPICAL
- d01308 PODOPHYLLUM RESIN TOPICAL
- d01309 PODOFILOX TOPICAL
- d01313 TRICHLOROACETIC ACID TOPICAL
- d01319 HYDROQUINONE TOPICAL
- d01321 CAPSAICIN TOPICAL
- d01322 ALUMINUM CHLORIDE HEXAHYDRATE TOPICAL
- d01325 ARNICA TOPICAL
- d01332 HEXACHLOROPHENE TOPICAL
- d01333 BENZALKONIUM CHLORIDE TOPICAL
- d01335 SODIUM HYPOCHLORITE TOPICAL
- d01348 MEGESTROL

```
d01353 LEUPROLIDE
d01373 HYDROXYUREA
d01385 BETA-CAROTENE
d01387 ALPROSTADIL
d01389 DISULFIRAM
d01395 CHLOROPROCAINE
d01402 DEFEROXAMINE
d01406 NALTREXONE
d01423 POTASSIUM CITRATE
d01427 BETHANECHOL
d01445 BARIUM SULFATE
d02376 ALBUMIN HUMAN
d03007 MEASLES; MUMPS; RUBELLA VIRUS VACCINE
d03034 NORGESTREL
d03041 ENOXAPARIN
d03050 LORATADINE
d03052 HYDROCHLOROTHIAZIDE-TRIAMTERENE
d03054 AMYLASE
d03061 BUTALBITAL
d03075 HYDROCODONE
d03077 ISOMETHEPTENE MUCATE
d03080 LIPASE
d03094 SALICYLAMIDE
d03096 SODIUM BENZOATE
d03098 SODIUM CITRATE
d03110 DIPHTH; PERTUSSIS, ACEL; TETANUS (OBSOLETE)
d03126 CALCITRIOL
d03128 ERGOCALCIFEROL
d03129 CHOLECALCIFEROL
d03130 THIAMINE
d03137 CALCIUM-VITAMIN D
d03140 MULTIVITAMIN
d03141 MULTIVITAMIN WITH IRON
d03145 MULTIVITAMIN WITH MINERALS
d03148 MULTIVITAMIN, PRENATAL
d03154 DOXYLAMINE
d03157 PAROXETINE
d03159 CHOLINE
d03160 SUMATRIPTAN
d03162 ETHANOL
d03169 TRIMETREXATE
d03170 FELBAMATE
d03180 RISPERIDONE
d03181 VENLAFAXINE
d03182 GABAPENTIN
d03183 FLUVASTATIN
d03189 TORSEMIDE
d03190 OXICONAZOLE TOPICAL
d03191 TERBINAFINE TOPICAL
d03192 ZINC OXIDE TOPICAL
d03193 AMILORIDE-HYDROCHLOROTHIAZIDE
d03195 MICONAZOLE TOPICAL
d03197 BETAMETHASONE TOPICAL
```

- d03200 ERYTHROMYCIN TOPICAL
 d03202 KETOCONAZOLE TOPICAL
 d03203 MINOXIDIL TOPICAL
 d03205 HYDROCORTISONE TOPICAL
 d03206 TRIAMCINOLONE TOPICAL
 d03208 METRONIDAZOLE TOPICAL
 d03210 SELENIUM SULFIDE TOPICAL
 d03211 CIPROFLOXACIN OPHTHALMIC
 d03214 KETOROLAC OPHTHALMIC
 d03220 FLURBIPROFEN OPHTHALMIC
 d03221 PREDNISOLONE OPHTHALMIC
 d03222 TOBRAMYCIN OPHTHALMIC
 d03228 LODOXAMIDE OPHTHALMIC
 - d03238 ETHINYL ESTRADIOL-NORETHINDRONE d03241 ETHINYL ESTRADIOL-NORGESTREL
 - d03242 ETHINYL ESTRADIOL-LEVONORGESTREL
 - d03244 CONJUGATED ESTROGENS-METHYLTESTOSTERONE d03245 ESTERIFIED ESTROGENS-METHYLTESTOSTERONE
 - d03247 HYDROCHLOROTHIAZIDE-SPIRONOLACTONE
 - d03251 HYDROCHLOROTHIAZIDE-RESERPINE d03257 HYDRALAZINE-HYDROCHLOROTHIAZIDE
- d03258 ATENOLOL-CHLORTHALIDONE
- d03261 HYDROCHLOROTHIAZIDE-PROPRANOLOL
- d03264 HYDROCHLOROTHIAZIDE-METOPROLOL
- d03265 BENAZEPRIL-HYDROCHLOROTHIAZIDE
- d03266 HYDROCHLOROTHIAZIDE-LISINOPRIL
- d03267 CHLORTHALIDONE-CLONIDINE
- d03276 DYPHYLLINE-GUAIFENESIN
- d03280 EPHEDRINE;PHENOBARBITAL;THEOPHYLLINE
- d03289 ACETAMINOPHEN-PSEUDOEPHEDRINE
- d03292 IBUPROFEN-PSEUDOEPHEDRINE
- d03296 ACETAMINOPHEN-CHLORPHENIRAMINE
- d03297 ACETAMINOPHEN-PHENYLTOLOXAMINE
- d03298 CHLORPHENIRAMINE-PSEUDOEPHEDRINE
- d03299 CHLORPHENIRAMINE-PHENYLPROPANOLAMINE
- d03300 CHLORPHENIRAMINE-PHENYLEPHRINE
- d03301 BROMPHENIRAMINE-PSEUDOEPHEDRINE
- d03302 BROMPHENIRAMINE-PHENYLPROPANOLAMINE
- d03313 CHLORPHENIRAMINE;PHENYLEPHRINE;PYRILAMINE
- d03314 CHLORPHENIRAMINE;PHENYLEPHRINE;PPA
- d03316 PSEUDOEPHEDRINE-TRIPROLIDINE
- d03317 PHENYLEPHRINE-PROMETHAZINE
- d03318 PHENIRAMINE; PPA; PYRILAMINE
- d03320 ACETAMINOPHEN;CHLORPHENIRAMINE;PSE
- d03338 CHLORPHENIRAMINE; METHSCOPOLAMINE; PE
- d03347 ACETAMINOPHEN;CHLORPHENIRAMINE;DM;PSE
- d03352 HYDROCODONE-PSEUDOEPHEDRINE
- d03353 HYDROCODONE-PHENYLPROPANOLAMINE
- d03356 CHLORPHENIRAMINE-HYDROCODONE
- d03357 CODEINE-PROMETHAZINE
- d03359 CHLORPHENIRAMINE-DEXTROMETHORPHAN
- d03360 DEXTROMETHORPHAN-PROMETHAZINE
- d03361 CHLORPHENIRAMINE;HYDROCODONE;PHENYLEPHRINE
- d03364 CODEINE; PHENYLEPHRINE; PROMETHAZINE

```
d03368 BROMPHENIRAMINE; DEXTROMETHORPHAN; PSE
d03369 CHLORPHENIRAMINE:DEXTROMETHORP:PHENYLEPHRINE
d03370 CHLORPHENIRAMINE;DEXTROMETHORPHAN;PSE
d03372 BROMPHENIRAMINE; DEXTROMETHORPHAN; PPA
d03379 GUAIFENESIN-PSEUDOEPHEDRINE
d03381 GUAIFENESIN-PHENYLEPHRINE
d03382 GUAIFENESIN-PHENYLPROPANOLAMINE
d03388 ETHINYL ESTRADIOL-ETHYNODIOL
d03389 ESTRADIOL-TESTOSTERONE
d03393 CODEINE-GUAIFENESIN
d03394 CODEINE-IODINATED GLYCEROL
d03396 GUAIFENESIN-HYDROCODONE
d03398 CODEINE; GUAIFENESIN; PSEUDOEPHEDRINE
d03400 DEXTROMETHORPHAN-GUAIFENESIN
d03409 DEXTROMETHORPHAN; GUAIFENESIN; PSEUDOEPHEDRINE
d03411 DEXTROMETHORPHAN; GUAIFENESIN; PPA
d03416 CHLORPHENIRAMINE; HYDROCODONE; PSE
d03423 ACETAMINOPHEN-CODEINE
d03424 ASPIRIN-CODEINE
d03425 ACETAMINOPHEN;BUTALBITAL;CAFFEINE;CODEINE
d03428 ACETAMINOPHEN-HYDROCODONE
d03429 ASPIRIN-HYDROCODONE
d03431 ACETAMINOPHEN-OXYCODONE
d03434 ACETAMINOPHEN-PROPOXYPHENE
d03437 ACETAMINOPHEN;ASPIRIN;CAFFEINE;SALICYLAMIDE
d03439 ACETAMINOPHEN; ASPIRIN; CAFFEINE
d03445 ACETAMINOPHEN-DIPHENHYDRAMINE
d03447 ASPIRIN; CAFFEINE; SALICYLAMIDE
d03449 ASPIRIN-CAFFEINE
d03455 ACETAMINOPHEN;BUTALBITAL;CAFFEINE
d03456 ACETAMINOPHEN-BUTALBITAL
d03457 ASPIRIN; BUTALBITAL; CAFFEINE
d03459 APAP; DICHLORALPHENAZONE; ISOMETHEPTENE
d03462 AMITRIPTYLINE-CHLORDIAZEPOXIDE
d03463 AMITRIPTYLINE-PERPHENAZINE
d03473 CARBIDOPA-LEVODOPA
d03474 ALUMINUM HYDROXIDE-MAGNESIUM HYDROXIDE
d03478 AL HYDROXIDE;MG HYDROXIDE;SIMETHICONE
d03485 ATROPINE;HYOSCYAMINE;PB;SCOPOLAMINE
d03492 CHLORDIAZEPOXIDE-CLIDINIUM
d03496 DOCUSATE-SENNA
d03498 CASANTHRANOL-DOCUSATE
d03506 ATROPINE-DIPHENOXYLATE
d03525 GRAMICIDIN:NEOMYCIN:POLYMYXIN B OPHTHALMIC
d03536 DEXAMETHASONE-TOBRAMYCIN OPHTHALMIC
d03546 HYDROCORTISONE-PRAMOXINE TOPICAL
d03561 BETAMETHASONE-CLOTRIMAZOLE TOPICAL
d03562 NYSTATIN-TRIAMCINOLONE TOPICAL
d03569 CARBINOXAMINE
d03570 CARBINOXAMINE-PSEUDOEPHEDRINE
d03618 HYOSCYAMINE;METHENAM;M-BLUE;PHENYL SALICYL
d03623 ACETIC ACID TOPICAL
```

d03624 ANTIPYRINE OTIC

```
d03627 ANTIPYRINE-BENZOCAINE OTIC
d03634 BENZOCAINE-CETYLPYRIDINIUM TOPICAL
d03640 BUDESONIDE NASAL
d03641 PETROLATUM TOPICAL
d03644 LACTOBACILLUS ACIDOPHILUS
d03646 LACTOBACILLUS ACIDOPHILUS AND BULGARICUS
d03647 ISOPROPYL ALCOHOL TOPICAL
d03650 CANDIDA ALBICANS EXTRACT
d03653 CALAMINE TOPICAL
d03655 LIDOCAINE-PRILOCAINE TOPICAL
d03656 ETHYL CHLORIDE TOPICAL
d03660 MULTIVITAMIN WITH IRON AND FLUORIDE
d03664 PHENOL TOPICAL
d03665 MENTHOL TOPICAL
d03666 MENTHOL-PHENOL TOPICAL
d03667 METHACHOLINE
d03669 METHYL SALICYLATE-MENTHOL TOPICAL
d03684 THROMBIN TOPICAL
d03687 ALUMINUM ACETATE TOPICAL
d03689 CALCIUM ACETATE
d03690 ALUMINUM SULFATE-CALCIUM ACETATE TOPICAL
d03692 BENZYLPENICILLOYL-POLYLYSINE
d03703 COAL TAR TOPICAL
d03707 ALOE VERA TOPICAL
d03735 TRIETHANOLAMINE POLYPEPTIDE OLEATE OTIC
d03740 ENALAPRIL-HYDROCHLOROTHIAZIDE
d03744 BISOPROLOL-HYDROCHLOROTHIAZIDE
d03752 TACROLIMUS
d03756 BACITRACIN TOPICAL
d03759 SALMETEROL
d03761 LANOLIN TOPICAL
d03768 OCULAR LUBRICANT
d03770 EMOLLIENTS, TOPICAL
d03773 STAVUDINE
d03775 FAMCICLOVIR
d03780 DESOGESTREL
d03781 ETHINYL ESTRADIOL-NORGESTIMATE
d03782 DESOGESTREL-ETHINYL ESTRADIOL
d03784 EPINEPHRINE-LIDOCAINE
d03788 CALCIPOTRIENE TOPICAL
d03796 MAGNESIUM CHLORIDE
d03797 MAGNESIUM OXIDE
d03804 FLUVOXAMINE
d03805 DORZOLAMIDE OPHTHALMIC
d03807 METFORMIN
d03808 NEFAZODONE
d03809 LAMOTRIGINE
d03818 LORATADINE-PSEUDOEPHEDRINE
d03819 CONJUGATED ESTROGENS-MEDROXYPROGESTERONE
d03820 HEPATITIS A VACCINE (OBSOLETE)
d03821 LOSARTAN
d03822 FERROUS GLUCONATE
d03823 IRON POLYSACCHARIDE
```

d03824 FERROUS SULFATE

```
d03825 NISOLDIPINE
d03826 TRAMADOL
d03827 CETIRIZINE
d03828 LANSOPRAZOLE
d03829 AMLODIPINE-BENAZEPRIL
d03830 HYDROCHLOROTHIAZIDE-LOSARTAN
d03832 VARICELLA VIRUS VACCINE
d03833 DIVALPROEX SODIUM
d03835 MOEXIPRIL
d03838 VALACYCLOVIR
d03839 MYCOPHENOLATE MOFETIL
d03846 ACARBOSE
d03847 CARVEDILOL
d03848 AZELAIC ACID TOPICAL
d03849 ALENDRONATE
d03850 BICALUTAMIDE
d03857 BENZOYL PEROXIDE-ERYTHROMYCIN TOPICAL
d03858 LAMIVUDINE
d03864 GLIMEPIRIDE
d03866 CALCIUM CITRATE
d03873 ANASTROZOLE
d03874 CEFTIBUTEN
d03882 CEFEPIME
d03884 TROLAMINE SALICYLATE TOPICAL
d03894 KAOLIN-PECTIN
d03897 LACTASE
d03898 SODIUM CHLORIDE, HYPERTONIC, OPHTHALMIC
d03908 APAP;CHLORPHENIRAMINE;DEXTROMETHORPHAN;PPA
d03927 BACITRACIN OPHTHALMIC
d03940 BENZOCAINE-DEXTROMETHORPHAN
d03973 ERYTHROMYCIN OPHTHALMIC
d03974 GENTAMICIN OPHTHALMIC
d03977 OFLOXACIN OPHTHALMIC
d03984 RITONAVIR
d03990 CARBAMIDE PEROXIDE OTIC
d03994 COLLOIDAL OATMEAL TOPICAL
d04002 PIPERONYL BUTOXIDE-PYRETHRINS TOPICAL
d04003 HYDROGEN PEROXIDE TOPICAL
d04008 TRANDOLAPRIL
d04011 INTERFERON BETA-1A
d04012 TERBINAFINE
d04015 ADAPALENE TOPICAL
d04017 LATANOPROST OPHTHALMIC
d04021 BENZOIC ACID-SALICYLIC ACID TOPICAL
d04025 MIRTAZAPINE
d04029 NEVIRAPINE
d04032 SULFACETAMIDE SODIUM-SULFUR TOPICAL
d04035 AMPHETAMINE-DEXTROAMPHETAMINE
d04037 TIMOLOL OPHTHALMIC
d04038 BETAXOLOL OPHTHALMIC
d04040 FEXOFENADINE
d04047 MIDODRINE
d04048 BRIMONIDINE OPHTHALMIC
```

```
d04049 AMMONIUM LACTATE TOPICAL
d04050 OLANZAPINE
d04051 ROPIVACAINE
d04052 PENTOSAN POLYSULFATE SODIUM
d04054 PENCICLOVIR TOPICAL
d04057 ZINC SULFATE
d04058 MELATONIN
d04061 BISMUTH SUBSALICYLATE; METRONIDAZOLE; TCN
d04063 BUTENAFINE TOPICAL
d04065 TRANDOLAPRIL-VERAPAMIL
d04066 ALBUTEROL-IPRATROPIUM
d04068 AZELASTINE NASAL
d04090 LACTIC ACID TOPICAL
d04099 DONEPEZIL
d04101 IVERMECTIN
d04102 TIZANIDINE
d04103 ZILEUTON
d04105 ATORVASTATIN
d04107 AMLEXANOX TOPICAL
d04109 LEVOFLOXACIN
d04110 MIGLITOL
d04111 GLATIRAMER
d04112 CABERGOLINE
d04113 VALSARTAN
d04115 TOPIRAMATE
d04117 OLOPATADINE OPHTHALMIC
d04118 NELFINAVIR
d04120 CAFFEINE-ERGOTAMINE
d04121 TAMSULOSIN
d04125 IMIQUIMOD TOPICAL
d04134 POLYMYXIN B OPHTHALMIC
d04138 TAZAROTENE TOPICAL
d04141 HYDROCHLOROTHIAZIDE-MOEXIPRIL
d04142 CHROMIUM PICOLINATE
d04145 PRAMIPEXOLE
d04155 ASPIRIN-DIPHENHYDRAMINE
d04156 LETROZOLE
d04159 SORBITOL
d04160 SODIUM BIPHOSPHATE-SODIUM PHOSPHATE
d04166 ACETAMINOPHEN; DM; GUAIFENESIN; PSEUDOEPHEDRINE
d04168 ACETAMINOPHEN; DIPHENHYDRAMINE; PSEUDOEPHEDRINE
d04172 CALAMINE-PRAMOXINE TOPICAL
d04186 PHENYLEPHRINE NASAL
d04192 COLISTIN;HC;NEOMYCIN;THONZONIUM OTIC
d04196 BACITRACIN;HC;NEOMYCIN;POLYMYXIN B TOPICAL
d04197 HYDROCORTISONE; NEOMYCIN; POLYMYXIN B TOPICAL
d04208 SILVER NITRATE TOPICAL
d04215 ROPINIROLE
d04219 LAMIVUDINE-ZIDOVUDINE
d04220 QUETIAPINE
d04221 TIAGABINE
d04222 IRBESARTAN
d04223 MOMETASONE NASAL
```

d04225 HYDROCODONE-IBUPROFEN

```
d04228 ACETIC ACID OTIC
```

d04233 TRIAMCINOLONE NASAL

d04242 SODIUM CHLORIDE NASAL

d04245 HYDROCHLOROTHIAZIDE-IRBESARTAN

d04248 METHYLCELLULOSE

d04253 ZOLMITRIPTAN

d04256 CEFDINIR

d04258 CLOPIDOGREL

d04261 RALOXIFENE

d04267 REPAGLINIDE

d04270 FEXOFENADINE-PSEUDOEPHEDRINE

d04271 DICLOFENAC-MISOPROSTOL

d04272 AMOXICILLIN:CLARITHROMYCIN;LANSOPRAZOLE

d04275 BECLOMETHASONE NASAL

d04276 BUDESONIDE

d04279 FLUNISOLIDE NASAL

d04281 EMEDASTINE OPHTHALMIC

d04283 FLUTICASONE NASAL

d04284 FLUTICASONE TOPICAL

d04285 NARATRIPTAN

d04286 FENOFIBRATE

d04287 CIPROFLOXACIN OTIC

d04289 MONTELUKAST

d04293 HYDROCHLOROTHIAZIDE-VALSARTAN

d04294 TOLTERODINE

d04298 PHENYLEPHRINE TOPICAL

d04299 SILDENAFIL

d04300 RISEDRONATE

d04301 BRINZOLAMIDE OPHTHALMIC

d04312 PARICALCITOL

d04317 DIPHTHERIA TOXOID

d04322 CANDESARTAN

d04323 PALIVIZUMAB

d04327 RIFAPENTINE

d04328 RIZATRIPTAN

d04332 CITALOPRAM

d04342 INFLIXIMAB

d04344 ROTAVIRUS VACCINE

d04349 LEFLUNOMIDE

d04355 EFAVIRENZ

d04360 HEMIN

d04362 COPPER GLUCONATE

d04363 SEVELAMER

d04364 TELMISARTAN

d04365 ETANERCEPT

d04369 INSULIN REGULAR

d04370 INSULIN ISOPHANE

d04375 ESTRADIOL-NORETHINDRONE

d04376 ABACAVIR

d04377 THYROTROPIN ALFA

d04378 MODAFINIL

d04380 CELECOXIB

d04382 CILOSTAZOL

- d04395 CLOTRIMAZOLE TOPICAL
- d04397 FLUORIDE TOPICAL
- d04399 NYSTATIN TOPICAL
- d04411 GARLIC
- d04412 GINSENG
- d04413 GINKGO
- d04414 GINGER
- d04416 VALERIAN
- d04418 GLUCOSAMINE
- d04419 CHONDROITIN
- d04420 CHONDROITIN-GLUCOSAMINE
- d04427 LEVALBUTEROL
- d04429 ORLISTAT
- d04432 CARBONYL IRON
- d04434 ROSIGLITAZONE
- d04435 DOXERCALCIFEROL
- d04436 MALATHION TOPICAL
- d04441 KETOTIFEN OPHTHALMIC
- d04442 PIOGLITAZONE
- d04446 PHENYLEPHRINE-PYRILAMINE
- d04448 RABEPRAZOLE
- d04452 ZALEPLON
- d04459 DOFETILIDE
- d04461 EXEMESTANE
- d04462 OSELTAMIVIR
- d04469 BEE POLLEN
- d04472 BLACK COHOSH
- d04481 ROYAL JELLY
- d04483 DANDELION
- d04497 ASPIRIN-DIPYRIDAMOLE
- d04499 LEVETIRACETAM
- d04500 MOXIFLOXACIN
- d04509 HYDROCHLOROTHIAZIDE-QUINAPRIL
- d04510 INSULIN LISPRO-INSULIN LISPRO PROTAMINE
- d04511 INSULIN LISPRO PROTAMINE
- d04513 OXCARBAZEPINE
- d04514 PANTOPRAZOLE
- d04521 NETTLES
- d04523 UBIQUINONE
- d04527 ZONISAMIDE
- d04532 MELOXICAM
- d04537 RIVASTIGMINE
- d04538 INSULIN GLARGINE
- d04539 FOSINOPRIL-HYDROCHLOROTHIAZIDE
- d04541 AZELASTINE OPHTHALMIC
- d04557 CLOBAZAM
- d04572 FORMOTEROL
- d04611 FLUTICASONE-SALMETEROL
- d04674 DIPHTH;HAEMOPHILUS;PERTUSSIS;TETANUS;POLIO
- d04675 DIPHTHERIA; PERTUSSIS, ACEL; TETANUS; POLIO
- d04685 HEPATITIS A-HEPATITIS B VACCINE
- d04695 COLESEVELAM
- d04697 INSULIN ASPART
- d04700 BALSALAZIDE

```
d04703 GLYBURIDE-METFORMIN d04704 EFLORNITHINE TOPICAL
```

d04706 CETRORELIX

d04708 ZOLEDRONIC ACID

d04711 CANDESARTAN-HYDROCHLOROTHIAZIDE

d04717 LOPINAVIR-RITONAVIR

d04722 DICLOFENAC TOPICAL

d04726 5-HYDROXYTRYPTOPHAN

d04727 ABACAVIR;LAMIVUDINE;ZIDOVUDINE

d04732 TRYPTOPHAN

d04737 HYDROCHLOROTHIAZIDE-TELMISARTAN

d04742 BENZOYL PEROXIDE-CLINDAMYCIN TOPICAL

d04743 NATEGLINIDE

d04746 PEGINTERFERON ALFA-2B

d04747 ZIPRASIDONE

d04749 ESOMEPRAZOLE

d04750 GALANTAMINE

d04753 TRAVOPROST OPHTHALMIC

d04754 BIMATOPROST OPHTHALMIC

d04757 ALMOTRIPTAN

d04758 IMATINIB

d04760 DROSPIRENONE-ETHINYL ESTRADIOL

d04764 CETIRIZINE-PSEUDOEPHEDRINE

d04766 ACETAMINOPHEN-TRAMADOL

d04771 DARBEPOETIN ALFA

d04772 ETONOGESTREL

d04773 ETHINYL ESTRADIOL-ETONOGESTREL

d04774 TENOFOVIR

d04776 FROVATRIPTAN

d04777 DEXMETHYLPHENIDATE

d04779 ETHINYL ESTRADIOL-NORELGESTROMIN

d04782 BOSENTAN

d04784 PIMECROLIMUS TOPICAL

d04785 DESLORATADINE

d04786 FONDAPARINUX

d04788 DUTASTERIDE

d04790 PEGFILGRASTIM

d04797 ALFUZOSIN

d04801 OLMESARTAN

d04802 TREPROSTINIL

d04803 VORICONAZOLE

d04812 ESCITALOPRAM

d04813 HORSE CHESTNUT

d04815 EPLERENONE

d04819 BUPRENORPHINE-NALOXONE

d04823 GLIPIZIDE-METFORMIN

d04824 EZETIMIBE

d04825 ARIPIPRAZOLE

d04826 NITAZOXANIDE

d04827 ATOMOXETINE

d04828 TERIPARATIDE

d04829 TIOTROPIUM

d04832 DIPHTHERIA;HEPB;PERTUSSIS,ACEL;POLIO;TETANUS

- d04835 ADALIMUMAB
- d04836 CYCLOSPORINE OPHTHALMIC
- d04839 INSULIN ASPART-INSULIN ASPART PROTAMINE
- d04844 CAMPHOR-MENTHOL TOPICAL
- d04849 ELETRIPTAN
- d04851 ROSUVASTATIN
- d04857 GATIFLOXACIN OPHTHALMIC
- d04860 MOXIFLOXACIN OPHTHALMIC
- d04861 DIPHENHYDRAMINE-PHENYLEPHRINE
- d04878 HYDROCHLOROTHIAZIDE-OLMESARTAN
- d04882 ATAZANAVIR
- d04884 EMTRICITABINE
- d04893 VARDENAFIL
- d04894 DAPTOMYCIN
- d04896 TADALAFIL
- d04898 EPINASTINE OPHTHALMIC
- d04899 MEMANTINE
- d04901 FOSAMPRENAVIR
- d04905 BROMPHENIRAMINE; DEXTROMETHORPH; PHENYLEPHRINE
- d04917 FLUOXETINE-OLANZAPINE
- d04920 PNEUMOCOCCAL 7-VALENT CONJUGATE VACCINE
- d04929 TROSPIUM
- d04986 ACAMPROSATE
- d05044 BETAMETHASONE-CALCIPOTRIENE TOPICAL
- d05048 AMLODIPINE-ATORVASTATIN
- d05218 CINACALCET
- d05265 NEBIVOLOL
- d05278 INSULIN GLULISINE
- d05283 BRIMONIDINE-TIMOLOL OPHTHALMIC
- d05294 RIFAXIMIN
- d05337 PNEUMOCOCCAL 23-POLYVALENT VACCINE
- d05338 DIPHTHERIA-TETANUS TOXOIDS (DT) PED
- d05343 HAEMOPHILUS B CONJUGATE (PRP-T) VACCINE
- d05348 EZETIMIBE-SIMVASTATIN
- d05350 POLYETHYLENE GLYCOL 3350
- d05352 EMTRICITABINE-TENOFOVIR
- d05354 ABACAVIR-LAMIVUDINE
- d05355 DULOXETINE
- d05357 IBANDRONATE
- d05361 CARBETAPENTANE-GUAIFENESIN
- d05366 ACETAMINOPHEN; DEXTROMETHORPHAN; DOXYLAMINE
- d05383 ACETAMINOPHEN;CHLORPHENIRAMINE;DM
- d05395 LANTHANUM CARBONATE
- d05413 SOLIFENACIN
- d05420 ALOH;DIPHENHYD;LIDOCAINE;MGOH;SIMETH TOPICAL
- d05421 ESZOPICLONE
- d05422 DARIFENACIN
- d05432 MENINGOCOCCAL CONJUGATE VACCINE
- d05433 DIGESTIVE ENZYMES;HYOSCYAMINE;PHENYLTOLOXAMIN
- d05436 INSULIN DETEMIR
- d05465 CICLESONIDE
- d05473 DESLORATADINE-PSEUDOEPHEDRINE
- d05508 PREGABALIN
- d05525 ENTECAVIR

```
d05526 ALENDRONATE-CHOLECALCIFEROL
d05529 EXENATIDE
d05540 HYDRALAZINE-ISOSORBIDE DINITRATE
d05543 DAPSONE TOPICAL
d05578 RAMELTEON
d05612 RASAGILINE
d05630 CALCIUM CARBONATE-RISEDRONATE
d05633 NEPAFENAC OPHTHALMIC
d05635 METFORMIN-PIOGLITAZONE
d05646 SACCHAROMYCES BOULARDII LYO
d05647 FERRIC SUBSULFATE TOPICAL
d05674 GLIMEPIRIDE-ROSIGLITAZONE
d05690 FERROUS FUMARATE-IRON POLYSACCHARIDE
d05694 ABATACEPT
d05696 LENALIDOMIDE
d05702 METHYLSULFONYLMETHANE
d05703 CHONDROITIN;GLUCOSAMINE;METHYLSULFONYLMETHANE
d05719 RANOLAZINE
d05736 LUBIPROSTONE
d05773 L-METHYLFOLATE
d05776 IODINE
d05781 TETANUS;DIPHTH;PERTUSS (TDAP) ADULT;ADOL
d05782 DIPHTHERIA; TETANUS; PERTUSSIS (DTAP) PED
d05807 VARENICLINE
d05813 ZOSTER VACCINE LIVE
d05817 HUMAN PAPILLOMAVIRUS VACCINE
d05819 DIPHENHYDRAMINE-IBUPROFEN
d05825 DARUNAVIR
d05831 DASATINIB
d05847 EFAVIRENZ; EMTRICITABINE; TENOFOVIR
d05851 LEVOCETIRIZINE
d05866 GUAR GUM
d05893 ARFORMOTEROL
d05896 SITAGLIPTIN
d05899 CICLESONIDE NASAL
d06008 BENZYL ALCOHOL TOPICAL
d06032 FLUOCINOLONE OTIC
d06297 PALIPERIDONE
d06507 CINNAMON
d06635 MILNACIPRAN
d06662 AMLODIPINE-VALSARTAN
d06663 LISDEXAMFETAMINE
d06665 ALISKIREN
d06720 METFORMIN-SITAGLIPTIN
d06831 RETAPAMULIN TOPICAL
d06841 AMBRISENTAN
d06842 ARMODAFINIL
d06848 LUTEIN
d06851 AZITHROMYCIN OPHTHALMIC
d06852 MARAVIROC
d06857 ACETIC;ANTIPYRINE;BENZOCAINE;POLYCOS OTIC
d06860 OXYGEN
d06867 BIOTIN
```

```
d06905 AMLODIPINE-OLMESARTAN
d07048 RALTEGRAVIR
d07057 NILOTINIB
d07063 BROMPHENIRAMINE-DIPHENHYDRAMINE
d07064 BROMPHENIRAMINE; DIPHENHYDRAMINE; PHENYLEPHRINE
d07076 ETRAVIRINE
d07110 NIACIN-SIMVASTATIN
d07113 DESVENLAFAXINE
d07130 NAPROXEN-SUMATRIPTAN
d07131 REGADENOSON
d07132 OLOPATADINE NASAL
d07137 DABIGATRAN
d07162 FESOTERODINE
d07298 DIFLUPREDNATE OPHTHALMIC
d07302 CHLOPHEDIANOL;GUAIFENESIN;PSEUDOEPHEDRINE
d07347 BIFIDOBACTERIUM INFANTIS
d07349 LACOSAMIDE
d07354 SILODOSIN
d07356 RIVAROXABAN
d07371 FENOFIBRIC ACID
d07373 D-XYLITOL
d07382 ADAPALENE-BENZOYL PEROXIDE TOPICAL
d07395 DEXLANSOPRAZOLE
d07397 FEBUXOSTAT
d07409 PRASUGREL
d07435 GOLIMUMAB
d07440 AMLODIPINE;HYDROCHLOROTHIAZIDE;VALSARTAN
d07441 ILOPERIDONE
d07453 TAPENTADOL
d07458 DRONEDARONE
d07466 LIRAGLUTIDE
d07467 SAXAGLIPTIN
d07473 ASENAPINE
d07486 ALISKIREN-VALSARTAN
d07505 COPPER
d07510 CHLOPHEDIANOL;DEXBROMPHENIRAMINE;PE
d07586 PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE
d07631 ESOMEPRAZOLE-NAPROXEN
d07637 PITAVASTATIN
d07640 DENOSUMAB
d07643 HEPATITIS B PEDIATRIC VACCINE
d07660 FORMOTEROL-MOMETASONE
d07668 AMLODIPINE; HYDROCHLOROTHIAZIDE; OLMESARTAN
d07684 ROFLUMILAST
d07685 CARBOXYMETHYLCELLULOSE
d07692 FINGOLIMOD
d07694 DEXBROMPHENIRAMINE-PHENYLEPHRINE
d07697 DROSPIRENONE;ETHINYL ESTRADIOL;LEVOMEFOLATE
d07705 LURASIDONE
d07709 METFORMIN-SAXAGLIPTIN
d07721 TICAGRELOR
d07727 PENICILLIN G BENZATHINE
d07739 SPINOSAD TOPICAL
d07740 VILAZODONE
```

```
d07754 AZILSARTAN
d07767 LINAGLIPTIN
d07774 BOCEPREVIR
d07776 RILPIVIRINE
d07777 TELAPREVIR
d07796 EMTRICITABINE;RILPIVIRINE;TENOFOVIR
d07818 AZILSARTAN-CHLORTHALIDONE
d07854 ASCORBIC ACID-CARBONYL IRON
d07899 COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOV
n08004 BIRTH CONTROL PILLS
n08027 BOSWELLIC ACID
n08029 CODEINE; ACETAMINOPHEN; CAFFEINE; BUTALBITAL
n08046 ACETAMIDE
n08053 ECZEMA CREAM
n08058 POMEGRANATE JUICE
n08067 VITAMIN B:VITAMIN E:ASCORBIC ACID:ERGOCALCIFEROL
n08073 HELICOBACTER PYLORI VACCINE
n08078 EMPIRIC ANTIBIOTICS
n08081 DABIGATRAN
n08105 RESVERATROL
n08202 BACTERIAL VACCINE
n08203 PENTAVALENT ROTAVIRUS VACCINE
n08207 THALLIUM
n08222 VITAMIN A-ASCORBIC ACID
n09002 CALCIUM CITRATE-MAGNESIUM
n09026 METHYLPREDNISOLONE-KETOROLAC
n09046 ACAI
n09146 HONEY-LEMON OIL
n09148 OMEGA-3 POLYUNSATURATED FATTY ACIDS;OMEGA-6 POLYUNSATURATED FATTY
      ACIDS: OMEGA-9 POLYUNSATURATED FATTY ACIDS
n09150 SODIUM CHLORIDE-SODIUM BICARBONATE
n09188 CISPLATIN; VINBLASTINE; BLEOMYCIN
n09189 RIVAROXABAN
n10022 BETAMETHASONE-BUPIVACAINE
n11008 CANNABIS (MEDICAL MARIJUANA)
```

n12004 FOLIC ACID;ASCORBIC ACID;NIACIN;THIAMINE;RIBOFLAVIN;PYRIDOXINE;

CYANOCOBALAMIN; PANTOTHENATE; BIOTIN

n12005 CLORETAZINE

n12008 CARISOPRODOL-TRAMADOL

B. DRUG ENTRY CODES AND NAMES IN NUMERIC ORDER

NOTE: This list of drugs only includes those found in the 2012 NAMCS CHC data.

- 00001 RYZOLT
- 00002 TAMIFLU
- 00004 LIDODERM PATCH
- 00008 VIACTIV
- 00009 BICILLIN L-A
- 00012 IPOL
- 00013 MYCOPHENOLATE MOFETIL
- 00019 HAWTHORN
- 00022 PREVNAR
- 00027 SYNAGIS
- 00032 EXCEDRIN MIGRAINE
- 00038 GLYSET
- 00039 SONATA
- 00040 SOY
- 00042 PROTONIX
- 00048 MOBIC
- 00052 SILDENAFIL CITRATE
- 00059 RHO IMMUNE GLOBULIN
- 00061 BISMUTH
- 00068 CLEOMYCIN
- 00073 LUXIQ
- 00076 TRILEPTAL
- 00078 AGGRENOX
- 00080 CARBIDOPA-LEVODOPA
- 00081 EXELON
- 00084 PREGABALIN
- 00091 ACT
- 00092 ESTROSTEP FE
- 00096 OSTEO-BIFLEX
- 00101 ISOSORBIDE DINITRATE
- 00102 ISOSORBIDE MONONITRATE
- 00106 ORLISTAT
- 00109 URSODIOL
- 00112 MEDERMA
- 00113 ANDROGEL
- 00114 DILTIA XT
- 00117 CRANBERRY
- 00119 K-MAG
- 00122 GATORADE
- 00123 NICOTINE
- 00125 AVELOX
- 00127 MONISTAT 3
- 00132 CAL-MAG
- 00133 CANDESARTAN
- 00150 NICODERM CQ PATCH
- 00151 TUSSIN
- 00154 CHILDREN'S IBUPROFEN
- 00159 KALETRA
- 00161 BISOPROLOL
- 00167 NOVOLIN N

- 00169 KETOROLAC TROMETHAMINE
- 00177 SALT WATER
- 00183 ABC COMPOUND W/CODEINE
- 00184 KEPPRA
- 00187 OPHTHALMIC DROPS
- 00198 ENOXAPARIN SODIUM
- 00206 ACTONEL
- 00208 CELECOXIB
- 00209 GLUCOVANCE
- 00213 PANTOPRAZOLE SODIUM
- 00218 CARBAMIDE PEROXIDE
- 00233 CONCERTA
- 00237 VANIQA
- 00251 VICODIN ES
- 00253 LISPRO
- 00254 CARTIA XT
- 00260 ACETAMINOPHEN
- 00267 LIQUID TEARS
- 00268 MOMETASONE FUROATE
- 00270 ACETAMINOPHEN NO. 3
- 00273 PROVIGIL
- 00274 QVAR
- 00280 ACETAMINOPHEN W/CODEINE
- 00283 ACETAMINOPHEN W/OXYCODONE
- 00287 CENESTIN
- 00293 AMLACTIN
- 00295 ACETAZOLAMIDE
- 00296 PENLAC
- 00305 ACETIC ACID
- 00311 BUPAP
- 00312 COMBIPATCH
- 00316 LEFLUNOMIDE
- 00317 NICOTROL INHALER
- 00329 DTAP-HEPB-IPV
- 00337 DTAP/IPV/HIB
- 00339 FEROCON
- 00340 ACHROMYCIN
- 00341 TDAP
- 00342 TRICYCLICS
- 00344 APIDRA SOLOSTAR
- 00351 VALTURNA
- 00361 FLOVENT HFA
- 00367 CONCEPT OB
- 00374 TYLENOL SINUS
- 00379 CETAPHIL CREAM
- 00387 JOLESSA
- 00388 LISPRO PROTAMINE
- 00407 FOLNATE
- 00419 ACETIC ACID/ANTIPYRINE/BENZOCAINE/POLYC
- 00540 ADIPEX
- 00597 ADVIL
- 00598 AEROBID
- 00645 AFRIN

- 00790 ALCOHOL
- 00800 ALCOHOL ISOPROPYL
- 00825 ALDACTAZIDE
- 00830 ALDACTONE
- 00845 ALDOMET
- 00953 ALLER-CHLOR
- 00975 ALLERFRIN
- 00980 ALLERGY RELIEF OR SHOTS
- 01001 CLARITIN D
- 01002 NEXIUM
- 01003 ANAPROX DS
- 01007 TIKOSYN
- 01008 ZONEGRAN
- 01012 BUDESONIDE
- 01017 BACTRIM DS
- 01018 MONSEL'S SOLUTION
- 01019 NIFEDICAL XL
- 01020 OPTIVAR
- 01021 BUTORPHANOL TARTRATE
- 01022 METOPROLOL TARTRATE
- 01027 STROMECTOL
- 01028 CODEINE COUGH SYRUP
- 01029 EFFEXOR XR
- 01030 ALLOPURINOL
- 01034 ADVAIR DISKUS
- 01036 GEODON
- 01037 GLUCOTROL XL
- 01038 HALDOL DECANOATE
- 01041 RABEPRAZOLE SODIUM
- 01043 ZIPRASIDONE HCL
- 01044 Z-PAK
- 01046 QUINOLONES
- 01047 IRBESARTAN
- 01050 TOLTERODINE TARTRATE
- 01055 ORAPRED
- 01056 ACTIVELLA
- 01057 DETROL LA
- 01062 RHINOCORT AQUA
- 01063 TEGRETOL XR
- 01064 WELLBUTRIN SR
- 01073 MAXALT-MLT
- 01076 STARLIX
- 01082 BENZACLIN
- 01083 BIESTROGEN
- 01084 LUMIGAN
- 01086 MSM
- 01094 CARDIZEM CD
- 01096 CLINDAGEL
- 01104 LOESTRIN FE
- 01106 LUTEIN
- 01109 SPIRULINA
- 01111 TRAVATAN
- 01119 INDERAL LA
- 01121 LESCOL XL

- 01124 ULTRACET
- 01137 PROMENSIL
- 01144 OLUX
- 01146 CHROMIUM PICOLINATE
- 01153 VAGIFEM
- 01156 MARCAINE/KENALOG
- 01161 ACCURETIC
- 01166 WELCHOL
- 01174 PROACTIVE
- 01178 PODOFILOX
- 01194 EMBREX
- 01199 NEOSURE
- 01201 STROVITE FORTE
- 01203 BACILLIN C-R
- 01206 COENZYME Q10
- 01207 LITHIUM CARBONATE
- 01211 PULMICORT RESPULES
- 01214 LANTUS
- 01216 OXCARBAZEPINE
- 01223 ALUMINUM CHLORIDE
- 01228 BECLOMETHASONE DIPROPIONATE
- 01229 PEG-INTRON
- 01234 RITALIN-SR
- 01236 VERAPAMIL SR
- 01242 CEFAZOLIN SODIUM
- 01249 METADATE CD
- 01250 ALUMINUM-MAGNESIUM HYDROX W/SIMETHICONE
- 01255 ALUPENT
- 01257 BARRIER OINTMENT
- 01259 MILK THISTLE
- 01262 CORICIDIN HBP COUGH & COLD
- 01263 VIDEX EC
- 01266 INSULIN GLARGINE
- 01267 HUMALOG MIX 75/25
- 01268 LORCET PLUS
- 01274 TRIZIVIR
- 01275 ZONISAMIDE
- 01278 METROLOTION
- 01281 ADDERALL XR
- 01282 LATANOPROST
- 01284 NOREL DM
- 01285 ZOMETA
- 01290 AMANTADINE
- 01293 CENTRUM KIDS COMPLETE
- 01297 NICOTINE GUM
- 01307 DORZOLAMIDE AND TIMOLOL
- 01310 PARICALCITOL
- 01450 AMINOPHYLLINE
- 01530 AMITRIPTYLINE
- 01535 AMITRIPTYLINE HCL W/PERPHENAZINE
- 01615 AMOLIN
- 01630 AMOXICILLIN
- 01635 AMOXICILLIN TRIHYDRATE

- 01640 AMOXIL
- 01660 AMPHETAMINE
- 01685 AMPICILLIN
- 01690 AMPICILLIN TRIHYDRATE
- 01755 ANACIN
- 01770 ANALBALM
- 01775 ANALGESIC
- 01838 ANAPROX
- 01860 ANBESOL
- 01865 ANCEF
- 01935 ANDROLONE
- 01983 ANESTHETIC
- 01995 ANEXSIA
- 02013 BENICAR
- 02016 CLARINEX
- 02018 FOCALIN
- 02019 FORADIL AEROLIZER
- 02026 YASMIN
- 02027 GLUCAGEN
- 02031 ELIDEL CREAM
- 02036 EXTRA STRENGTH TYLENOL
- 02037 LEVETIRACETAM
- 02038 LO-OGESTREL
- 02039 DTAP-HIB
- 02042 DUONEB
- 02047 AUGMENTIN ES
- 02054 TRIMETHOPRIM SULFATE/POLYMYXIN B SULFAT
- 02059 AZMACORT
- 02060 DIAMOX SEQUELS
- 02061 GUAIFENESIN/PSEUDOEPHEDRINE
- 02064 INVANZ
- 02074 LUPRON
- 02075 ANTABUSE
- 02076 MAPAP
- 02079 NITROGLYCERIN SUBLINGUAL
- 02080 ANTACID
- 02083 UNITHROID
- 02087 SOAPSUDS ENEMA
- 02088 ANTACID AND ADSORBENT
- 02093 OATMEAL BATH
- 02099 DEPAKOTE ER
- 02103 LEVALBUTEROL HCL
- 02104 MAGNESIUM HYDROXIDE
- 02107 ZALEPLON
- 02108 COLAZAL
- 02116 ERYCIN
- 02117 PLAN B
- 02119 LEXAPRO
- 02125 ANTIACID
- 02128 BENZONATATE
- 02129 CLORAZEPATE DIPOTASSIUM
- 02131 ESOMEPRAZOLE MAGNESIUM
- 02133 NITROGLYCERIN TRANSLINGUAL
- 02134 PEDIALYTE FREEZER POPS

- 02135 ANTI-ITCH
- 02140 THIAMINE HCL
- 02143 FOLTX
- 02144 ORTHO-EVRA
- 02147 METHYLIN
- 02152 KENALOG/LIDOCAINE
- 02153 VITAMIN B12/FOLIC ACID
- 02154 ENTOCORT EC
- 02156 GLEEVEC
- 02158 ANTIBIOTIC AGENT
- 02168 BLACK COHOSH
- 02169 ICAR
- 02173 BORAGE OIL
- 02176 ALPHA LIPOIC ACID
- 02186 ORTHO EVRA
- 02187 ALPHAGAN P
- 02188 DEXEDRINE SPANSULES
- 02189 GLUCOPHAGE XR
- 02191 ZYRTEC-D 12 HOUR TABLETS
- 02195 ANTIPYRINE
- 02203 ABILIFY
- 02207 ROBAXIN-750
- 02209 NOVOLOG
- 02213 ELIDEL
- 02214 NULEV
- 02217 ARANESP
- 02223 ZETIA
- 02226 FROVA
- 02231 ADALAT CC
- 02232 BENEFIBER
- 02233 EMERGEN-C
- 02234 TAZTIA XT
- 02236 TRIEST
- 02237 CLORPRES
- 02239 DOVE SOAP
- 02244 CALAN SR
- 02247 FLOXIN OTIC
- 02249 PEPCID AC
- 02250 ANTIVERT
- 02256 ESCITALOPRAM OXALATE
- 02259 NEULASTA
- 02261 VORICONAZOLE
- 02268 RETIN-A MICRO GEL
- 02279 PULMICORT
- 02280 APRI
- 02281 CHICKEN POX VACCINE
- 02282 5-HYDROXYTRYPTOPHAN
- 02298 CYCLESSA
- 02299 SENNA-GEN
- 02303 REMIFEMIN
- 02304 TWINRIX
- 02310 ANUSOL
- 02311 PIOGLITAZONE HCL

- 02312 CABERGOLINE
- 02315 ANUSOL-HC
- 02316 PAXIL CR
- 02321 TENOFOVIR DISOPROXIL FUMARATE
- 02331 NEOMYCIN/POLYMYXIN B SULFATES/HYDROCORT
- 02333 ROXICODONE
- 02335 APAP
- 02347 CALMOSEPTINE
- 02349 LIDOCAINE W/MARCAINE
- 02351 FEMARA
- 02358 PROCTOSOL
- 02359 VIREAD
- 02364 CALCITRATE
- 02367 NUVARING
- 02370 APLISOL
- 02371 SCALPICIN SOLUTION
- 02376 MULTIVITAMIN W/D
- 02379 TRIPLE PASTE
- 02384 DOC-Q-LACE
- 02396 VARICELLA VIRUS VACCINE
- 02470 AQUAPHOR
- 02520 ARALEN
- 02575 ARISTOCORT
- 02580 ARISTOCORT A
- 02627 ARMOUR THYROID
- 02630 ARNICA
- 02645 ARTANE
- 02705 ASCORBIC ACID
- 02725 ASCRIPTIN
- 02730 ASCRIPTIN NO. 2
- 02775 ASMALIX ELIXIR
- 02805 ASPIRIN
- 02820 ASPIRIN COMPOUND #3
- 02875 ATARAX
- 02900 ATIVAN
- 02940 ATROPINE
- 02982 ATROVENT
- 02987 AUGMENTIN 125
- 02995 AURALGAN
- 03002 AVODART
- 03003 CORTISPORIN OINTMENT
- 03012 DEPAKOTE SPRINKLE
- 03013 DILANTIN INFATABS
- 03017 TIGER BALM
- 03019 REYATAZ
- 03021 MOTRIN CHILDREN'S COLD SUSP
- 03039 IMODIUM A-D
- 03040 AVC
- 03041 OVIDE
- 03044 RENAL CAPS
- 03046 NEPRO
- 03048 RELPAX
- 03050 AVEENO
- 03051 LITTLE NOSES GENTLE FORMULA

- 03054 RYNATAN PEDIATRIC SUSPENSION
- 03055 AVEENO LOTION
- 03057 MEGESTROL ACETATE
- 03067 COX-2 INHIBITOR
- 03069 NYSTOP
- 03071 OXYTROL
- 03072 A+D OINTMENT
- 03080 STRATTERA
- 03081 AMOXICILLIN AND CLAVULANATE POTASSIUM
- 03084 SYSTANE
- 03089 ATACAND HCT
- 03091 AZELASTINE HCL
- 03099 CILOSTAZOL
- 03101 AXID
- 03104 METROCREAM
- 03106 ONE A DAY VITAMIN
- 03113 AYGESTIN
- 03115 AYR SALINE MIST
- 03116 URSO
- 03117 AZACTAM
- 03122 GINGER
- 03123 AZATHIOPRINE
- 03127 CARDIZEM LA
- 03129 DIPROLENE AF
- 03131 DUAC
- 03134 RESTASIS
- 03137 BROVEX
- 03138 CIPRO XR
- 03139 HECTOROL
- 03141 LISINOPRIL/HCTZ
- 03142 NIFEDIPINE ER
- 03148 AVIANE
- 03151 STERAPRED DS
- 03156 BUPROPION SR
- 03159 ONE A DAY VITAMINS MEN
- 03161 MICROGESTIN FE
- 03162 PEGASYS
- 03163 ROSULA
- 03177 CALCARB 600
- 03179 PEDIARIX
- 03180 LEVITRA
- 03181 METAGLIP
- 03184 WELLBUTRIN XL
- 03185 XANAX XR
- 03187 CRESTOR
- 03188 MUCINEX
- 03189 ORTHO-TRICYCLEN LO
- 03192 VIGAMOX
- 03193 ABELCET
- 03194 AVAR
- 03197 CIPRODEX
- 03201 MEMANTINE
- 03208 ALAVERT

- 03209 ATAZANAVIR SULFATE
- 03211 CIALIS
- 03221 ENDOMYCIN
- 03222 MICARDIS HCT
- 03225 AZULFIDINE
- 03226 ENALAPRIL MALEATE
- 03228 AVINZA
- 03229 RED YEAST RICE
- 03232 PORTIA
- 03234 TERAZOL 3
- 03236 TERAZOL 7
- 03237 ATOMOXETINE HCL
- 03241 TESTIM
- 03247 COLESEVELAM HCI
- 03250 B COMPLEX
- 03251 RANITIDINE HCI
- 03253 GREEN TEA EXTRACT
- 03257 PRIMACARE
- 03267 INDOCIN SR
- 03269 SEASONALE
- 03272 METOPROLOL SUCCINATE
- 03273 NOVOLIN R
- 03276 SUBOXONE
- 03279 AMPHETAMINE SALT COMBO
- 03283 CEFDINIR
- 03286 KARIVA
- 03289 PRE-HIST-D
- 03296 IVERMECTIN
- 03303 RESCON
- 03306 NOVALOG
- 03309 PROVENTIL HFA
- 03312 CORAL CALCIUM DAILY
- 03319 TRAMADOL HCL
- 03328 ENALAPRIL/HCTZ
- 03332 BENADRYL ALLERGY
- 03354 L-LYSINE
- 03355 B-12
- 03378 DANDELION
- 03379 KENALOG IN ORABASE
- 03381 MELOXICAM
- 03392 TYLENOL ELIXIR
- 03410 BACITRACIN
- 03411 FLAX SEED
- 03415 BACITRACIN-NEOMYCIN-POLYMYXIN
- 03420 BACITRACIN-POLYMYXIN
- 03423 BACLOFEN
- 03426 DIATX
- 03427 HUMIRA
- 03428 EMTRICITABINE
- 03430 BACTRIM
- 03433 CORTANE-B
- 03434 HYOSCYAMINE
- 03438 BACTROBAN
- 03442 SILVASORB

- 03590 BARIUM
- 03635 BASALJEL
- 03700 BECLOMETHASONE
- 03709 BECONASE
- 03800 BELLADONNA
- 03805 BELLADONNA ALKALOIDS W/PHENOBARBITAL
- 03825 BELLADONNA W/PHENOBARBITAL
- 03900 BEN-GAY
- 03905 BENADRYL
- 04000 BENTYL
- 04002 CALCIUM-MAGNESIUM-ZINC SUPPLEMENT
- 04011 NAMENDA
- 04014 ARIPIPRAZOLE
- 04020 BENZAC
- 04021 BENICAR HCT
- 04023 BISOPROLOL/HCTZ
- 04029 CEROVITE TABLETS
- 04030 BENZAGEL
- 04041 ALBUTEROL/ATROVENT
- 04042 SPIRIVA
- 04043 SYMBYAX
- 04045 CLEMASTINE FUMARATE
- 04049 CULTURELLE
- 04051 CYMBALTA
- 04054 CUBICIN
- 04058 DIALYVITE
- 04059 DOCUSATE -SENNA
- 04063 FERREX
- 04071 FORTEO
- 04072 NASAL SALINE
- 04079 GLYCOLAX
- 04085 BENZOYL
- 04087 ICAR-C
- 04088 BENZOYL PEROXIDE
- 04092 EYE-VITE
- 04094 LACLOTION
- 04097 LEXIVA
- 04100 BEROCCA
- 04113 FORTAMET
- 04114 VYTORIN
- 04120 BETADINE
- 04121 NOVAREL
- 04129 MYCELEX TROCHES
- 04136 NOVOLOG MIX 70/30
- 04143 CATAPRES-TTS-1
- 04144 POLY-IRON 150 CAPSULES
- 04146 EZETIMIBE
- 04154 SILVER NITRATE STICK
- 04162 FLUMIST
- 04168 REFRESH TEARS
- 04170 BETAMETHASONE
- 04171 EMTRIVA
- 04174 ROBAFEN

- 04175 METFORMIN HYDROCHLORIDE ER
- 04176 SENNA-S
- 04178 TESSALON
- 04190 BETHANECHOL
- 04194 BUFFERED ASPIRIN
- 04196 CADUET
- 04197 CALCARB 600 WITH VITAMIN D
- 04199 CALCIUM MAGNESIUM CHELATED
- 04200 CALCIUM ZINC MAGNESIUM
- 04201 CALTRATE PLUS
- 04204 CARMEX
- 04213 COLON CLENZ
- 04217 THERA H TABS
- 04221 CEREFOLIN
- 04228 DIABETIC TUSSIN
- 04232 CARBINOXAMINE MALEATE
- 04235 BICILLIN
- 04236 DEEP SEA NASAL SPRAY
- 04237 DILEX -G
- 04238 ELESTAT
- 04240 BICILLIN C-R
- 04243 FIBER TAB
- 04244 FLORAJEN
- 04245 FLORANEX TABS
- 04246 FLORASTOR
- 04248 TEARS NATURALE FREE
- 04266 GARLIC OIL
- 04277 RIBASPHERE
- 04278 RISPERDAL CONSTA
- 04282 ZEMPLAR
- 04287 SEA-OMEGA
- 04288 SENNALAX
- 04292 SENSIPAR
- 04304 TEARS AGAIN
- 04307 SENNOSIDES
- 04311 Q-TUSSIN
- 04316 ARIXTRA
- 04320 ATENOLOL/CHLORTHALIDONE
- 04327 BOUDREAUX'S BUTT PASTE
- 04331 ST. JOSEPH ASPIRIN
- 04333 GENERLAC
- 04339 HERBAL DRUG (UNSPECIFIED)
- 04345 BIOTIN
- 04351 JANTOVEN
- 04367 NASCOBAL
- 04368 CONTRACEPTIVE AGENT
- 04370 BISACODYL
- 04383 PROCTOZONE HC CREAM
- 04393 TRUVADA
- 04416 AMIBID LA
- 04422 BABY SHAMPOO
- 04423 LETROZOLE
- 04431 BROMHIST DM PEDIATRIC SYRUP
- 04434 BI-EST

- 04437 URELLE
- 04440 BISMUTH SUBSALICYLATE
- 04446 LYCOPENE
- 04448 AMMONIUM LACTATE
- 04451 CANDIDA ALBICANS SKIN TEST ANTIGEN
- 04456 CLINDAMAX
- 04463 LORTUSS DM
- 04465 ICAR-C PLUS
- 04476 MODIFIED CITRUS PECTIN
- 04480 BLEPH
- 04489 METADATE
- 04491 SYMBICORT
- 04494 IMIQUIMOD
- 04503 PEDIATEX
- 04512 TRINESSA
- 04514 TRISPRINTEC
- 04529 METHYLPREDNISOLONE SODIUM SUCCINATE
- 04536 ABX OINTMENT
- 04541 TYLENOL INFANT'S
- 04544 HYDROCORTISONE VALERATE
- 04549 ACECOL
- 04556 SEVELAMER HYDROCHLORIDE
- 04558 CALCIUM CHANNEL BLOCKER
- 04561 RAZADYNE
- 04562 CALCIPOTRIENE
- 04564 DIABETES MEDICATION
- 04569 INNOPRAN XL
- 04571 ISTALOL
- 04576 DULOXETINE
- 04577 HORSE CHESTNUT
- 04578 L-ARGININE
- **04580 BONINE**
- 04585 BONTRIL PDM
- 04589 TIOTROPIUM BROMIDE
- 04593 VITEYES
- 04594 COPEGUS
- 04614 CRYSELLE
- 04617 ACCUNEB
- 04619 PARAFFIN
- 04622 EXEMESTANE
- 04623 NICOTINE NASAL SPRAY
- 04624 PRAZIQUANTEL
- 04627 TRAVOPROST
- 04631 EPZICOM
- 04632 FOSAMPRENAVIR CALCIUM
- 04634 HEMIN
- 04642 OYST-CAL
- 04654 TRACLEER
- 04664 MIRENA
- 04674 NATEGLINIDE
- 04679 STATINS
- 04682 UTIRA
- 04803 BROMFED

- 04808 BROMOCRIPTINE
- 04820 BROMPHEN
- 04845 BROMPHENIRAMINE
- 05010 BUFFERIN
- 05024 BUMEX
- 05026 ASCENSIA ELITE
- 05033 LUNESTA
- 05035 BUPIVACAINE
- 05051 VESICARE
- 05054 SUBUTEX
- 05056 ZEGERID
- 05063 FLUORABON
- 05066 CAMPRAL
- 05072 BONIVA
- 05074 ENABLEX
- 05083 PROLACTIN RIA
- 05087 DIABETIC TUSSIN DM
- 05090 NEVANAC
- 05095 BUTALBITAL
- 05097 LYRICA
- 05099 CLOTRIMAZOLE-BETAMETHASONE DIPROPRIONAT
- 05102 CHOLEST-OFF
- 05103 BUTALBITAL W/CODEINE
- 05106 GLIPIZIDE ER
- 05109 ALDEX
- 05116 CARDIOTEK RX
- 05122 METHYLIN ER
- 05124 ENPRESSE
- 05127 MONONESSA
- 05133 RENAX
- 05156 ERYTHROMYCIN BASE-NEOMYCIN
- 05162 BYETTA
- 05169 POLYVENT
- 05174 ANTARA
- 05178 FOSRENOL
- 05184 DUET DHA
- 05192 ABSORBASE
- 05197 LOSARTAN-HCTZ
- 05203 ENFALYTE
- 05207 CEFUROXIME AXETIL
- 05218 CICLOPIROX
- 05222 PYRANTEL
- 05233 MOXILIN
- 05244 ROZEREM
- 05250 CAFERGOT
- 05252 DIGESTIVE ADVANTAGE
- 05264 ASMANEX TWISTHALER
- 05265 CAFFEINE
- 05266 SANCTURA
- 05269 INSPRA
- 05271 METANX
- 05277 DEPO-MEDROL W/ LIDOCAINE
- 05278 OCUVITE LUTEIN
- 05307 ATRIDOX

- 05308 MUCINEX DM
- 05310 CALADRYL
- 05322 AMCINONIDE
- 05324 EPLERENONE
- 05327 SPRINTEC
- 05329 CAMILA
- 05331 COMMIT
- 05333 NORTREL
- 05335 CALAMINE LOTION
- 05337 LOFIBRA
- 05338 FLUTICASON-SALMETEROL
- 05344 FLUOR-A-DAY
- 05347 CALAN
- 05348 NATALCARE PLUS
- 05349 NEOMYCIN SULFATE
- 05351 ORTHO MICRONOR
- 05375 CALCIFEROL
- 05393 CALCITONIN
- 05394 CALCITREL
- 05395 CALCIUM ACETATE
- 05405 CALCIUM CARBONATE
- 05415 CALCIUM
- 05465 CALCIUM-D
- 05541 CALTRATE W/VITAMIN D
- 05595 CANTHARIDIN
- 05640 CAPITAL W/CODEINE
- 05663 CARAFATE
- 05680 CARBAMAZEPINE
- 05750 CARDEC-DM
- 05789 CARDIZEM
- 05810 CARISOPRODOL
- 05820 CARMOL
- 05895 CATAPRES
- 05983 CEFADROXIL
- 05993 CEFTIN
- 05995 CEFAZOLIN
- 06001 ALAVERT D
- 06002 AMBIEN CR
- 06004 FOCALIN XR
- 06005 CELESTONE
- 06014 ERRIN
- 06015 CELESTONE SOLUSPAN
- 06016 TAB-A-VITE
- 06017 AMLODIPINE/BENAZEPRIL
- 06038 AMITIZA
- 06044 CATAPRES-TTS-2
- 06045 FEMRING
- 06054 FORTICAL
- 06059 XODOL
- 06061 ACTOPLUS MET
- 06062 CEPHADYN
- 06064 GLYBURIDE/METFORMIN
- 06068 ANASTROZOLE

- 06071 IMATINIB
- 06086 VANDAZOLE
- 06089 XIFAXAN
- 06093 TACLONEX
- 06094 XIBROM
- 06095 CENTRAX
- 06100 CENTRUM
- 06101 TYLENOL COLD
- 06102 BIDIL
- 06108 GARDASIL
- 06109 YAZ
- 06110 CEPACOL
- 06118 AZILECT
- 06120 CEPASTAT
- 06121 RANEXA
- 06122 RIFAXIMIN
- 06125 CEPHALEXIN
- 06126 AVANDARYL
- 06129 ADACEL
- 06138 BOOSTRIX
- 06153 DEXPAK
- 06162 CEFUROXIME
- 06164 LEVEMIR
- 06166 ALFUZOSIN
- 06170 CERUMENEX
- 06172 DAYTRANA
- 06173 ROTATEQ
- 06176 OLOPATADINE
- 06192 CHANTIX
- 06193 JANUVIA
- 06196 SOLODYN
- 06203 TANDEM-OB
- 06204 CIPROXIN
- 06210 CETAPHIL
- 06212 CLARINEX-D
- 06213 DILT-XR
- 06216 LENALIDOMIDE
- 06219 DESOGESTREL
- 06229 DAPTOMYCIN
- 06236 ATRIPLA
- 06237 CERAVE
- 06242 LEVSIN/SL
- 06247 FLECAINIDE
- 06249 SALONPAS
- 06253 JUNEL FE
- 06256 Q-DRYL
- 06258 ZOSTER VACCINE LIVE
- 06261 LESSINA
- 06278 FAZACLO
- 06291 TELMISARTAN
- 06294 CHEMOTHERAPY
- 06302 OLMESARTAN
- 06318 CHERATUSSIN
- 06322 DICEL

- 06323 TRIDERM
- 06374 CHILDREN'S TYLENOL
- 06470 CHLORASEPTIC
- 06475 CHLORASEPTIC CHILDREN'S
- 06495 CHLORDIAZEPOXIDE
- 06605 CHLORPHENIRAMINE
- 06620 CHLORPROMAZINE
- 06625 CHLORPROPAMIDE
- 06645 CHLORTHALIDONE
- 06661 CHLORZOXAZONE
- 06720 CHOLINE
- 06798 CHROMIUM
- 06815 CIMETIDINE
- 06839 CIPRO
- 06860 CITRATE OF MAGNESIA
- 06895 CLEAR EYES
- 06900 CLEARASIL
- 06905 CLEOCIN
- 06913 CLEOCIN T
- 06920 CLINDAMYCIN
- 06925 CLINDAMYCIN (PHOSPHATE)
- 06930 CLINDEX
- 06935 CLINORIL
- 06975 CLOMID
- 06980 CLONAZEPAM
- 06985 CLONIDINE
- 06990 CLONOPIN
- 06993 CLORAZEPATE
- 07001 OSELTAMIVIR
- 07003 CLOTRIMAZOLE
- 07004 EZOL
- 07016 MENACTRA
- 07018 ORENCIA
- 07031 SULFAZINE
- 07049 APIDRA
- 07058 ESTROVEN
- 07061 REVLIMID
- 07064 ADOL
- 07065 NONI JUICE
- 07069 ENJUVIA
- 07072 TEA TREE OIL
- 07075 COAL TAR
- 07076 INVEGA
- 07079 BROVANA
- 07081 BUDEPRION SR
- 07087 DERMACERIN
- 07090 BANOPHEN
- 07096 FLUTICASONE PROPIONATE
- 07099 CALCIUM CITRATE W/VITAMIN D
- 07106 CINNAMON
- 07117 OPANA
- 07118 FOCUS SMART
- 07137 EXFORGE

- 07140 COCOA BUTTER
- 07141 ZOSTAVAX
- 07144 PROAIR HFA
- 07145 COCONUT OIL
- 07150 COD LIVER OIL
- 07153 ARB
- 07154 ASPIRIN FREE
- 07159 FOSAMAX PLUS D
- 07163 NOREL EX
- 07166 DERMOTIC OIL
- 07167 SEASONIQUE
- 07170 BENAZEPRIL-HYDROCHLOROTHIAZIDE
- 07171 LAMISIL AT
- 07173 SELSEB
- 07180 CODEINE
- 07182 PATADAY
- 07183 JANUMET
- 07188 ATUSS DS
- 07190 CODEINE SULFATE
- 07198 GINGERMAX
- 07203 GUMMIVITES
- 07207 FEMCON FE
- 07208 IODORAL
- 07211 SPRYCEL
- 07218 GLUMETZA
- 07223 OPANA ER
- 07228 THERA-M
- 07229 BUDEPRION XL
- 07232 LUTERA
- 07234 KELNOR
- 07237 DEPLIN
- 07239 ICAPS AREDS
- 07243 ED-CHLOR-TAN
- 07250 COGENTIN
- 07251 PERCOCET 10
- 07252 PERCOCET 7.5
- 07257 VERAMYST
- 07263 QUALAQUIN
- 07265 COLACE
- 07266 RENA-VITE
- 07275 COLCHICINE
- 07283 TANDEM PLUS
- 07291 TRI-VITE
- 07293 COLD RELIEF
- 07294 V-C FORTE
- 07299 VISION FORMULA
- 07318 HYDROPHOR
- 07331 PHENADOZ
- 07348 SUPER B-50 COMPLEX
- 07349 TEKTURNA
- 07352 TRAVATAN Z
- 07358 NIFEDIAC CC
- 07366 VITAMIN D3
- 07371 CARBOXYMETHYLCELLULOSE

- 07386 BARACLUDE
- 07389 ENTECAVIR
- 07393 CLINDAMYCIN TOPICAL
- 07398 ALTABAX
- 07401 HUMAN PAPILLOMAVIRUS VACCINE
- 07406 VYVANSE
- 07409 COBAL-1000
- 07412 ASA
- 07420 PROPO-N
- 07431 AMRIX
- 07434 GUAIFENESIN-HYDROCODONE
- 07450 PREZISTA
- 07454 AZOR
- 07470 COMPAZINE
- 07473 BENADRYL CREAM
- 07474 INFANRIX
- 07477 NEEVO
- 07478 COMPOUND W
- 07481 XYZAL
- 07486 J-MAX
- 07491 LEVACET
- 07492 LIDOCAINE/MAALOX/BENADRYL COMPOUND
- 07494 LOVAZA
- 07499 CATAPRES-TTS-3
- 07534 ETONOGESTREL
- 07539 OPTIVE
- 07543 CONJUGATED ESTROGENS
- 07552 ISOMETHEPTENE
- 07567 HYDROCERIN
- 07571 FLULAVAL
- 07572 HYALURONIC ACID
- 07573 MMR VACCINE
- 07576 ALIGN
- 07581 BIOSIL
- 07592 ACCUHIST
- 07596 CORFEN-DM
- 07608 ALLI
- 07616 DERMABOND
- 07622 FLUARIX
- 07623 COPPER
- 07633 QUASENSE
- 07634 TYROSINE
- 07635 PRENATAL PLUS
- 07639 IMPLANON
- 07642 SULFAC
- 07652 ETHINYL ESTRADIOL-NORETHINDRONE
- 07655 FIORTAL
- 07657 Q-TAPP
- 07669 GERI-HYDROLAC
- 07670 CORGARD
- 07673 METOCLOPHEN
- 07680 CORICIDIN
- 07683 ABC PLUS

- 07688 INSULIN ASPART
- 07693 CALCIUM, MAGNESIUM AND VITAMIN D
- 07755 CORTAID
- 07778 CORTICOTROPIN
- 07795 CORTISONE
- 07800 CORTISPORIN OPHTHALMIC SOLUTION
- 07913 COUGH FORMULA
- 07920 COUGH SYRUP
- 07930 COUMADIN
- 07997 CREON
- 08002 NORA-BE
- 08006 TAMSULOSIN
- 08007 BCP
- 08008 OB COMPLETE DHA
- 08009 INSULIN N
- 08015 CROMOLYN
- 08031 BALZIVA
- 08032 BYSTOLIC
- 08033 LYBREL
- 08042 DIGEX
- 08043 SERUM
- 08045 MVI
- 08047 LIALDA
- 08049 M-END DM
- 08058 PRENATAL
- 08071 VISINE TEARS
- 08077 ESOMEPRAZOLE
- 08082 BOSWELLIN
- 08089 METOPROLOL/HYDROCHLOROTHIAZIDE
- 08090 CYANOCOBALAMIN
- 08097 EMTRICITABINE/TENOFOVIR
- 08116 SIMCOR
- 08122 ALA-HIST D
- 08123 TYLENOL SINUS MAXIMUM STRENGTH
- 08124 FIBER CAPSULES
- 08131 CERON-DM
- 08137 BALSALAZIDE
- 08140 CYCLOGYL
- 08147 MICRO-K
- 08149 ADVAIR
- 08151 FLECTOR
- 08153 CYCLOPHOSPHAMIDE
- 08157 COMBIGAN
- 08159 VARDENAFIL
- 08161 ROSUVASTATIN
- 08162 CARDURA XL
- 08164 ALA HIST
- 08165 ACULAR
- 08168 ACETAMIDE
- 08169 CORTISPORIN TC OTIC
- 08173 DURAFLU
- 08174 ERYTHROMYCIN BENZOYL PEROXIDE
- 08177 ONE A DAY WOMENS FORMULA
- 08179 SANCTURA XR

- 08180 CYPROHEPTADINE
- 08181 DILTIAZEM CD
- 08185 DICLOFENAC XR
- 08191 GLIPIZIDE/METFORMIN
- 08194 ALLERTEC
- 08196 ECZEMA CREAM
- 08197 TREXIMET
- 08202 ALBUTEROL/IPRATROPIUM
- 08203 OMNARIS
- 08204 TADALAFIL
- 08208 SALINE GARGLES
- 08209 MUCINEX D
- 08212 SEROQUEL XR
- 08214 TYLENOL CHILDRENS COUGH
- 08217 POMEGRANATE JUICE
- 08219 SUDOGEST
- 08224 CITRANATAL
- 08228 CHLORPHENIRAMINE/HYDROCODONE
- 08230 CYTOMEL
- 08234 PRISTIQ
- 08241 VITAMINS E, C, D, B, B12
- 08246 OXYCODONE ER
- 08249 PATANASE
- 08255 NIACIN SR
- 08258 NIASPAN ER
- 08261 ALVESCO
- 08267 HELICOBACTER PYLORI VACCINE
- 08272 PHENYLEPHRINE/GUAIFENESIN
- 08276 EMPIRIC ANTIBIOTICS
- 08284 DABIGATRAN
- 08293 SITAGLIPTIN
- 08303 BACITRACIN ZINC
- 08306 PHENYTOIN SODIUM EXTENDED
- 08308 SENNA PLUS
- 08329 ULTRAM ER
- 08337 RESVERATROL
- 08341 CALCIUM CARBONATE W/VIT D
- 08343 OCEAN NASAL SPRAY
- 08346 DIET PILLS
- 08347 ADVIL PM
- 08351 IRON SULFATE
- 08354 VICODIN HP
- 08378 VARENICLINE
- 08384 BLOOD PRESSURE MEDICATION
- 08385 DALLERGY
- 08398 RIBAPAK
- 08412 HEP A+B COMBO
- 08413 LACTAID
- 08414 ANTI REFLUX
- 08418 POLYMYXIN B SULFATE DROPS
- 08420 DANTRIUM
- 08423 PENTACEL
- 08426 DOXYLAMINE

- 08432 NOVOLOG FLEXPEN
- 08437 OMNIPRED
- 08439 FLORICET
- 08440 DAPSONE
- 08448 PEDIATRIC MULTIVITAMINS
- 08450 DARAPRIM
- 08451 MOISTURIZING CREAM OTC
- 08452 TUSSIONEX PENNKINETIC
- 08464 ENSURE PLUS
- 08470 DARVOCET-N
- 08476 DHA
- 08478 COREG CR
- 08481 ADIPEX-P
- 08490 DARVON-N
- 08492 NETIPOT
- 08499 PNEUPED
- 08513 OPHTHALMIC SOLUTION
- 08518 BACTERIAL VACCINE
- 08519 LIVE ORAL PRV
- 08521 RECLIPSEN
- 08522 RECLAST
- 08527 DARUNAVIR
- 08530 JAY-PHYL
- 08534 YEAST CREAM
- 08535 DDAVP
- 08536 THALLIUM
- 08546 ESTER-C
- 08547 PCV
- 08551 A/B OTIC
- 08552 PEG 3350
- 08553 HIB-PRP-T
- 08561 CENTURY
- 08565 DEBROX
- 08573 VITAMIN A & C
- 08576 YOGURT
- 08585 DECADRON
- 08588 FLEXPEN
- 08591 ISENTRESS
- 08603 SKIN CREAM
- 08605 DECADRON-LA
- 08606 OPIOIDS
- 08611 BENZAC AC
- 08624 CETRAXAL
- 08627 PRENAFIRST
- 08665 DECONEX
- 08666 CHILDRENS VITAMINS
- 08670 DECONGESTANT
- 08671 RU-HIST FORTE
- 08679 GLATIRAMER
- 08681 ETRAVIRINE
- 08745 DELESTROGEN
- 08753 DELSYM
- 08770 DELTASONE
- 08805 DEMULEN

- 08835 DEPAKENE
- 08836 DEPAKOTE
- 08860 DEPO-ESTRADIOL
- 08865 DEPO-MEDROL
- 08870 DEPO-PROVERA
- 08880 DEPO-TESTOSTERONE
- 08900 DEPOTESTOGEN
- 09003 CALCIUM CITRATE W MAG
- 09015 DESFERAL
- 09020 DESIPRAMINE
- 09025 DESITIN
- 09029 BAKING SODA BATHS
- 09032 DEPOMEDROL/TORADOL
- 09033 DESOWEN
- 09037 FALCON EYE DROPS
- 09038 TOPICAL SKIN CREAM
- 09059 ACAI
- 09075 DEXAMETHASONE
- 09080 DEXAMETHASONE ACETATE
- 09095 DEXAMETHASONE SODIUM PHOSPHATE
- 09098 OCP
- 09108 DTAP-POLIO
- 09109 PREVIDENT
- 09119 ALAHIST DM
- 09120 DEXEDRINE
- 09122 ULORIC
- 09127 NEUTREXIN
- 09133 PROMISEB
- 09138 PROCENTRA
- 09140 APPLE CIDER VINEGAR
- 09141 GELNIQUE
- 09146 MULTIVITAMIN FOR HER
- 09149 INSULIN R
- 09151 STEROID
- 09152 VERIPRED
- 09153 ULESFIA
- 09154 CHILDREN ANTIHISTAMINE
- 09167 COMPOUND MEDICATION
- 09170 DEXTROAMPHETAMINE
- 09175 DEXTROSE
- 09184 XYLITOL
- 09189 HYDROCODONE CP
- 09207 SELZENTRY
- 09213 ESZOPICLONE
- 09215 CHOLESTEROL MED
- 09223 EFFIENT
- 09227 ENFAMIL LIPIL
- 09231 HEADACHE MED
- 09237 DEXLANSOPRAZOLE
- 09239 ED CHLORPED
- 09253 EPIPEN JR
- 09265 MILLIPRED
- 09266 POLY-VENT DM

- 09279 DUREZOL
- 09281 SALMON OIL
- 09284 ACID REDUCER
- 09286 NUCYNTA
- 09287 HUMALOG MIX 50/50
- 09293 DIVALPROEX ER
- 09296 KEPPRA XR
- 09297 VALSARTAN/HYDROCHLOROTHIAZIDE
- 09300 TIVA
- 09305 DIAMOX
- 09311 INTEGRAF
- 09318 MYCOLOG II
- 09324 CELOX
- 09326 METFORMIN ER
- 09327 LEXISCAN
- 09334 PALIPERIDONE
- 09336 TYLAPRIN
- 09353 MULTAQ
- 09361 PRENATAL AD
- 09362 CENTRUM CARDIO
- 09364 DROSPIRENONE/ETHINYL ESTRADIOL
- 09367 SIMILAC ADVANCE
- 09368 KRILL OIL
- 09370 DIAZEPAM
- 09374 SPRIX
- 09377 Z-PACK
- 09378 MAALOX MAX
- 09381 C-PHEN DM
- 09384 DEXMETHYLPHENIDATE
- 09386 PROMETHEGAN
- 09391 SAPHRIS
- 09394 SSRI
- 09396 INTUNIV
- 09398 PRENATAL DHA TABS
- 09404 VORTEX
- 09407 TASIGNA
- 09408 FOSINOPRIL/HCTZ
- 09409 VITAMIN B & D
- 09417 THERA-M PLUS
- 09424 DICLOX
- 09428 HONEY AND LEMON COUGH SYRUP
- 09431 EEMT HS
- 09433 DICLOXACILLIN
- 09438 OMEGA 3/6/9
- 09444 ONGLYZA
- 09450 NEILMED SINUS RINSE
- 09451 MUCINEX MAX STRENGTH
- 09453 FELODIPINE ER
- 09455 DICYCLOMINE
- 09461 FLINTSTONES PLUS IRON CHEW
- 09465 DIDREX
- 09505 TRI-SPRINTEC
- 09545 DIGOXIN
- 09561 HONEY

- 09562 DEXTROMETHORPHAN/GUAIFENSIN
- 09567 PHOSPHA
- 09569 SMZ TMP DS
- 09571 NIACIN CR
- 09576 POTASSIUM CITRATE
- 09577 NYQUIL
- 09579 DESOGESTREL ETHINYL-ESTRADIOL
- 09581 ALMOTRIPTAN
- 09582 OXYCODONE CR
- 09583 LANTUS SOLOSTAR
- 09585 DILANTIN
- 09587 BUPROPION XL
- 09588 CONJUGATED ESTROGENS/METHYLTESTOSTERONE
- 09593 DILATRATE
- 09597 KINRIX
- 09600 DILAUDID
- 09601 RENVELA
- 09608 ALLERCLEAR
- 09614 ZOLPIDEM
- 09616 VOSOL
- 09618 ASTEPRO
- 09619 TELMISARTAN/HCTZ
- 09624 CLOBETASOL PROPIONATE
- 09626 JUNEL
- 09627 AZURETTE
- 09637 NECON 777
- 09640 DIMENHYDRINATE
- 09644 PREVIFEM
- 09645 EPIDUO
- 09647 OCELLA
- 09651 ACETAMINOPHEN-TRAMADOL
- 09652 TRILIPIX
- 09655 IV FLUIDS
- 09658 LIDOCAINE HURRICANE
- 09681 CITRANATAL ASSURE
- 09687 TESTOSTERONE CYPIONATE
- 09689 HUMALOG INSULIN PUMP
- 09690 DIMETAPP
- 09701 DIGESTIVE ENZYMES
- 09702 AZO
- 09703 THYROID DESICCATED
- 09709 LATRIX
- 09711 LEVOCARNITINE
- 09716 KETOCONAZOLE SHAMPOO
- 09722 CHOLECALCIFEROL
- 09723 INTELENCE
- 09729 MALATHION
- 09733 CORVITE
- 09734 ASPIRIN/ACETAMINOPHEN/CAFFEINE
- 09737 IBUDONE
- 09741 FEROSUL
- 09751 HYDROCODONE/IBUPROFEN
- 09752 SULFAMETHAZOLE TRIMETHOPRIM

- 09753 THYROID STIMULATING HORMONE
- 09757 ACZONE
- 09760 KETOTIFEN FUMARATE
- 09764 VITAFOL-OB+DHA
- 09772 TOVIAZ
- 09791 VENTOLIN\ATROVENT
- 09795 EXFORGE HCT
- 09797 RAPAFLO
- 09798 OS-CAL ULTRA
- 09801 AZASITE
- 09806 LETAIRIS
- 09807 POLY HIST FORTE
- 09809 ASPIR-LOW
- 09831 OSTEO NUTRIENTS
- 09834 DITROPAN XL
- 09837 LIPOFEN
- 09839 DIPHENHIST
- 09841 DMPA INJECTION
- 09842 STRONG START VITAMINS
- 09843 FERROSOL
- 09845 DIPHENHYDRAMINE COUGH SYRUP
- 09850 DIPHENHYDRAMINE
- 09853 GLIPIZIDE XL
- 09854 SAVELLA
- 09856 ROTARIX
- 09861 NUVIGIL
- 09862 GAS RELIEF
- 09868 MUCUS RELIEF DM
- 09869 AMLODIPINE/ATORVASTATIN
- 09870 DIPHENHYDRAMINE HCL SYRUP
- 09880 DIPHENOXYLATE HCL & ATROPINE SULFATE
- 09882 DEXTROMETHORPHAN
- 09886 REFRESH PLUS
- 09887 LOTION
- 09888 INSULIN DETEMIR
- 09889 CALCIUM ALGINATE
- 09892 MOXATAG
- 09903 NICORELIEF
- 09910 VIMPAT
- 09911 SINUS MEDICATION
- 09913 ZOVIA
- 09914 EAR WAX REMOVAL
- 09915 DIPROSONE
- 09917 SLEEP AID
- 09918 ORTHO INJECTIONS
- 09920 DIPYRIDAMOLE
- 09925 DISALCID
- 09928 DASATINIB
- 09937 SRONYX
- 09938 CENTRUM WOMENS
- 09954 DIVALPROEX
- 09956 PVB
- 09957 ALAWAY EYE DROPS
- 09958 RIVAROXABAN

- 09968 APRISO
- 09978 LUVOX CR
- 09982 BMX SOLUTION
- 09990 DIPHTHERIA TETNUS TOXOIDS PERTUSSIS
- 09993 DIPHTHERIA TOXOID
- 09995 DITROPAN
- 10004 LUBRICANT DROPS
- 10008 RENAL GEL
- 10012 ACTONEL W/ CALCIUM
- 10016 TRI-PREVIFEM
- 10026 GLUCOSAMINE AND CHONDROITIN W MSM
- 10028 INVEGA SUSTENNA
- 10045 DOAK OIL
- 10058 ASPIRIN/SALICYLAMIDE/CAFFEINE
- 10061 ZENPEP
- 10064 UBIQUINONE
- 10070 BUDEPRION
- 10087 DOCUSATE
- 10089 DOCUSATE CALCIUM
- 10092 IPV
- 10109 ZIPSOR
- 10121 DULERA
- 10123 VICTOZA
- 10126 DOLOBID
- 10130 DOLOPHINE
- 10134 PPV 23
- 10135 DEXILANT
- 10145 DOMEBORO
- 10159 CERON
- 10164 DOSEPAK
- 10166 BUPRENORPHINE-NALOXONE
- 10169 MCV4
- 10179 CLINDAMYCIN/BENZOYL GEL
- 10181 LISDEXAMFETAMINE
- 10192 SALINE FLUSH
- 10204 BUTALBITAL-ACETAMINOPHEN
- 10210 DONNATAL
- 10216 HPV VACCINE
- 10223 REPREXAIN
- 10231 NEOMYCIN/POLYMYXIN B/HYDROCORTISONE
- 10236 ABACAVIR-LAMIVUDINE
- 10242 D-VI-SOL
- 10244 TRIBENZOR
- 10246 INSULIN LISPRO MIX
- 10248 FEXOFENADINE-PSEUDOEPHEDRINE
- 10251 TROSPIUM
- 10256 NICOTINE POLACRILEX
- 10261 LYSTEDA
- 10262 HYDROCORTISONE-PRAMOXINE
- 10277 TANDEM
- 10282 TIROSINT
- 10290 ECASA
- 10298 PROPHYLACTIC ANTIBODIES

- 10301 VITAMIN D2
- 10312 CELADRIN
- 10316 PCV 13
- 10322 HYDROCHLOROTHIAZIDE/TRIAMTERENE
- 10325 DOXEPIN
- 10355 DOXYCYCLINE
- 10356 PRADAXA
- 10368 LEVOCETIRIZINE DIHYDROCHLORIDE
- 10369 FLEX-A-MIN
- 10376 NITAZOXANIDE
- **10386 BUTRANS**
- 10389 DEXTROAMPHETAMINE/AMPHETAMINE
- 10393 LORATADINE-PSEUDOEPHEDRINE
- 10396 DIAPER OINTMENT
- 10421 ALER-TAB
- 10422 OMEGA FATTY ACIDS
- 10423 SALINE CLEANSER
- 10435 ORBIVAN
- 10437 PRASUGREL
- 10440 DRISDOL
- 10467 DEX 4
- 10471 ZYMAXID
- 10478 VIMOVO
- 10479 SAXAGLIPTIN
- 10481 EXALL
- 10499 MARCAINE/CELESTONE SOLUSPAN
- 10509 COLCRYS
- 10518 DRYSOL
- 10525 DSS
- 10528 PRORENAL
- 10575 DULCOLAX
- 10630 DUOFILM
- 10800 DURICEF
- 10815 DYAZIDE
- 10905 E-MYCIN
- 10925 EAR DROPS
- 10975 ECOTRIN
- 11014 PENNSAID
- 11016 MOXEZA
- 11017 NASOHIST
- 11018 VANATAB DX
- 11023 BEYAZ
- 11025 EFUDEX
- 11028 URIBEL
- 11041 GILENYA
- 11044 SILENOR
- 11045 ELASE
- 11051 LIVALO
- 11058 DERMATROPHIN
- 11065 ELAVIL
- 11078 GRALISE
- 11105 CALCIO DEL MAR
- 11125 GENTLEASE
- 11128 PROLIA

- 11130 ELECTROLYTE
- 11142 LATUDA
- 11143 VIIBRYD
- 11152 ELOCON
- 11154 EDARBI
- 11188 TELAPREVIR
- 11190 EMETROL
- 11195 CATALYN
- 11197 LURASIDONE
- 11198 AMORYN
- 11203 NOVOFINE
- 11216 ZARAH
- 11226 TRAJENTA
- 11228 QUINAPRIL-HCTZ
- 11229 EXALGO
- 11258 KOMBIGLYZE XR
- 11267 MEDICAL MARIJUANA
- 11275 PRENATABS
- 11276 POLY-VI-FLOR WITH IRON AND FLUORIDE
- 11278 INCIVEK
- 11283 PEDIATEX TD
- 11303 FANAPT
- 11334 COMPLERA
- 11336 EDURANT
- 11353 DALIRESP
- 11355 ENFAMIL
- 11359 Q-TUSSIN DM
- 11390 ENSURE
- 11393 XARELTO
- 11402 ZUTRIPRO
- 11540 EPINEPHRINE
- 11548 EPIPEN
- 11549 EPITOL
- 11575 EPSOM SALT
- 11615 ERGOCALCIFEROL
- 11651 ERYC
- 11657 ERYPED
- 11665 ERYTHROMYCIN
- 11668 ERYTHROMYCIN OPHTHALMIC
- 11688 ESGIC
- 11740 ESTRACE
- 11745 ESTRADIOL
- 11765 ESTRATEST
- 11800 ESTROGEN
- 11898 ETHOSUXAMIDE
- 11915 ETHYL CHLORIDE
- 11945 EUCERIN
- 11960 EURAX
- 12002 ACCUFLORA
- 12006 MICROGESTIN
- 12007 MIDAZOLAM
- 12008 MORPHINE ER 12009 ALENDRONATE

- 12010 ALDEX D
- 12011 NEXPLANON
- 12013 NICOTINE PATCH
- 12014 NOHIST
- 12016 NORETHINDRONE
- 12017 NORGESTREL/ETHINYL ESTRADIOL
- 12022 OGESTREL
- 12027 COLD MEDICATION
- 12028 OXYCODONE
- 12029 OXYBUTYNIN
- 12031 OXYMETAZOLINE
- 12032 ARBINOXA
- 12033 PAIN MEDICATIONS
- 12034 PANTOPRAZOLE
- 12035 EXCEDRIN
- 12036 PARAGARD
- 12042 ASPIR 81
- 12044 PEN-VK
- 12046 PERCOCET
- **12049 AXIRON**
- 12054 POLIO VACCINE
- 12056 POLYMYXIN B-TRIMETHOPRIM
- 12057 TUBERCULIN PURIFIED PROTEIN DERIVATIVE
- 12059 BENZOCAINE/CETYLPYRIDINIUM
- 12060 BENZOCAINE/DEXTROMETHORPHAN
- 12062 BIRTH CONTROL PILLS
- 12066 CARDEC
- 12070 CAZIANT
- 12071 CHERATUSSIN AC
- 12072 CHERATUSSIN DAC
- 12073 CHILDRENS TYLENOL COLD AND COUGH
- 12074 CHLO TUSS
- 12077 PROBIOTIC
- 12081 PROCTOSOL HC
- 12082 PROMETHAZINE DM
- 12084 CLOBEX
- 12087 ROBITUSSIN D
- 12088 ROBITUSSIN DM
- 12089 ROBITUSSIN PE
- 12090 ROMYCIN
- 12091 RONDEC
- 12093 LIV-PRO
- 12096 SALINE MIST
- 12097 MEGA RED
- 12101 SELENIUM SULFIDE
- 12102 SIMPLY SALINE
- 12104 SINUS RINSE
- 12105 SMOKING CESSATION
- 12108 DILTIAZEM ER
- 12112 TRADJENTA
- 12113 ENGERIX-B PEDIATRIC
- 12118 VENLAFAXINE ER
- 12122 GUAIFENESIN DM
- 12123 ZYRTEC-D

- 12124 HYOMAX SL
- 12126 INTEGRA
- 12129 KAPVAY
- 12136 ALA HIST PE
- 12138 VINATE ULTRA
- 12140 FASTIN
- 12141 ASPIRIN W/HYDROCODONE
- 12149 CORTISPORIN
- 12151 DEXTROMETHORPHAN/PROMETHAZINE
- 12154 ESCITALOPRAM
- 12157 LEVOCETIRIZINE
- 12158 LEUPROLIDE
- 12161 MOMETASONE
- 12162 PRILOSEC OTC
- 12167 OPV/IPV
- 12168 PEDIADERM TA
- 12169 NOHIST-DM
- 12171 NORGESTIMATE-ETHINYL ESTRADIOL
- 12176 PREPARATION H
- 12177 RHINOFLEX
- 12180 STAXYN
- 12182 BUPROBAN
- 12187 PYRIL D
- 12188 FOLBIC
- 12189 GARLIC
- 12191 LEVALBUTEROL
- 12192 LOSEASONIQUE
- 12193 FELDENE
- 12195 SALINE NASAL SPRAY
- 12196 SULFAMETHOXAZOLE-TRIMETHOPRIM
- 12198 CORICIDIN HBP
- 12199 CORTIZONE-10
- 12200 EDARBYCLOR
- 12204 TRIAMINIC COLD & ALLERGY
- 12206 TRIAMINIC NIGHT TIME COLD & COUGH
- 12207 TRIPHROCAPS
- 12208 CLORETAZINE
- 12219 NATURAL BALANCE TEAR
- 12223 GUAIASORB
- 12224 ADVACAL
- 12225 FEMIRON
- 12231 RYNEX DM
- 12232 RYNEX PSE
- 12233 CARISOPRODOL-TRAMADOL
- 12236 CAMPHOR-MENTHOL
- 12237 PRENACARE
- 12249 GENERESS FE
- 12255 FEOSOL
- 12263 ONFI
- 12266 MEGACE ES
- 12274 HEMP TINCTURE
- 12285 FER-IN-SOL
- 12287 CETIRIZINE-PSEUDOEPHEDRINE

- 12294 GOLD BOND ANTI-ITCH
- 12300 FERGON
- 12308 APHTHASOL
- 12309 VANACOF DX
- 12311 STRIBILD
- 12312 BOCEPREVIR
- 12314 BENSAL HP
- 12317 NATROBA
- 12326 TRI-DEX
- 12331 ALA-SCALP HP
- 12337 BIFIDOBACTERIUM INFANTIS
- 12341 BPO
- 12342 BRILINTA
- 12347 EFAVIRENZ-EMTRICITABINE-TENOFOVIR
- 12349 ESCAVITE
- 12358 TROLAMINE SALICYLATE CREAM
- 12359 TYVASO
- 12364 RASPBERRY KETONE
- 12367 DILTZAC
- 12371 SIMPONI
- 12374 TOPIRAGEN
- 12377 VEMMA
- 12378 WILD MEXICAN YAM
- 12382 APETIMAR
- 12383 ASPIRIN-DIPHENHYDRAMINE
- 12389 BRAIN & MEMORY POWER BOOST
- 12399 MATZIM LA
- 12403 PROSVENT
- 12411 VILAZODONE
- 12412 WILLOW BARK
- 12421 OCUDYNE
- 12422 PYGEUM
- 12424 REZIRA
- 12426 SOY ISOFLAVONOES
- 12428 BIO-ALLAY
- 12436 PHENYLEPHRINE-CHLORPHENIRAMINE-DEXTROME
- 12443 CETROTIDE
- 12448 CONZIP
- 12454 SEROGEN
- 12465 FERROUS FUMARATE
- 12480 FERROUS GLUCONATE
- 12485 FERROUS PLUS
- 12490 FERROUS SULFATE
- 12521 FIBERCON
- 12550 FIORINAL
- 12585 FLAGYL
- 12600 FLEET BAGENEMA
- 12620 FLEET ENEMA
- 12635 FLEXERIL
- 12650 FLEXON
- 12690 FLUOCINOLONE
- 12715 FLUORESCEIN
- 12735 FLUORIDE
- 12755 FLUORITAB

- 12770 FLUOROURACIL
- 12780 FLUPHENAZINE
- 12785 FLURA-DROPS
- 12810 FLURAZEPAM
- 12830 FLUZONE
- 12865 FOLIC ACID
- 13008 FREEZONE
- 13096 FUNGOID
- 13118 FUROSEMIDE
- 13205 GARAMYCIN
- 13208 GARGLE
- 13220 GAVISCON
- 13320 GENTAMICIN
- 13325 GENTIAN VIOLET
- 13455 GERITOL
- 13515 GINSENG
- 13535 GLUCAGON
- 13550 GLUCOSE
- 13553 GLUCOTROL
- 13655 GLYCOPYRROLATE
- 13785 GRIFULVIN
- 13790 GRIS-PEG
- 13800 GRISEOFULVIN
- 13830 GUAIFENESIN & DEXTROMETHORPHAN HBR
- 13835 GUAIFENESIN
- 13838 GUAIFENESIN W/CODEINE
- 13875 GUIATUSS
- 13885 GUIATUSSIN
- 13890 GUIATUSSIN W/CODEINE
- 13930 GYNE-LOTRIMIN
- 13999 HALCION
- 14000 HALDOL
- 14040 HALOPERIDOL
- 14090 HEAD & SHOULDERS
- 14095 HEB CREAM BASE
- 14180 HEMORRHOIDAL OINTMENT
- 14190 HEMORRHOIDAL HC
- 14240 HEPARIN
- 14279 HEPTAVAX-B
- 14415 HIBICLENS
- 14683 HORMONE
- 14713 HUMAN CHORIONIC GONADOTROPIN
- 14727 HUMULIN
- 14770 HYCODAN
- 14840 HYDRALAZINE
- 14870 HYDRATE
- 14875 HYDREA
- 14903 HYDROCORT
- 14930 HYDROCHLOROTHIAZIDE
- 14935 HYDROCHLOROTHIAZIDE W/RESERPINE
- 14953 HYDROCO
- 14955 HYDROCODONE
- 14960 HYDROCODONE PA SYRUP

- 14965 HYDROCORTISONE
- 14985 HYDRODIURIL
- 14990 HYDROGEN PEROXIDE
- 15005 HYDROMORPHONE
- 15025 HYDROPHILIC OINTMENT
- 15040 HYDROQUINONE
- 15065 HYDROXY-PROGESTERONE
- 15070 HYDROXYCHLOROQUINE
- 15090 HYDROXYUREA
- 15100 HYDROXYZINE
- 15105 HYDROXYZINE PAMOATE
- 15115 HYGROTON
- 15305 HYTONE
- 15307 HYTRIN
- 15395 IBUPROFEN
- 15455 ICY HOT ANALGESIC BALM
- 15520 IMIPRAMINE
- 15545 IMODIUM
- 15555 IMURAN
- 15575 INDERAL
- 15590 INDOCIN
- 15600 INDOMETHACIN
- 15630 INH
- 15678 INSULATARD NPH
- 15680 INSULIN
- 15685 INTAL
- 15730 IODINE
- 15865 IRON & B COMPLEX PLUS
- 15870 IRON PREPARATION
- 15873 IRON PEDIATRIC
- 15990 ISONIAZID
- 16003 ISOPHANE INSULIN SUSPENSION
- 16095 ISORDIL
- 16105 ISOSORBIDE
- 16210 K-LOR
- 16268 K-TAB
- 16365 KAOPECTATE
- 16405 KARAYA GUM
- 16455 KAYEXALATE
- 16475 KEFLEX
- 16505 KENALOG
- 16535 KERODEX
- 16710 KLOR-CON
- 16728 KLOTRIX
- 16895 L-THYROXINE
- 16915 LACRI-LUBE
- 16950 LACTINEX
- 16955 LACTOBACILLUS ACIDOPHILUS
- 16970 LACTOSE
- 16975 LACTULOSE
- 17070 LANOLIN
- 17115 LANOXIN
- 17165 LASIX
- 17205 LAVATAR

- 17243 LAXATIVE
- 17345 LEVODOPA
- 17365 LEVOTHROID
- 17370 LEVOTHYROXINE
- 17375 LEVSIN
- 17440 LIBRAX
- 17450 LIBRIUM
- 17475 LIDEX
- 17485 LIDOCAINE
- 17490 LIDOCAINE HCL
- 17495 LIDOCAINE HCL W/EPINEPHRINE
- 17530 LIMBITROL
- 17540 LINCOCIN
- 17545 LINCOMYCIN
- 17548 LINDANE
- 17560 LIORESAL
- 17563 LIOTHYRONINE SODIUM
- 17595 LIPODERM
- 17600 LIPOFLAVONOID
- 17705 LISTERINE
- 17715 LITHIUM
- 17725 LITHOBID
- 17825 LO/OVRAL
- 17833 LOCAL ANESTHETIC
- 17838 LODRANE
- 17840 LOESTRIN
- 17865 LOMOTIL
- 17880 LOPERAMIDE
- 17883 LOPID
- 17885 LOPRESSOR
- 17888 LORAZEPAM
- 17889 LOPURIN
- 17925 LOTRIMIN
- 17940 LOXAPINE
- 17945 LOXITANE
- 17975 LUBRIDERM
- 18015 LUMINAL
- 18020 LURIDE DROPS
- 18050 LYSINE
- 18078 M.T.E.
- 18080 M.V.I.
- 18125 MAALOX
- 18130 MACRODANTIN
- 18189 MAGNESIUM CARBONATE
- 18190 MAGNESIUM CHLORIDE
- 18195 MAGNESIUM CITRATE
- 18205 MAGNESIUM OXIDE
- 18215 MAGNESIUM SULFATE
- 18395 MARCAINE
- 18498 MAXAIR
- 18520 MAXITROL
- 18523 MAXZIDE
- 18540 MEASLES VIRUS VACCINE

- 18552 MEBENDAZOLE
- 18555 MECLIZINE
- 18605 MEDICATED FOOT POWDER
- 18640 MEDROL
- 18643 MEDROXYPROGESTERONE
- 18655 MEGACE
- 18663 MEGESTROL
- **18695 MENEST**
- 18760 MEPERIDINE
- 18920 MESTINON
- 18930 METAMUCIL
- 18980 METHACHOLINE
- 18985 METHADONE
- 19035 METHENAMINE
- 19045 METHERGINE
- 19070 METHOCARBAMOL
- 19090 METHOTREXATE
- 19155 METHYLDOPA
- 19175 METHYLPHENIDATE
- 19180 METHYLPREDNISOLONE
- 19185 METHYLTESTOSTERONE
- 19208 METOCLOPRAMIDE
- 19210 METOLAZONE
- 19218 METOPROLOL
- 19231 METRO
- 19233 METRONIDAZOLE
- 19242 MEVACOR
- 19280 MICATIN
- 19290 MICONAZOLE
- 19320 MICRONOR
- 19350 MIDOL
- 19360 MIDRIN
- 19375 MILK OF MAGNESIA
- 19445 MINERAL OIL
- 19455 MINIPRESS
- 19460 MINOCIN
- 19465 MINOCYCLINE
- 19478 MINOXIDIL
- 19618 MODURETIC
- 19635 MICONAZOLE NITRATE
- 19640 MONISTAT 7
- 19650 MORPHINE
- 19675 MOTRIN
- 19680 MOUTHWASH
- 19699 MS CONTIN
- 19730 MUCOPLEX
- 19785 MULTI-VITAMIN
- 19815 MULTIPLE VITAMIN
- 19825 MULTIPLE VITAMINS
- 19840 MULTIVITAMIN
- 19853 MULTIVITAMIN/FLUORIDE
- 19865 MULTIVITAMIN/MULTIMINERAL
- 19870 MULTIVITAMINS & MINERALS
- 19948 MUSCLE RELAXANT

- 20010 MYCELEX
- 20055 MYCOLOG
- 20060 MYCOSTATIN
- 20080 MYLANTA
- 20095 MYLICON
- 20135 MYSOLINE
- 20185 NAFTIN
- 20215 NALIDIXIC ACID
- 20255 NAPHAZOLINE
- 20260 NAPHCON
- 20270 NAPHCON-A
- 20285 NAPROSYN
- 20290 NAPROXEN
- 20320 NASAHIST
- 20325 NASAL DECONGESTANT
- **20435 NAVANE**
- 20688 NEOM/POLY M GRAMICIDIN OPHTH
- 20690 NEOMYCIN
- 20693 NEOMYCIN-POLYMYXIN B
- 20730 NEOSPORIN
- 20798 NEPHROCAPS
- 20815 NESACAINE
- 20855 NEUTROGENA
- 20885 NIACIN
- 20890 NIACINAMIDE
- 21130 NITRO-BID
- 21143 NITRO-DUR
- 21145 NITROFURANTOIN
- 21160 NITROGLYCERIN
- 21176 NITROLINGUAL
- 21185 NITROSTAT
- 21203 NIZORAL
- 21228 NORDETTE
- 21278 NORETHIN
- 21280 NORFLEX
- 21300 NORINYL
- 21390 NORPACE
- 21403 NORTRIPTYLINE
- 21405 NOSE DROPS
- 21513 NTG
- 21550 NUBAIN
- 21585 NUPERCAINAL
- 21695 NYSTATIN
- 21701 NYSTATIN W/TRIAMCINOLONE
- 21750 OCEAN MIST
- 21785 OLIVE OIL
- 21802 ONE-A-DAY-ESSENTIAL
- 21925 ORABASE
- 21958 ORAP
- 22065 ORPHENADRINE
- 22090 ORTHO-NOVUM
- 22110 OS-CAL
- 22120 OS-CAL 500

- 22160 OTIC DROPS
- 22210 OVCON
- 22215 OVRAL
- 22242 OXAZEPAM
- 22287 OXYBUTYNIN CHLORIDE
- 22303 OXYCODONE HCL
- 22305 OXYCODONE HCL & ACETAMINOPHEN
- 22315 OXYGEN
- 22345 OXYTOCIN
- 22348 OYSCO 500
- 22350 OYSTER SHELL & VITAMIN D
- 22520 PAMELOR
- 22630 PANCREASE
- 22643 PANCRELIPASE
- 22675 PANOXYL
- 22725 PANTOTHENIC ACID
- 22810 PARAFON FORTE
- 22885 PARNATE
- 23120 PEDIALYTE
- 23185 PEN-VEE K
- 23215 PENICILLIN
- 23221 PENICILLIN G POTASSIUM
- 23225 PENICILLIN V
- 23228 PENICILLIN V POTASSIUM
- 23230 PENICILLIN VK
- 23370 PEPTO-BISMOL
- 23385 PERCOCET-5
- 23430 PERI-COLACE
- 23440 PERIACTIN
- 23523 PERPHENAZINE
- 23535 PERSANTINE
- 23585 PETROLATUM
- 23715 PHENAZOPYRIDINE
- 23755 PHENERGAN
- 23790 PHENERGAN VC EXPECTORANT W/CODEINE
- 23792 PHENERGEN W/DEXTROMETHORPHAN
- 23798 PHENERGAN W/CODEINE
- 23845 PHENOBARBITAL
- 23935 PHENOL
- 23970 PHENTERMINE
- 24015 PHENYLEPHRINE
- 24045 PHENYTOIN
- 24058 PHILLIPS MILK OF MAGNESIA
- 24080 PHISOHEX
- 24195 PILOCARPINE
- 24280 PLACEBO
- 24300 PLAQUENIL
- 24355 PNEUMOVAX
- 24370 PODOPHYLLUM
- 24405 POLIOMYELITIS VACCINE
- 24415 POLY-VI-FLOR
- 24418 POLY-VI-FLOR W/IRON
- 24420 POLY-VI-SOL
- 24422 POLY-VITAMIN FLUORIDE

- 24470 POLYMYXIN
- 24510 POLYSPORIN
- 24525 POLYVITAMIN
- 24530 POLYVITAMIN DROPS
- 24535 POLYVITAMIN FLUORIDE
- 24550 PONSTEL
- 24645 POTASSIUM CARBONATE
- 24650 POTASSIUM
- 24653 POTASSIUM CHLORIDE
- 24685 UROCIT-K
- 24695 POTASSIUM GLUCONATE
- 24805 PRAZOSIN
- 24830 PRE-NATAL VITAMINS
- 24850 PRED FORTE
- 24885 PREDNISOLONE
- 24890 PREDNISONE
- 24895 PREDOXINE
- 24950 PREMARIN
- 24960 PREMARIN VAGINAL
- 24975 PRENATAL FORMULA (VITAMINS)
- 24985 PRENATAL W/FOLIC ACID
- 24988 PRENATAL W/FOLIC ACID & IRON
- 24989 PRENATAL 1+1
- 24990 PRENATAMIN
- 25055 PRIMIDONE
- 25060 PRIMOLINE
- 25078 PRINIVIL
- 25150 PROBENECID
- 25213 PROCARDIA
- 25220 PROCHLORPERAZINE
- 25240 PROCTOCORT
- 25243 PROCTOCREAM-HC
- 25250 PROCTOFOAM
- 25255 PROCTOFOAM-HC
- 25305 PROGESTERONE
- 25330 PROLIXIN
- 25365 PROMETHAZINE
- 25375 PROMETHAZINE COMPOUND W/CODEINE
- 25390 PROMETHAZINE EXPECTORANT W/CODEINE
- 25415 PROMETHAZINE HCL W/CODEINE EXPECTORANT
- 25430 PROMETHAZINE VC W/CODEINE
- 25432 PROMETHAZINE W/CODEINE
- 25433 PROMETHAZINE W/DM
- 25435 PROMETHAZINE W/PHENYLEPHRINE HCL
- 25560 PROPYLTHIOURACIL
- 25638 PROVENTIL
- 25640 PROVERA
- 25674 PROZAC
- 25695 PSEUDOEPHEDRINE
- 25800 PYRAZINAMIDE
- 25810 PYRIDIUM
- 25820 PYRIDOSTIGMINE
- 25825 PYRIDOXINE HCL

- 25965 QUESTRAN
- 26199 RECOMBIVAX-HB
- 26255 REGLAN
- 26280 REGULOID
- 26453 RESTORIL
- 26475 RETIN-A
- 26477 RETROVIR
- 26510 RHEUMATREX
- 26685 RIBOFLAVIN
- 26695 RID
- 26715 RIFAMPIN
- 26760 RITALIN
- 26785 ROBAXIN
- 26805 ROBINUL
- 26830 ROBITUSSIN
- 26835 ROBITUSSIN A-C SYRUP
- 26840 ROBITUSSIN-CF
- 26855 ROBITUSSIN-DM COUGH CALMERS
- 26870 ROCALTROL
- 26883 ROGAINE
- 26890 ROLAIDS
- 26895 ROLOX
- **26928 RONASE**
- 26930 RONDEC SYRUP
- 26958 ROXICET
- 27075 RUBELLA VIRUS VACCINE LIVE
- 27120 RULOX
- 27170 RYNA
- 27190 RYNATAN
- 27335 SALICYLAMIDE
- 27345 SALICYLIC ACID
- 27368 SALINE
- 27374 SALIVA SUBSTITUTE
- 27405 SALSALATE
- 27545 SCOPOLAMINE
- 27725 SELENIUM
- 27730 SELSUN
- 27735 SELSUN BLUE
- 27770 SENNA
- 27785 SENOKOT
- 27810 SENOLAX
- 27835 SEPTRA
- 27840 SEPTRA DS
- 27855 SERAX
- 27960 SIGTAB
- 27985 SILVADENE
- 27995 SILVER NITRATE
- 28015 SILVER SULFADIAZINE
- 28030 SIMETHICONE
- 28035 SIMILAC
- 28080 SINEMET
- 28085 SINEQUAN
- 28350 SKELAXIN
- 28366 SLO-NIACIN

- 28391 SLOW-MAG
- 28450 SODIUM BENZOATE
- 28455 SODIUM BICARBONATE
- 28495 SODIUM CHLORIDE
- 28545 SODIUM CHLORIDE FOR IRRIGATION
- 28575 SODIUM CITRATE
- 28595 SODIUM FLUORIDE
- 28800 SOLU-MEDROL
- 28825 SOMA
- 28910 SORBITOL
- 29250 SPIRONOLACTONE
- 29255 SPIRONOLACTONE W/HYDROCHLOROTHIAZIDE
- 29285 STADOL
- 29435 STERAPRED
- 29498 STEROID(S)
- 29533 STOOL SOFTENER
- 29570 STRESS FORMULA
- 29675 SUCRETS
- 29705 SUDAFED
- 29815 SULFACETAMID
- 29825 SULFADIAZINE
- 29840 SULFAMETHOXAZOLE
- 29843 SULFAMETHOX W/TRIMETHOPRIM
- 29850 SULFANILAMIDE
- 29865 SULFASALAZINE
- 29888 SULFATRIM
- 29998 SULINDAC
- 30030 SUNSCREEN
- 30035 SUMYCIN
- 30195 SURFAK
- 30330 SYNALAR
- 30395 SYNTHROID
- 30468 T-STAT
- 30495 TAGAMET
- 30515 TALC
- 30553 TAMOXIFEN
- 30585 TAPAZOLE
- 30630 TAVIST
- 30655 TEARS NATURALE
- 30730 TEGRETOL
- 30756 TEMAZEPAM
- 30777 TENEX
- 30781 TENORETIC
- 30782 TENORMIN
- 30800 TERAZOL
- 30880 TESSALON PERLE
- 30915 TESTOSTERONE
- 30930 TESTOSTERONE ENANTHATE
- 31000 TETANUS ANTITOXIN
- 31005 TETANUS DIPHTHERIA TOXOID
- 31010 TETANUS IMMUNE GLOBULIN
- 31015 TETANUS TOXOID
- 31045 TETRACYCLINE

- 31050 TETRACYCLINE HCL
- 31219 THEOPHENYLLINE
- 31235 THEOPHYLLINE
- 31318 THERA-GESIC BALM
- 31335 THERAGRAN-M
- 31390 THERAPEUTIC MULTIVITAMIN
- 31400 THERAPEUTIC VITAMIN & MINERAL -
- 31408 THERAVIM
- 31455 THIAMINE
- 31542 THIOTHIXENE
- 31543 THIORIDAZINE
- 31550 THORAZINE
- 31630 THYROID
- 31655 TIGAN
- 31658 TIMOLOL
- 31660 TIMOPTIC
- 31670 TINACTIN
- 31723 TOBRADEX
- 31725 TOBRAMYCIN
- 31728 TOBREX OPHTHALMIC
- 31740 TOFRANIL
- 31880 TOTAL B W/C
- 31895 TPN ELECTROLYTES
- 31939 TRANSDERM-SCOP
- 31945 TRANXENE
- 31997 TRAZODONE
- 32013 TRENTAL
- 32135 TRI-VERT
- 32140 TRI-VI-FLOR
- 32145 TRI-VI-SOL
- 32190 TRIAM
- 32195 TRIAMCINOLONE
- 32200 TRIAMCINOLONE ACETONIDE
- 32245 TRIAMINIC
- 32273 TRIAMTERENE
- 32310 TRICHLOROACETIC ACID
- 32363 TRIFLUOPERAZINE
- 32390 TRIHEXYPHENIDYL
- 32423 TRIMETHOPRIM W/SULFASOXAZOLE
- 32430 TRIMOX
- 32438 TRIMETHOPRIM
- 32515 TRIPLE ANTIBIOTIC
- 32543 TRIPLEX
- 32610 TRIVITAMIN DROPS
- 32660 TRYPTOPHAN
- 32695 TUBERSOL
- 32710 TUCKS
- 32735 TUMS
- 32845 TUSSI-ORGANIDIN
- 32855 TUSSIONEX
- 32905 TYLENOL
- 32920 TYLENOL NO. 3
- 32925 TYLENOL NO. 4
- 32930 TYLENOL W/CODEINE

- 32945 TYLOX
- 32960 TYPHOID VACCINE
- 33170 UNISOM
- 33215 UREA
- 33448 VACCINATION
- 33530 VALERIAN
- 33555 VALIUM
- 33573 VALPROIC ACID
- 33575 VANCERIL
- 33585 VANCOCIN HCL
- 33588 VANCOMYCIN
- 33670 VASELINE
- 33677 VASERETIC
- 33843 VENTOLIN
- 33858 VERAPAMIL
- 34090 VIBRAMYCIN
- 34103 VICKS VAPORUB
- 34110 VICODIN
- 34158 VINBLASTINE
- 34260 VISINE
- 34270 VISTARIL
- 34310 VITABEE
- 34360 VITAMIN A
- 34365 VITAMIN A + VITAMIN D
- 34370 VITAMIN A & D
- 34425 VITAMIN B COMPLEX
- 34430 VITAMIN B COMPLEX B-12 W/C
- 34450 VITAMIN B COMPLEX W/VITAMIN C
- 34455 VITAMIN B-1
- 34460 VITAMIN B-1 & B-12
- 34495 VITAMIN B-12
- 34510 VITAMIN B-6
- 34520 VITAMIN C
- 34545 VITAMIN C PLUS E
- 34560 VITAMIN CHEWABLE CHILDREN'S
- 34565 VITAMIN D
- 34570 VITAMIN D-2 IN OIL
- 34575 VITAMIN E
- 34623 VITAMIN K
- 34625 VITAMIN(S)
- 34628 VITAMINS AND MINERALS
- 34675 VITRON-C
- 34725 VOLTAREN
- 34730 VONTROL
- 34740 VOSOL OTIC
- 34745 VOSOL HC
- 34775 WARFARIN
- 34780 WART OFF
- 34855 WESTCORT
- 34875 WHEAT GERM OIL
- 35023 XANAX
- 35050 XEROFOAM DRESSING
- 35060 XYLOCAINE

- 35085 XYLOCAINE VISCOUS
- 35110 YELLOW FEVER VACCINE
- 35155 ZAROXOLYN
- 35224 ZESTRIL
- 35240 ZINC
- 35250 ZINC OXIDE
- 35260 ZINC SULFATE
- 35341 ZOVIRAX
- 35350 ZYLOPRIM
- 35425 ANTIDIARRHEAL AGENT
- 35430 ANTIEMETIC AGENT
- 35445 ANTIFUNGAL AGENT
- 35450 ANTIHISTAMINE
- 35495 ANTIPYRETIC AGENT
- 35595 TRIMETHOPRIM/SULFAMETHOXAZOLE
- 40185 BAYER ASPIRIN
- 40285 CALTRATE
- 40455 CYCLOPENTOLATE
- 40460 CYTOTEC
- 40520 DESYREL
- 40580 DIABETA
- 40585 DIHYDROERGOTOXINE MESYLATE
- 40615 DIPROLENE
- 40735 ESTROGENS
- 40830 HYDRALAZINE W/HCTZ
- 40905 ISOPTIN
- 40950 LOPROX
- 41115 MULTI VIT
- 41310 POLY-VI-SOL W/IRON
- 41315 POLYETHYLENE GLYCOL
- 41395 QUINIDINE GLUCONATE
- 41470 SLOW FE
- 41505 SPECTAZOLE
- 41670 TRI-NORINYL
- 41685 TRI-VI-SOL W/IRON
- 41780 ZANTAC
- 41800 HCTZ
- 41820 GLYCERIN SUPPOSITORIES
- 41830 PSYLLIUM
- 41845 PTU
- 41850 KCL
- 41855 NPH INSULIN
- 41860 FOLATE
- 41865 MOM
- 41875 CAPTOPRIL
- 41895 HUMULIN INSULIN
- 41905 THYROXINE
- 42425 GOLYTELY
- 42780 NEOSPORIN OPHTHALMIC
- 42800 NORMAL SALINE
- 42985 PROPRANOLOL
- 42990 PROPRANOLOL W/HCTZ
- 60035 ACLOVATE
- 60040 ADALAT

- 60115 AUGMENTIN
- 60120 AUGMENTIN 250
- 60125 AUGMENTIN 500
- 60150 BACITRACIN OPHTHALMIC
- 60175 BENZAMYCIN
- 60180 BENZTROPINE MESYLATE
- 60195 BETAMETHASONE SOD PHOSPHATE
- 60200 BETAMETHASONE VALERATE
- 60260 BUGS BUNNY VIT PLUS MINERALS
- 60265 BUPRENEX
- 60270 BUSPAR
- 60310 CHLORPHENIRAMINE W/PHENYLPROPANOLAMINE
- 60325 CITRUCEL
- 60340 CO-GESIC
- 60355 COLYTE
- 60370 CORDARONE
- 60385 CORTISPORIN OPHTHALMIC
- 60485 DORYX
- 60545 ESTRADERM
- 60550 EYE DROPS
- 60595 FIORICET
- 60640 GENTAMICIN OPHTHALMIC
- 60665 GLYCERIN
- 60695 HIB-IMUNE
- 60700 HIB-VAX
- 60735 INFLUENZA VIRUS VACC
- **60750 IOPHEN**
- 60755 IOPHEN DM
- 60775 K-DUR
- 60790 KLONOPIN
- 60795 LACHYDRIN
- 60835 LOTRISONE
- 60870 MARINOL
- 60940 MSIR
- 60950 MURINE EAR DROPS
- 61025 NICORETTE
- 61035 NIX
- 61045 NOVOLIN
- 61130 PAIN RELIEVER
- 61135 PEDIACARE
- 61140 PEDIAPRED
- 61160 PEPCID
- 61205 POVIDONE-IODINE
- 61245 PROPRANOLOL HCL
- 61295 ROCEPHIN
- 61305 RYMED
- 61330 SECTRAL
- 61380 STUART PRENATAL
- 61385 SULFACETAMIDE SODIUM
- 61440 TEMOVATE
- 61480 TOLNAFTATE
- 61495 TOPICORT
- 61565 VASOTEC

- 61605 WELLBUTRIN
- 61625 TRIAMTERENE W/HCTZ
- 89004 AMILORIDE HCL W/HCTZ
- 89009 ANUCORT-HC
- 89010 BETAMETHASONE DIPROPIONATE
- 89012 BROMFED-DM
- 89017 CHILDREN'S ADVIL
- 89018 CLINDAMYCIN HCL
- 89019 CLONIDINE HCL
- 89020 CYCLOBENZAPRINE HCL
- 89025 DOXEPIN HCL
- 89028 ERYTHROMYCIN ETHYLSUCCINATE
- 89031 ESTRADIOL VALERATE
- 89035 FLUOCINONIDE
- 89037 HUMULIN 70/30
- 89038 HYDROCODONE BITARTRATE W/APAP
- 89039 HYDROCODONE W/ACETAMINOPHEN
- 89040 HYDROCORTISONE ACETATE
- 89045 LIDOCAINE HCL VISCOUS
- 89049 METHYLPREDNISOLONE ACETATE
- 89050 MOTRIN IB
- 89053 NITROFURANTOIN MACROCRYSTALS
- 89056 OS-CAL 500+D
- 89061 POLYTRIM
- 89062 PRAZOSIN HCL
- 89066 PRELONE
- 89067 PROCARDIA XL
- 89069 PROCHLORPERAZINE MALEATE
- 89076 SUPRAX
- 89080 TIMOLOL MALEATE
- 89081 TOBRAMYCIN SULFATE
- 91000 ALBUTEROL SULFATE
- 91003 ANTIPYRINE W/BENZOCAINE
- 91009 BUTALBITAL/APAP/CAFFAINE
- 91015 DOXYCYCLINE HYCLATE
- 91027 GUAIFENESIN AC
- 91029 HYDROXYZINE HCL
- 91031 ISOPTIN S.R.
- 91034 LOTRIMIN AF
- 91035 LUPRON DEPOT
- 91039 NIFEDIPINE
- 91040 ONE TOUCH TEST STRIPS
- 91043 PRILOSEC
- 91061 ACYCLOVIR
- 91062 ALPRAZOLAM
- 91063 ATENOLOL
- 91066 BUSPIRONE HCL
- 91068 CEFTAZIDIME
- 91069 CEFTRIAXONE
- 91070 CEFUROXIME SODIUM
- 91072 DILTIAZEM HCL
- 91074 ENALAPRIL
- 91078 FLECAINIDE ACETATE
- 91079 FLUOXETINE

- 91081 GLIPIZIDE
- 91084 IPRATROPIUM BROMIDE
- 91085 KETOCONAZOLE
- 91088 LOVASTATIN
- 91089 METHIMAZOLE
- 91091 MISOPROSTOL
- 91096 OMEPRAZOLE
- 91099 RANITIDINE
- 91102 TRETINOIN
- 92000 ACCUPRIL
- 92003 ALTACE
- 92005 BENYLIN
- 92006 BIAXIN
- 92011 CALCIUM ANTACID
- 92012 CARDURA
- 92015 CILOXAN
- 92016 CLOZARIL
- 92017 CUTIVATE
- 92018 DESOXIMETASONE
- 92024 DURAGESIC
- 92025 DYNACIRC
- 92031 FLOXIN
- 92033 FLUPHENAZINE DECANOATE
- 92038 GENTAMICIN SULFATE
- 92042 HYDROMET
- 92043 HYOSCYAMINE SULFATE
- 92051 LODINE
- 92052 LOTENSIN
- 92055 MIACALCIN
- 92057 MONOPRIL
- 92061 NASACORT
- 92063 NEOMYCIN/POLYMYXIN/DEXAMETH
- 92070 ORAMORPH SR
- 92076 PRAVACHOL
- 92078 PROCRIT
- 92083 RINGERS
- 92085 ROBITUSSIN PEDIATRIC
- 92093 TOLMETIN SODIUM
- 92100 ULTRAVATE
- 92105 ZOFRAN
- 92107 BENAZEPRIL
- 92109 CEFACLOR
- 92110 CEFIXIME
- 92111 CIPROFLOXACIN
- 92112 CLARITHROMYCIN
- 92114 CLOMIPHENE
- 92115 CLOZAPINE
- 92116 DICLOFENAC
- 92120 DOXAZOSIN MESYLATE
- 92124 ETODOLAC
- 92125 FELODIPINE
- 92126 FLUTICASONE
- 92128 FOSINOPRIL

- 92130 HALOBETASOL
- 92131 HEPATITIS B VACCINE
- 92132 ISRADIPINE
- 92134 LEVONORGESTREL
- 92135 MESALAMINE
- 92137 METROGEL
- 92138 NADOLOL
- 92139 NORGESTREL
- 92140 OFLOXACIN
- 92141 ONDANSETRON
- 92143 PENTOXIFYLLINE
- 92145 PIROXICAM
- 92146 PRAVASTAN
- 92149 QUINAPRIL
- 92150 RAMIPRIL
- 92152 TERCONAZOLE
- 92156 DIFLUCAN
- 92157 ELIMITE
- 92159 MINITRAN
- 92160 PRINZIDE
- 92161 TORADOL
- 92163 ZESTORETIC
- 92164 LISINOPRIL
- 92178 **HUMIBID**
- 92180 LORTAB
- 92187 PRENATE
- 93010 ALIMENTUM
- 93014 ALLERGY MEDICATION
- 93016 ANALPRAM HC
- 93022 ARTIFICIAL TEAR SOLUTION
- 93023 ASACOL
- 93024 ASPERCREME
- 93029 BETA CAROTENE
- 93030 BLEPH-10
- 93037 CARNITINE
- 93038 CEFZIL
- 93041 CITRACAL
- 93042 CONDYLOX
- 93046 DERMA-SMOOTHE
- 93048 DILACOR-XR
- 93049 DIPHEN
- 93053 E-LOR
- 93059 EPOGEN
- 93062 FISH OIL
- 93064 FLEXALL
- 93065 GAS-X
- 93067 GENTAK
- 93069 GLYNASE
- 93080 ISMO
- 93082 ISOMIL
- 93089 LORCET 93090 MACROBID
- 93093 MAXAQUIN
- 93101 NASAL SPRAY

- 93102 NESTAB
- 93104 NEUPOGEN
- 93105 NICODERM
- 93106 NICOTINE TRANDERMAL SYSTEM
- 93107 NICOTROL
- 93113 OCUVITE
- 93116 ORAGEL
- 93117 ORTH-CYCLEN
- 93120 PEDIASURE
- 93121 PERIDEX
- 93124 PINDOLOL
- 93127 PROSCAR
- 93131 REFRESH
- 93132 RELAFEN
- 93133 REPLENS
- 93136 RHOGAM
- 93150 SULFONYLUREAS
- 93151 SUPPOSITORY
- 93152 TAC
- 93154 THEREMS
- 93156 TOPROL XL
- 93164 VAGISIL
- 93166 VANTIN
- 93167 VARICELLA-ZOSTER IMMUNE GLOBULIN
- 93173 WART TREATMENT
- 93176 ZANTRYL
- 93179 ZITHROMAX
- 93181 ZOCOR
- 93183 ZOLOFT
- 93186 ANTIHYPERTENSIVE AGENT
- 93187 NORVASC
- 93188 NALTREXONE
- 93193 SERTRALINE
- 93195 HISTAMINE H-2 BLOCKER/ANTAGONIST
- 93197 RYTHMOL
- 93202 CYCLOSPORINE
- 93203 LABETALOL
- 93210 FIBER SUPPLEMENT
- 93211 AMIODARONE
- 93212 PAXIL
- 93213 GEMFIBROZIL
- 93214 AZITHROMYCIN
- 93215 FLUCONAZOLE
- 93217 DAIRY EASE
- 93218 ORTHO-CEPT
- 93220 KETOROLAC
- 93224 CLARITIN
- 93227 GUAIMAX-D
- 93230 DYNACIN
- 93231 IMITREX
- 93237 SIMVASTATIN
- 93239 FLURBIPROFEN
- 93243 LAMISIL

- 93248 SUMATRIPTAN
- 93256 PNEUMOCOCCAL VACCINE
- 93257 LORATADINE
- 93304 NEPHRO-VITE
- 93305 GLYBURIDE
- 93307 ENGERIX-B
- 93308 DAKIN'S SOLUTION
- 93309 BENZODIAZEPINES
- 93311 PEDVAX HIB
- 93312 KETOPROFEN
- 93315 PROPAFENONE
- 93316 MEFLOQUINE
- 93325 EMLA
- 93326 INJECTION
- 93327 ITRACONAZOLE
- 93334 CLEMASTINE
- 93341 FELBATOL
- 93347 AMBIEN
- 93348 PHOSLO
- 93352 FAMOTIDINE
- 93355 BUPROPION
- 93363 DESOGEN
- 93371 MIDODRINE
- 93372 BETASERON
- 93383 IMMUNIZATION
- 93394 AEROSOL THERAPY
- 93395 INHALER
- 93396 AMLODIPINE
- 93399 OXAPROZIN
- 93400 NEBULIZER
- 93404 SUCRALFATE
- 93415 REZINE
- 93417 CEFPROZIL
- 93418 FILGRASTIM
- 93419 TRIAZOLAM
- 93420 NEVIRAPINE
- 93421 SELENIUM SULFIDE SHAMPOO
- 93422 FLUNISOLIDE
- 93424 FLUDROCORTISONE ACETATE
- 93427 INSECT/BUG REPELLANT
- 93438 GREEN GRASSHOPPER
- 93440 CONDOMS
- 93442 HAEMOPHILUS B CONJUGATE VACCINE
- 93446 BETAXOLOL
- 93447 EMOLLIENT / LOTION / CREAM /MOISTURIZER
- 93450 APRODINE
- 93451 CLOMIPRAMINE
- 93453 RH IMMUNE GLOBUIN
- 93455 PERTUSSIS IMMUNE GLOBULIN
- 94001 SOTALOL
- 94002 BENZONATE
- 94004 PAROXETINE
- 94010 PENTASA
- 94011 CATAFLAM

- 94014 VENLAFAXINE
- 94016 ZIAC
- 94020 ALOMIDE
- 94022 BREWERS YEAST
- 94031 IMDUR
- 94034 ORTHO-TRICYCLEN
- 94035 ZOLPIDEM TARTRATE
- 94040 OXY-5
- 94041 PINK COCKTAIL
- 94043 TYLENOL ALLERGY SINUS
- 94048 METROGEL VAGINAL
- 94049 OYSTER SHELL CALCIUM
- 94052 TRIAMETERNE
- 94054 ACE INHIBITOR
- 94059 DOVONEX
- 94070 EFFEXOR
- 94071 INDAPAMIDE
- 94072 NSAID
- 94073 OCUFLOX
- 94074 PULMOZYME
- 94075 SEREVENT
- 94079 CORTICOSTEROID(S)
- 94080 DESMOPRESSIN
- 94081 DIVALPROEX SODIUM
- 94089 ICAPS
- 94091 VAGINAL LUBRICANT
- 94094 GLIBENCLAMIDE
- 94097 MEPRON
- 94099 NEURONTIN
- 94100 NIZATIDINE
- 94101 OXISTAT
- **94103 QUININE**
- 94104 RISPERIDONE
- 94110 LOZENGES
- 94113 DIFLUNISAL
- 94114 GABAPENTIN
- 94116 HUMULIN R
- 94117 LOVENOX
- 94119 NORETHINDRONE ACETATE
- 94123 BECONASE AQ
- 94124 CHOLESTYRAMINE
- 94125 ALEVE
- 94126 DEMADEX
- 94127 DAYPRO
- 94128 DAYQUIL
- 94129 DOXY
- 94131 GARLIC PILL
- 94133 TERAZOSIN
- 94134 DESONIDE
- 94136 LAMIVUDINE
- 94137 SULFA
- 94139 CEFPODOXIME
- 94141 BACTIGEN

- 94143 DEPO INJECTION
- 94145 OINTMENT
- 94146 PENICILLIN G BENZATHINE
- 94149 ESGIC PLUS
- 94158 RISPERDAL
- 94163 ALOE VERA
- 94167 ED A-HIST
- 94174 RHINOCORT
- 94175 ANTIBACTERIAL AGENT
- 94176 ASTROGLIDE
- 94179 NABUMETONE
- 94182 FLU-SHIELD
- 94188 FENTANYL
- 94190 MG
- 94191 MONISTAT
- 95003 ECONAZOLE
- 95005 FLONASE
- 95016 ADDERALL
- 95017 FAMVIR
- 95022 FEVERALL
- 95023 CHILDRENS MOTRIN
- 95024 FLUVOXAMINE
- 95025 LUVOX
- 95029 DOK
- 95033 MAC
- 95036 BUPRENORPHINE
- 95039 GUAIFENEX PSE
- 95044 ROBITUSSIN W/ CODEINE
- 95045 TYLENOL PM
- 95046 AMYLASE
- 95047 ATOVAQUONE
- 95050 ULTRAM
- 95054 ACTHIB
- 95057 DTAP
- 95062 STROVITE
- 95064 ZIDOVUDINE
- 95072 BENZTROPINE
- 95074 DIMETAPP DM
- 95082 PAMIDRONATE
- 95084 STAVUDINE
- 95086 LIQUID NITROGEN
- 95087 PROPHYLAXIS
- 95088 ESTROPIPATE
- 95089 METAXALONE
- 95092 PRAVASTATIN
- 95097 CARDIOLITE
- 95100 PROTEIN SUPPLEMENT
- 95111 GLUCOPHAGE
- 95114 TRUSOPT
- 95116 CAPSAICIN
- 95118 HEPATITIS A VACCINE
- 95119 MULTIVITAMIN W/ IRON
- 95122 PREVACID
- 95130 ULTRASE

- 95133 METFORMIN
- 95137 ALFALFA
- 95141 NEFAZODONE
- 95142 PREMPRO
- 95144 LOTREL
- 95145 MENINGOCOCCAL VACCINE
- 95148 HEPATITIS C VACCINE
- 95152 COZAAR
- 95154 QUERCETIN
- 95155 FLAX SEED OIL
- 95156 MYCOCIDE
- 95157 COLESTIPOL
- 95160 CLIMARA
- 95164 DORZOLAMIDE
- 95171 HYZAAR
- 95173 LEVBID
- 95174 PROGRAF
- 95177 FINASTERIDE
- 95178 FIORICET/ CODEINE
- 95181 LAMICTAL
- 95182 VARIVAX
- 95183 FOSAMAX
- 95188 PREMPHASE
- 95189 UNIVASC
- 95191 EPIVIR
- 95192 CASODEX
- 96003 PERMETHRIN
- 96005 ALENDRONATE SODIUM
- 96006 AZELEX
- 96007 CETIRIZINE
- 96008 HUMULIN N
- 96009 BENZOCAINE
- 96010 VAPORIZER
- 96020 LEVOXYL
- 96021 TSH
- 96022 ZYRTEC
- 96024 CLOBETASOL
- 96027 DOCUSATE SODIUM
- 96028 ACETAMINOPHEN-HYDROCODONE
- 96033 LEVOBUNOLOL
- 96034 RIFAPENTINE
- 96038 MUPIROCIN
- 96041 TRAMADOL
- 96043 VALTREX
- 96044 NASAREL
- 96045 DEMEROL
- 96046 GOUT MEDICATION
- 96049 HEPATITIS VACCINE
- 96055 LEVOTHYROID
- 96058 PRECOSE
- 96059 PRENAVITE
- 96066 NORVIR
- 96067 ANTIOXIDANTS

- 96068 TRIAZ
- 96070 CEDAX
- 96072 TIAZAC
- 96077 HYDROCOLLOID DRESSINGS
- 96083 NAPRELAN
- 96084 OPCON-A
- 96086 SULAR
- 96091 FLOVENT
- 96093 RITONAVIR
- 96094 ACARBOSE
- 96102 EC-NAPROSYN
- 96105 TEGADERM
- 96107 BUMETANIDE
- 96109 OXYCONTIN
- 96111 AYR NASAL GEL
- 96115 SALMETEROL
- 96119 CAVERJECT
- 96121 DIMETAPP COLD/ALLERGY
- 96122 REMERON
- 96123 ZEBETA
- 96124 HAVRIX
- 96125 MELATONIN
- 96128 AVONEX
- 96130 LANSOPRAZOLE
- 96131 COVERA HS
- 96135 PHENERGAN DM
- 96137 DHEA
- 96138 AMARYL
- 96141 VIVELLE
- 96144 ACCOLATE
- 96147 CELLCEPT
- 96156 VITAFOL
- 96157 AEROCHAMBER
- 96158 ALCLOMETASONE DIPROPRIONATE
- 96165 ELMIRON
- 96167 XALATAN
- 96168 MAVIK
- 96169 ACIDOPHILUS
- 96171 MENTAX
- 96173 ZYPREXA
- 96174 ALLEGRA
- 96176 DIFFERIN
- 97002 OLANZAPINE
- 97016 ARICEPT
- 97017 HUMALOG
- 97018 MOEXIPRIL
- 97019 SAW PALMETTO
- 97020 LIPITOR
- 97024 ZYFLO
- 97027 FLINTSTONES VITAMINS
- 97028 ALPHAGAN
- 97029 ATUSS DM
- 97030 NEOCATE
- 97035 ASTELIN

- 97036 DIOVAN
- 97037 PATANOL
- 97043 BROMFED PD
- 97045 LEVAQUIN
- 97047 MAGNESIUM
- 97049 TOPAMAX
- 97051 VIRACEPT
- 97052 VIRAMUNE
- 97056 MIRTAZAPINE
- 97060 FAMCICLOVIR 97073 LOSARTAN
- 97078 ANDRODERM PATCHES
- 97085 TORSEMIDE
- 97086 ALESSE
- 97089 GUANFACINE
- 97092 TRANDOLAPRIL
- 97098 PRAMIPEXOLE
- 97101 NIFEREX FORTE
- 97105 COMBIVENT
- 97108 HELIDAC
- 97109 REVIA
- 97111 TARKA
- 97113 ZANAFLEX
- 97114 TAURINE
- 97126 FLOMAX
- 97129 ST JOHNS WORT
- 97130 TACROLIMUS
- 97135 VALACYCLOVIR
- 97136 LAMOTRIGINE
- 97138 TUSSIN DM
- 97141 COMBIVIR
- 97142 COREG
- 97145 AVAPRO
- 97146 ESTRING
- 97150 REQUIP
- 97151 CHONDROITIN SULFATE
- 97152 MIRAPEX
- 97154 VINEGAR
- 97157 ATORVASTATIN
- 97159 CALCITRIOL
- 97163 LEVOFLOXACIN
- 97168 SEROQUEL
- 97170 CENTRUM SILVER
- 97174 BABY ASPIRIN
- 97179 DENAVIR
- 98001 MAG-OX
- 98006 ARTHROTEC
- 98008 CARVEDILOL
- 98010 NASONEX
- 98011 CONSTULOSE
- 98013 BEE POLLEN
- 98017 PROPECIA
- 98018 VANICREAM

- 98022 ZOMIG
- 98030 ECHINACEA
- 98033 ALDARA
- 98036 NORCO
- 98038 SINGULAIR
- 98041 VIAGRA
- 98043 VICOPROFEN
- 98046 MICROZIDE
- 98047 NORITATE
- 98049 DONEPEZIL HCL
- 98051 OS-CAL +D
- 98053 PREVPAC
- 98054 TAZORAC
- 98065 DETROL
- 98071 THERAFLU
- 98073 DOMPERIDONE
- 98075 CALCIUM CITRATE
- 98076 TUBERCULOSIS VACCINE
- 98083 AZOPT
- 98085 NIASPAN
- 98086 PLAVIX
- 98089 TERBINAFINE
- 98090 ARIMIDEX
- 98092 DOXIL
- 98093 MONTELUKAST
- 98095 SUSTIVA
- 98097 AMERGE
- 98098 COSOPT
- 98101 PRANDIN
- 98109 CHLORHEXIDINE GLUCONATE
- 98114 CARBATROL
- 98115 CELEXA
- 98116 GABITRIL
- 98117 FENOFIBRATE
- 98123 ANTIRETROVIRAL AGENT
- 98126 FLUVIRIN
- 98131 TOPIRAMATE
- 98136 PROMETRIUM
- 98139 TIZANIDINE
- 98141 VALSARTAN
- 98143 COPAXONE
- 98144 KADIAN
- 98146 EFAVIRENZ
- 98150 DEHYDROEPIANDROSTERONE
- 98156 MAXALT
- 98158 TRICOR
- 98160 ARAVA
- 98167 GRAPESEED EXTRACT
- 99001 CEFEPIME
- 99002 CELEBREX
- 99005 REMICADE
- 99006 RENAGEL
- 99007 ROPIVACAINE HCL
- 99008 ALLEGRA D

- 99011 NALEX
- 99013 NASACORT AQ
- 99014 OMNICEF
- 99015 ORTHO-NOVUM 7/7/7
- 99016 PRIMROSE OIL
- 99017 RIBAVIRIN
- 99018 ROTAVIRUS VACCINE
- 99019 SYNVISC
- 99023 CORTISPORIN OTIC
- 99026 GLUCOSAMINE
- 99028 TYLENOL ARTHRITIS
- 99030 AVANDIA
- 99031 ATACAND
- 99033 CLOPIDOGREL
- 99036 GLUCOSAMINE CHONDROITIN
- 99039 LOTENSIN HCT
- 99042 PACERONE
- 99043 PROAMATINE
- 99049 XENICAL
- 99051 AVALIDE
- 99052 ACTIVATED CHARCOAL
- 99056 GLIMEPIRIDE
- 99057 HEMOCYTE PLUS
- 99059 MICARDIS
- 99066 SINEMET CR
- 99073 CIPRO HC
- 99074 CITALOPRAM
- 99075 ENBREL
- 99076 GLUCOSAMINE SULFATE
- 99080 MIRALAX
- 99081 MULTIVITAMINS W/ FOLIC ACID
- 99088 ZIAGEN
- 99089 ACIPHEX
- 99090 ACTOS
- 99098 NITROQUICK
- 99099 PLETAL
- 99101 QUETIAPINE FUMARATE
- 99106 XOPENEX
- 99107 ZADITOR
- **99114 ENDOCET**
- 99118 NECON
- 99123 MORPHINE SULFATE
- 99128 LIPASE
- 99129 Q-PAP
- 99132 EVISTA
- 99133 ALBUTEROL
- 99138 KELP
- 99139 MAGIC MOUTHWASH
- 99141 PIN-X
- 99142 PRENATAL VITAMINS W/ IRON
- 99145 UROGESIC BLUE
- 99148 ARMIDEX
- 99152 EVENING PRIMROSE OIL

- 99156 LIPID LOWERING AGENT
- 99161 ROPINIROLE HCL
- 99163 ANAPLEX DM
- 99167 COQ-10
- 99170 DR. SMITH'S OINTMENT
- 99171 NETTLE
- 99172 NOVOLIN 70/30
- 99174 PHOSPHORUS
- 99182 RICOLA
- 99184 TRIVORA
- 99185 UNIRECTIC
- 99189 CALCIUM W/ VITAMIN D
- 99194 ABACAVIR SULFATE
- 99198 EMADINE
- 99201 ORTHO-CYCLEN
- 99202 PRENATAL VITAMINS W/ CALCIUM
- 99207 BRIMONIDINE
- 99210 CARTIA
- 99211 CITRACAL + D
- 99213 DIASTAT
- 99214 DIOVAN HCT
- 99216 FEXOFENADINE
- 99218 FORMULA SUPPLEMENT
- 99219 GINKGO BILOBA
- 99223 LEVORA
- 99224 OMEGA-3
- 99225 RALOXIFENE
- 99227 UNIRETIC
- 99999 ILLEGIBLE

C. MULTUM LEXICON END-USER LICENSE AGREEMENT

The Multum Lexicon End-User License Agreement for the 2012 NAMCS Community Health Center Public Use Micro-Data File is the same as that used for the 2012 National Ambulatory Medical Care Survey Public Use Micro-Data File and is available here.

D. MULTUM CLASSIFICATION OF THERAPEUTIC CLASSES (DRUG CATEGORIES)

The Multum Classification of Therapeutic Classes for the 2012 NAMCS Community Health Center Public Use Micro-Data File is the same as that used for the 2012 National Ambulatory Medical Care Survey Public Use Micro-Data File and is available here.